

Author Index

- Aaronson NK, 514
Abbott MH, 488
Abe K, (suppl 7): S41
Abou-Sleiman PM, 283
Abrams EJ, (suppl 7): S112
Abu-Asab M, 769
Abu-Mouch S, 796, (suppl 7): S57
Abu-Shakra S, (suppl 7): S32
Achim C, 638
Acosta MT, (suppl 6): S73, (suppl 7): S107; S114; S152
Acsadi G, (suppl 7): S108
Adams C, 719
Adams HP Jr., 439, (suppl 7): S66
Adamson V, (suppl 7): S44; S63
Adams RJ, 559
Adler C, 848
Agamanolis DP, 547
Agarwala KL, (suppl 7): S54
Agid Y, 176, (suppl 7): S39; S70
Ahmed A, (suppl 7): S41
Ahmed F, (suppl 7): S77
Ahn J, (suppl 7): S61
Ahn Y, (suppl 7): S60
Aiba I, (suppl 7): S52
Aimonovitch M, (suppl 7): S147
Akagi T, (suppl 7): S54
Akbadak E, (suppl 7): S76
Akins P, (suppl 7): S121
Akiwumi O, (suppl 7): S65
Akman CI, (suppl 7): S132; S134
Aksamit A, (suppl 7): S22
Al-Barghouthy G, (suppl 7): S40
Alberici A, 833
Alberts L, (suppl 7): S148
Al-Chalabi A, 130
Alexander GG, (suppl 7): S28
Alexander JS, (suppl 7): S59
Alfonso I, (suppl 7): S156; S158
Alford M, (suppl 7): S29
Al-Futaisi A, (suppl 7): S148
Alizadeh M, 119
Allen A, (suppl 7): S143
Allen AJ, (suppl 7): S106
Allen FH, Jr., (suppl 7): S50
Allen J, (suppl 7): S109
Ally RA, 849
Almli CR, (suppl 7): S122
Al-Nouri D, (suppl 7): S119
Alpaidze M, (suppl 7): S141
ALS Study Group, 700
Altaye M, (suppl 7): S136
Altintas A, (suppl 7): S37
Altmann D, (suppl 7): S38
Amano K, (suppl 7): S54
Aminoff AR, (suppl 7): S139
Amor S, (suppl 7): S62
Anan K, (suppl 7): S64
Anchisi D, 833
Andermann E, 30
Andermann F, 30
Andersen PM, 130
Anderson F, 700
Anderson JH, 725
Anderson P, (suppl 7): S138
Andreasson K, 155
Andreou A, (suppl 7): S132
Andreu AL, 524, 527
Andrews H, 507, 693
Anguelov RA, (suppl 7): S108
Annoni JM, 556
Anselm I, (suppl 7): S156
Antalfy BA, (suppl 7): S104
Anthony DC, 790, (suppl 7): S155
Aoki M, (suppl 7): S53
Aoyama K, 850
Apisarnthanarax S, (suppl 7): S31
Appel M, (suppl 7): S106
Appel SH, (suppl 7): S43
Apse K, (suppl 7): S119
Arai A, (suppl 7): S73
Arai H, 276
Aranow BJ, (suppl 7): S118
Arbusov V, 678
Arenas AC, (suppl 7): S150
Arenson A, (suppl 7): S152
Armon C, (suppl 7): S78
Armstrong D, 398, (suppl 7): S104; S140
Arnason BGW, (suppl 7): S38; S45
Arnold LA, (suppl 6): S46
Aronow B, (suppl 7): S58; S108
Aronson S, (suppl 7): S69
Arroyo S, (suppl 7): S112; S135
Asada T, 137, 553
Asano T, 732
Ascherio A, 170
Aschoff J, (suppl 7): S32
Ashwal S, (suppl 7): S111; S125; S128; S153
Askalan R, (suppl 7): S141
Askanas V, 848, (suppl 7): S43
Assadi AH, (suppl 7): S104
Assmann B, (suppl 6): S18; S56
Assouline J, (suppl 7): S132
Augood SJ, (suppl 7): S116
Aulwurm S, 388
Aurino S, 674
Austin JK, (suppl 7): S133
Averbooch E, (suppl 7): S128
Avila MR, (suppl 7): S54
Avison MJ, (suppl 7): S48; S49
Avison RG, (suppl 7): S48; S49
Aviv RI, (suppl 7): S140
Azizian A, (suppl 7): S146
Azuma M, (suppl 7): S44
Baaijen H, 514
Baas PW, (suppl 7): S117
Bababeygy S, (suppl 7): S117
Baba M, 352, 383
Baba Y, (suppl 7): S58
Babron MC, 119
Back SA, (suppl 7): S103
Badgett D, (suppl 7): S36
Bae SJ, (suppl 7): S38
Bae SW, (suppl 7): S79
Bahn E, (suppl 7): S116
Bai DS, (suppl 7): S54
Baier M, (suppl 7): S36
Baird AE, (suppl 7): S24
Bai Y, (suppl 7): S49
Baker M, (suppl 7): S58
Bakshi R, (suppl 7): S59
Balabanov R, (suppl 7): S78
Bale JF Jr., (suppl 7): S137
Balmain A, (suppl 7): S109
Balsamo LM, (suppl 7): S105
Bamford NS, (suppl 7): S106
Bandy DJ, (suppl 7): S149
Bang OY, 227, (suppl 7): S65
Bansal AS, (suppl 7): S143
Bao X, 239
Baptista M, 848
Baram TZ, 701, (suppl 7): S54
Barbaro NM, (suppl 7): S53
Barber PA, (suppl 7): S25; S65
Barbieri CA, (suppl 7): S76
Barbiero L, 833
Barcellos LF, 849, (suppl 7): S34; S35
Baric I, (suppl 7): S151
Barkovich AJ, 123, (suppl 7): S108; S111; S121; S138
Barkovich JA, (suppl 7): S159
Barlow CH, (suppl 7): S103
Barnwell A, (suppl 7): S111
Bartko JJ, (suppl 7): S129
Bartzokis G, (suppl 7): S29
Bassan H, (suppl 7): S121; S122; S123; S124
Bassuk AG, (suppl 7): S157
Bastian LA, 699
Bates GP, 186, 844
Batocchi AP, (suppl 7): S47
Bauer I, 110, 367
Bauer P, 110, 367
Baum CM, 699
Baumgartner WA, (suppl 7): S67
Bawle EV, (suppl 7): S159
Baxter LC, (suppl 7): S28
Bealmear BM, (suppl 7): S38
Beam M, (suppl 7): S49
Beardsley DJ, (suppl 7): S103
Becker DA, 330
Becker JT, (suppl 7): S67
Becker M, (suppl 7): S147
Bedoya G, 163
Beers DR, (suppl 7): S43
Beffert U, (suppl 7): S104
Beggarty M, (suppl 7): S125
Begovich AB, 849
Behen M, (suppl 7): S129
Belayev A, 330
Belayev L, 330
Belleau B, (suppl 7): S46
Bell RD, (suppl 7): S25
Belmont JW, 398
Bender RA, (suppl 7): S54
Benecke R, (suppl 7): S41

- Benedict RHB, (suppl 7): S59
 Bengel JL, (suppl 7): S133
 Benjamins JA, (suppl 7): S38
 Bensimon G, (suppl 7): S39; S70
 Bensler SM, (suppl 7): S140
 Benson CB, (suppl 7): S122; S124
 Benussi L, 833
 Benzinger TLS, (suppl 7): S122
 Berg D, 135
 Berg-Dammer E, (suppl 7): S25
 Berger I, (suppl 7): S144
 Berger JR, (suppl 7): S48; S49
 Bergeron C, (suppl 5): S24
 Bergman H, (suppl 7): S68
 Berlitz PD, (suppl 7): S25; S62
 Berman JL, (suppl 7): S35
 Berman N, 669
 Bermel RA, (suppl 7): S59
 Bernard BA, (suppl 7): S69
 Bernasconi A, 30
 Berry-Kravis E, (suppl 7): S144; S150
 Berthoz A, 615
 Bertini E, 719
 Bertoni C, (suppl 7): S43
 Besley GTN, (suppl 7): S151
 Bespalova I, 825
 Beth Israel Germinoma Consortium, (suppl 7): S109
 Beunard JL, 844
 Bevan S, 796, (suppl 7): S57
 Bhardwaj A, (suppl 7): S26; S64; S66
 Bhise V, (suppl 7): S114
 Biancato J, 848
 Bibat G, (suppl 7): S108; S118
 Bibl M, 263
 Bigalke H, (suppl 7): S71
 Biggio G, (suppl 6): S81
 Bigio EH, (suppl 5): S20
 Bilbao JM, (suppl 7): S76
 Binetti G, 833
 Bingham PM, (suppl 7): S120
 Bingley M, 748
 Bird H, 310
 Bird T, (suppl 5): S29, (suppl 7): S57
 Bird TD, (suppl 7): S21; S68
 Birebent B, 119
 Birnbaum G, (suppl 7): S35
 Bisgaier CL, 848
 Bit-Avragim N, 552
 Bitsch A, (suppl 7): S37
 Bittner RE, 821
 Black DF, 360
 Black JB, (suppl 7): S112
 Black SE, (suppl 7): S29; S67
 Blakely EL, 521
 Blanco M, 812
 Bland P, 75
 Blank SC, 310
 Blood CL, (suppl 7): S76
 Blount JP, (suppl 7): S140
 Blue ME, (suppl 7): S104; S118
 Bluhmki E, 696, (suppl 7): S18
 Blumenfeld S, (suppl 7): S148
 Blumen SC, 796, (suppl 7): S57
 Blumhardt LD, (suppl 7): S78
 Bodell A, (suppl 7): S119
 Bodensteiner JB, (suppl 7): S123; S130; S149
 Bodnar J, (suppl 7): S155
 Boecker H, 445
 Boespflug-Tangy O, 769
 Boeve BF, (suppl 5): S15, (suppl 7): S22
 Bogen JE, 126
 Bogousslavsky J, 321
 Bohan TP, (suppl 7): S147
 Bollen A, (suppl 7): S159
 Bonavita S, 769
 Bond J, (suppl 7): S119
 Boneh A, 473
 Bonell S, (suppl 7): S62; S63
 Bone RB, (suppl 7): S69
 Bonifati V, 176, 271
 Bonner AM, 176
 Bonthius DJ, (suppl 7): S132
 Boone KB, 669
 Borchelt DR, (suppl 7): S29
 Borchert LD, (suppl 7): S33
 Borg M, (suppl 7): S39
 Bornemann A, 135
 Borowicz LM, (suppl 7): S67
 Bosch F, 719
 Bottiglieri T, (suppl 6): S3; S81
 Bouchard JP, 9
 Bougerie H, 119
 Bouquiaux O, 248
 Bouras C, (suppl 7): S50
 Bourgeois B, (suppl 7): S136
 Boutry S, (suppl 7): S25
 Bowman R, (suppl 7): S157
 Bradley EA, 38
 Braendgaard H, (suppl 7): S51
 Brandt J, 488
 Brandt T, 678
 Brasic JR, (suppl 7): S118
 Brassat D, 849
 Braun E, (suppl 7): S48
 Bräutigam C, (suppl 6): S56
 Breakefield XO, (suppl 7): S116
 Bredesen DE, 781
 Bredt DS, (suppl 7): S53
 Breedveld G, 573
 Brem H, 851
 Brenner M, (suppl 7): S157
 Bressler SB, (suppl 7): S28
 Bressman S, 102
 Breteler MMB, 275
 Breuer S, 534
 Brewster AL, (suppl 7): S54
 Brex PA, (suppl 7): S38
 Breznitz Z, (suppl 7): S145
 Briani C, (suppl 7): S75
 Brice A, 176
 Briem E, 521
 Brin MF, 403
 Briones P, 665
 Britt JP, 126
 Broberg E, 267
 Bronner-Fraser M, (suppl 7): S117
 Brook GA, 534
 Brooks BR, 700, (suppl 7): S36
 Brooks DJ, 93, 692
 Brooks-Kayal A, (suppl 7): S104
 Broussolle E, 176
 Brown AD, 696, (suppl 7): S18
 Brown J, (suppl 7): S128
 Brown JK, (suppl 7): S125
 Brown RH, (suppl 7): S57
 Brown RH Jr., 130
 Brown S, (suppl 7): S112
 Bruck W, (suppl 7): S37
 Brueck W, (suppl 7): S116
 Buccellato FR, (suppl 7): S52
 Buchan AM, (suppl 7): S65
 Buchanan TM, (suppl 7): S147
 Buchhalter JR, (suppl 7): S115
 Buckley C, (suppl 7): S20
 Budreck E, (suppl 7): S104
 Buerger K, 263
 Buhlmann S, 367
 Bukelis I, (suppl 7): S105
 Buljevac D, 829
 Bunse M, 552
 Burack GD, (suppl 7): S114
 Burakgazi E, (suppl 7): S55
 Burghes AHM, 647
 Burgoon MP, 459
 Bürk K, 110
 Burmeister M, 825
 Burn DJ, 235, (suppl 7): S70
 Burnham WM, 219
 Burns TM, 136
 Burrowes DM, (suppl 7): S157
 Burton BK, (suppl 7): S157
 Bushby K, 719
 Bushby KMD, 748
 Bushnell CD, 697, 699
 Busto R, 330
 Butler II, (suppl 7): S130
 Buyse G, 850
 Byars AW, (suppl 7): S109
 Cadavid D, (suppl 7): S49
 Cady RK, (suppl 7): S33
 Caggiula M, (suppl 7): S47
 Caillier SJ, 849
 Cain V, 697
 Cai X, 206
 Calamante F, (suppl 7): S138
 Callahan J, 725
 Callahan MJ, 848
 Callen PW, 123, (suppl 7): S138
 Calos MP, (suppl 7): S43
 Cambi F, (suppl 7): S57
 Camfield C, (suppl 7): S153
 Camfield P, (suppl 7): S153
 Campistol J, 665
 Caputy A, (suppl 7): S55
 Carasso RL, 796, (suppl 7): S57
 Caravale B, (suppl 7): S124
 Carbon M, 102
 Carhuapoma JR, 699
 Carney PR, (suppl 7): S55
 Caro JJ, 698
 Carpenter S, 9
 Carrara F, 521
 Carrozzo R, 30
 Caselli RJ, (suppl 5): S20, (suppl 7): S28
 Cassetta E, 833
 Castillo AE, (suppl 7): S72
 Castillo E, (suppl 7): S74
 Castillo JC, 812
 Castleberry RP, (suppl 7): S140
 Castollano AS, 849
 Cattaneo E, (suppl 7): S75
 Caveny EA, 547
 Ceballos-Baumann AO, 445
 Cedarbaum JM, (suppl 7): S19
 Cepek L, 263
 Cernak I, (suppl 7): S77
 Chadarevian JP, (suppl 7): S132
 Chakraverty S, 163
 Chalela JA, 66

- Chalenski CJ, (suppl 7): S116
 Champion S, (suppl 7): S112
 Chan A, (suppl 7): S138
 Chan AK, (suppl 7): S110
 Chang B, (suppl 7): S119
 Chang L, (suppl 7): S48
 Chang T, (suppl 7): S114; S152
 Chang Y, (suppl 7): S64
 Chang YC, 706
 Chang YJ, (suppl 7): S79
 Chang YY, 706
 Chan LL, 838
 Chan P, 239
 Chaovallitwongse W, (suppl 7): S55
 Chard DT, (suppl 7): S38
 Charles PD, 700
 Charlesworth BR, (suppl 7): S32
 Chaturvedi S, 699
 Chawda S, (suppl 7): S137
 Chen DH, (suppl 7): S21
 Cheng EM, 695, (suppl 7): S17
 Cheng H, 115, 693
 Chen H, 170
 Chen L, (suppl 6): S91
 Chen S, 379
 Chen TY, (suppl 7): S64; S66
 Chen X, 647
 Chen Y, 239, 850
 Chertkow HM, (suppl 7): S68
 Chez MG, (suppl 7): S146; S147
 Chinnery PF, 521
 Chiocca EA, 851
 Chiriboga CA, (suppl 7): S112
 Chiverton AM, (suppl 7): S142
 Choi NC, (suppl 7): S56
 Choi T, (suppl 7): S35
 Choi YK, (suppl 7): S34
 Cho KK, (suppl 7): S54
 Chong WK, (suppl 7): S137; S138
 Chow CW, 473
 Cho WM, (suppl 7): S53
 Christova PS, 725
 Chugani DC, (suppl 7): S129
 Chugani HT, (suppl 7): S129
 Chu K, (suppl 7): S54
 CINRG Investigators, 850
 Cizek B, 698
 Civitello L, (suppl 7): S152
 Claiborne S, 696, (suppl 7): S17
 Clancy RR, (suppl 7): S110
 Clanet M, 119
 Clarke CE, 682
 Clarke D, (suppl 7): S149
 Clark GD, (suppl 7): S104; S154
 Clark H, (suppl 7): S111
 Clemens PR, (suppl 7): S42
 Clemons TE, (suppl 7): S28
 Clerget-Darpoux F, 119
 Clover L, 530, (suppl 7): S20
 Coenen HH, 479
 Coenen MJH, 665
 Cohen B, (suppl 7): S50
 Cohen LG, 464
 Colcher A, 699, (suppl 7): S50
 Coleman AE, 625
 Comella CL, (suppl 7): S72
 Comi AM, (suppl 7): S116
 Commichau C, (suppl 7): S26
 Conant K, (suppl 7): S19
 Concas A, (suppl 6): S81
 Concerta Study Group, (suppl 7): S27
 Conforto AB, 464
 Conklin HS, (suppl 7): S113
 Connelly A, (suppl 7): S138
 Connolly AM, (suppl 7): S117; S146; S155
 Connolly ES, 698
 Connolly MB, (suppl 7): S114
 Connolly SE, (suppl 7): S26
 Conry JA, (suppl 7): S114
 Constantinescu CS, (suppl 7): S78
 Contag CH, (suppl 7): S43
 Conti M, 697
 Conturo TE, (suppl 7): S76
 Cook JD, (suppl 7): S151
 Cook S, (suppl 7): S58
 Cookson M, 848
 Cooney K, (suppl 7): S139
 Cooper JM, 552
 Cooper RA Jr., (suppl 7): S24
 Covert DD, 647
 Coplin WM, 699
 Corey-Bloom J, (suppl 7): S29; S42
 Cornford E, (suppl 7): S54
 Corse AM, (suppl 7): S73
 Cortez MA, 219
 Cote L, 507, 693
 Cotelli M, (suppl 7): S75
 Cotman CW, (suppl 7): S50
 Coticelli B, (suppl 7): S75
 Cournu-Rebeix I, 119
 Cox TC, (suppl 7): S137; S140
 Cramer JA, (suppl 7): S55
 Crawley A, 271, 848
 Cree BAC, 849, (suppl 7): S34; S35
 Creswell J, 126
 Creveaux I, 769
 Cribbs D, (suppl 7): S68
 Crino PB, 251
 Crisci C, 197
 Croen LA, (suppl 7): S126
 Croes EA, 275, 555
 Crooks D, 682
 Croquelois A, 321
 Cross DA, (suppl 7): S117
 Cross SA, 38
 Crowe A, 682
 Crowther RA, 573
 Cruts M, 275
 Cruz-Flores S, (suppl 7): S66
 Cudkowicz ME, 130
 Culver D, 849
 Cummings JL, 147, (suppl 7): S29
 Cunnane M, (suppl 7): S31
 Curtis R, (suppl 7): S138
 Cvitanovic-Sojat L, (suppl 7): S151
 Daga A, (suppl 7): S57
 D'Agostino D, 30
 Dail D, (suppl 7): S49; S50; S63
 Daims R, (suppl 7): S54
 Dai R, (suppl 7): S62
 Dalakas MC, (suppl 7): S45; S75
 Dalton CM, (suppl 7): S38
 Dalvi A, (suppl 7): S108; S118
 Daly JJ, (suppl 7): S64
 Dambrosia J, 66
 Damian HL, (suppl 7): S46
 Danko CG, (suppl 7): S105
 Danon MJ, (suppl 7): S20
 Daraksan M, (suppl 7): S149
 D'Arcangelo G, (suppl 7): S104
 Darras BT, 790, (suppl 7): S155
 Das BK, (suppl 7): S64
 Daskalakis C, (suppl 7): S25
 Das S, 30
 Daube JR, 690
 Dauer WT, 849
 Dávalos A, 812
 David WS, 790, (suppl 7): S155
 Davies S, (suppl 7): S138
 Davis AA, 849
 Davis DA, (suppl 7): S39
 Davis M, 93
 Davis TL, 700, (suppl 7): S71
 Davis-Williams A, (suppl 7): S57
 Dawson JD, (suppl 7): S39
 Dawson TM, 281
 Dawson VL, 281
 D'Cruz ONF, (suppl 7): S151
 Deasy N, (suppl 7): S39
 Debs OM, (suppl 7): S113
 Debus OM, (suppl 7): S110
 de Chaderevian JP, (suppl 7): S103; S117; S158
 DeCock K, (suppl 7): S118
 Deering WM, (suppl 7): S149
 Defebvre L, (suppl 7): S39
 Degaetano M, (suppl 7): S148
 de Graaf R, (suppl 7): S106
 de Grauw T, (suppl 7): S139
 de Klerk JBC, (suppl 6): S56
 DeKosky ST, (suppl 7): S67
 Delacourte A, (suppl 5): S24
 DeLeon GA, (suppl 7): S157
 Delgado M, (suppl 7): S149
 Delgado S, (suppl 7): S60
 Delgado-Escueta AV, (suppl 7): S54
 Delivoria-Papadopoulos M, (suppl 7): S103
 Della Marca G, (suppl 7): S47
 Delmaire C, (suppl 7): S39
 Delucia-Deranja E, (suppl 7): S24
 De Luna N, (suppl 7): S74
 Del Valle L, (suppl 7): S117
 De Meirleir LJ, (suppl 7): S151
 De Michele G, 176
 Denckla MB, (suppl 7): S129
 Dennis B, (suppl 7): S35
 Derfuss T, 678
 Dermaut B, 275, 555
 Derugin N, (suppl 7): S26; S65
 Desaka-Akita H, 277
 Destee A, 542
 Destée A, 176
 Detre JA, (suppl 7): S153
 Deutsch M, (suppl 7): S152
 deVeber GA, (suppl 7): S110; S138; S140; S141
 DeVincent C, (suppl 7): S146
 De Vivo DC, (suppl 6): S1
 de Vos R, 542
 Dezawa M, 352
 Dhawan V, 102

- Diamond AL, (suppl 7): S66; S75
Diaz JH, (suppl 7): S32
Dib M, (suppl 7): S70
Dickson DW, 848, (suppl 5): S24, (suppl 7): S51
Diederich NJ, (suppl 7): S47
Diehl J, (suppl 5): S7; S32
Dieni S, (suppl 7): S121
Diguet E, 843
DiMario FJ Jr., (suppl 7): S129
DiMauro S, 524
Ding K, 239
Dingman A, (suppl 7): S65
Dingman S, (suppl 7): S26
Dinopoulos A, (suppl 7): S139
Dionisi-Vici C, (suppl 7): S151
Dionisi-Vici C, (suppl 6): S56
Diringer MN, (suppl 7): S28
Dirnagl U, 582, 591
DiSalvo D, (suppl 7): S122; S124
Dispenzieri A, (suppl 7): S44
DiTaranto PE, (suppl 7): S156
Dittmar C, 479, (suppl 7): S30
Divry P, (suppl 7): S151
Dixon C, (suppl 7): S39
Djuric P, (suppl 7): S118
Dlugos DJ, (suppl 7): S135
Dobyns WB, 30
Doddapaneni S, (suppl 7): S152
Dogan AS, (suppl 7): S118
Domi T, (suppl 7): S138
Dong W, (suppl 7): S25
Dooijes D, 573
Doran E, (suppl 7): S107
Dore-Duffy P, (suppl 7): S78
Doré S, 155
Doudet D, 599
Douglas VC, 696, (suppl 7): S17
Dowd CF, (suppl 7): S139
Drauner DA, (suppl 7): S142
Dreier JP, 591
Dressler D, (suppl 7): S41; S71
Drislane FW, 625
Dromerick AW, 418, 699
Dubeau F, 30
Dulaney E, 825
Duncan JS, 421
Dunn D, (suppl 7): S106; S143
Dunn DW, (suppl 7): S133
Dunphy N, (suppl 7): S24
du Plessis AJ, (suppl 7): S121; S122; S123; S124; S125
Dupré N, 9
Dupuis A, (suppl 7): S149
Dure L, (suppl 7): S106
Durif F, (suppl 7): S39
Durr A, 176
Dutra A, 848
Dyck R, (suppl 7): S65
Eberhart C, (suppl 7): S30
Eberini I, (suppl 7): S52
Eberly LE, 75
Ebringer A, (suppl 7): S62; S63
Echols JD, (suppl 7): S60
Edan G, 119
Edwards DF, 699
Edwards KR, (suppl 7): S31
Egashira K, 388
Eguchi K, 277
Eguchi M, (suppl 7): S127
Ehrlich ME, 848
Eichholz S, 719
Eidelberg D, 102
Eikelenboom MJ, 459
Einhäupl KM, 591
Eisa M, 695, (suppl 7): S17
Elger CE, 425
Elkahloun A, (suppl 7): S24
Endres M, 582
Engel AG, 805
Engelberts NHJ, 514
Engel SK, 848
Engel WK, (suppl 7): S43
Engle T, (suppl 6): S46
Enikolopov G, (suppl 7): S118
Enriquez R, (suppl 7): S137
Epilepsy Impact Project, (suppl 7): S55
Epstein L, (suppl 7): S50
Erenberg G, (suppl 7): S106
Ergezinger K, 686
Erlich HA, 849
Ernst T, (suppl 7): S48
Escobar GJ, (suppl 7): S126
Escolar DM, 850
Esselmann H, 263
Ess KC, 251
Esteban R, (suppl 7): S46
Ettl MM Jr., (suppl 7): S149
Eunson P, (suppl 7): S125
European Consortium on Genetic Susceptibility in Parkinson's Disease, 176
Evans J, (suppl 7): S138
Evidente VGH, (suppl 7): S46
Eyaid W, (suppl 7): S119
Fabiano AJ, (suppl 7): S59
Faden AI, (suppl 7): S77
Faerber EN, (suppl 7): S158
Fagan AM, 115, 693
Fahn S, 507, 693
Fang JY, 700, (suppl 7): S71
Fan QW, 850
Farbman ES, (suppl 7): S52
Farrer M, 848
Fayed N, (suppl 7): S30
Feasby TE, 696, (suppl 7): S18
Fedatari E, 833
Fedder W, 697
Fedio P, 297
Feichter J, (suppl 7): S36
Feldman BM, (suppl 7): S140
Feldman E, (suppl 7): S44; S73
Feldman H, (suppl 5): S29
Felix AC, (suppl 7): S49
Ferin M, 433
Fermanian J, (suppl 7): S39
Fernando K, (suppl 7): S38
Ferrari MD, 360
Ferriero DM, 123, 846, (suppl 7): S23; S26; S111; S121; S138; S139; S159
Feucht M, 821
Feuerstein B, (suppl 7): S109
Ficker DM, (suppl 7): S108; S118
Field K, (suppl 7): S148
Fife TD, (suppl 7): S45
Filosto M, 524
Fink K, 843
Firschbeck KH, 647
Fischer D, 674
Fischer LR, 849
Fishel MA, (suppl 7): S68
Fishman I, (suppl 7): S59
Fishman RA, 557
Fisman DN, (suppl 7): S70
Fitzsimmons BF, 698, (suppl 7): S26
Fleishman S, (suppl 7): S112
Flinter F, 30
Florence J, 850
Flores-Sarnat L, (suppl 7): S119
Follette PL, (suppl 7): S103
Foniok T, (suppl 7): S25
Fontaine B, 119
Fontana EJ, 851
Ford B, 507, 693
Ford KL, 126
Fordyce S, (suppl 7): S136; S137
Fox CK, (suppl 7): S26; S65
Fox NC, (suppl 7): S51
Fraix V, 176
Frants RR, 360
Franz D, (suppl 7): S58; S108; S118
Fratta P, 848, (suppl 7): S43
Frauendienst-Egger G, 686
Fredrickson E, (suppl 7): S44
Fredrickson ER, (suppl 7): S63; S64
Freedman M, (suppl 5): S7
Freeman D, (suppl 7): S145
Freeman TB, 403
Freilich E, (suppl 7): S131
Freimer ML, (suppl 7): S19
French Parkinson's Disease Genetics Study Group, 176
Fridlyand J, (suppl 7): S109
Friedgen M, (suppl 7): S47
Friedlander RM, 843
Friedman JA, (suppl 7): S66
Friedman MN, 625
Friefeld S, (suppl 7): S138
Frisoni GB, 833
Frisullo G, (suppl 7): S47
Frucht S, 507, 693
Frye RE, (suppl 7): S156
Fryer JD, 379
Fryer TD, 343
Fu DD, (suppl 7): S132
Fujioka M, 732
Fujioka T, (suppl 7): S52
Fujiwara M, 732
Fukaura H, (suppl 7): S61
Fukazawa T, (suppl 7): S61; S62
Fukuda T, 277
Fukui T, (suppl 5): S32
Fukushima R, (suppl 7): S67
Fulbright RK, (suppl 6): S25
Fulci G, 851
Fullerton HJ, (suppl 7): S23; S139
Fullwood E, (suppl 7): S130
Fumic K, (suppl 7): S151
Furiya Y, (suppl 7): S46; S56; S58
Furuya H, (suppl 7): S74
Gabel A, (suppl 7): S20
Gabis L, (suppl 7): S146
Gadia CA, (suppl 7): S150
Gaillard WD, (suppl 7): S56; S105; S114
Galaburda AM, 279
Galiffa S, (suppl 7): S124
Gallardo E, (suppl 7): S74
Gallardo M, 271
Galván J, (suppl 7): S33
Galvin JE, (suppl 7): S30

- Gamgebeli Z, (suppl 7): S141
 Gandossini S, (suppl 7): S75
 Gandy S, 848
 Ganesan V, (suppl 7): S110; S140
 Ganguly M, (suppl 7): S51
 Gao-Hickman X, (suppl 7): S56
 Garcia-Arumi E, 527
 Garcia G, 163
 Garcia N, (suppl 7): S65
 Garcia PA, (suppl 7): S53
 Garg BP, (suppl 7): S138
 Garlip G, 479, (suppl 7): S30
 Garnier P, 850
 Garrard J, 75
 Garrison B, (suppl 7): S151
 Garside S, (suppl 7): S42
 Gärtner J, (suppl 7): S152
 Garvey MA, (suppl 7): S129
 Garvin J, (suppl 7): S109
 Gash DM, 849
 Gasparini F, 176
 Gasser T, 176
 Gastard MC, 393
 Gawel M, (suppl 7): S32
 Gaynor JW, (suppl 7): S110
 Genain CP, (suppl 7): S37; S38; S47; S60
 Genin E, 119
 Gennarelli M, 833
 Gennaro P, (suppl 7): S150
 George EM, (suppl 7): S51
 Gerhardt GA, 849
 Germano IM, (suppl 7): S71
 Gerry G, (suppl 7): S119
 Gertz K, 582
 Geschwind DH, 669, (suppl 5): S29
 Ghadge G, (suppl 7): S76
 Ghali WA, 696, (suppl 7): S18
 Ghazi-Noori S, 186
 Ghez C, 102
 Ghidoni R, 833
 Ghilardi MF, 102
 Giallonardo AT, 137
 Gianazza E, (suppl 7): S52
 Gianni D, 851
 Gibson KM, 686, (suppl 6): S25; S73; S81, (suppl 7): S106; S107
 Gibson R, (suppl 7): S125
 Giedd JN, (suppl 7): S27
 Giffard RG, 851, (suppl 7): S24
 Gilbert AL, (suppl 7): S20
 Gilbert D, (suppl 7): S58; S108
 Gilbert DL, (suppl 7): S118; S143
 Gilden DH, 459
 Gill MJ, 605
 Ginebra T, (suppl 7): S74
 Ginsberg MD, 330
 Giraldo EA, (suppl 7): S25
 Glantz MJ, (suppl 7): S31
 Glass JD, 849
 Glauser T, (suppl 7): S58; S108; S136; S137
 Glauser TA, (suppl 7): S113; S118; S136
 Glick HA, 699
 Glidden D, (suppl 7): S111; S121
 Goate AM, 163
 Gobuty S, (suppl 7): S108
 Godbold J, 403
 Goedert M, 573
 Goemans NMLA, 719
 Goerres H, (suppl 7): S155
 Goetz CG, 403, (suppl 7): S40; S41; S50; S69; S72
 Golan N, (suppl 7): S144
 Goldin E, 769, (suppl 7): S24
 Goldman J, (suppl 7): S157
 Goldman JG, (suppl 7): S72
 Gold R, (suppl 7): S36
 Goldstein J, (suppl 7): S44; S73; S130
 Goldstein LB, 695, 697, 699, (suppl 7): S17
 Goldstein R, (suppl 7): S121
 Goldzweig G, (suppl 7): S144
 Gollomp SM, (suppl 7): S41
 Golumbek PT, (suppl 7): S117
 Gomez CM, 725
 Gomi H, (suppl 7): S54
 Gondim FAA, 555, (suppl 7): S22; S55
 Gonzalo ITG, 669
 Goodchild RE, 849
 Goodin D, (suppl 7): S34; S35
 Goodkin R, (suppl 7): S69
 Gorbach AM, 297
 Gorman MJ, 699
 Gorni K, 850
 Gossman A, 479
 Goto Y, 553
 Gourley LM, 488
 Gowda N, 700
 Gracies JM, (suppl 7): S71
 Graff-Raford N, (suppl 5): S29
 Graf M, (suppl 7): S39; S70
 Graf WD, (suppl 7): S119
 Graner CA, (suppl 7): S148
 Grant PE, (suppl 7): S127
 Grattan-Smith P, 719
 Graus F, 530
 Gray JW, (suppl 7): S109
 Greenberg B, (suppl 7): S150
 Greenberg RN, (suppl 7): S48; S49
 Greene JD, (suppl 7): S126
 Green N, (suppl 7): S113
 Greenstone MA, 682
 Grega MA, (suppl 7): S67
 Grether JK, (suppl 7): S126
 Grierson AJ, 748
 Griffin JW, 287, (suppl 7): S19
 Grimard L, (suppl 7): S141
 Grob C, (suppl 7): S48
 Grohmann K, 719
 Grompe M, (suppl 6): S81
 Gropman A, (suppl 6): S66
 Gropman AL, (suppl 7): S116
 Gross CR, 75
 Gross DS, (suppl 7): S39
 Gross M, (suppl 7): S128; S153
 Grossman JAI, (suppl 7): S156
 Grossman M, (suppl 5): S11
 Gross-Tsur V, (suppl 7): S144; S145
 Grover WD, (suppl 7): S150
 Grundman M, (suppl 5): S32
 Guarner J, 547
 Gucuyener K, (suppl 7): S113
 Guenther UP, 719
 Guerrini R, 30
 Guest S, (suppl 7): S76
 Guffon N, (suppl 7): S151
 Gulick C, 271
 Gunasekara RS, (suppl 6): S46
 Gundogdu B, (suppl 7): S45
 Gupta M, (suppl 6): S81
 Gupta N, (suppl 7): S139
 Gurnett CA, (suppl 7): S155
 Gutierrez J, (suppl 7): S31
 Gutmann DH, 251
 Gwinn-Hardy K, 271, 848
 Haacke EM, (suppl 7): S111; S153
 Haan J, 360
 Haas JT, (suppl 7): S66
 Habedank B, (suppl 7): S78
 Hacin-Bey L, 697
 Hachiya NS, 553
 Hackett CS, (suppl 7): S109
 Hackman P, 248
 Haddadin MH, (suppl 7): S119
 Haenggeli C, (suppl 7): S20
 Hagenah J, 415
 Hague S, 271, 848
 Hahn MG, 699
 Haier R, (suppl 7): S50; S107
 Haines JL, 849, (suppl 7): S35; S50
 Hajioff D, (suppl 7): S26
 Halgren E, (suppl 7): S54
 Halks-Miller M, 638
 Hall C, (suppl 7): S49
 Haller RG, 539
 Hallett M, 464
 Halliday W, 244
 Hamamcioglu K, (suppl 7): S63
 Hamilton JM, (suppl 7): S42
 Hamiwka L, (suppl 7): S133
 Hammack BN, 459
 Hampel H, 263
 Hamrick SEG, 123, (suppl 7): S121; S138
 Han X, 115
 Handisurya A, (suppl 7): S29
 Handschug K, (suppl 7): S154
 Hand T, 155
 Hansen LA, (suppl 7): S29
 Hansen MD, 439, (suppl 7): S66
 Hansen VK, 130
 Hanson M, 271, 848
 Han X, 693
 Haque R, 851
 Hara H, (suppl 7): S45; S73
 Harati J, 700
 Hardie N, 75
 Hardison HH, (suppl 7): S151
 Hardy J, 143, 271, 848
 Harms S, 75
 Haroutunian V, 638
 Harris J, 415, 507, 693
 Hart CC, (suppl 7): S33
 Hartmann C, 256
 Hasegawa Y, (suppl 7): S54
 Haselgrove JC, (suppl 7): S153
 Hashikawa T, (suppl 7): S54
 Hashimoto T, (suppl 7): S127
 Hashizume Y, (suppl 7): S52
 Haslinger B, 445
 Hattori N, 19
 Hauer P, (suppl 7): S74
 Haupt WF, (suppl 7): S78
 Hauser RA, 93
 Hauser SL, 849, (suppl 7): S34; S35; S37; S38; S60
 Hauser TK, (suppl 7): S39

- Häussler M, (suppl 6): S56
 Haward MF, 123, (suppl 7): S138
 Hawkins C, (suppl 7): S131; S141
 Hayashi T, (suppl 7): S74
 Hayden DL, 130
 Head E, (suppl 7): S50; S68; S107
 Healy DG, 283
 Heath C, (suppl 7): S151
 Hebert MD, (suppl 7): S51
 Hedderick E, (suppl 7): S115
 Hedreen JC, (suppl 7): S116
 Hedrich K, 415
 Heeren MM, (suppl 7): S142
 Heimans JJ, 514
 Heine W, (suppl 7): S19
 Heiss J, 297, 769
 Heiss WD, 479, (suppl 7): S30; S78
 Helmstaedter C, 425
 Helton KJ, 564
 Hemling N, 267
 Hemmati HD, (suppl 7): S117
 Henderson D, 760
 Henkel JS, (suppl 7): S43
 Henricson E, 850
 Henriksson KG, 494
 Henry RG, (suppl 7): S35; S52
 Hentz JG, (suppl 7): S28
 Herberger S, 678
 Herholz K, (suppl 7): S30
 Hernandez D, 271
 Hernandez JL, (suppl 7): S28; S46
 Hernandez-Peña J, 527
 Hernán MA, 170
 Herrera C, (suppl 7): S150
 Herrmann N, (suppl 7): S29; S67
 Hersch S, 843
 Hershey A, (suppl 7): S108; S118
 Herz J, (suppl 7): S104
 Herzog AG, 625
 Hess EJ, (suppl 7): S116
 Hetts S, (suppl 7): S108
 Heutink P, 271, 573, 682
 Hewett JW, (suppl 7): S116
 Higashi K, (suppl 7): S72
 Higuchi S, 276
 Hildebrand D, (suppl 7): S137
 Hill A, (suppl 7): S126
 Hill B, 647
 Hill MD, 695, (suppl 7): S17
 Hillis A, (suppl 5): S1; S3; S11
 Hillis AE, 846, 851
 Hiner BC, (suppl 7): S50
 Hino H, (suppl 7): S73
 Hinson VK, (suppl 7): S72
 Hintzen RQ, 829
 Hirano M, 524, (suppl 7): S46; S56; S58
 Hirata K, 383
 Hirayama M, 19
 Hirose G, (suppl 7): S72
 Hishikawa N, (suppl 7): S52
 Hmairness G, (suppl 7): S159
 Hobdell EF, (suppl 7): S150
 Hobson G, (suppl 7): S57
 Hochberg F, (suppl 7): S31
 Hockly E, 186, 844
 Hodges JR, 343
 Hodgson G, (suppl 7): S109
 Hoefnagels WAJ, 360
 Hoffbuhr KC, 206
 Hoff-Lindquist J, 695, (suppl 7): S17
 Hoffman EP, 206, (suppl 7): S118
 Hoffmann D, 615
 Hoffmann GF, (suppl 6): S18; S56
 Hofman A, 275
 Hof PR, (suppl 7): S50
 Hogancamp WE, (suppl 7): S75
 Hogan E, (suppl 7): S55
 Hogema BM, (suppl 6): S81
 Hohimer AR, (suppl 7): S103
 Hoke A, 287, (suppl 7): S19; S77
 Holden JK, 605
 Holden KR, (suppl 7): S154
 Holder D, (suppl 7): S136; S137; S139
 Holland SK, (suppl 7): S109
 Holmes GL, (suppl 7): S132; S134
 Holshouser BA, (suppl 7): S111
 Holshouser BH, (suppl 7): S128; S153
 Holton JL, (suppl 7): S51
 Holtzman DM, 115, 379, 693, 848
 Ho M, (suppl 7): S141
 Hong YH, (suppl 7): S53
 Honma Y, (suppl 7): S79
 Hoo KS, (suppl 7): S53
 Hopkin R, (suppl 7): S58
 Hopkin RJ, (suppl 7): S108; S118
 Hop W, 829
 Hori A, (suppl 7): S72
 Horner RD, 695, (suppl 7): S17
 Horstink MWIM, 176
 Horuk R, 638
 Hosain SA, (suppl 7): S113
 Hoshii Y, (suppl 7): S54
 Hosozawa K, (suppl 7): S64
 Hospod FE, (suppl 7): S24
 Hottenga JJ, 360
 Houle S, 244, (suppl 7): S29; S67
 Houwing-Duistermaat JJ, 275
 Howard HC, 9
 Howard JR, (suppl 7): S44; S73
 Howell B, (suppl 7): S116
 Howell N, 521
 Hoyte L, (suppl 7): S65
 Hsieh MY, (suppl 7): S28
 Hsin I, 379
 Hsu CY, 379
 Hsu E, (suppl 7): S141
 Huang AM, 706
 Huang CC, 706
 Huang MY, (suppl 7): S72
 Huang W, (suppl 7): S118; S146
 Huang WC, 851
 Huang Z, (suppl 7): S57
 Hubble JP, (suppl 7): S50
 Hübner C, 719
 Huebner A, (suppl 7): S154
 Huff T, (suppl 7): S143
 Hughes E, 30
 Hughes L, (suppl 7): S62; S63
 Huh K, 227, (suppl 7): S65
 Hukkanen V, 267
 Hulihan M, 848
 Hulvershorn LA, (suppl 7): S70
 Hunter SF, (suppl 7): S70
 Hunt RW, (suppl 7): S126
 Huppi PS, (suppl 7): S122; S123; S125
 Huq AM, (suppl 7): S119
 Hurd M, (suppl 7): S63
 Hurn PD, 155, (suppl 7): S26; S66
 Hurtig H, 699
 Husaini BA, 697
 Hussein MA, (suppl 7): S147
 Hussey D, (suppl 7): S29; S67
 Hutchinson M, (suppl 7): S36
 Hutton M, (suppl 5): S29, (suppl 7): S58
 Hu Y, (suppl 7): S132
 Huynh TN, 647
 Hyland K, (suppl 6): S13; S46; S49
 Iadecola C, 141
 Iasemidis LD, (suppl 7): S55
 Ichord R, (suppl 7): S110
 Iguchi H, (suppl 7): S52
 Iijima M, 19
 Ikeda H, (suppl 7): S64
 Ikeda K, (suppl 7): S53; S64
 Ikezoe K, (suppl 7): S74
 Illa I, (suppl 7): S74
 Inder TE, (suppl 7): S121; S124; S126
 INDEX Study Group, (suppl 7): S32
 Innocenti GM, 51
 Inoue M, (suppl 7): S45; S73
 INT 26 Study Group, (suppl 7): S112
 Inwards DJ, (suppl 7): S44
 Inzelberg R, 796, (suppl 7): S57
 Irizarry MC, 7
 Isenmann S, 388
 Ishak KJ, 698
 Ishigaki A, (suppl 7): S53
 Ishihara T, (suppl 7): S54
 Islar J, (suppl 7): S47
 Ito H, 19
 Itohara S, (suppl 7): S54
 Itoh M, 259
 Ito M, (suppl 7): S107
 Itoyama Y, 276, (suppl 7): S53; S67; S69
 Itti E, 669
 Itti L, 669
 Iwanaga K, 277
 Iwasaki Y, (suppl 7): S52; S53; S64
 Jaafar M, (suppl 7): S152
 Jackson M, (suppl 7): S40
 Jacobs AH, 479, (suppl 7): S30
 Jacobs AR, 625
 Jacobs B, 126
 Jacobs BC, 829
 Jacobs BL, 700
 Jacobs BS, 699
 Jacobs D, (suppl 7): S112
 Jacobs H, 415
 Jacobson MW, (suppl 7): S42
 Jacobson P, (suppl 7): S125
 Jaggi J, 699
 Jahng GH, (suppl 7): S153
 Jain A, (suppl 7): S109
 Jakobs C, (suppl 6): S73; S81, (suppl 7): S107
 Jakubiczka S, (suppl 7): S154
 Janelidze M, (suppl 7): S141
 Janetzki C, 719
 Janko KA, (suppl 7): S72

- Jankovic J, (suppl 7): S50
 Jansen LA, 251
 Jarecki J, 647
 Jarosz J, (suppl 7): S39
 Jarosz JM, 30
 Jarrachian S, (suppl 7): S43
 Jarrar MH, (suppl 7): S108
 Jeerakathil T, 695, (suppl 7): S17
 Jeffries N, (suppl 7): S24
 Jenkins R, (suppl 7): S109
 Jenner P, (suppl 7): S40
 Jennings MH, (suppl 7): S59
 Jensen FE, (suppl 7): S103
 Jensen MA, (suppl 7): S38
 Jeong SW, (suppl 7): S54
 Jeppesen TD, 86
 Jeschke R, 686
 Jeuken J, 256
 Jiang Y, 239
 Jiang Z, (suppl 7): S42
 Jia Y, (suppl 7): S25
 Jimenez MR, (suppl 7): S25
 Jimi T, (suppl 7): S45; S73
 Jin K, (suppl 7): S67; S69
 Jin LW, 848
 Ji S, (suppl 7): S65
 Johns DR, 422
 Johnsen SD, (suppl 7): S123
 Johnson J, 271, 848
 Johnson LL, (suppl 7): S126
 Johnson MI, (suppl 7): S128
 Johnson MW, (suppl 7): S121
 Johnson P, (suppl 7): S114
 Johnson RT, 1, 694
 Johnson SA, (suppl 7): S70
 Johnston D, (suppl 7): S141
 Johnston MV, 694, (suppl 6): S1, (suppl 7): S104; S118
 Johnston SC, 439, 697, (suppl 7): S66
 Jones HR, 136, 790
 Jones HR Jr., (suppl 7): S155
 Jones R, (suppl 7): S55
 Jones VA, (suppl 7): S131
 Jones W, (suppl 7): S77
 Joo IS, 227, (suppl 7): S65
 Joo SY, 227
 Jordan LC, 279
 Josephs KA, (suppl 7): S51
 Joshi A, (suppl 7): S157
 Juhasz C, (suppl 7): S129
 Junge B, (suppl 7): S25
 Jung KH, (suppl 7): S54
 Jy W, (suppl 7): S60
 Kachergus J, 848
 Kadhim H, (suppl 7): S159
 Kadam N, 464
 Kahana M, 796, (suppl 7): S57
 Kahane P, 615
 Kaindl AM, (suppl 7): S154
 Kaito M, (suppl 7): S72
 Kakulas B, 534
 Kalita J, (suppl 7): S64
 Kamakura K, 276
 Kamen BA, (suppl 7): S117
 Kamii R, (suppl 7): S53
 Kammerer WA, 297
 Kamphorst W, 573
 Kaneko K, 553
 Kaneski CR, 769
 Kang DW, 66
 Kang L, (suppl 7): S53
 Kang PB, 790, (suppl 7): S155
 Kang UJ, (suppl 6): S103
 Kann M, 415
 Kanno H, 352
 Kaplan AM, (suppl 7): S149
 Kapur S, (suppl 7): S29; S67
 Karacay B, (suppl 7): S132
 Kariya S, (suppl 7): S46; S56; S58
 Karni A, (suppl 7): S145
 Karpati G, 9
 Kashihara H, (suppl 7): S64
 Kasper BS, 501
 Kasteleijn-Nolst Trenité DGA, 514
 Kastenbauer S, 451
 Kasten M, 415
 Kataoka S, (suppl 7): S72
 Katayama T, (suppl 7): S52
 Katchanov J, 582
 Kates WR, (suppl 7): S144
 Katsetos CD, (suppl 7): S103; S117; S132; S158
 Kau ASM, (suppl 7): S105
 Kaufer DI, (suppl 7): S52
 Kaufman M, (suppl 7): S54
 Kaufmann WE, (suppl 7): S105; S108
 Kawabe S, (suppl 7): S52
 Kawaguchi N, (suppl 7): S127
 Kawai T, 244
 Kaye J, (suppl 7): S22
 Kean M, (suppl 7): S126
 Keating GF, (suppl 7): S157
 Keegan M, (suppl 7): S70
 Keeling R, (suppl 7): S117
 Keeling RM, (suppl 7): S155
 Keene D, (suppl 7): S141
 Kelley RE, (suppl 7): S59
 Kelly DR, (suppl 7): S140
 Kelly JJ, (suppl 7): S103
 Kelly K, (suppl 7): S56
 Kelsey D, (suppl 7): S106; S143
 Kennedy C, (suppl 7): S114
 Kennedy J, 696, (suppl 7): S18
 Kennedy WR, 197
 Kent DM, 696, 698, (suppl 7): S18
 Kern RZ, 696, (suppl 7): S18; S76
 Kerrigan JF, (suppl 7): S130
 Kershaw P, (suppl 7): S69
 Kertesz A, (suppl 5): S1; S3; S7; S11
 Kessler J, (suppl 7): S78; S147; S157
 Keswani SC, 287, (suppl 7): S77
 Kevanishvili Z, (suppl 7): S141
 Khan J, 849
 Khan LR, (suppl 7): S29; S67
 Khan O, (suppl 7): S35
 Khateb A, 556
 Kho A, (suppl 7): S57
 Kho N, (suppl 7): S130
 Khoutorova L, 330
 Khurana DS, (suppl 7): S132; S150; S151
 Khurana P, (suppl 7): S103
 Kido D, (suppl 7): S111; S125; S153
 Kieburz K, (suppl 7): S50
 Kieran MW, (suppl 7): S142
 Kikuchi S, (suppl 7): S51; S61; S62
 Kilford L, 235
 Kim HJ, (suppl 7): S53
 Kim JI, (suppl 7): S79
 Kim JM, (suppl 7): S53
 Kim M, (suppl 7): S53; S54
 Kim NH, (suppl 7): S53
 Kim R, (suppl 7): S68
 Kim RC, (suppl 7): S50
 Kimura H, 553
 King WM, (suppl 7): S19
 Kinoshita T, 553
 Kira J, (suppl 7): S61; S62; S74
 Kirby DM, 473
 Kirby LC, (suppl 7): S46
 Kirkham FJ, (suppl 7): S110; S137; S138; S140
 Kirkpatrick M, (suppl 7): S125
 Kirnbauer R, (suppl 7): S29
 Kirsch JR, (suppl 7): S26; S66
 Kirton A, (suppl 7): S133
 Kis B, (suppl 7): S62
 Kitamoto T, (suppl 7): S69
 Klein C, 415
 Kleiner-Fisman G, 244, (suppl 7): S70
 Klein M, 451, 514
 Klein P, 625
 Kline JK, 433
 Klunk W, (suppl 7): S67
 Knoblach SM, (suppl 7): S77
 Knopman D, (suppl 5): S29
 Koedel U, 451
 Koehler RC, (suppl 7): S26; S66
 Koeppen AH, 367
 Kohane I, (suppl 7): S57
 Koh SB, (suppl 7): S34
 Koike H, 19
 Kojima H, (suppl 7): S45
 Koliatsos VE, 393
 Koller WC, (suppl 7): S50; S71
 Kölmel C, 110
 Kolodgie MJ, (suppl 7): S114
 Kompoliti KA, (suppl 7): S41
 Konapacki RA, (suppl 7): S36
 Kondo Y, 732
 Konrad PE, 700
 Kon S, (suppl 7): S61
 Koo EH, 781
 Korade Mirnics Z, (suppl 7): S119
 Korall H, 686
 Kordower JH, 403
 Kornblum HI, (suppl 7): S117
 Kornek B, 821
 Kornhuber J, 263
 Kors EE, 360
 Kosch A, (suppl 7): S110
 Kosik KS, 163
 Kossoff E, (suppl 7): S134
 Kossoff EH, 279
 Kothare SV, (suppl 7): S132; S151; S158
 Kowalski RG, 698, (suppl 7): S26
 Kracht L, 479, (suppl 7): S30
 Kraft E, (suppl 7): S39
 Kramer PL, 415
 Krasnik C, (suppl 7): S42
 Krause M, 445
 Krauss GL, 280
 Kreiter KT, 698, (suppl 7): S26
 Kretz A, 388
 Kretzschmar HA, 263
 Krishnamoorthy KS, (suppl 7): S127
 Kroenke K, (suppl 7): S77
 Kroos MA, (suppl 7): S76
 Kros JM, 573
 Krusz JC, (suppl 7): S34
 Krym M, 760

- Kryzer TJ, 38
Kuban KCK, (suppl 7): S147
Kubota T, 259, (suppl 7): S41
Kuehler A, 445
Kufta C, 297
Kuo MF, (suppl 7): S28
Kuo YM, 706
Kurjakovic Z, (suppl 7): S62
Kurlan R, (suppl 7): S106
Kurlemann G, (suppl 7): S113
Kuroda MM, (suppl 7): S142
Kuroiwa Y, 352
Kurthen M, 425
Kuschinsky W, 582
Kuwabara H, (suppl 7): S118
Kuwayama A, (suppl 7): S64
Kwon JW, (suppl 7): S79
Kwon OY, (suppl 7): S56
- Labar D, (suppl 7): S113
Lachhwani DK, (suppl 7): S134
Lacomblez L, (suppl 7): S39; S70
LaFemina MJ, (suppl 7): S23
Lage MJ, (suppl 7): S33
Lagenaur CF, (suppl 7): S116
Lai F, 433
Lai MC, 123, (suppl 7): S138
Láinez MJA, (suppl 7): S33
Lam BL, 38
Lamhonwah AM, (suppl 7): S151
Lancon JA, (suppl 7): S155
Lancrôt KL, (suppl 7): S29; S67
Landesman B, (suppl 7): S126
Land S, (suppl 7): S38
Landwehrmeyer B, (suppl 7): S39; S70
Lang AE, 93, 244, 271, 415, (suppl 5): S15, (suppl 7): S70
Lang B, 277, (suppl 7): S20
Lange KW, 445
Lange M, (suppl 7): S71
Langford LR, 725, (suppl 7): S40
Langston JW, 564
Lanham DC, (suppl 7): S144
Larsen MB, (suppl 7): S157
Larson S, (suppl 7): S45
Lassmann H, (suppl 7): S37
- Lass U, 256
Latal B, (suppl 7): S111
Latimer E, (suppl 7): S127
Latour LL, 66
Laufs U, 582
Laursen H, (suppl 7): S51
Lavenstein BL, (suppl 7): S127
Law ME, (suppl 7): S109
Law R, (suppl 7): S30
Lawson MA, (suppl 7): S149
Laxer KD, (suppl 7): S53
Laxer RM, (suppl 7): S140
Lazareff JA, (suppl 7): S117
Lea PM IV, (suppl 7): S77
Lee CM, (suppl 7): S79
Lee CS, (suppl 7): S19
Lee DH, (suppl 7): S34
Lee GH, (suppl 7): S79
Lee HSL, (suppl 7): S23
Lee J, (suppl 7): S32; S143
Lee JM, 379, (suppl 7): S34
Lee JS, 227
Lee JW, (suppl 7): S31
Lee K, (suppl 7): S103
Lee KW, (suppl 7): S53
Lee LA, (suppl 7): S73
Lee M, 695, (suppl 7): S17
Lee PH, 227, (suppl 7): S65
Lees AJ, 235, 283, (suppl 7): S70
Lee SJ, (suppl 7): S40
Lee VMY, 682
Lee YJM, (suppl 7): S108
Legido A, (suppl 7): S103; S117; S132; S150; S151; S158
Leigh NP, (suppl 7): S39
Leigh PN, 130, (suppl 7): S39; S70
Leigh RJ, 825
Leira EC, 439, (suppl 7): S66
Leira R, 812, (suppl 7): S33
Lennon VA, 38, (suppl 7): S19; S70
Leopold D, 206
Leppik IE, 75
Leshner B, 850
Leslie MJ, 547
Leung JC, (suppl 7): S116
Leurgans S, (suppl 7): S41; S69
Leurgans SE, (suppl 7): S72
Leverenz JB, (suppl 7): S68
Levey AI, 144
Levine SR, 698
Levisohn PM, (suppl 7): S135
Lev M, (suppl 7): S31
Levy G, 507, 693
Lewis D, (suppl 7): S106
Lewis DA, (suppl 7): S119
- Lewis DW, (suppl 7): S131
Lewis KM, (suppl 7): S51
Ley JJ, 330
Liang Y, (suppl 7): S105; S120
Liao KK, (suppl 7): S40
Li B, (suppl 7): S51
Liblau R, 119
Licht D, (suppl 7): S110; S153
Lidov HGW, 790, (suppl 7): S155
Li H, (suppl 7): S24
Li HF, (suppl 7): S30
Likhodii SS, 219
Li L, (suppl 7): S49
Li M, 698
Lim BH, (suppl 7): S56
Lim LL, (suppl 7): S41
Limperopoulos C, (suppl 7): S111; S121; S122; S123; S124
Linares M, (suppl 7): S150
Lincoln R, (suppl 7): S35
Lincoln S, 848
Lindauer U, 582
Lindberg C, 494
Lindblad AS, (suppl 7): S28
Linder S, (suppl 7): S106
Lindvall B, 494
Lin FY, (suppl 7): S126
Lin X, (suppl 7): S78
Lipinski WJ, 848
Li S, 825
Lisak RP, (suppl 7): S38
Litvan I, (suppl 5): S15
Litzow MR, (suppl 7): S44
Liu CJ, (suppl 7): S153
Liu J, 850
Liu RS, (suppl 7): S40
Liu S, (suppl 7): S72
Liu X, 239
Li W, 251
Li Z, (suppl 7): S68
Lizasoain I, 812
Lochmüller H, 719
Loddenkemper T, (suppl 7): S134
Lodi R, 552
Logigian EL, (suppl 7): S76
Lohmann E, 176
Lomen-Hoerth C, (suppl 5): S20, (suppl 7): S52
Lopera F, 163
Lopez FA, (suppl 7): S143
Lopez OL, (suppl 7): S67
Lopez-Perez MJ, 527
Lori NF, (suppl 7): S76
Lott IT, (suppl 7): S50; S107
Lotze TE, (suppl 7): S123; S154
Louis ED, 507, 693
Love S, 534
Lowden P, 844
Lowden PAS, 186
Lo WHY, 239
- Lowry A, (suppl 7): S117
Lozano A, (suppl 7): S70
Lu A, (suppl 7): S58; S108; S118
Lucchinetti CF, (suppl 7): S37; S70
Luciano CA, (suppl 7): S74
Lu DC, 781
Lu J, 239
Ludolph AC, (suppl 7): S39; S70
Luecke T, (suppl 7): S154
Luo NL, (suppl 7): S103
Lupski JR, 398
Lupton BA, (suppl 7): S126
Luque J, (suppl 7): S116
Lux S, 425
Lyon P, (suppl 7): S47
Lyons K, (suppl 7): S50
- MacCollin M, (suppl 7): S31
MacDonald TJ, (suppl 7): S152
MacGregor D, (suppl 7): S138
Machado-Salas J, (suppl 7): S54
Machin GA, (suppl 7): S126
Maciel P, 119
MacKay N, (suppl 7): S158
Mackenzie IRA, (suppl 5): S24
Mack KJ, (suppl 7): S130
Mador N, (suppl 7): S48
Mahal A, 186
Mahamid A, 796
Mahmoudi M, 638
Mahone EM, (suppl 7): S145
Mahoney J, (suppl 7): S132
Maini A, (suppl 7): S118
Majamaa K, 665
Majnemer A, (suppl 7): S105; S111; S145; S146
Majoer-Krakauer D, 573
Majors HE, (suppl 7): S53
Mak E, (suppl 7): S19
Makori B, (suppl 7): S117
Maldonado JR, (suppl 7): S27
Malecki E, (suppl 7): S73
Maler M, 263
Maletic-Savatic M, (suppl 7): S118
Malholtra A, (suppl 7): S131
Malin BT, (suppl 7): S126
Mancinelli E, (suppl 7): S75
Mancuso G, (suppl 7): S47
Mancuso M, 524
Mandelbaum DE, (suppl 7): S114; S131
Manger PR, 51

- Mangiola F, (suppl 7): S74
Mankodi A, 760
Mannix MK, (suppl 7): S128
Manor O, (suppl 7): S145
Mao J, (suppl 7): S109
Maradin M, (suppl 7): S151
Maragakis NJ, (suppl 7): S20
Maragnore D, 848
Maraziotis T, (suppl 7): S117
Marchand S, 248
Marcus K, (suppl 7): S140
Marder K, 415, 507, 693, (suppl 7): S50
Margolis RL, 488
Maris MA, (suppl 7): S118
Markowitz JA, 647
Marra C, (suppl 7): S74
Marsden D, (suppl 7): S156
Martens WB, (suppl 7): S76
Martin D, 534
Martin ER, 416, (suppl 7): S50
Martínez M, 163
Martinez S, (suppl 7): S47
Martin R, (suppl 7): S45
Martins RN, 848
Martins Silva B, 119
Martinuzzi A, (suppl 7): S57
Maryama M, (suppl 7): S52
Masaki T, 276
Masliah E, 781, (suppl 7): S29
Mason G, (suppl 7): S106
Mass M, (suppl 7): S35
Mastaglia F, (suppl 7): S50
Masterman D, (suppl 7): S50
Masterman-Smith M, (suppl 7): S117
Matchar DB, 695, (suppl 7): S17
Mateos V, (suppl 7): S33
Mathern GW, (suppl 7): S54
Mathew NT, (suppl 7): S33
Mathews P, 848
Mathias N, (suppl 7): S39
Mathieu J, 9
Mathur A, (suppl 7): S122
Matsuda F, 119
Matsuda J, (suppl 7): S107
Matsuda T, (suppl 7): S79
Matsuo Y, 732
Matsushita S, 276
Matsuzaki Y, (suppl 7): S73; S107
Mattaliano RJ, (suppl 7): S20
Maurage CA, 542
Maybach AL, 459
Mayer SA, 698, (suppl 7): S26
Mayeux R, 433
Mayr WT, (suppl 7): S37
Maytal J, (suppl 7): S114
Mazarib A, 796, (suppl 7): S57
Mazumdar M, (suppl 7): S157
McArthur JC, 287, (suppl 7): S50; S74
McBee WL, (suppl 7): S28
McC Campbell A, (suppl 7): S57
McCarter R, 850
McCarthy CM, (suppl 7): S149
McCarthy M, (suppl 7): S47
McClelland RL, (suppl 7): S37; S66
McCracken BS, (suppl 7): S19
McDaniel DO, (suppl 7): S40
McDermott CJ, 748
McDermott K, (suppl 7): S26
McDermott MP, (suppl 7): S50
McDonnell MT, 521
McGeer PL, 599
McGovern RA, (suppl 7): S129
McGrath TM, (suppl 7): S140
McGuigan C, (suppl 7): S36
McKeel DW, (suppl 7): S30
McKelvey R, (suppl 7): S68
McKenna CE, (suppl 6): S49
McKenzie J, (suppl 7): S19
McKercher SR, (suppl 7): S43
McKhann GM, (suppl 7): S67
McKinstry RC, (suppl 7): S122
McLellan A, (suppl 7): S125
McNeil RS, (suppl 7): S104
Meaney B, (suppl 7): S138
Meco G, 176
Medeiros H, 244
Mehta A, (suppl 7): S26
Mei D, 30
Mejia-Santana H, 507, 693
Melikishvili G, (suppl 7): S141
Melvin JJ, (suppl 7): S150; S151; S158
Mendell JR, (suppl 7): S19
Mendez M, (suppl 5): S7
Menge T, (suppl 7): S37; S38; S47; S60
Menk S, (suppl 7): S37
Mennerick S, 251
Mennuni G, (suppl 7): S47
Meola G, (suppl 7): S75
Messenheimer JA, (suppl 7): S113
Messing A, (suppl 7): S157
Mesulam MM, (suppl 5): S11
Metselaar JM, (suppl 7): S36
Meuli R, 321
Meyhew J, 850
Micaleff IN, (suppl 7): S44
Michelson DJ, (suppl 7): S125; S143
Middleton LT, (suppl 7): S50
Mikol DD, (suppl 7): S61
Miller BL, (suppl 5): S7; S32
Miller DH, 848, (suppl 7): S38
Miller G, 398
Miller-Horn JW, (suppl 7): S150
Miller MM, (suppl 7): S152
Miller SP, 123, (suppl 7): S111; S121; S138
Milone M, (suppl 7): S155
Milton D, (suppl 7): S106
Minagar A, (suppl 7): S59; S60
Minera M, (suppl 7): S117
Mines JA, 38
Minich LA, (suppl 7): S137
Mink JW, (suppl 7): S130
Minnis R, (suppl 7): S125
Minohara M, (suppl 7): S61
Minotti L, 615
Mintz J, (suppl 7): S29
Mintz M, (suppl 7): S106; S148
Mirabella M, (suppl 7): S47
Mirnics K, (suppl 7): S119
Mirmics ZK, (suppl 7): S105
Mishima K, 732
Mishkin FS, 669
Mishra OP, (suppl 7): S103
Misra A, (suppl 7): S109
Misra UK, (suppl 7): S64
Miszkiel KA, (suppl 7): S38
Mitake S, (suppl 7): S52
Mito T, 155
Mittelstaedt B, (suppl 7): S117
Mitzscherling P, (suppl 7): S154
Mixon TH, 769
Miyamoto M, (suppl 7): S46
Miyasaki A, 732
Mi ZP, (suppl 7): S116
Mizuguchi M, (suppl 7): S127
Mizusawa H, 553
Mochida GH, (suppl 7): S119
Mochizuki H, 276
Modoni A, (suppl 7): S74
Modrego PJ, (suppl 7): S30
Moenning U, 638
Mohamed IS, (suppl 7): S139
Mohandoss E, (suppl 7): S112; S136
Molitero AR, (suppl 7): S73
Mollenhauer B, 263
Momiigliano-Richiardi P, 119
Momoi M, (suppl 7): S127
Monti AL, (suppl 7): S76
Montine TJ, 848
Montoya J, 527
Moo LR, (suppl 7): S25
Moonis M, 697
Moore DF, (suppl 7): S24
Moore DJ, 281
Moore M, (suppl 7): S121
Morgan S, (suppl 7): S35
Morgenstern LB, (suppl 7): S65
Mori K, 19
Mori M, (suppl 7): S127
Morita D, (suppl 7): S136; S137
Mörk SJ, (suppl 7): S117
Morocz IA, (suppl 7): S145
Moro F, 30
Moro MA, 812
Morris CM, (suppl 7): S31
Morrisey M, (suppl 7): S72
Morrish PK, 692
Morris JC, 115, 693, (suppl 7): S30
Morrison D, (suppl 7): S113
Morris RG, 30
Morrisey M, (suppl 7): S41; S69
Morton TL, (suppl 7): S72
Moses L, 206
Motomura M, 277
Mousny M, (suppl 7): S159
Moutchens M, (suppl 7): S31
Movesyan V, (suppl 7): S77
Moxley RT, (suppl 7): S75
Moxley RT III, (suppl 7): S76
Moxley RT IV, (suppl 7): S76
Moye LA, (suppl 7): S65
Mrazek S, (suppl 7): S147
Mueller W, 256
Muenster M, 848
Muenzer J, (suppl 7): S151
Mulkern RV, (suppl 7): S125

- Mullaney BC, (suppl 7): S104
Muller M, 514
Muller RN, (suppl 7): S25
Multiple Sclerosis Genetics Group, 849, (suppl 7): S35
Muniz R, (suppl 7): S143
Munk-Martin TL, (suppl 6): S46
Munoz DG, (suppl 5): S1; S3; S24
Munschauer FE, (suppl 7): S59
Muntoni F, 719
Muraro PA, (suppl 7): S45
Murata K, (suppl 7): S44
Murdoch G, (suppl 7): S22
Murphy D, 848
Murphy J, (suppl 7): S52
Murphy P, 219
Murumathu K, 699
Mutri E, (suppl 7): S52
Muzarek MF, (suppl 7): S42
Muzik O, (suppl 7): S129
- Nabi R, (suppl 7): S119
Nagai M, (suppl 7): S53
Nagaraja HN, (suppl 7): S19
Nagashima K, (suppl 7): S51
Nag S, (suppl 7): S141
Nahmias C, 93
Naidu S, 206, (suppl 7): S104; S108; S118
Nakagawa E, (suppl 7): S127
Nakagawara A, (suppl 7): S109
Nakamura K, (suppl 6): S103
Nakano I, (suppl 7): S117
Nakao Y, 277
Nanba E, (suppl 7): S107
Nance MA, 5, (suppl 7): S50
Nanda A, (suppl 7): S59
Nanjiani Z, 850
Narayanan V, (suppl 7): S116
Narayan K, (suppl 7): S49; S50; S63
Natale JAE, (suppl 7): S77
Nath A, (suppl 7): S48; S49
Nathanson D, (suppl 7): S58
Nauert GM, 403
Naumann M, (suppl 6): S56
Naumann U, 388
Navarro C, 719
Navon R, 796, (suppl 7): S57
- NEAD Consortium, (suppl 7): S50
Neary JT, (suppl 7): S47
Neft RA, (suppl 7): S133
Negus D, 796, (suppl 7): S57
Neil J, (suppl 7): S155
Neil JJ, (suppl 7): S121; S122; S126
Neitzel H, 719
Nestor PJ, 343
Neto W, (suppl 7): S135
Neuberger I, (suppl 7): S105
Neumann M, 263
Neville B, (suppl 7): S140
Newman GC, (suppl 7): S24
Newman J, 697
Newman TB, (suppl 7): S126
Newman WJ, 700
Ng Y, (suppl 7): S130; S149
Nicholas AP, (suppl 7): S60
Nicholl D, 176, 682
Nickenig G, 582
Nick TG, (suppl 7): S56
Nicolson S, (suppl 7): S110
Nicosia F, 833
Nigro MA, (suppl 7): S159
Nigro V, 674
Niino M, (suppl 7): S51; S62
Nijtmans LGJ, 665
Niki H, (suppl 7): S54
Nischal KK, (suppl 7): S137
Nishihira J, (suppl 7): S51
Nishikawa H, (suppl 7): S46
Nishimoto Y, 383
Nishimura Y, (suppl 7): S61
Nishiwaki T, (suppl 7): S46; S56; S58
Nishiyama N, (suppl 6): S32
Nisipeanu P, 796, (suppl 7): S57
Nitz N, 75
Niu S, (suppl 7): S104
Nixon RA, 848
NNIPPS Study Group, (suppl 7): S39; S70
Nochlin D, (suppl 7): S68
Nolano M, 197
Nomura Y, (suppl 6): S32
Nordli DR Jr., (suppl 7): S142
Norton J, 163
Noseworthy J, (suppl 7): S37
Noth J, 534
Novotny EJ, (suppl 6): S73, (suppl 7): S107
- Novotny EJ Jr., (suppl 6): S25, (suppl 7): S106
Nowak-Görtl U, (suppl 7): S110
Nuechterlein KH, (suppl 7): S29
Nussbaum R, 848
Nylander KD, (suppl 7): S105; S120
- Obayashi K, (suppl 7): S73
Ochi H, (suppl 7): S62
Odoardi F, (suppl 7): S47
Ogata A, (suppl 7): S51; S61
Ogawa S, (suppl 7): S107
Oger J, (suppl 7): S45
Ogoshi K, 732
Ohara S, 276
O'Hearn E, (suppl 7): S42
Ohkawa S, (suppl 7): S46
Ohkubo T, 553
Ohno K, (suppl 7): S107
Ohshima J, (suppl 7): S79
Ohtake A, 473
Ohyagi Y, (suppl 7): S74
O'Keefe T, (suppl 7): S68
Oken B, (suppl 7): S22
Oksenberg JR, 849, (suppl 7): S34; S35
Olanow CW, 403, (suppl 7): S40; S71
Oldfield EH, 297
Oldfors A, 494
Olivares EC, (suppl 7): S43
Oliveira GR, 555, (suppl 7): S22; S55
Oliveira SA, 416, (suppl 7): S50
Olpin SE, (suppl 7): S151
Olsen DB, 86
Omer S, (suppl 7): S20
Ondersma R, (suppl 7): S129
Ondo WG, (suppl 7): S50
O'Neill GN, (suppl 7): S57
Oniki H, (suppl 7): S45
Onizuka R, (suppl 7): S151
O'Regan M, (suppl 7): S125
Orso G, (suppl 7): S57
Osborne D, (suppl 7): S28
Oshima A, (suppl 7): S107
Oskoui M, (suppl 7): S141
Osoegawa M, (suppl 7): S62
Ostapovich N, 698
Osterdock R, (suppl 7): S128; S153
Osterziel KJ, 552
Ota H, (suppl 7): S46
Otsuka T, 155
Ottman R, 507, 693
Otto M, 263
Ouallet JC, (suppl 7): S37
Ouimet C, 848
- Ouvrier R, 719
Owens GP, 459
Oyoyo U, (suppl 7): S125
Ozawa T, (suppl 7): S51
Ozelius LJ, 415
- Pachner AR, (suppl 7): S49; S50; S63
Packer R, (suppl 7): S139; S152
Packer RJ, (suppl 7): S109; S152
Padaliya BB, 700
Pagotto LT, (suppl 7): S137
Pahwa R, (suppl 7): S50
Palace J, (suppl 7): S20
Paleologos NA, (suppl 7): S31
Palumbo DR, (suppl 7): S27; S143
Panet A, (suppl 7): S48
Pang D, 433
Pan H, 239
Paolini JL, (suppl 7): S129
Papazian O, (suppl 7): S156; S158
Papouli M, (suppl 7): S132
Paradas C, (suppl 7): S74
Pardalos PM, (suppl 7): S55
Pardo CA, 287, (suppl 7): S116; S147
Parent A, 599
Parent JM, (suppl 7): S77; S103
Parikh N, (suppl 7): S103
Paripovic I, 678
Parisi JE, 38, (suppl 7): S37; S51; S70
Park D, 732
Parker CA, 848
Park HK, (suppl 7): S54
Park JH, (suppl 7): S53
Park KJ, (suppl 7): S56
Park KW, (suppl 7): S34
Park MK, (suppl 7): S34
Parkinson Study Group, (suppl 7): S27
Parmeggiani L, 30
Parra A, (suppl 7): S26
Parrini E, 30
Partigianoni R, (suppl 7): S124
Parton MJ, 130
Partridge JC, (suppl 7): S111
Pascual J, (suppl 7): S33
Pasquali L, 850
Pasquier F, (suppl 5): S32
Pastor P, 163
Pastor W, (suppl 7): S114
Patel BN, 433
Patel K, 850, (suppl 7): S152
Patlak CS, (suppl 7): S24

- Patrick K, (suppl 7): S36
 Paul S, 263
 Paulsen JS, (suppl 7): S70
 Paulus W, 501
 Pavlakis S, 559
 Pawlikowska-Haddal A, 669
 Payan CAM, (suppl 7): S39; S70
 Pearl GS, (suppl 7): S51
 Pearl P, (suppl 7): S106
 Pearl PL, (suppl 6): S25; S73; S81, (suppl 7): S107; S114
 Peavy GM, (suppl 7): S42
 Pech K, 534
 Peery S, 698
 Pelletier D, (suppl 7): S35
 Pellock JM, (suppl 7): S112
 Peltier A, (suppl 7): S44
 Peltier AC, (suppl 7): S73
 Perani D, 833
 Perez-Gosiengfiao KTB, (suppl 7): S54
 Perhac JS, 647
 Pericak-Vance MA, 416, 849, (suppl 7): S35; S50
 Periquet M, 176
 Perkins SM, (suppl 7): S133
 Perl DP, 403
 Perry EK, 235
 Perry RH, 235
 Perthen J, (suppl 7): S138
 Pesa JA, (suppl 7): S33
 Pestreich L, (suppl 7): S143
 Petanceska S, 848
 Petersen RC, (suppl 7): S51
 Perzold GC, 591
 Peuralinna T, 848
 Pfannl R, (suppl 7): S31
 Pfister HW, 451
 Pfister R, 445
 Phillips P, (suppl 7): S152
 Piao H, (suppl 7): S61
 Piatt J, (suppl 7): S117; S158
 Pijnenburg Y, (suppl 5): S32
 Pilipenko E, (suppl 7): S76
 Pillar G, (suppl 7): S128; S144
 Piña-Garza JE, (suppl 7): S113
 Pinda MA, (suppl 7): S30
 Pinter J, (suppl 7): S148
 Pinto A, 277
 Pirko I, (suppl 7): S60
 Pitchford EB, 700
 Pittock SJ, (suppl 7): S37; S63; S70
 Pizzuti A, 137
 Plane JM, (suppl 7): S103
 Plant GT, (suppl 7): S38
 Platten M, 388
 Platt R, (suppl 7): S105; S146
 Playan A, 527
 Plotz PH, (suppl 7): S20
 Poewe WH, 93
 Pohl D, (suppl 7): S152
 Polak M, 849
 Polat L, 534
 Pöllänen P, 267
 Polley M, 287, (suppl 7): S77
 Pollitt RJ, (suppl 7): S151
 Polster T, 719
 Pomeroy J, (suppl 7): S146
 Pomeroy SL, (suppl 7): S140; S142
 Pomponi MG, (suppl 7): S74
 Poppe M, (suppl 7): S154
 Porter B, (suppl 7): S104
 Poser S, 263
 Poskitt K, (suppl 7): S126
 Postma TJ, 514
 Potanos K, (suppl 7): S144; S150
 Potoicchio SJ, (suppl 7): S55
 Potts E, 697
 Power C, 605
 Pozo-Rosich P, 530
 Pradhan PK, (suppl 7): S64
 Prahme C, (suppl 7): S145
 Pramstaller PP, 415
 Pratt P, 30
 Prengler M, (suppl 7): S110; S137; S138
 Price AE, (suppl 7): S156
 Price B, (suppl 7): S31
 Price LL, 698
 Price R, (suppl 7): S69
 Privitera M, (suppl 7): S108; S118
 Provencio JJ, (suppl 7): S25
 Provitera V, 197
 Przuntek H, 110
 Purohit D, 638
 Pyzik P, (suppl 7): S134
 Qiang B, 239
 Qiao Y, 851, (suppl 7): S24
 Quan H, 696, (suppl 7): S18
 Quarles RH, 769
 Quattrochi CC, (suppl 7): S104
 Quelvennec E, 119
 Quiney RE, (suppl 7): S26
 Quinn J, (suppl 7): S22
 Quinn N, 283
 Quinn NP, (suppl 7): S51
 Raben N, (suppl 7): S20
 Rabins PV, 138
 Rabinstein AA, (suppl 7): S44; S66
 Rackley RJ, (suppl 7): S72
 Raffelsberger T, 821
 Raffini L, (suppl 7): S110
 Rafii B, (suppl 7): S117
 Raghavanpillai R, (suppl 7): S75
 Raike RS, 725
 Rajab A, (suppl 7): S119
 Rajagopalan B, 552
 Raju R, (suppl 7): S45
 Rakocevic G, (suppl 7): S75
 Ramanathan M, (suppl 7): S36
 Ramesh V, (suppl 7): S116
 Rando TA, (suppl 7): S43
 Ranjan P, (suppl 7): S64
 Ransil BJ, 625
 Raol Y, (suppl 7): S104
 Rao SC, (suppl 7): S139
 Rao SD, (suppl 7): S43
 Rascol O, 93, 176
 Rascovsky K, (suppl 5): S7
 Raskind MA, (suppl 7): S68
 Raskind WH, (suppl 7): S21
 Raskin S, 176
 Ratner N, (suppl 7): S58; S108; S118
 Ravid R, 573
 Ravid S, (suppl 7): S128; S144
 Ravina B, 271
 REAL-PET Study Group, 93
 Reddy AT, (suppl 7): S140
 Reddy G, (suppl 7): S117
 Reddy S, (suppl 7): S108
 Reder AT, (suppl 7): S61; S63
 Rees S, (suppl 7): S121
 Regan M, (suppl 7): S20
 Reichhart M, 321
 Reich SG, (suppl 7): S42; S73
 Reid E, 796, (suppl 7): S57
 Reiman EM, (suppl 7): S28
 Remy P, 93
 Renfro AL, (suppl 7): S104
 Reske S, 93
 Resnick T, (suppl 7): S150
 Restrepo CE, 51
 Reszka R, 479
 Reuber M, 425
 Revesz T, (suppl 7): S51
 Reynolds D, (suppl 7): S152
 Reynolds R, 849
 Rezanian K, (suppl 7): S45
 Ribeiro MJ, 93
 Richard I, 248
 Richardson PK, (suppl 7): S55
 Richtand NW, (suppl 7): S108; S118
 Richter R, 479
 Riess O, 110, 135, 367
 Rigamonti AE, (suppl 6): S81
 Ringer SA, (suppl 7): S121; S122
 Ringholz GM, (suppl 7): S22
 Rinne J, 267
 Rios S, 163
 Risser JMH, (suppl 7): S65
 Ritacco DR, (suppl 7): S157
 Ritter FJ, (suppl 7): S112
 Rivkin M, (suppl 7): S157
 Rivkin MJ, (suppl 7): S142
 Rizzo M, (suppl 7): S23; S39
 Rizzu P, 682
 Roach ES, 559
 Robb MJ, (suppl 7): S45
 Robertson K, (suppl 7): S49
 Robertson P, (suppl 7): S109
 Robertson R, (suppl 7): S140
 Robertson RL, (suppl 7): S122; S123; S125
 Robertson W, 698, (suppl 7): S49
 Roberts W, (suppl 7): S149
 Robins A, (suppl 7): S138
 Robinson BH, (suppl 7): S157; S158
 Robinson FR, 825
 Robinson RL, (suppl 7): S77
 Roche P, (suppl 7): S146
 Rodnitzky RL, (suppl 7): S39
 Rodriguez M, 418, (suppl 7): S37
 Roe CM, 163
 Roe CR, (suppl 7): S151
 Rogava E, 244, 271
 Rogers LR, 138, (suppl 7): S31
 Rogove AD, 655
 Roh JK, (suppl 7): S54
 Rohlicek C, (suppl 7): S111
 Roig M, 527
 Rojas-Garcia R, (suppl 7): S74
 Roka J, 821
 Roland EH, (suppl 7): S126
 Rolfs A, 367
 Rolland Y, (suppl 7): S39
 Romero MS, (suppl 7): S40
 Ronnett GV, 206
 Roos RP, (suppl 7): S76
 Rorke L, (suppl 7): S109
 Rosebush P, (suppl 7): S42
 Rosenbaum K, (suppl 7): S139
 Rosenblatt A, 488
 Rosenblatt B, (suppl 7): S111
 Rosenblum WI, 376
 Rose S, (suppl 7): S40

- Rosman NP, (suppl 7): S129
 Ross CA, 488
 Rosser T, (suppl 7): S139; S152
 Rossetto MG, (suppl 7): S57
 Rossi M, 638
 Rossini PM, 833
 Rossi R, (suppl 7): S110
 Rossmanith W, 821
 Rossor M, (suppl 7): S20; S51
 Rosso S, 573, (suppl 5): S29
 Rostasy K, (suppl 7): S116; S152
 Rothman DL, (suppl 6): S25, (suppl 7): S106
 Rothstein JD, 851, (suppl 7): S20; S30
 Rouland R, 843
 Rouleau GA, 9
 Røyttä M, 267
 Rubenstein J, (suppl 7): S134
 Ruberg M, 176
 Rubin MR, (suppl 7): S23
 Ruchoux MM, 542
 Rudnik-Schöneborn S, 719
 Ruff RL, (suppl 7): S44; S63; S64
 Rumberg B, (suppl 7): S62
 Rumpel H, 838
 Rundek T, (suppl 7): S23
 Russell J, (suppl 7): S44; S73
 Ruthazer R, 696, (suppl 7): S18
 Ruth TJ, (suppl 7): S19
 Rutledge SL, (suppl 7): S140
 Ryan MT, 473

 Sable C, (suppl 7): S152
 Sacco RL, (suppl 7): S23
 Sachs BC, (suppl 7): S105
 Sackellares JC, (suppl 7): S55
 Sacktor N, (suppl 7): S50
 Sahay A, (suppl 7): S108; S118
 Sahenk Z, (suppl 7): S19
 Saifi GM, 398
 Saiki M, (suppl 7): S72
 Saiki S, (suppl 7): S72
 Saint-Cyr J, (suppl 7): S70
 Saint Martin C, (suppl 7): S159
 Saiz A, 530
 Sakai K, (suppl 7): S72
 Sakaki T, 732
 Sakamoto T, (suppl 7): S53; S54
 Sakasegawa Y, 553

 Sallee FR, (suppl 7): S106; S143
 Salomao DR, 38
 Sambandam T, (suppl 7): S60
 Samii A, (suppl 7): S57; S69
 Samsa GP, 695, (suppl 7): S17
 Sandkuijl LA, 360
 Sandrini G, (suppl 7): S75
 Saneto R, (suppl 7): S148
 Sanjak M, (suppl 7): S36
 Sano K, 259
 Sansone V, (suppl 7): S75
 Santiago ME, (suppl 7): S40
 Santoro L, 197
 Sarazin M, (suppl 5): S32
 Sarnie M, (suppl 7): S124
 Sartori E, (suppl 7): S57
 Sasaki H, (suppl 7): S21
 Sathasivam K, 186
 Sato C, 244
 Sato S, 297, (suppl 7): S56
 Satoyoshi E, (suppl 7): S53; S64
 Saul JP, (suppl 6): S49
 Saul RA, (suppl 7): S154
 Saunders D, (suppl 7): S138; S140
 Sawada H, 352
 Saxton J, (suppl 7): S67
 Scalabrino G, (suppl 7): S52
 Scarpace L, (suppl 7): S31
 Schäfer N, 415
 Schapira AHV, 552
 Schapiro MB, (suppl 7): S109
 Scheffler MD, 130
 Schellenberg GD, (suppl 7): S68
 Schenck JF, (suppl 7): S68
 Scherer SS, (suppl 7): S120
 Scher MS, (suppl 7): S121; S125
 Schiffmann R, 769
 Schifitto G, (suppl 7): S50
 Schmidt J, (suppl 7): S36; S75
 Schmidt S, 848, 849
 Schmithorst VJ, (suppl 7): S109
 Schmitt AB, 534
 Schmitt FA, (suppl 7): S48; S49
 Schneider-Gold C, 135
 Schneider R, (suppl 7): S140
 Schoenen J, 534
 Schöls L, 110, 367
 Schomer DL, 625
 Schopflocher DP, 695, (suppl 7): S17
 Schor NF, (suppl 7): S105; S119; S120

 Schorry E, (suppl 7): S58; S108; S118
 Schott J, (suppl 7): S20
 Schott K, 725
 Schröck H, 582
 Schröder R, 674
 Schroeder ML, 638
 Schroeder U, 445
 Schubert R, 433
 Schuelke M, 719
 Schuh K, (suppl 7): S106
 Schulte T, 110
 Schultze J, 582
 Schulzer M, (suppl 7): S19
 Schupf N, 433
 Schussler K, 647
 Schuster VH, 686
 Schwab C, 599
 Schwalb M, (suppl 7): S58
 Schwartz M, 86
 Schwartz S, (suppl 7): S159
 Schwarzschild MA, 170
 Schwinger E, 415
 Scornaiench J, (suppl 7): S148
 Scott BL, (suppl 7): S50
 Scott D, (suppl 7): S131
 Scott RM, (suppl 7): S140
 Scott WK, 416, (suppl 7): S50
 Sébire G, (suppl 7): S159
 Segawa M, (suppl 6): S32
 Selcen D, 805
 Seligman A, (suppl 7): S35
 Selker HP, 696, 698, (suppl 7): S18
 Selnes OA, (suppl 7): S67
 Seltzer WK, (suppl 7): S75
 Semana G, 119
 Sepp AN, (suppl 7): S42
 Sequeiros J, 119
 Serajee FJ, (suppl 7): S119
 Serbanescu I, 219
 Serena J, 812
 Serna T, (suppl 7): S111; S128; S153
 Serverijnen LA, 573
 Sethuraman G, (suppl 7): S143
 Seyffert M, (suppl 7): S148
 Sfikas N, (suppl 7): S113
 Shahar E, (suppl 7): S128; S144
 Shaked GM, 781
 Shalev RS, (suppl 7): S144; S145
 Shamin E, 698
 Shan DE, (suppl 7): S40
 Shannon KM, 403
 Shanske S, 524
 Sharif U, (suppl 7): S110
 Sharif UM, (suppl 7): S129
 Sharma J, (suppl 7): S59
 Sharma K, (suppl 7): S76
 Sharp CD, (suppl 7): S59
 Sharp FR, (suppl 7): S58; S108; S118

 Shaw CE, 130
 Shaw PJ, 748
 Sheffield RA, (suppl 7): S23
 Sheftell FD, (suppl 7): S33
 Sheldon RA, (suppl 7): S23
 Shen J, (suppl 7): S77
 Shen Y, 239
 Sheremata WA, (suppl 7): S60
 Sherkat D, 697
 Sherr EH, (suppl 7): S53; S108
 Shevell M, (suppl 7): S105; S111; S141; S145; S146; S148
 Shi SY, (suppl 7): S135
 Shiao DS, (suppl 7): S55
 Shibuya S, (suppl 7): S45; S73
 Shieh WJ, 547
 Shiga Y, (suppl 7): S67; S69
 Shimazu S, 352
 Shimony JS, (suppl 7): S76
 Shinnoh N, (suppl 7): S74
 Shiraishi H, 277
 Shiraishi K, 259
 Shmueli D, (suppl 7): S144
 Shumway-Cook A, (suppl 7): S69
 Shurtleff H, (suppl 7): S148
 Siderowf AD, 699, (suppl 7): S17
 Siegert S, (suppl 7): S116
 Siemers ER, (suppl 7): S70
 Siesjö BK, 732
 Siffert J, (suppl 7): S109
 Signorini S, 833
 Silva C, 605
 Silva RR, (suppl 7): S143
 Silverberg SJJ, (suppl 7): S23
 Silverman ED, (suppl 7): S140
 Silverstein FS, (suppl 7): S103
 Silvestri G, 102, (suppl 7): S74
 Sime E, (suppl 7): S70
 Simpson EP, (suppl 7): S43
 Singer HS, (suppl 7): S144; S145
 Singer R, (suppl 7): S32
 Singleton A, 271, 848
 Singleton JR, (suppl 7): S44; S73
 Sinha SR, 280
 Sisodia SS, (suppl 7): S119
 Skundric D, (suppl 7): S38; S62
 Slevin JT, 849
 Slimp JC, (suppl 7): S69
 Slor H, 796
 Slotnick SD, (suppl 7): S25
 Small GW, (suppl 7): S50

- Smathers SA, (suppl 7): S159
- Smeets R, 665
- Smeitink JAM, 665
- Smielewski P, 343
- Smirnov A, 263
- Smith AG, (suppl 7): S44; S73
- Smith AK, (suppl 7): S117
- Smith BN, 130
- Smith CD, (suppl 7): S76
- Smith DL, 186
- Smith EM, (suppl 7): S128
- Smith JD, 848
- Smith L, (suppl 7): S40
- Smith LH, (suppl 7): S138
- Smith MA, (suppl 7): S65
- Smith P, (suppl 7): S62
- Smith S, (suppl 7): S110
- Smith TR, (suppl 7): S34
- Smith Y, (suppl 7): S127
- Smoot KA, (suppl 7): S22
- Smothers JL, (suppl 7): S39
- Snead OC III, 219, (suppl 6): S3; S81, (suppl 7): S149
- Sobue G, 19
- Sogawa Y, (suppl 7): S114
- Sogliano C, (suppl 6): S81
- Solano A, 527
- Soliven B, (suppl 7): S45
- Solomon J, 297
- Soong BW, (suppl 7): S40
- Soror E, (suppl 7): S76
- Sossi V, 403, (suppl 7): S19
- Soul JS, (suppl 7): S121; S122; S123; S124; S125
- Southern CA, (suppl 7): S142
- Spalding W, (suppl 7): S33
- Spanaki MV, 697
- Speck O, (suppl 7): S48
- Speller NB, (suppl 6): S49
- Spencer AS, (suppl 7): S150
- Spenger C, 51
- Sposto R, (suppl 7): S109; S152
- Spray TL, (suppl 7): S110
- Squires L, (suppl 7): S112; S135; S136
- Squires S, (suppl 7): S112
- Squitti R, 833
- Srivastava AK, (suppl 7): S154
- St. George-Hyslop PH, 244, 271
- Stack C, (suppl 7): S157
- Stajich JM, (suppl 7): S50
- Stancanelli A, 197
- Standaert D, (suppl 7): S116
- Stanley P, (suppl 7): S109
- Starr A, (suppl 7): S68
- Starr HL, (suppl 7): S27; S143
- Stebbins GT, (suppl 7): S40
- Steenbergen-Spanjers GCH, (suppl 6): S56
- Steen RG, 564
- Stefan H, 501
- Steffen LM, (suppl 7): S65
- Steglich C, 719
- Steinacker P, 263
- Steinbart E, (suppl 7): S68
- Steiner I, (suppl 7): S48
- Steiner L, 849
- Steppe D, (suppl 7): S125
- Stern JL, (suppl 7): S31
- Stern MB, 699, (suppl 7): S27; S50
- Stern Y, 433
- Stevens-Tuttle D, (suppl 7): S120
- Stockhammer F, 256
- Stoessl AJ, 93, 403, (suppl 7): S19
- Stoica BA, (suppl 7): S77
- Stolz P, 719
- Storm G, (suppl 7): S36
- Stout JC, (suppl 7): S70
- Stracter R, (suppl 7): S110
- Strassburg HM, (suppl 6): S56
- Sträter R, (suppl 7): S110
- Strawsburg RH, (suppl 7): S109
- Streif E, (suppl 7): S117; S146; S155
- Strong MJ, (suppl 5): S20
- Strupp M, 678
- Stumpf DA, (suppl 7): S128
- Sturm V, 479
- Su JH, (suppl 7): S50
- Subramaniam S, (suppl 7): S65
- Subramanian K, (suppl 7): S58
- Subramony SH, 725, (suppl 7): S40; S51
- Sugie K, (suppl 7): S44
- Sugiura M, 19
- Sugo N, 155
- Suh SW, 850
- Sultz D, (suppl 7): S29
- Sulzer D, (suppl 7): S106
- Sumner CJ, 647
- Sun CM, (suppl 7): S40
- Sundaram N, (suppl 7): S155
- Sun DK, (suppl 7): S135
- Sung JJ, (suppl 7): S53
- Sun X, (suppl 7): S61
- Surguchov A, 542
- Surtees R, (suppl 6): S18
- Susuki K, 383
- Suzuki O, (suppl 7): S107
- Suzuki T, (suppl 7): S54
- Suzuki Y, (suppl 7): S107
- Svenson L, 695, (suppl 7): S17
- Swanson M, 760
- Swanson RA, 850
- Swartz B, 825, (suppl 7): S54
- Swarztrauber K, 695, (suppl 7): S17
- Sweetman LL, (suppl 7): S130; S151
- Sweet RA, (suppl 7): S67
- Swerdin A, (suppl 7): S35
- Swerdloff RS, 669
- Swoboda KJ, (suppl 6): S49
- Szaflarski JP, (suppl 7): S108; S118
- Szigeti K, 398
- Tabbutt S, (suppl 7): S110
- Tabira T, 137
- Tadevosyan A, (suppl 7): S103; S117; S132
- Tagliati M, 102
- Taguchi Y, (suppl 7): S69
- Tajsharghi H, 494
- Takahashi S, (suppl 7): S67
- Takahashi Y, (suppl 7): S79
- Takamure M, (suppl 7): S44
- Takashima S, 259
- Takeda A, 276
- Taki S, (suppl 7): S72
- Talos DM, (suppl 7): S103
- Tamada Y, (suppl 7): S44
- Tamura M, (suppl 7): S64
- Tanabe H, (suppl 5): S29
- Tanahashi H, 137
- Tanaka K, (suppl 7): S73
- Tan EK, 838
- Tang Y, (suppl 7): S58; S108; S118
- Tani LY, (suppl 7): S137
- Tanuma N, (suppl 7): S37; S47
- Taoka T, 732
- Taphoorn MJB, 514
- Tapio V, 267
- Tarby TJ, (suppl 7): S149
- Tashiro K, (suppl 7): S21; S51; S61; S62
- Taylor GA, 521
- Taylor JP, 647
- Taylor RW, 521
- Tcervenkov C, (suppl 7): S111
- Tein I, (suppl 7): S151; S157; S158
- Teive H, 176
- Telfer P, (suppl 7): S138
- Tench CR, (suppl 7): S78
- Teng-Umnay P, 760
- Tennant P, 849
- Terakawa H, (suppl 7): S41
- Terrano D, (suppl 7): S119
- Terwindt GM, 360
- Tesi-Rocha C, 850
- Testa C, 833
- Thal LJ, (suppl 7): S29
- Theiben MJ, (suppl 7): S22
- Theil D, 678
- Theodore WH, (suppl 7): S56
- Thevarajah S, (suppl 7): S105
- Thiel A, (suppl 7): S78
- Thomas FP, (suppl 7): S22; S75
- Thomason C, (suppl 7): S143
- Thompson AJ, (suppl 7): S38
- Thompson E, (suppl 7): S62; S63
- Thompson PJ, 421
- Thorburn DR, 473
- Thornell LE, 494
- Thornton CA, 760, (suppl 7): S76
- Thurberg BL, (suppl 7): S20
- Thyagarajan D, 473
- Tierney E, (suppl 7): S105
- Tiete J, (suppl 7): S47
- Tift C, (suppl 7): S139
- Timoshkin E, (suppl 7): S129
- Tiraboschi P, (suppl 7): S29
- Tirado V, 163
- Tison F, 843
- Tjoa CW, (suppl 7): S59
- Toczek MT, (suppl 7): S56
- Tomioka N, (suppl 7): S109
- Tomita T, (suppl 7): S142
- Tonali PA, (suppl 7): S47; S74
- Tong DC, 696, (suppl 7): S17
- Tong KA, (suppl 7): S111; S128; S153
- Tong T, (suppl 7): S130
- Topaloglu H, 719
- Topka H, 110, 367
- Torre ER, (suppl 7): S51
- Torres A, 790, (suppl 7): S155
- Tortorella G, 30
- Toth G, (suppl 7): S108
- Toung TJK, (suppl 7): S26; S64; S66
- Tourtellotte WW, (suppl 7): S60
- Toyka KV, 135, (suppl 7): S36
- Tramontana MG, 700
- Tran D, (suppl 7): S152
- Traystman RJ, 155, (suppl 7): S26; S66
- Trentin L, (suppl 7): S75
- Triepels RH, 665
- Trojano M, 119
- Trojanowski JQ, 682
- Troncoso JC, 393, 488, (suppl 7): S29

- Tronnier VM, 445
 Tsang C, (suppl 7): S53
 Tsang LM, (suppl 7): S140
 Tse W, (suppl 7): S71
 Tsirka AE, 655
 Tsirka SE, 655
 Tsokos M, 769
 Tsuang DW, (suppl 7): S68
 Tsuboi Y, (suppl 7): S58
 Tsuchida TN, (suppl 7): S159
 Tsuda M, 732
 Tsujihata M, 277
 Tsuji S, (suppl 7): S21; S73
 Tsutsui S, 605
 Tu HC, (suppl 7): S72
 Tu JV, 695, (suppl 7): S17
 Tuchman M, (suppl 7): S32
 Tudorica A, (suppl 7): S24
 Tuor UI, (suppl 7): S25
 Turkheimer F, 310
 Turnbull DM, 521
 Turner B, 848, (suppl 7): S78
 Turner MR, 130
 Turner RP, (suppl 7): S134
 Twyman RE, (suppl 7): S135
 Tycko B, 433
 Tyler B, 851
 Tyrrell PN, (suppl 7): S140
- Ubel PA, 699
 Uc EY, (suppl 7): S39
 Uchikawa O, (suppl 7): S46
 Uchino K, (suppl 7): S65
 Uchino M, (suppl 7): S73
 Udd B, 248
 Ueda S, 383
 Uede T, (suppl 7): S61
 Ueno S, (suppl 7): S44; S46; S56; S58
 Ugalde C, 665
 Uhlmann EJ, 251
 Utti RJ, (suppl 7): S58
 Ukadike KC, (suppl 7): S154
 Ulrich NJ, (suppl 7): S140
 Uusimaa J, 665
 Uyama E, (suppl 7): S73
- Vahlberg T, 267
 Vaidya C, (suppl 7): S105
 Vaisleib II, (suppl 7): S133
 Valencia I, (suppl 7): S132; S150; S151; S158
 Vanasse M, 9, (suppl 7): S121
 van Broeckhoven C, 275, 555
 Vance JM, 416, (suppl 7): S50
 Vancor M, (suppl 7): S155
 van de Graaf R, 573
- Van den Bergh PYK, 248
 Van den Broeck M, 275
 van den Heuvel LP, 665
 van den Maagdenberg AMJM, 360
 van der Ploeg HM, 514
 Vandertop WP, 514
 Vanderver A, (suppl 7): S114
 van der Zwaan LA, 829
 van Doorn PA, 829
 van Duijn CM, 275, 555
 VanDyke DL, (suppl 7): S159
 van Herpen E, 573
 Van Maldergem L, 719
 Vanmolkot KRJ, 360
 van Netten HG, (suppl 7): S19
 vanSwieten J, 573, (suppl 5): S29
 Varelas PN, 697
 Vargas DL, (suppl 7): S147
 Vargiami E, (suppl 7): S132
 Varon R, 719
 Vasconcellos E, (suppl 7): S150; S158
 Vasconcelos OM, (suppl 7): S45
 Vasilescu A, 119
 Vassiladyi M, (suppl 7): S141
 Vattei G, (suppl 7): S43
 Vaughn B, (suppl 7): S151
 Vaur-Barriere C, 769
 Veber D, (suppl 7): S52
 Vecera SP, (suppl 7): S23
 Vedanarayanan VV, (suppl 7): S155
 Veelken J, 256
 Velasquez L, (suppl 7): S109
 Venkateswaran S, (suppl 7): S131
 Venstrom JM, (suppl 7): S71
 Ventureyra E, (suppl 7): S141
 Veracruz E, (suppl 7): S124
 Verellen C, 248
 Verhoeff NPLG, (suppl 7): S29; S67
 Verin M, (suppl 7): S39
 Verkooyen RP, 829
 Vernino S, (suppl 7): S19; S22
 Verpillat P, 176, (suppl 5): S29
 Verret L, (suppl 7): S68
 Vervoort VS, (suppl 7): S154
 Vexler ZS, (suppl 7): S26; S65
 Vezina LG, (suppl 7): S114; S152
 Viallet F, (suppl 7): S39
- Vianey-Saban C, (suppl 7): S151
 Vicari S, (suppl 7): S124
 Vick NA, (suppl 7): S31
 Vickrey BG, 695, (suppl 7): S17
 Vidailhet M, 176, (suppl 7): S70
 Vidaurre I, (suppl 7): S47
 Vieregge P, 415
 Vilà MR, 524
 Vilchez J, (suppl 7): S74
 Villegas A, 163
 Vincent A, 530, (suppl 7): S20
 Vink R, (suppl 7): S77
 Vissing J, 86, 539
 Vitale E, (suppl 7): S58
 Vives-Bauza C, 524, 527
 Vogel JE, (suppl 7): S69
 Vogelsang GB, (suppl 7): S73
 Voges J, 479
 Volpe JJ, (suppl 7): S103; S121; S122; S123; S124; S125; S156
 Volzone A, 30
 von Aster M, (suppl 7): S145
 von Büdingen HC, (suppl 7): S37; S38; S47; S60
 von Deimling A, 256
 von Eckardstein K, 256
 Vonsattel JP, 843
- Waber DP, (suppl 7): S142
 Wacławik AJ, (suppl 7): S36
 Wade A, (suppl 7): S137
 Wafapoor H, (suppl 7): S40
 Wainwright MS, (suppl 7): S128
 Wakayama Y, (suppl 7): S45; S73
 Wakefield JL, (suppl 7): S109
 Waldemar G, (suppl 7): S51
 Walker JA, (suppl 7): S53
 Walker LC, 848
 Walker M, (suppl 7): S57
 Walker RH, (suppl 7): S71
 Walsh CA, (suppl 7): S119
 Walsh GO, (suppl 7): S54
 Walter G, (suppl 7): S121
 Walter U, (suppl 7): S41
 Wamberra K, (suppl 7): S114
 Wang H, (suppl 7): S126
 Wang HS, (suppl 7): S28; S124
 Wang J, 655, (suppl 7): S25
 Wang JJ, (suppl 7): S153
- Wang L, (suppl 7): S52; S76
 Wang M, 849
 Wang S, (suppl 7): S112; S135
 Wang ST, 706
 Wang TW, (suppl 7): S77
 Wang X, (suppl 7): S78
 Wang Y, (suppl 7): S135
 Warach S, 66
 Ward A, 698
 Warfield SK, (suppl 7): S121; S122; S123; S124
 Warnock CR, (suppl 7): S113
 Warren AC, (suppl 7): S59
 Wassermann EM, (suppl 7): S129; S143
 Wassmer E, (suppl 7): S131; S157; S158
 Watabe K, (suppl 7): S53
 Waters C, 507, 693
 Watts RL, 93, (suppl 7): S50
 Wauben MHM, (suppl 7): S36
 Weaver KD, 851, (suppl 7): S30
 Weber CA, (suppl 7): S149
 Webster R, (suppl 7): S105; S145; S146
 Wee AS Jr., (suppl 7): S56
 Wegner C, (suppl 7): S37
 Weibel TD, 769
 Weigand S, (suppl 7): S66
 Weiner LP, (suppl 7): S47
 Weiner WJ, 418
 Weinshenker BG, (suppl 7): S60; S63
 Weinstein SL, (suppl 7): S114
 Weinstock-Guttman B, (suppl 7): S36; S59
 Weintraub S, (suppl 5): S11
 Weiser R, 271
 Weiss JH, (suppl 7): S43
 Weiss MD, 769
 Weiss S, (suppl 7): S149
 Weiss WA, 850, (suppl 7): S109
 Weisz DJ, (suppl 7): S71
 Wellenbrock C, 415
 Weller M, 388
 Wendelschafer-Crabb G, 197
 Wendland MF, (suppl 7): S26; S65
 Werhahn KJ, 464
 Wernovsky G, (suppl 7): S110
 West DLA, (suppl 7): S22
 Wevers RA, (suppl 6): S56
 Wharton SB, 748
 Wheeler TM, (suppl 7): S43

- Wheless JW, (suppl 7): S135
 White DM, (suppl 7): S38
 Whone AL, 93, 692
 Wick W, 256
 Wiegner AW, (suppl 7): S76
 Wienhard K, 479, (suppl 7): S30
 Wijdicks EFM, (suppl 7): S28; S44; S63; S66
 Wilder-Smith E, 838
 Willemsen R, 573
 Williams L, (suppl 7): S77
 Williams MM, (suppl 7): S30
 Williams S, (suppl 7): S57
 Williams SD, (suppl 7): S133
 Wilmot GR, (suppl 7): S51
 Wilson C, (suppl 7): S62; S63
 Wilson G, (suppl 7): S32
 Wiltfang J, 263
 Wilverman W, 433
 Winhuisen L, (suppl 7): S78
 Winner P, (suppl 7): S106
 Winstanley S, (suppl 7): S53
 Wintermark M, 321
 Wirrell E, (suppl 7): S133
 Wise RJS, 310
 Withers D, 796, (suppl 7): S57
 Wolfson C, (suppl 7): S68
 Wollack JB, (suppl 7): S117
 Wong CGT, (suppl 6): S3
 Wong DF, (suppl 7): S118
 Wong K, 769, (suppl 7): S106
 Wong M, 251
 Wong MC, 838
 Wong PKH, (suppl 7): S114
 Wong STC, (suppl 7): S53
 Wood JD, 748
 Woodman B, 186
 Wood NW, 176, 283
 Woods CG, (suppl 7): S119
 Woodward LK, (suppl 7): S124
 Wright V, (suppl 7): S24
 Wszolek ZK, (suppl 7): S19; S58
 Wu H, 239
 Wu L, 155
 Wu X, 239
 Wu YW, 123, (suppl 7): S126
 Wu YY, (suppl 7): S28
 Wul YW, (suppl 7): S138
 Wyllie E, (suppl 7): S134
 Wynshaw-Boris A, (suppl 7): S104
 Wysong A, (suppl 7): S27
 Xiong C, 115, 693, (suppl 7): S30
 Xiong X, 564
 Xu B, (suppl 7): S105
 Xu H, (suppl 7): S51; S135
 Xu J, 379
 Xu K, 239
 Xu L, 851
 Xu Y, (suppl 7): S42
 Yabe I, (suppl 7): S21
 Yaffe K, (suppl 7): S28
 Yamada HY, 352
 Yamada KA, 251
 Yamada M, 383
 Yamagata T, (suppl 7): S127
 Yamakawa K, (suppl 7): S54
 Yamamoto I, 352
 Yamanouchi H, (suppl 7): S127
 Yamashita I, (suppl 7): S21
 Yan C, (suppl 7): S105; S120
 Yang J, (suppl 7): S25
 Yang W, (suppl 5): S20
 Yao B, (suppl 7): S38
 Yao J, 848
 Yaouanq J, 119
 Yao Z, 239
 Yardumian A, (suppl 7): S138
 Yasaki S, (suppl 7): S79
 Yates A, (suppl 7): S152
 Yaylali I, (suppl 7): S156; S158
 Yelin K, (suppl 7): S103; S117; S132
 Yen AA, (suppl 7): S43
 Yenari MA, 851, (suppl 7): S24
 Yiannokoulis N, 695, (suppl 7): S17
 Yildirim-Toruner C, (suppl 7): S58
 Yin HZ, (suppl 7): S43
 Yin K, 379
 Yoder B, (suppl 7): S121
 Yohay KH, 851, (suppl 7): S30
 Yoon S, (suppl 7): S79
 Yoshida H, 573
 Yoshida M, (suppl 7): S52
 Yoshimura T, 277
 Young AB, 849
 Yuasa H, (suppl 7): S52
 Yu GX, 838
 Yuki N, 383
 Yum S, (suppl 7): S120; S151
 Zafeiriou DI, (suppl 7): S132
 Zaidel E, 126
 Zaja F, (suppl 7): S75
 Zakarian V, (suppl 7): S62
 Zaki SR, 547
 Zambello R, (suppl 7): S75
 Zamora ED, (suppl 7): S29
 Zanetti O, 833
 Zara G, (suppl 7): S75
 Zeger S, (suppl 7): S67
 Zelko FA, (suppl 7): S142
 Zerres K, 719
 Zerr I, 263
 Zeviani M, 521
 Zhang F, (suppl 7): S50
 Zhang G, (suppl 7): S104
 Zhang H, (suppl 7): S77
 Zhang J, (suppl 7): S143
 Zhang K, 605
 Zhang S, (suppl 7): S143
 Zhang Y, 239, 330
 Zhang Z, (suppl 7): S26
 Zhao S, 697
 Zhao W, 330
 Zheng Z, (suppl 7): S24
 Zhong H, (suppl 7): S119
 Zhuang X, (suppl 6): S91
 Zhukareva V, (suppl 5): S24
 Ziai WC, 557
 Ziemann U, (suppl 7): S129
 Zientara GP, (suppl 7): S122; S123; S125
 Zimmerman AW, (suppl 7): S147
 Zimmerman EA, (suppl 7): S68
 Zohar Y, 851
 Zolo P, (suppl 7): S54
 Zuberi S, (suppl 7): S125
 Zuckerman J, (suppl 7): S26
 Zühlke C, 110
 Zweig RM, (suppl 7): S39

Subject Index

14-3-3 protein

specification of 14-3-3 proteins in Lewy bodies (Berg et al) 2003;54:135 (Letter)

Acetone

anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet (Likhodii et al) 2002;54:219

Acetylcholine

determination of presynaptic acetylcholine terminal densities and its clinical correlation in Rett's syndrome (Bibat et al) 2003;54:(suppl 7) S118

Acetylcholinesterase

cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54:(suppl 7) S31

Acinetobacter sp.

antibodies to specific proteins of *Acinetobacter sp.* and *Pseudomonas aeruginosa* in multiple sclerosis patients (Hughes et al) 2003;54:(suppl 7) S63

cross-reactive antibodies against myelin basic protein, *Acinetobacter sp.* and *Pseudomonas aeruginosa* in multiple sclerosis patients (Wilson et al) 2003;54:(suppl 7) S62

Activities of daily living

prediction of neuropathological severity in 100 patients with Huntington's disease (Rosenblatt et al) 2003;54:488

Adenosine triphosphase gene *ATP1A2*

novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360

Adenovirus

therapeutic effect of combined CTLA4Ig and dystrophin gene transfer to *Mdx* muscle using high-capacity adenoviral vectors (Clemens and Jiang) 2003;54:(suppl 7) S42

Adolescents

efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder (Dunn et al) 2003;54:(suppl 7) S143

prevalence and risk of sleep disturbances in adolescents after minor head injury (Ravid et al) 2003;54:(suppl 7) S128

a prospective study of topiramate in 500+ children/adolescents with refractory epilepsy (Ritter et al) 2003;54:(suppl 7) S112

tolerability and safety of topiramate as first-line monotherapy in children and adolescents (Dlugos et al) 2003;54:(suppl 7) S135

topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135

topiramate as first-line therapy in children/adolescents with newly diagnosed epilepsy (Pellock et al) 2003;54:(suppl 7) S112

topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136

transition/transfer from child neurology to adult neurology care (Camfield and Camfield) 2003;54:(suppl 7) S153

the use of interferon β -1a in children and adolescents with multiple sclerosis (Pohl et al) 2003;54:(suppl 7) S152

Adrenoleukodystrophy, X-linked

oligonucleotide microarray expression analysis of X-linked adrenoleukodystrophy fibroblasts (O'Neill et al) 2003;54:(suppl 7) S57

Adult neurology care

transition/transfer from child neurology to adult neurology care (Camfield and Camfield) 2003;54:(suppl 7) S153

Affective function

longitudinal stability of cognitive and affective functioning in PD patients: a dissociation between behavioral and motoric decline (Bernard et al) 2003;54:(suppl 7) S69

African Americans

African American multiple sclerosis patients suffer from a more aggressive disease course than Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S35

comparison of response to treatment with interferon β -1a in African Americans and Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S34

neurofibromatosis in African Americans: is there a delay in diagnosis? (Jones et al) 2003;54:(suppl 7) S131

Age

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58

onset of dementia is associated with age at menopause in women with Down's syndrome (Schupf et al) 2003;54:433

Age of onset

disinhibition-dysexecutive syndrome associated with differential age of onset in a family with SCA-17 (Farbman and Kaufer) 2003;54:(suppl 7) S52

Age-Related Eye Disease Study (AREDS)

a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28

Agent Orange

Agent Orange exposure is adversely associated with peripheral nerve function (Li et al) 2003;54:698

Aggresomes

novel identification of aggresomes in sporadic inclusion-body myositis (s-IBM) muscle fibers suggests that inhibition of 26S/20S proteasome and misfolded proteins play a pathogenic role (Fratta et al) 2003;54:848

Aging

effect of aging on brain metabolism in antiretroviral-naïve HIV patients (Ernst and Chang) 2003;54:(suppl 7) S48

heterogeneous age-related breakdown of white matter structural integrity: implications for "disconnection" in aging and Alzheimer's disease (Bartzokis et al) 2003;54:(suppl 7) S29

patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately paral-

July issue, pp 1-140; August issue, pp 141-280; September issue, pp 281-420; October issue, pp 421-558; November issue, pp 559-700; December issue, pp 701-928.

- lel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848
- Agrypnia, autoimmune**
autoantibodies to a 108Kd protein in relapsing-remitting autoimmune agrypnia (Frisullo et al) 2003;54:(suppl 7) S47
- Alcohol consumption**
alcohol consumption and the incidence of Parkinson's disease (Hernán et al) 2002;54:170
- Alcoholic neuropathy**
alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy (Koike et al) 2003;54:19
- Alexander disease**
fulminant Alexander disease with a novel mutation in glial fibrillary acidic protein gene (Bassuk et al) 2003;54:(suppl 7) S157
- Allergic encephalomyelitis, experimental**
time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
- Almotriptan**
almotriptan efficacy in achieving pain relief and pain-free status 1 and 2 hours after treatment of acute migraine (Mathew) 2003;54:(suppl 7) S33
almotriptan in acute migraine: maximizing efficacy and minimizing adverse events (Smith) 2003;54:(suppl 7) S34
an evaluation of the effectiveness and tolerability of almotriptan for acute migraine in patients managed by neurologists in Spain (Pascual et al) 2003;54:(suppl 7) S33
- Alpha-glucosidase gene**
dual mutation of alpha-glucosidase gene presenting as adult-onset respiratory failure (Kern et al) 2003;54:(suppl 7) S76
- Alpha-sarcoglycan gene**
on symptomatic heterozygous alpha-sarcoglycan gene mutation carriers (Fischer et al) 2003;54:674
- α -galactosidase A**
hearing loss in Fabry's disease: the effect of α -galactosidase A replacement therapy (Hajioff et al) 2003;54:(suppl 7) S26
- α -synuclein**
 α -synuclein toxicity in yeast (Dixon et al) 2003;54:(suppl 7) S39
triplication of alpha-synuclein is causal of neuropathologically confirmed Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy in a single kindred (Gwinn-Hardy et al) 2003;54:848
- ALS CARE Database**
amyotrophic lateral sclerosis (ALS) outcomes in US military veterans compared with non-veterans: neuroepidemiological insights from the ALS CARE Database (Brooks et al) 2003;54:700
- Alzheimer's disease, analysis**
association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697
comparisons of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease (AD) versus controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S29
herpesviruses in brains in Alzheimer's and Parkinson's diseases (Hemling et al) 2002;54:267
heterogeneous age-related breakdown of white matter structural integrity: implications for "disconnection" in aging and Alzheimer's disease (Bartzokis et al) 2003;54:(suppl 7) S29
high field strength (3T) magnetic resonance imaging of brain iron in Alzheimer's disease (Zimmerman et al) 2003;54:(suppl 7) S68
limbic hypometabolism in Alzheimer's disease and mild cognitive impairment (Nestor et al) 2003;54:343
patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately parallel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848
a subgroup analysis of the association between depression and death in Alzheimer's disease (Lopez et al) 2003;54:(suppl 7) S67
survival but not dementia progression differs in DLB versus AD (Williams et al) 2003;54:(suppl 7) S30
- Alzheimer's disease, early**
caspase activation in the limbic cortex of subjects with early Alzheimer's disease (Gastard et al) 2003;54:393
- Alzheimer's disease, early-onset**
c954C→T polymorphism in the *Fe65L2* gene is associated with early-onset Alzheimer's disease (Tanahashi et al) 2002;54:137 (Correction)
- Alzheimer's disease, familial**
Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE ϵ 4 (Leverenz et al) 2003;54:(suppl 7) S68
- Alzheimer's disease, genetics**
absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Dermaut et al) 2003;54:555 (Reply)
absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Ohkubo et al) 2003;54:553 (Letter)
- Alzheimer's disease, mild**
expected cognitive decline and risk of nursing home admission for patients with mild or moderate Alzheimer's disease (Ward et al) 2003;54:698
- Alzheimer's disease, moderate**
expected cognitive decline and risk of nursing home admission for patients with mild or moderate Alzheimer's disease (Ward et al) 2003;54:698
- Alzheimer's disease, onset**
apolipoprotein ϵ 4 modifies Alzheimer's disease onset in an E280A PS1 kindred (Pastor et al) 2002;54:163
- Alzheimer's disease, pathogenesis**
Alzheimer's disease: genetic evidence points to a single pathogenesis (Hardy) 2002;54:143 (Editorial)
brain magnetic resonance spectroscopy in mild cognitive impairment predicts conversion to Alzheimer's disease (Modrego et al) 2003;54:(suppl 7) S30
CCR1 is an early and specific marker of Alzheimer's disease (Halks-Miller et al) 2003;54:638
- Alzheimer's disease, pathology**
chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology (Levey) 2002;54:144 (Editorial)
the E4 allele predicts neuropathological severity, but not cholinergic dysfunction, in Alzheimer's disease (Tiraboschi et al) 2003;54:(suppl 7) S29
increased Alzheimer's pathology in Parkinson's disease related to antimuscarinic drugs (Perry et al) 2002;54:235
- Alzheimer's disease, treatment**
a turn of the sulfate in Alzheimer's disease (Irizarry) 2002;54:7 (Editorial)

Ambulatory dysfunction

cerebellar gray matter MRI T2 hypointensity is independently associated with ambulatory dysfunction and clinical course in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59

γ -Aminobutyric acid

brain GABA in SSADH deficiency (Novotny Jr. et al) 2003;54:(suppl 7) S106

GABA, γ -aminobutyric acid, and neurological disease (Wong et al) 2003;54:(suppl 6) S3

Amnesia, chronic

chronic amnesic states and temporal lobe complex partial status epilepticus (Perez-Gosienfiao et al) 2003;54:(suppl 7) S54

AMPA receptors

AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia (Follett et al) 2003;54:(suppl 7) S103

Amygdala

a human amygdalo-fusiform pathway (Smith et al) 2003;54:(suppl 7) S76

Amyloid angiopathy, cerebral

matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379

Amyloid β

amyloid β protein toxicity mediated by the formation of amyloid- β protein precursor complexes (Lu et al) 2003;54:781

β -amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (Wiltfang et al) 2002;54:263
circulating β amyloid protein is elevated in patients with acute ischemic stroke (Lee et al) 2003;54:(suppl 7) S65
patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately parallel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848

Amyotrophic lateral sclerosis

ALS is a "dying-back" distal axonopathy: evidence in mice and man (Glass et al) 2003;54:849

amyotrophic lateral sclerosis (ALS) outcomes in US military veterans compared with non-veterans: neuroepidemiological insights from the ALS CARE Database (Brooks et al) 2003;54:700

ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis (Al-Chalabi et al) 2003;54:130

disruption of glial glutamate transport by reactive oxygen species produced in motor neurons in response to excitotoxic activation: an in vitro model of ALS pathogenesis (Weiss et al) 2003;54:(suppl 7) S43

high expression of macrophage migration inhibitory factor (MIF) in spinal cord and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients (Ogata et al) 2003;54:(suppl 7) S51

Amyotrophic lateral sclerosis, sporadic

an evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis (Armon) 2003;54:(suppl 7) S78

Amyotrophic lateral sclerosis dementia

longitudinal analysis of the anatomic, neuropsychological, and behavioral features of ALS dementia (Murphy et al) 2003;54:(suppl 7) S52

Anandamide

the dark side of endocannabinoids: a neurotoxic role for anandamide (Faden et al) 2003;54:(suppl 7) S77

Aneurysm, miliary

cerebral hemorrhage produced by ruptured dissecting aneurysm in miliary aneurysm (Rosenblum) 2003;54:376

Angelman's syndrome

do loss-of-function UBE3A mutations account for the complete Angelman's syndrome phenotype? (Gerry and Graf) 2003;54:(suppl 7) S119

Angiitis of the central nervous system, primary

outcome for biopsy-proven primary angiitis of the central nervous system in children treated with pulse cyclophosphamide and prednisone (McGrath et al) 2003;54:(suppl 7) S140

transient cerebral arteriopathy and primary angiitis of the central nervous system in children: a spectrum of cerebral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140

Angiopathy, cerebral amyloid

matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379

Animal models

acute motor axonal neuropathy rabbit model: immune attack on nerve root axons (Susuki et al) 2003;54:383

addition of levodopa in combination with entacapone increases "On" time without potentiating peak dyskinesia: a study in the MPTP-treated primate (Jenner et al) 2003;54:(suppl 7) S40

ALS is a "dying-back" distal axonopathy: evidence in mice and man (Glass et al) 2003;54:849

behavioral pharmacology of ramelteon (TAK-375) in small mammals (Miyamoto et al) 2003;54:(suppl 7) S46

L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

cell death in transgenic mice model of Lafora's disease (Machado-Salas et al) 2003;54:(suppl 7) S54

cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid (Gianazza et al) 2003;54:(suppl 7) S52

detecting neutralizing antibodies against botulinum toxin type B with a mouse diaphragm assay (Dressler et al) 2003;54:(suppl 7) S71

the effects of bone marrow transplants on the progression of motoneuron disease in PU.1^{-/-} mice (Beers et al) 2003;54:(suppl 7) S43

enzyme replacement therapy in the tolerant mouse model of Pompe's disease (Raben et al) 2003;54:(suppl 7) S20

facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53

genetic analyses of murine neuroblastoma: implications for human disease (Hackett et al) 2003;54:(suppl 7) S109

graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103

the HPH-1 mouse: a model for dominantly inherited GTP-clycohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice (Sherr et al) 2003;54:(suppl 7) S53

impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model (Wong et al) 2002;54:251

increases in plasma arginine vasopressin after transient focal ischemia in rats (Chang et al) 2003;54:(suppl 7) S64

- intravenous human neural stem cell transplantation ameliorated the epileptogenesis in rat epilepsy model (Chu et al) 2003;54:(suppl 7) S54
- κ opioid receptor selectivity for ischemic neuroprotection with BRL-52537 in rats (Zhang et al) 2003;54:(suppl 7) S26
- magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
- matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379
- mechanisms of neuroprotection by the 70kD heat shock protein in transgenic mice: influence of astrocytes (Zheng et al) 2003;54:(suppl 7) S24
- minocycline is not beneficial in a phenotypic mouse model of Huntington's disease (Diguett et al) 2003;54:843 (Letter)
- minocycline is protective in a mouse model of Huntington's disease (Hersch et al) 2003;54:843 (Letter)
- minocycline is protective in a mouse model of Huntington's disease (Hockly et al) 2003;54:844 (Reply)
- modeling human neurodegenerative diseases in *Drosophila* (Daga et al) 2003;54:(suppl 7) S57
- modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103
- mouse model of immune-mediated cerebellar diseases (Golumbek et al) 2003;54:(suppl 7) S117
- a mouse model of Lyme neuroborreliosis: comparison of American and European strains of *B. burgdorferi* (Li et al) 2003;54:(suppl 7) S49
- the multiple functions of herpes simplex virus type 1 latency-associated gene (LAG) in a LAG-expressing transgenic mouse (Steiner et al) 2003;54:(suppl 7) S48
- murine succinic semialdehyde dehydrogenase deficiency (Gupta et al) 2003;54:(suppl 6) S81
- natural history and response to weekly oral prednisolone in the *dyw* mouse model of congenital muscular dystrophy (Connolly et al) 2003;54:(suppl 7) S155
- neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103
- papillomavirus-like particle A β vaccine induces strong antibody response in APP/PS1 transgenic mice (Zamora et al) 2003;54:(suppl 7) S29
- preliminary studies on prenatal ethanol exposure and reduced grip strength in rats (Johnson and Smith) 2003;54:(suppl 7) S128
- presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration (McGeer et al) 2003;54:599
- a primate model of cerebral injury in the premature infant (Inder et al) 2003;54:(suppl 7) S121
- prolonged therapeutic window for ischemic neuroprotection with selective κ opioid receptor agonist, BRL 52537 in rat (Chen et al) 2003;54:(suppl 7) S66
- protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage (Wang et al) 2003;54:655
- repetitive febrile seizures in rat pups impair long-term memory and hippocampal cAMP response-element binding protein phosphorylation (Chang et al) 2003;54:706
- retinoic acid stimulates neurogenesis in the postnatal rodent subventricular zone-olfactory bulb pathway (Wang et al) 2003;54:(suppl 7) S77
- reversal of clinical signs by IL-16-targeted therapy in MOG35-55-induced relapsing-remitting EAE in H-2b/s mice (Skundric et al) 2003;54:(suppl 7) S62
- time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
- transgenic mouse models of dopamine deficiency (Chen and Zhuang) 2003;54:(suppl 6) S91
- Annals of Neurology**
message from the editor (Johnson) 2002;54:1
- Antibodies**
antibodies to specific proteins of *Acinetobacter sp.* and *Pseudomonas aeruginosa* in multiple sclerosis patients (Hughes et al) 2003;54:(suppl 7) S63
autoimmune limbic encephalitis associated with potassium channel antibodies (Theiben et al) 2003;54:(suppl 7) S22
brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connolly et al) 2003;54:(suppl 7) S146
a capture ELISA and its use in an outpatient MS population to screen for antibody-mediated decreased bioactivity (Dail et al) 2003;54:(suppl 7) S63
cross-reactive antibodies against myelin basic protein, *Acinetobacter sp.* and *Pseudomonas aeruginosa* in multiple sclerosis patients (Wilson et al) 2003;54:(suppl 7) S62
detecting neutralizing antibodies against botulinum toxin type B with a mouse diaphragm assay (Dressler et al) 2003;54:(suppl 7) S71
epitope recognition differentially controls effector functions of myelin/oligodendrocyte glycoprotein-specific autoantibodies and phenotypic expression of autoimmune demyelination (von Büdingen et al) 2003;54:(suppl 7) S37
jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pittock et al) 2003;54:(suppl 7) S70
paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Motomura et al) 2002;54:277 (Reply)
paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Pinto and Lang) 2002;54:277 (Letter)
time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
voltage-gated potassium channel antibodies in limbic encephalitis (Pozo-Rosich et al) 2003;54:530
voltage-gated potassium channel antibody-associated limbic encephalitis is relatively common, potentially treatable, and usually nonparaneoplastic (Vincent et al) 2003;54:(suppl 7) S20
why doesn't a specific antibody kill spirochetes? expression of dbpA by *B. burgdorferi* in peripheral nerve in the presence of high titers of anti-dbpA antibody (Narayan et al) 2003;54:(suppl 7) S50
- Anticholinergics**
chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology (Levey) 2002;54:144 (Editorial)

Antiepileptic drugs

antiepileptic drug use in nursing home admissions (Garard et al) 2003;54:75

the Cincinnati antiepileptic drug side effect neurologic subscale detects and quantifies significant interpatient variability in antiepileptic drug neurologic toxicity (Morita et al) 2003;54:(suppl 7) S137

development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cincinnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136

Antimuscarinic drugs

increased Alzheimer's pathology in Parkinson's disease related to antimuscarinic drugs (Perry et al) 2002;54:235

Antineuronal nuclear autoantibody-type 2

jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pitcock et al) 2003;54:(suppl 7) S70

Antioxidants

meningitis-associated hearing loss: protection by adjunctive antioxidant therapy (Klein et al) 2003;54:451

a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28

stilbazulenyl nitron, a novel antioxidant, is highly neuroprotective in focal ischemia (Ginsberg et al) 2003;54:330

Antipsychotic medications

rapid induction of proapoptotic proteins in nigral dopamine neurons by antipsychotic medication (Mazurek et al) 2003;54:(suppl 7) S42

Antiretroviral therapy

HIV-associated painful neuropathy in the era of highly active antiretroviral therapy (Schifitto et al) 2003;54:(suppl 7) S50

reduced dependence of BBB compromise on microglial activation in HIV patients on HAART (Avison et al) 2003;54:(suppl 7) S48

reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49

Anxiety

the economic impact of migraine and comorbid anxiety and depression in children: results from a case-control study (Pesa and Lage) 2003;54:(suppl 7) S33

Aphasia

aphasia in hyperacute stroke: language follows brain penumbra dynamics (Croquelois et al) 2003;54:321

the core and halo of primary progressive aphasia and semantic dementia (Mesulam et al) 2003;54:(suppl 5) S11

Apolipoprotein Eε4

apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred (Pastor et al) 2002;54:163

the E4 allele predicts neuropathological severity, but not cholinergic dysfunction, in Alzheimer's disease (Tiraboschi et al) 2003;54:(suppl 7) S29

Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE ε4 (Leverenz et al) 2003;54:(suppl 7) S68

longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ε4 allele (Caselli et al) 2003;54:(suppl 7) S28

patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately paral-

lel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848

Apomorphine

a phase I, open-label, three-way crossover study in healthy volunteers to compare the pharmacokinetics of apomorphine HCl delivered from a cartridge using a pen device to that delivered using a syringe manually filed from either a cartridge or an ampoule (Morton et al) 2003;54:(suppl 7) S72

Apparent diffusion coefficient

apparent diffusion coefficient values in posterior limb of internal capsule predictive of outcome after perinatal asphyxia (Neil et al) 2003;54:(suppl 7) S126

Aprataxin

alternatively spliced transcripts of aprataxin in early-onset ataxia with oculomotor apraxia and hypalbuminemia (Hirano et al) 2003;54:(suppl 7) S58

Apraxia, oculomotor

alternatively spliced transcripts of aprataxin in early-onset ataxia with oculomotor apraxia and hypalbuminemia (Hirano et al) 2003;54:(suppl 7) S58

Aquaporin 7

expression of aquaporin 7 and its localization in normal human skeletal myofibers (Wakayama et al) 2003;54:(suppl 7) S45

AREDS Ancillary Trial

a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28

Arginine vasopressin

increases in plasma arginine vasopressin after transient focal ischemia in rats (Chang et al) 2003;54:(suppl 7) S64

Aromatic L-amino acid decarboxylase deficiency

aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes (Swoboda et al) 2003;54:(suppl 6) S49

Arterial ischemic stroke, neonatal

neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138

Arteriopathy, cerebral

transient cerebral arteriopathy and primary angiitis of the central nervous system in children: a spectrum of cerebral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140

Arthrogryposis multiplex congenita

diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita (Kang et al) 2003;54:790

the diagnostic value of electromyography and muscle pathology in the evaluation of arthrogryposis multiplex congenita (Kang et al) 2003;54:(suppl 7) S155

Asperger's syndrome

Asperger's syndrome: is pharmacological response indicative of distinct subtype? (Bohan) 2003;54:(suppl 7) S147

Asphyxia, perinatal

apparent diffusion coefficient values in posterior limb of internal capsule predictive of outcome after perinatal asphyxia (Neil et al) 2003;54:(suppl 7) S126

selective cerebral white matter injury in asphyxiated term newborns (Landesman et al) 2003;54:(suppl 7) S126

Astrocytes

mechanisms of neuroprotection by the 70kD heat shock protein in transgenic mice: influence of astrocytes (Zheng et al) 2003;54:(suppl 7) S24

Astrocytoma

high-dose preirradiation chemotherapy for children with newly diagnosed high-grade astrocytomas (MacDonald et al) 2003;54:(suppl 7) S152

Ataxia, early onset

alternatively spliced transcripts of aprataxin in early-onset ataxia with oculomotor apraxia and hypoalbuminemia (Hirano et al) 2003;54:(suppl 7) S58

Ataxia, febrile episodic

novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725

Ataxia, Friedreich's

cardiac bioenergetics in Friedreich's ataxia (Bir-Avragim et al) 2003;54:552 (Reply)

cardiac bioenergetics in Friedreich's ataxia (Lodi et al) 2003;54:552 (Letter)

simultaneous tuberous sclerosis and Friedreich's ataxia: no evidence for interaction (Walker et al) 2003;54:(suppl 7) S57

Ataxia, recessive

pathogenesis of clinical signs in recessive ataxia with sacadic intrusions (Swartz et al) 2003;54:825

Ataxia, spinocerebellar

clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) (Rolfs et al) 2003;54:367

disinhibition-dysexecutive syndrome associated with differential age of onset in a family with SCA-17 (Farbman and Kaufer) 2003;54:(suppl 7) S52

disrupted nuclear organization and function in Machado-Joseph disease (Lewis et al) 2003;54:(suppl 7) S51

do CTG expansions at the SCA8 locus cause ataxia? (Schöls et al) 2003;54:110

pathogenesis of clinical signs in recessive ataxia with sacadic intrusions (Swartz et al) 2003;54:825

SCA2-related parkinsonism in Taiwan: clinical and PET studies (Shan et al) 2003;54:(suppl 7) S40

seeking clarity through the genetic lens: a work in progress (Nance) 2002;54:5 (Editorial)

spinocerebellar ataxia type 14 is caused by a mutation in protein kinase C γ (Yabe et al) 2003;54:(suppl 7) S21

visual function in Machado-Joseph disease (Subramony et al) 2003;54:(suppl 7) S40

Atomoxetine

atomoxetine for the treatment of attention deficit hyperactivity disorder and comorbid tics in children (Lewis et al) 2003;54:(suppl 7) S106

efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder (Dunn et al) 2003;54:(suppl 7) S143

Atrophy, gray matter

progressive gray matter atrophy occurs in the earliest clinical stages of relapse onset multiple sclerosis (Dalton et al) 2003;54:(suppl 7) S38

Atrophy, multiple system

cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: the NNIPPS project (Leigh et al) 2003;54:(suppl 7) S70

lesions of hippocampus in multiple system atrophy (Wang et al) 2003;54:(suppl 7) S52

neuroprotection and natural history in parkinson plus syndromes: construction and validation of a clinical scale to assess disease progression in progressive supranuclear palsy and multiple system atrophy (Payan et al) 2003;54:(suppl 7) S39

neuroprotection and natural history in parkinson plus syndromes: cross-sectional description of magnetic resonance imaging findings in a large prospective cohort of patients with progressive supranuclear palsy and multiple system atrophy (Kraft et al) 2003;54:(suppl 7) S39

Atrophy, spinal cord

spinal cord atrophy and disability in multiple sclerosis over 4 years: application of a new technique in monitoring disease progression (Lin et al) 2003;54:(suppl 7) S78

Atrophy, spinal muscular

infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann et al) 2003;54:719

valproic acid increases SMN levels in spinal muscular atrophy patient cells (Sumner et al) 2003;54:647

Attention, social

impaired social attention after frontal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

Attention, spatial

the resolution of spatial attention after parietal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

Attention deficit hyperactivity disorder

association of cortical versus behavioral disinhibition in Tourette's syndrome and attention deficit hyperactivity disorder (Gilbert et al) 2003;54:(suppl 7) S143

atomoxetine for the treatment of attention deficit hyperactivity disorder and comorbid tics in children (Lewis et al) 2003;54:(suppl 7) S106

comparative school-day efficacy of Ritalin LA, Concerta, and placebo in children with attention deficit hyperactivity disorder (Lopez et al) 2003;54:(suppl 7) S143

daytime sleepiness in children with attention deficit hyperactivity disorder (Ravid et al) 2003;54:(suppl 7) S144

efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder (Dunn et al) 2003;54:(suppl 7) S143

the impact of gender and subtypes on attention deficit hyperactivity disorder (Gross-Tsur et al) 2003;54:(suppl 7) S144

once-daily dosing with the OROS formulation of methylphenidate has minimal impact on tics in children with ADHD (Palumbo et al) 2003;54:(suppl 7) S27

once-daily OROS methylphenidate: impact on tics in children with attention deficit hyperactivity disorder (Palumbo et al) 2003;54:(suppl 7) S143

OROS methylphenidate (MPH) treatment for attention deficit/hyperactivity disorder: long-term effect on growth (Giedd and Concerta Study Group) 2003;54:(suppl 7) S27

Audiogenic seizures, juvenile

identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice (Sherr et al) 2003;54:(suppl 7) S53

Auditory based category decision

language networks underlying auditory based category decision in children identified with fMRI (Balsamo et al) 2003;54:(suppl 7) S105

Auditory evoked potentials, brainstem

brainstem auditory evoked potential abnormalities in twins in the first year of life (Zafeiriou et al) 2003;54:(suppl 7) S132

Auras, dialeptic

heart rate analysis can differentiate dialeptic temporal lobe epilepsy from dialeptic auras and dialeptic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55

Autism

autism with facial port-wine stain: a new syndrome? (Chugani et al) 2003;54:(suppl 7) S129

brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connelly et al) 2003;54:(suppl 7) S146

investigation of 40 positional and functional candidate genes for autism (Huq et al) 2003;54:(suppl 7) S119

neuroglial activation in autism: a potential neuroinflammatory pathogenic mechanism (Vargas et al) 2003;54:(suppl 7) S147

Autism with regression

brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connelly et al) 2003;54:(suppl 7) S146

Autistic behavior

increased protein acetylation in lymphocytes predicts autistic behavior in fragile X syndrome (Kaufmann et al) 2003;54:(suppl 7) S105

Autistic spectrum disorders

association of autistic spectrum disorders and Tourette's syndrome (Hussein and Kuban) 2003;54:(suppl 7) S147

the prevalence of autistic spectrum disorder in children seen in a tertiary care epilepsy clinic (Clarke et al) 2003;54:(suppl 7) S149

psychostimulant use in children with autistic spectrum disorder (Chez et al) 2003;54:(suppl 7) S147

Autoantibodies

autoantibodies to a 108Kd protein in relapsing-remitting autoimmune agrypnia (Frisullo et al) 2003;54:(suppl 7) S47

epitope recognition differentially controls effector functions of myelin/oligodendrocyte glycoprotein-specific autoantibodies and phenotypic expression of autoimmune demyelination (von Büdingen et al) 2003;54:(suppl 7) S37

jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pittock et al) 2003;54:(suppl 7) S70

Autoimmune agrypnia, relapsing-remitting

autoantibodies to a 108Kd protein in relapsing-remitting autoimmune agrypnia (Frisullo et al) 2003;54:(suppl 7) S47

Autoimmune autonomic neuropathy

passive transfer of autoimmune autonomic neuropathy (Vernino and Lennon) 2003;54:(suppl 7) S19

Autoimmune demyelination

epitope recognition differentially controls effector functions of myelin/oligodendrocyte glycoprotein-specific autoantibodies and phenotypic expression of autoimmune demyelination (von Büdingen et al) 2003;54:(suppl 7) S37

Autoimmune disorders

neuropathology of dementia associated with relapsing polychondritis an autoimmune disorder (Starr et al) 2003;54:(suppl 7) S68

Autoimmune limbic encephalitis

autoimmune limbic encephalitis associated with potassium channel antibodies (Theiben et al) 2003;54:(suppl 7) S22

Autoimmune optic neuritis

paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38

Autonomic neuropathy, autoimmune

passive transfer of autoimmune autonomic neuropathy (Vernino and Lennon) 2003;54:(suppl 7) S19

Autosomal dominant CNS disorders

human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syndrome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118

Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency

autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease) (Segawa et al) 2003;54:(suppl 6) S32

the *HPH-1* mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Autosomal dominant spinocerebellar ataxia

clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) (Rolfs et al) 2003;54:367

Autosomal dominant variable occipital cephalocele

variable occipital cephalocele with autosomal-dominant inheritance: a three-generation pedigree (Bassuk et al) 2003;54:(suppl 7) S157

Autosomal recessive microcephaly

multiple genetic loci lead to distinctive autosomal recessive microcephaly syndromes (Mochida et al) 2003;54:(suppl 7) S119

Axonal neuropathy, distal

ALS is a "dying-back" distal axonopathy: evidence in mice and man (Glass et al) 2003;54:849

Axonal neuropathy, motor

acute motor axonal neuropathy rabbit model: immune attack on nerve root axons (Susuki et al) 2003;54:383

Bacteriophage ϕ C31 integrase

a novel nonviral approach to gene therapy for muscle disease mediated by phage ϕ C31 integrase (Wheeler et al) 2003;54:(suppl 7) S43

Baylor College of Medicine (BCM) Cognitive and Neurobehavioral Status (CNS) Examination

validation of the Baylor College of Medicine Cognitive and Neurobehavioral Status Examination (West and Ringholz) 2003;54:(suppl 7) S22

Bcl-2

Bcl-2-mediated induction of neural differentiation: a role for NGF/TrkA (Liang et al) 2003;54:(suppl 7) S105

Behavior

clinical response to psychopharmacology for behavior in fragile X syndrome (Berry-Kravis and Potanos) 2003;54:(suppl 7) S144

the effects of huperzine A on cognitive functioning and behavior in patients with Huntington's disease (Peavy et al) 2003;54:(suppl 7) S42

longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ϵ 4 allele (Caselli et al) 2003;54:(suppl 7) S28

Behavior, autistic

increased protein acetylation in lymphocytes predicts autistic behavior in fragile X syndrome (Kaufmann et al) 2003;54:(suppl 7) S105

Behavior disorders

- comorbidity of childhood-onset epilepsy and psychiatric and behavioral disorders: a population-based study (Hedderick and buchhalter) 2003;54:(suppl 7) S115
- oxcarbazepine for the treatment of behavior/mood disorders in children (Alberts et al) 2003;54:(suppl 7) S148

Behavioral disinhibition

- association of cortical versus behavioral disinhibition in Tourette's syndrome and attention deficit hyperactivity disorder (Gilbert et al) 2003;54:(suppl 7) S143

Behavioral problems

- sleep disruption and behavioral problems in children with new-onset seizures (Dunn et al) 2003;54:(suppl 7) S133

Behçet's disease

- clinical and neuroradiological heterogeneities of neurological complications of Behçet's disease (Honma et al) 2003;54:(suppl 7) S79

Belgium

- tibial muscular dystrophy in a Belgian family (Van den Bergh et al) 2002;54:248

Benzodiazepines

- phenobarbital and benzodiazepines alter expression of genes involved in inhibitory transmission long after treatment has stopped (Raol et al) 2003;54:(suppl 7) S104

Beth Israel Germinoma Consortium

- intensive chemotherapy followed by response-based radiotherapy: preliminary results of the Beth Israel Germinoma Consortium (Allen et al) 2003;54:(suppl 7) S109

Biopsy, brain

- the diagnostic yield of brain biopsy in children presenting to neurology (Venkateswaran et al) 2003;54:(suppl 7) S131

Biopsy, microvascular

- vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838

Biopsy, muscle

- congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy (Gurnett et al) 2003;54:(suppl 7) S155
- diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita (Kang et al) 2003;54:790

Biopsy, olfactory

- olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome (Ronnelt et al) 2002;54:206

Birth injuries, brachial plexus

- new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156
- outcome following nonoperative treatment of brachial plexus birth injuries (DiTaranto et al) 2003;54:(suppl 7) S156
- predictive value of electrodiagnostic studies in brachial plexus injuries (Vednarayanan et al) 2003;54:(suppl 7) S155

Blood

- autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45
- decreased fibronectin expression in meningeal blood vessels of Sturge-Weber's syndrome (Comi et al) 2003;54:(suppl 7) S116

Blood-brain barrier compromise

- reduced dependence of BBB compromise on microglial activation in HIV patients on HAART (Avison et al) 2003;54:(suppl 7) S48
- viremia in the presence of blood-brain barrier compromise increases severity of HIV-associated neurocognitive impairment (Avison et al) 2003;54:(suppl 7) S49

Blood volume, cerebral

- cerebral blood volume measurements by T2*-weighted magnetic resonance imaging and contrast injection (Newman et al) 2003;54:(suppl 7) S24

Body mass index

- topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136

Bone marrow transplantation

- acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44
- the effects of bone marrow transplants on the progression of motoneuron disease in PU.1^{-/-} mice (Beers et al) 2003;54:(suppl 7) S43

Book reviews

- Advances in Neurology: Volume 91 Parkinson's Disease*, edited by Gordin et al (Weiner) 2003;54:418
- Asymmetrical Brain*, edited by Hugdahl and Davidson (Galaburda) 2002;54:279
- Cancer Neurology in Clinical Practice*, edited by Schiff and Wen (Rogers) 2002;54:138
- The Changing Brain: Alzheimer's Disease and advanced in Neuroscience*, by Black (Rabins) 2002;54:138
- Childhood Headache*, edited by Abu-Arafeh (Jordan and Kossoff) 2002;54:279
- A Clinical Guide to Epileptic Syndromes and Their Treatments: Based on the New ILAE Diagnostic Scheme*, by Panayiotopoulos (Krauss and Sinha) 2002;54:280
- The Clinical Practice of Critical Care Neurology, 2nd ed*, by Wijdicks (Ziai) 2003;54:557
- The Clinical Science of Neurologic Rehabilitation, 2nd edition*, by Dobkin (Dromerick) 2003;54:419
- The Cognitive and Neural Bases of Spatial Neglect*, edited by Karnath et al (Hillis) 2003;54:846
- Encyclopedia of the Neurological Sciences*, edited by Aminoff and Daroff 2003;54:694
- Fetal and Neonatal Brain Injury, Mechanisms, Management and the Risks of Practice, Third Edition*, edited by Stevenson et al (Ferriero) 2003;54:846
- Fundamental Neuroscience, 2nd ed*, by Squire et al (Johnston) 2003;54:694
- Multiple Sclerosis Immunology, Pathology, and Pathophysiology*, by Herndon (Rodriguez) 2003;54:418
- Neurological Disorders: Course and Treatment, 2nd ed*, edited by Brandt et al (Fishman) 2003;54:557

Borrelia burgdorferi

- a mouse model of Lyme neuroborreliosis: comparison of American and European strains of *B. burgdorferi* (Li et al) 2003;54:(suppl 7) S49
- why doesn't a specific antibody kill spirochetes? expression of dbpA by *B. burgdorferi* in peripheral nerve in the presence of high titers of anti-dbpA antibody (Narayan et al) 2003;54:(suppl 7) S50

Borreliosis; see Neuroborreliosis

Botulinum toxin type B

- clinical experiences with botulinum toxin type B (Myobloc) in the treatment of cervical dystonia: secondary resistance and electrophysiologic observations (Gollop) 2003;54:(suppl 7) S41

detecting neutralizing antibodies against botulinum toxin type B with a mouse diaphragm assay (Dressler et al) 2003;54:(suppl 7) S71

Boys

frontal white matter reductions in healthy boys with complex stereotypies (Kates et al) 2003;54:(suppl 7) S144

Brachial plexus birth injuries

new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156

outcome following nonoperative treatment of brachial plexus birth injuries (DiTaranto et al) 2003;54:(suppl 7) S156

predictive value of electrodiagnostic studies in brachial plexus injuries (Vednarayanan et al) 2003;54:(suppl 7) S155

Brain

brain GABA in SSADH deficiency (Novotny Jr. et al) 2003;54:(suppl 7) S106

Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003; 54:851

dynamical entrainment among epileptic brain areas (Shiau et al) 2003;54:(suppl 7) S55

increased osteopontin in cerebrospinal fluid and brains from patients with multiple sclerosis (Fukaura et al) 2003;54:(suppl 7) S61

SIRPa-associated molecules (SGT and ArsA) in the brain (Narayanan et al) 2003;54:(suppl 7) S116

torsinA protein and mRNA expression in the human brain of newborns, infants, and children (Siebert et al) 2003; 54:(suppl 7) S116

Brain Attack Coalition (BAC)

are the Brain Attack Coalition's recommended criteria for primary stroke centers associated with better care and outcomes in patients with stroke? (Douglas et al) 2003; 54:696, (suppl 7) S17

Brain Attack Surveillance in Corpus Christi (BASIC) project

designing multi-ethnic stroke studies: the Brain Attack Surveillance in Corpus Christi (BASIC) project (Morgenstern et al) 2003;54:(suppl 7) S65

Brain biopsy

the diagnostic yield of brain biopsy in children presenting to neurology (Venkateswaran et al) 2003;54:(suppl 7) S131

Brain damage

clinical research of fastigial nucleus stimulation in treatment of disorders of consciousness by brain damage (Yang et al) 2003;54:(suppl 7) S25

Brain damage, early focal

persistent unilateral spatial neglect in young children with early focal brain damage (Heeren and Trauner) 2003; 54:(suppl 7) S142

Brain-derived neurotrophic factor

association between a polymorphism of *brain-derived neurotrophic factor* gene and sporadic Parkinson's disease (Masaki et al) 2002;54:276 (Letter)

brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connelly et al) 2003;54:(suppl 7) S146

Brain development

expression profiling of developing PS1-deficient brain (Korade Mirnics et al) 2003;54:(suppl 7) S119

MeCP2 expression is dynamically regulated during brain development (Mullaney et al) 2003;54:(suppl 7) S104

Reelin and Lis1 signaling are coordinated in brain development (Assadi et al) 2003;54:(suppl 7) S104

Brain imaging

brain imaging, clinical correlates, and social consequences of intellectual impairment in myotonic dystrophy type 1 (Meola et al) 2003;54:(suppl 7) S75

high field strength (3T) magnetic resonance imaging of brain iron in Alzheimer's disease (Zimmerman et al) 2003;54:(suppl 7) S68

intraoperative infrared functional imaging of human brain (Gorbach et al) 2003;54:297

Brain injury

brain injury in children with sickle cell disease: prevalence and etiology (Steen et al) 2003;54:564

L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

Brain injury, traumatic

association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128

proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153

Brain parenchyma sonography

differential findings on brain parenchyma sonography in tauopathies and synucleinopathies (Walter et al) 2003; 54:(suppl 7) S41

Brain surgery, childhood

neuropsychological profiles after brain surgery in childhood (Kuroda et al) 2003;54:(suppl 7) S142

Brain tumors

inhibition of brain tumor-mediated excitotoxic destruction and invasion implementing a glutamate release antagonist (Haque et al) 2003;54:851

Brain tumors, childhood

the clinical application of positron emission tomography in childhood brain tumors (Kaplan et al) 2003;54:(suppl 7) S149

moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140

pediatric brain tumor stem cells (Hemmati et al) 2003;54:(suppl 7) S117

Brain tumors, malignant

cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54:(suppl 7) S31

Brainstem auditory evoked potentials

brainstem auditory evoked potential abnormalities in twins in the first year of life (Zafeiriou et al) 2003;54:(suppl 7) S132

BRL 52537

κ opioid receptor selectivity for ischemic neuroprotection with BRL-52537 in rats (Zhang et al) 2003;54:(suppl 7) S26

prolonged therapeutic window for ischemic neuroprotection with selective κ opioid receptor agonist, BRL 52537 in rat (Chen et al) 2003;54:(suppl 7) S66

Broca's area

Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003; 54:851

Butyrylcholinesterase

cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54: (suppl 7) S31

C1q

C1q expression increases in the central and peripheral nervous system during neuroborreliosis (Bai et al) 2003;54: (suppl 7) S49

CACNA1A gene

novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725

CACNA1H gene

association between genetic variation of *CACNA1H* and childhood absence epilepsy (Chen et al) 2002;54:239

Calbindin-D28

modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103

Calbindin-D28k

anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132

Calcium

serum calcium is associated with carotid artery plaque thickness: the Northern Manhattan Study (Rundek et al) 2003;54:(suppl 7) S23

Calcium channel gene CACNA1A

novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725

Calcium channel gene CACNA1H

association between genetic variation of *CACNA1H* and childhood absence epilepsy (Chen et al) 2002;54:239

Calcium channels, P/Q-type

paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Motomura et al) 2002;54: 277 (Reply)

paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Pinto and Lang) 2002;54: 277 (Letter)

Calcium-dependent proteinase

analysis of calcium-dependent proteinase and cytoskeletal proteins in muscle from patients with inflammatory myopathy (Murata et al) 2003;54:(suppl 7) S44

cAMP response-element binding protein

repetitive febrile seizures in rat pups impair long-term memory and hippocampal cAMP response-element binding protein phosphorylation (Chang et al) 2003;54: 706

Cardiac surgery, newborn

stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003; 54:(suppl 7) S110

Carbamazepine

topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135

Carbidopa

the effects of carbidopa on sinemet CR in Parkinson's disease (Fang et al) 2003;54:(suppl 7) S71

Cardiac arrest

electrocardiographic activity after terminal cardiac arrest in catastrophic neurological injury: consequences for non-heart beating protocols? (Wijidick and Diringer) 2003; 54:(suppl 7) S28

induced hypothermia for the treatment of cardiac arrest survivors: a systematic review (Haas et al) 2003;54: (suppl 7) S66

Cardiac bioenergetics

cardiac bioenergetics in Friedreich's ataxia (Bit-Avragim et al) 2003;54:552 (Reply)

cardiac bioenergetics in Friedreich's ataxia (Lodi et al) 2003;54:552 (Letter)

Cardiac scintigraphy

cardiac ¹²³I-MIBG scintigraphy could assess disease severity and phenotype in patients with Parkinson's disease (Saiki et al) 2003;54:(suppl 7) S72

Cardiac surgery

long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111

postoperative sedation and the incidence of delirium and cognitive deficits in cardiac surgery patients (Maldonado and Wyson) 2003;54:(suppl 7) S27

stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003; 54:(suppl 7) S110

Cardiomyopathy

novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151

Caregiver burden

factors of caregiver burden in Parkinson's disease (Janko et al) 2003;54:(suppl 7) S72

Carnitine

novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151

L-Carnitine

L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

Carotid artery plaque

serum calcium is associated with carotid artery plaque thickness: the Northern Manhattan Study (Rundek et al) 2003;54:(suppl 7) S23

Carotid endarterectomy

association between surgical specialty and appropriateness of carotid endarterectomy (Kennedy et al) 2003;54:696, (suppl 7) S18

Caspase

caspase activation in the limbic cortex of subjects with early Alzheimer's disease (Gastard et al) 2003;54:393

Caspase-3

modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment

- with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103
- Cat scratch disease**
cat scratch disease mimicking a spinal cord tumor (Hmaimess et al) 2003;54:(suppl 7) S159
- Category decision, auditory based**
language networks underlying auditory based category decision in children identified with fMRI (Balsamo et al) 2003;54:(suppl 7) S105
- Caucasians**
African American multiple sclerosis patients suffer from a more aggressive disease course than Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S35
comparison of response to treatment with interferon β -1a in African Americans and Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S34
the factor V G1691A mutation is significantly associated with childhood porencephaly in white children: a case-control study (Debus et al) 2003;54:(suppl 7) S110
- CD31**
interferon- β 1a reduces plasma CD31+ endothelial microparticles in MS (Jy et al) 2003;54:(suppl 7) S60
- Cell death**
cell death in transgenic mice model of Lafora's disease (Machado-Salas et al) 2003;54:(suppl 7) S54
neuronal death and cognitive impairment caused by severe hypoglycemia can be prevented by delayed administration of poly(ADP-ribose) polymerase inhibitors (Swanson et al) 2003;54:850
- Cell differentiation**
Bcl-2-mediated induction of neural differentiation: a role for NGF/TrkA (Liang et al) 2003;54:(suppl 7) S105
- Cell growth**
small interfering RNAs directed against Δ EGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850
- Cell migration**
role of *N*-methyl-D-aspartate receptors in cerebral transendothelial migration of neutrophils (Sharp et al) 2003;54:(suppl 7) S59
- Cell proliferation**
molecular mechanisms for cyclophosphamide induction of oncolytic viral proliferation in tumor (Fontana et al) 2003;54:851
neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103
- Central nervous system**
central nervous system microvascular pericyte response to hypoxia (Dore-Duffy et al) 2003;54:(suppl 7) S78
CNS involvement in DM1: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74
Clq expression increases in the central and peripheral nervous system during neuroborreliosis (Bai et al) 2003;54:(suppl 7) S49
transient cerebral arteriopathy and primary angiitis of the central nervous system in children: a spectrum of cerebral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140
- Central nervous system disorders, autosomal dominant**
human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syndrome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118
- Central nervous system vascular disease**
the occurrence of central nervous system vascular disease following cranial radiotherapy (Keene et al) 2003;54:(suppl 7) S141
- Central nervous system vasculitis**
suspected central nervous system vasculitis in young stroke patients (Berlit et al) 2003;54:(suppl 7) S25
- Centrosomes**
alterations of γ -tubulin cellular distribution in human gliomas: implication of centrosome amplification in malignant tumor progression (Katsetos et al) 2003;54:(suppl 7) S117
- Cephalocele, occipital**
variable occipital cephalocele with autosomal-dominant inheritance: a three-generation pedigree (Bassuk et al) 2003;54:(suppl 7) S157
- Cerebellar deficits, interictal**
novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725
- Cerebellar degeneration, paraneoplastic**
paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Motomura et al) 2002;54:277 (Reply)
paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Pinto and Lang) 2002;54:277 (Letter)
- Cerebellar diseases, immune-mediated**
mouse model of immune-mediated cerebellar diseases (Golumbek et al) 2003;54:(suppl 7) S117
- Cerebellar gray matter**
cerebellar gray matter MRI T2 hypointensity is independently associated with ambulatory dysfunction and clinical course in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- Cerebellar growth, impaired**
impaired cerebellar growth in preterm infants without brain injury (Limperopoulos et al) 2003;54:(suppl 7) S122
- Cerebellar hemorrhage**
ultrasonographic accompaniments and predictors of cerebellar hemorrhage in the preterm infant (Limperopoulos et al) 2003;54:(suppl 7) S122
- Cerebellar stroke**
is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Annoni and Khateb) 2003;54:556 (Reply)
is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Gondim and de Oliveira) 2003;54:555 (Letter)
- Cerebellar volume, reduced**
reduced cerebellar volume in premature infants with cerebral parenchymal injury (Limperopoulos et al) 2003;54:(suppl 7) S123
- Cerebral amyloid angiopathy**
matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379
- Cerebral arterial disease**
transient cerebral arteriopathy and primary angiitis of the central nervous system in children: a spectrum of cerebral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140
- Cerebral arteriopathy, transient**
transient cerebral arteriopathy and primary angiitis of the central nervous system in children: a spectrum of cere-

- bral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140
- Cerebral blood volume**
cerebral blood volume measurements by T2*-weighted magnetic resonance imaging and contrast injection (Newman et al) 2003;54:(suppl 7) S24
- Cerebral dysplasia**
magnetic resonance imaging for the diagnosis of cerebral dysplasia in new-onset seizures in children (Vanderver et al) 2003;54:(suppl 7) S114
- Cerebral hemorrhage**
altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121
cerebral hemorrhage produced by ruptured dissecting aneurysm in miliary aneurysm (Rosenblum) 2003;54:376
neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158
- Cerebral infarction**
neuronal overexpression of cyclooxygenase-2 increases cerebral infarction (Doré et al) 2002;54:155
- Cerebral injury**
a primate model of cerebral injury in the premature infant (Inder et al) 2003;54:(suppl 7) S121
- Cerebral injury, acute**
stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003;54:(suppl 7) S110
- Cerebral ischemia**
early recovery after cerebral ischemia risk of subsequent neurological deterioration (Johnston et al) 2003;54:439
early recovery of cerebral ischemia is associated with risk of subsequent neurological deterioration (Johnston et al) 2003;54:(suppl 7) S66
ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space (Petzold et al) 2003;54:591
- Cerebral ischemia, focal**
magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
- Cerebral laterality**
functional neuroimaging provides evidence of anomalous cerebral laterality in adults with Klinefelter's syndrome (Itti et al) 2003;54:669
- Cerebral metabolites**
abnormalities of cerebral metabolite levels in children with pervasive developmental disorder: a preliminary ¹H magnetic resonance spectroscopy study (Gabis et al) 2003;54:(suppl 7) S146
- Cerebral palsy**
cerebral palsy in the extremely premature: additional clinical and anatomical description (Johnsen et al) 2003;54:(suppl 7) S123
cerebral palsy in the extremely premature: frequency of cerebellar injury (Johnsen and Bodensteiner) 2003;54:(suppl 7) S123
risk factors and neuroimaging findings in term infants with cerebral palsy (Wu et al) 2003;54:(suppl 7) S126
- Cerebral palsy, hemiplegic**
constraint-induced movement therapy in children with hemiplegic cerebral palsy (Weber and Delgado) 2003;54:(suppl 7) S149
- Cerebral parenchymal injury**
reduced cerebellar volume in premature infants with cerebral parenchymal injury (Limperopoulos et al) 2003;54:(suppl 7) S123
- Cerebral perfusion**
cerebral perfusion, cerebrovascular disease, and hematology in sickle cell disease: a longitudinal study (Prengler et al) 2003;54:(suppl 7) S138
- Cerebral radiation necrosis**
clinical outcome, including response to therapy, in cerebral radiation necrosis: 31 patients (Rogers et al) 2003;54:(suppl 7) S31
- Cerebral sinovenous thrombosis**
neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138
- Cerebral tissue oxygenation**
altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121
- Cerebral volume**
altered MR cerebral volumes correlate with neurodevelopmental outcome at 2 years in VLBW infants (Inder et al) 2003;54:(suppl 7) S124
- Cerebral white matter**
reduction in *N*-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125
- Cerebral white matter injury**
graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103
selective cerebral white matter injury in asphyxiated term newborns (Landesman et al) 2003;54:(suppl 7) S126
- Cerebrospinal fluid**
 β -amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (Wiltfang et al) 2002;54:263
autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45
cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54:(suppl 7) S31
cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (Han et al) 2003;54:693 (Correction)
cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid (Gianazza et al) 2003;54:(suppl 7) S52
high expression of macrophage migration inhibitory factor (MIF) in spinal cord and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients (Ogata et al) 2003;54:(suppl 7) S51
increased osteopontin in cerebrospinal fluid and brains from patients with multiple sclerosis (Fukaura et al) 2003;54:(suppl 7) S61
oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV (Burgoon et al) 2003;54:459

Cerebrovascular disease

association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697

cerebral perfusion, cerebrovascular disease, and hematology in sickle cell disease: a longitudinal study (Prengler et al) 2003;54:(suppl 7) S138

spectrum of cerebrovascular disease in a population of children with neurofibromatosis type 1 (Rosser et al) 2003;54:(suppl 7) S139

Cerebrovascular ischemic tolerance

the release of tumor necrosis factor- α and the reduction of the inflammatory response are associated with human cerebrovascular ischemic tolerance (Castillo et al) 2003;54:812

Ceruloplasmin

low ceruloplasmin in heterozygotes for Wilson's disease: a copper herring (Reich and O'Hearn) 2003;54:(suppl 7) S42

Cervical dystonia

clinical experiences with botulinum toxin type B (Myobloc) in the treatment of cervical dystonia: secondary resistance and electrophysiologic observations (Gollop) 2003;54:(suppl 7) S41

Charcot-Marie-Tooth disease

neurotrophin-3 treatment promotes nerve regeneration and improvements in sensory function in patients with CMT1A (Sahenk et al) 2003;54:(suppl 7) S19

Chemical chaperone therapy

a new compound *N*-octyl-4-epi-b-valienamine for chemical chaperone therapy of GM1 gangliosidosis (Matsuda et al) 2003;54:(suppl 7) S107

Chemokine receptor CCR1

CCR1 is an early and specific marker of Alzheimer's disease (Halks-Miller et al) 2003;54:638

Chemokines

cytokine and chemokine induction after neonatal focal ischemia reperfusion (Derugin et al) 2003;54:(suppl 7) S65

Chemotherapy

childhood ependymomas: possible improved survival with the use of preirradiation chemotherapy followed by radiotherapy (Garvin et al) 2003;54:(suppl 7) S109

high-dose preirradiation chemotherapy for children with newly diagnosed high-grade astrocytomas (MacDonald et al) 2003;54:(suppl 7) S152

intensive chemotherapy followed by response-based radiotherapy: preliminary results of the Beth Israel Germinoma Consortium (Allen et al) 2003;54:(suppl 7) S109

Chick embryo spinal cord electroelution

chick embryo spinal cord electroelution as a tool in investigations of neurovirological and neurodegenerative disease (Roos et al) 2003;54:(suppl 7) S76

Child neurology care

a novel child neurology resident case-log program: improved utilization, compliance, and resident satisfaction (Lotze and Clark) 2003;54:(suppl 7) S154

transition/transfer from child neurology to adult neurology care (Camfield and Camfield) 2003;54:(suppl 7) S153

Childhood brain surgery

neuropsychological profiles after brain surgery in childhood (Kuroda et al) 2003;54:(suppl 7) S142

Childhood brain tumors

the clinical application of positron emission tomography in childhood brain tumors (Kaplan et al) 2003;54:(suppl 7) S149

pediatric brain tumor stem cells (Hemmati et al) 2003;54:(suppl 7) S117

Childhood ependymoma

childhood ependymomas: possible improved survival with the use of preirradiation chemotherapy followed by radiotherapy (Garvin et al) 2003;54:(suppl 7) S109

Childhood epilepsy

association between genetic variation of *CACNA1H* and childhood absence epilepsy (Chen et al) 2002;54:239

baseline cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy (Mandelbaum et al) 2003;54:(suppl 7) S114

brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connelly et al) 2003;54:(suppl 7) S146

development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cincinnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136

the effect of lamotrigine therapy on electroencephalogram in children with refractory epilepsies (Akman and Holmes) 2003;54:(suppl 7) S134

the effect of music periodicity on rolandic spikes: a randomized, single-blinded, crossover, clinical trial of the effect of music with distinctive long-term periodicity and repeated melodic line on interictal spike discharges of children with benign childhood epilepsy with centrotemporal spikes (Turner) 2003;54:(suppl 7) S134

extensive clinical experience with oxcarbazepine (Trileptal) in children with epilepsy demonstrates good safety and tolerability profiles (Bourgeois) 2003;54:(suppl 7) S136

oxcarbazepine (Trileptal) is safe and tolerable in children with epilepsy (Brown and Black) 2003;54:(suppl 7) S112

a prospective study of topiramate in 500+ children/adolescents with refractory epilepsy (Ritter et al) 2003;54:(suppl 7) S112

seizure alerting and response behaviors in dogs living with epileptic children (Kirtan et al) 2003;54:(suppl 7) S133

tolerability and safety of topiramate as first-line monotherapy in children and adolescents (Dlugos et al) 2003;54:(suppl 7) S135

topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135

topiramate as add-on or monotherapy in pediatric epilepsy (Wang et al) 2003;54:(suppl 7) S135

topiramate as first-line therapy in children/adolescents with newly diagnosed epilepsy (Pellock et al) 2003;54:(suppl 7) S112

topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136

Childhood-onset dystonia

approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia (Assmann et al) 2003;54:(suppl 6) S18

Childhood-onset epilepsy

comorbidity of childhood-onset epilepsy and psychiatric and behavioral disorders: a population-based study (Hedderick and Buchhalter) 2003;54:(suppl 7) S115

Childhood porencephaly

the factor V G1691A mutation is significantly associated with childhood porencephaly in white children: a case-control study (Debus et al) 2003;54:(suppl 7) S110

Children; *see also* Pediatrics

- abnormalities of cerebral metabolite levels in children with pervasive developmental disorder: a preliminary ^1H magnetic resonance spectroscopy study (Gabis et al) 2003;54:(suppl 7) S146
- association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111
- atomoxetine for the treatment of attention deficit hyperactivity disorder and comorbid tics in children (Lewis et al) 2003;54:(suppl 7) S106
- brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connolly et al) 2003;54:(suppl 7) S146
- brain injury in children with sickle cell disease: prevalence and etiology (Steen et al) 2003;54:564
- clinical and radiological features of moyamoya syndrome in British children (Ganesan et al) 2003;54:(suppl 7) S140
- clinical features of physiologic stereotypies in children (Mahone et al) 2003;54:(suppl 7) S145
- constraint-induced movement therapy in children with hemiplegic cerebral palsy (Weber and Delgado) 2003;54:(suppl 7) S149
- daytime sleepiness in children with attention deficit hyperactivity disorder (Ravid et al) 2003;54:(suppl 7) S144
- the diagnostic yield of brain biopsy in children presenting to neurology (Venkateswaran et al) 2003;54:(suppl 7) S131
- dual pathology in two hypotonic children with Prader-Willi syndrome and muscle mitochondrial complex I deficiency (Wassmer et al) 2003;54:(suppl 7) S157
- the economic impact of migraine and comorbid anxiety and depression in children: results from a case-control study (Pesa and Lage) 2003;54:(suppl 7) S33
- effectiveness and tolerability of ketorolac for severe headaches in children seen in the emergency department (Vasconcellos et al) 2003;54:(suppl 7) S150
- efficacy of atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder (Dunn et al) 2003;54:(suppl 7) S143
- glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128
- high-dose preirradiation chemotherapy for children with newly diagnosed high-grade astrocytomas (MacDonald et al) 2003;54:(suppl 7) S152
- identification of a specific deficit in memory for narrative in children treated for craniopharyngioma (Waber et al) 2003;54:(suppl 7) S142
- language networks underlying auditory based category decision in children identified with fMRI (Balsamo et al) 2003;54:(suppl 7) S105
- magnetic resonance imaging for the diagnosis of cerebral dysplasia in new-onset seizures in children (Vanderver et al) 2003;54:(suppl 7) S114
- masturbation presenting as a movement disorder in young girls (Fullwood et al) 2003;54:(suppl 7) S130
- maturation of motor-evoked potentials in healthy children (Timoshkin et al) 2003;54:(suppl 7) S129
- moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140
- once-daily dosing with the OROS formulation of methylphenidate has minimal impact on tics in children with ADHD (Palumbo et al) 2003;54:(suppl 7) S27
- once-daily OROS methylphenidate: impact on tics in children with attention deficit hyperactivity disorder (Palumbo et al) 2003;54:(suppl 7) S143
- outcome for biopsy-proven primary angitis of the central nervous system in children treated with pulse cyclophosphamide and prednisone (McGrath et al) 2003;54:(suppl 7) S140
- oxcarbazepine for the treatment of behavior/mood disorders in children (Alberts et al) 2003;54:(suppl 7) S148
- oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133
- physiological and morphological abnormalities in HIV-infected children (Luciano et al) 2003;54:(suppl 7) S74
- the prevalence of autistic spectrum disorder in children seen in a tertiary care epilepsy clinic (Clarke et al) 2003;54:(suppl 7) S149
- proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153
- psychostimulant use in children with autistic spectrum disorder (Chez et al) 2003;54:(suppl 7) S147
- sleep disruption and behavioral problems in children with new-onset seizures (Dunn et al) 2003;54:(suppl 7) S133
- spectral Doppler imaging of central retinal vessels in children: a potential non-invasive alternative method of measuring intracranial pressures (Chang et al) 2003;54:(suppl 7) S152
- spectrum of cerebrovascular disease in a population of children with neurofibromatosis type 1 (Rosser et al) 2003;54:(suppl 7) S139
- succinic semialdehyde dehydrogenase deficiency in children and adults (Pearl et al) 2003;54:(suppl 6) S73
- susceptibility-weighted magnetic resonance imaging: a new neuroimaging technology with application to children (Tong et al) 2003;54:(suppl 7) S153
- topiramate monotherapy for the prevention of headaches in children (Vasconcellos et al) 2003;54:(suppl 7) S150
- torsinA protein and mRNA expression in the human brain of newborns, infants, and children (Siebert et al) 2003;54:(suppl 7) S116
- transient cerebral arteriopathy and primary angitis of the central nervous system in children: a spectrum of cerebral arterial disease? (Benseler et al) 2003;54:(suppl 7) S140
- transition/transfer from child neurology to adult neurology care (Camfield and Camfield) 2003;54:(suppl 7) S153
- the use of interferon β -1a in children and adolescents with multiple sclerosis (Pohl et al) 2003;54:(suppl 7) S152
- vertebrobasilar insufficiency and hearing loss in children: is there any link? (Melikishvili et al) 2003;54:(suppl 7) S141
- what causes new daily persistent headache in children? (Mack) 2003;54:(suppl 7) S130

Children, preschool

- developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146
- developmental and functional outcomes at school age of preschool children with specific language impairment (Shevell et al) 2003;54:(suppl 7) S105

- long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111
- Children, school-age**
developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146
developmental and functional outcomes at school age of preschool children with specific language impairment (Shevell et al) 2003;54:(suppl 7) S105
fine motor and gross motor function in school-age children with a preschool diagnosis of specific language impairment (Webster et al) 2003;54:(suppl 7) S145
- Children, young**
persistent unilateral spatial neglect in young children with early focal brain damage (Heeren and Trauner) 2003;54:(suppl 7) S142
- Chlamydia pneumoniae***
Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients (Buljevac et al) 2003;54:829
- Chorea, benign hereditary**
benign hereditary chorea: clinical, genetic, and pathological findings (Kleiner-Fisman et al) 2002;54:244
- Choroid plexus**
folate receptor function in cultured choroid plexus epithelial cells (Wollack et al) 2003;54:(suppl 7) S117
- Chromosome 1q24-q32**
a locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:796
a locus for complicated spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:(suppl 7) S57
- Chromosome 12p12**
a new genetic variant associated with multiple sclerosis on 12p12 in a large North American pedigree (Subramanian et al) 2003;54:(suppl 7) S58
- Chromosome 17q11**
linkage and association to the NOS2A locus on ch.17q11 in multiple sclerosis (MS) (Barcellos et al) 2003;54:849
- Chromosome 19q**
no preferential loss of paternal 19q alleles in oligodendroglial tumors (Hartmann et al) 2002;54:256
- Chromosome 20**
mosaicism and ring 20 chromosome (Nishiwaki et al) 2003;54:(suppl 7) S56
- Chromosome abnormalities**
a novel chromosome abnormality associated with severe mental retardation and dysmorphic features (Smathers et al) 2003;54:(suppl 7) S159
- Chronic progressive and neurological disease**
the differential responsiveness of quality of life and health status instruments in chronic progressive and episodic neurological diseases: a measure of disease adaptation (Kern and Brown) 2003;54:696, (suppl 7) S18
- Ciliary neurotrophic factor**
ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis (Al-Chalabi et al) 2003;54:130
- Cinnnati antiepileptic drug side effect scale**
the Cinnnati antiepileptic drug side effect neurologic subscale detects and quantifies significant interpatient variability in antiepileptic drug neurologic toxicity (Morita et al) 2003;54:(suppl 7) S137
development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cinnnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136
- CIT-SPECT**
[¹²³I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Katzenschlager R et al) 2002;54:278 (Correction)
- Clarke's nucleus**
retrograde reactions of Clarke's nucleus neurons after human spinal cord injury (Schmitt et al) 2003;54:534
- Clinical research**
a comparative audit of clinical research in pediatric neurology (Al-Futaisi and Shevell) 2003;54:(suppl 7) S148
- Cloning**
autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45
- Cobalamin (vitamin B12)-deficiency**
cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid (Gianazza et al) 2003;54:(suppl 7) S52
- Coding**
accuracy of coding for cerebral thrombolysis administration (Chaturvedi et al) 2003;54:699
- Cognition**
longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE ε4 allele (Caselli et al) 2003;54:(suppl 7) S28
a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28
- Cognitive decline**
expected cognitive decline and risk of nursing home admission for patients with mild or moderate Alzheimer's disease (Ward et al) 2003;54:698
- Cognitive decline, early**
early cognitive decline is associated with prion protein codon 129 polymorphism (Croes et al) 2002;54:275 (Letter)
- Cognitive deficits**
postoperative sedation and the incidence of delirium and cognitive deficits in cardiac surgery patients (Maldonado and Wysong) 2003;54:(suppl 7) S27
- Cognitive function**
Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003;54:851
chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy (Helmstaedter et al) 2003;54:425
the cognitive consequences of epilepsy (Duncan and Thompson) 2003;54:421 (Editorial)
cognitive outcomes after coronary artery bypass surgery: a prospective controlled study (Selnes et al) 2003;54:(suppl 7) S67
the effects of huperzine A on cognitive functioning and behavior in patients with Huntington's disease (Peavy et al) 2003;54:(suppl 7) S42
epilepsy in low-grade gliomas: the impact on cognitive function and quality of life (Klein et al) 2003;54:514
longitudinal stability of cognitive and affective functioning in PD patients: a dissociation between behavioral and motoric decline (Bernard et al) 2003;54:(suppl 7) S69
- Cognitive impairment**
CNS involvement in DM1: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74

- cognitive impairment, frontotemporal dementia, and the motor neuron diseases (Strong et al) 2003;54:(suppl 5) S20
- neuronal death and cognitive impairment caused by severe hypoglycemia can be prevented by delayed administration of poly(ADP-ribose) polymerase inhibitors (Swanson et al) 2003;54:850
- subcortical gray matter MRI T2 hypointensity is independently associated with cognitive impairment in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- viremia in the presence of blood-brain barrier compromise increases severity of HIV-associated neurocognitive impairment (Avison et al) 2003;54:(suppl 7) S49
- Cognitive impairment, mild**
- brain magnetic resonance spectroscopy in mild cognitive impairment predicts conversion to Alzheimer's disease (Modrego et al) 2003;54:(suppl 7) S30
- limbic hypometabolism in Alzheimer's disease and mild cognitive impairment (Nestor et al) 2003;54:343
- what are the characteristics of patients with mild cognitive impairment who do not progress to dementia? (Chertkow et al) 2003;54:(suppl 7) S68
- Cognitive reserve**
- the influence of cognitive reserve on seizure-induced injury (Akman et al) 2003;54:(suppl 7) S132
- Cognitive screening**
- validation of the Baylor College of Medicine Cognitive and Neurobehavioral Status Examination (West and Ringholz) 2003;54:(suppl 7) S22
- Collapsin response-mediator protein-5 (CRMP-5)**
- paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38
- Coma**
- association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111
- Combinatorial peptide libraries**
- autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45
- Complex I**
- impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene (Ugalde et al) 2003;54:665
- Complex I deficiency**
- dual pathology in two hypotonic children with Prader-Willi syndrome and muscle mitochondrial complex I deficiency (Wassmer et al) 2003;54:(suppl 7) S157
- succinate improves clinical symptoms and whole-cell oxidation in a patient with complex-I deficiency (Wassmer et al) 2003;54:(suppl 7) S158
- Complex partial seizures, intractable**
- oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133
- Complex partial status epilepticus, temporal lobe**
- chronic amnesic states and temporal lobe complex partial status epilepticus (Perez-Gosienfiao et al) 2003;54:(suppl 7) S54
- Concerta**
- comparative school-day efficacy of Ritalin LA, Concerta, and placebo in children with attention deficit hyperactivity disorder (Lopez et al) 2003;54:(suppl 7) S143
- Congenital disorder of glycosylation**
- mechanism of stroke-like events in congenital disorder of glycosylation (Dinopoulos et al) 2003;54:(suppl 7) S139
- Congenital heart defects**
- long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111
- Congenital hypomyelinating neuropathy**
- disturbance of muscle fiber differentiation in congenital hypomyelinating neuropathy caused by a novel *myelin protein zero* mutation (Szigeti et al) 2003;54:398
- Congenital muscular dystrophy**
- natural history and response to weekly oral prednisolone in the *dyw* mouse model of congenital muscular dystrophy (Connolly et al) 2003;54:(suppl 7) S155
- POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154
- Congenital myasthenic syndrome**
- congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy (Gurnett et al) 2003;54:(suppl 7) S155
- Connexin26 (Cx26)**
- cellular mechanism of Cx26 mutations causing dominant hearing loss (Yum and Scherer) 2003;54:(suppl 7) S120
- Consciousness disorders**
- clinical research of fastigial nucleus stimulation in treatment of discords of consciousness by brain damage (Yang et al) 2003;54:(suppl 7) S25
- CONSORT reporting guidelines**
- REAL-PET and CONSORT (Brooks and Whone) 2003;54:692 (Reply)
- REAL-PET and CONSORT (Morrish) 2003;54:692 (Letter)
- Constraint-induced movement therapy**
- constraint-induced movement therapy in children with hemiplegic cerebral palsy (Weber and Delgado) 2003;54:(suppl 7) S149
- Convulsions, infantile**
- novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360
- Cooperative International Neuromuscular Research Group (CINRG)**
- creatine and glutamine therapeutic trial in Duchenne muscular dystrophy (DMD) by the Cooperative International Neuromuscular Research Group (CINRG) (Escobar et al) 2003;54:850
- Copper**
- correlation of copper levels and electroencephalogram abnormalities in patients with Menkes' disease (Valencia et al) 2003;54:(suppl 7) S150
- Coronary artery bypass surgery**
- cognitive outcomes after coronary artery bypass surgery: a prospective controlled study (Selnes et al) 2003;54:(suppl 7) S67
- Corpus callosotomy**
- quantitative analysis of cortical pyramidal neurons after corpus callosotomy (Jacobs et al) 2003;54:126
- Corpus callosum agenesis**
- agenesis of the corpus callosum: analysis of the phenotypic spectrum (Sherr et al) 2003;54:(suppl 7) S108
- agenesis of the corpus callosum is associated with significant feeding difficulties: oral/pharyngeal motor and sensory disorder (Ng et al) 2003;54:(suppl 7) S149

- hereditary motor and sensory neuropathy with agenesis of the corpus callosum (Dupré et al) 2002;54:9
- Cortical development, altered**
immature cortex lesions alter retinotopic maps and inter-hemispheric connections (Restrepo et al) 2003;54:51
- Cortical disinhibition**
association of cortical versus behavioral disinhibition in Tourette's syndrome and attention deficit hyperactivity disorder (Gilbert et al) 2003;54:(suppl 7) S143
- Cortical microdysgenesis**
anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132
- Cortical pyramidal neurons**
quantitative analysis of cortical pyramidal neurons after corpus callosotomy (Jacobs et al) 2003;54:126
- Corticobasal degeneration**
corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia (Boeve et al) 2003;54:(suppl 5) S15
- Costs of care**
the economic impact of migraine and comorbid anxiety and depression in children: results from a case-control study (Pesa and Lage) 2003;54:(suppl 7) S33
subthalamic nucleus stimulation reduces the cost of the pharmacologic treatment of Parkinson's disease (Newman et al) 2003;54:700
- Cranial radiotherapy**
moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140
the occurrence of central nervous system vascular disease following cranial radiotherapy (Keene et al) 2003;54:(suppl 7) S141
- Craniopharyngioma**
identification of a specific deficit in memory for narrative in children treated for craniopharyngioma (Waber et al) 2003;54:(suppl 7) S142
- Creatine**
creatine and glutamine therapeutic trial in Duchenne muscular dystrophy (DMD) by the Cooperative International Neuromuscular Research Group (CINRG) (Escobar et al) 2003;54:850
- Creatine deficiency syndrome**
creatine deficiency syndrome: a case of defective creatine transport presenting with episodic dystonia (Mazumdar and Rivkin) 2003;54:(suppl 7) S157
- Creatine transport defects**
creatine deficiency syndrome: a case of defective creatine transport presenting with episodic dystonia (Mazumdar and Rivkin) 2003;54:(suppl 7) S157
- Creatine transporter 1 deficiency**
defective mitochondrial energy metabolism in creatine transporter 1 deficiency (Anselm et al) 2003;54:(suppl 7) S156
- Creutzfeldt-Jakob disease**
β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (Wiltfang et al) 2002;54:263
- Creutzfeldt-Jakob disease, familial**
characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67
homozygous prion protein genotype at codon 129 is not a predisposing factor for developing familial Creutzfeldt-Jakob disease with a point mutation of Val to Ile at codon 180 (Shiga et al) 2003;54:(suppl 7) S69
- Creutzfeldt-Jakob disease, sporadic**
characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67
- Crying, pathological**
a case series of "pathological laughter and crying" and a proposal for a new classification (Gondim et al) 2003;54:(suppl 7) S22
- Cryptogenic stroke**
frequency and mechanisms of stroke recurrence after cryptogenic stroke (Bang et al) 2002;54:227
- αB-Crystallin**
myofibrillar myopathy caused by novel dominant negative αB-crystallin mutations (Selcen and Engel) 2003;54:805
- Cu/Zn-induced toxicity**
pyruvate protects motor neuronal cells expressing mutated superoxide dismutase (SOD1) against Cu/Zn-induced toxicity (Kim et al) 2003;54:(suppl 7) S53
- Cu/Zn superoxide dismutase**
facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53
- Cycling tests**
a diagnostic cycle test for McArdle's disease (Vissing et al) 2003;54:539
- Cyclooxygenase-2**
cyclooxygenase-2 and stroke: the long and short if (Iadecola) 2002;54:141 (Editorial)
neuronal overexpression of cyclooxygenase-2 increases cerebral infarction (Doré et al) 2002;54:155
- Cyclophosphamide**
molecular mechanisms for cyclophosphamide induction of oncolytic viral proliferation in tumor (Fontana et al) 2003;54:851
outcome for biopsy-proven primary angitis of the central nervous system in children treated with pulse cyclophosphamide and prednisone (McGrath et al) 2003;54:(suppl 7) S140
- Cystic periventricular leukomalacia**
is cystic periventricular leukomalacia disappearing? (Hamrick et al) 2003;54:(suppl 7) S121
- Cytokines**
cytokine and chemokine induction after neonatal focal ischemia reperfusion (Derugin et al) 2003;54:(suppl 7) S65
cytokine-induced early gene regulation in glial cell cultures: differential effects of Th1, Th2, and monocyte cytokines (Lisak et al) 2003;54:(suppl 7) S38
- Cytoskeletal proteins**
analysis of calcium-dependent proteinase and cytoskeletal proteins in muscle from patients with inflammatory myopathy (Murata et al) 2003;54:(suppl 7) S44
- Cytotoxic T lymphocyte-associated antigen 4**
genetic interaction of *CTLA-4* with HLA-DR15 in multiple sclerosis patients (Alizadeh et al) 2003;54:119
therapeutic effect of combined CTLA4Ig and dystrophin gene transfer to *Mdx* muscle using high-capacity adenoviral vectors (Clemens and Jiang) 2003;54:(suppl 7) S42
- Cytotoxic T lymphocytes**
inducible costimulatory molecule and ICOS-ligand are upregulated in patients with sporadic inclusion body myositis and correlate with perforin expression by the autoinvasive cytotoxic T cells (Schmidt et al) 2003;54:(suppl 7) S75

Cytotoxicity

some flavonoids prevent cytotoxicity and *cis*-effect of expanded CTG repeats in stable transformant of PC12 neuronal cell (Furuya et al) 2003;54:(suppl 7) S74

Daytime sleepiness

daytime sleepiness in children with attention deficit hyperactivity disorder (Ravid et al) 2003;54:(suppl 7) S144

DCX gene

nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30

ddC

erythropoietin protects dorsal root ganglion neurons against gp120 and ddC-induced neurotoxicity (Keswani et al) 2003;54:(suppl 7) S77

Death

a subgroup analysis of the association between depression and death in Alzheimer's disease (Lopez et al) 2003;54:(suppl 7) S67

Decorin-binding protein dbpA

why doesn't a specific antibody kill spirochetes? expression of dbpA by *B. burgdorferi* in peripheral nerve in the presence of high titers of anti-dbpA antibody (Narayan et al) 2003;54:(suppl 7) S50

Deep brain stimulation

bilateral STN DBS for Parkinson's disease after successful pallidotomy (Kleiner-Fisman et al) 2003;54:(suppl 7) S70

clinical research of fastigial nucleus stimulation in treatment of disorders of consciousness by brain damage (Yang et al) 2003;54:(suppl 7) S25

the effects of unilateral versus bilateral subthalamic nuclei stimulation on tremor and gait in persons with Parkinson's disease (Shumway-Cook et al) 2003;54:(suppl 7) S69

subthalamic nucleus stimulation affects a frontotemporal network: a PET study (Schroeder et al) 2003;54:445

subthalamic nucleus stimulation reduces the cost of the pharmacologic treatment of Parkinson's disease (Newman et al) 2003;54:700

unilateral stimulation of the subthalamic nucleus in Parkinson's disease: a prospective double-blind 12-month study (Germano et al) 2003;54:(suppl 7) S71

Deletions

clinical and histological variability of PMP22 deletions (Diamond et al) 2003;54:(suppl 7) S75

homozygous β -sarcoglycan gene deletion in a family with limb-girdle muscular dystrophy type 2E (Kaindl et al) 2003;54:(suppl 7) S154

Delirium

postoperative sedation and the incidence of delirium and cognitive deficits in cardiac surgery patients (Maldo and Wysong) 2003;54:(suppl 7) S27

Dementia

entorhinal cortex hypermetabolism in Down's syndrome: implications for dementia and development (Haier et al) 2003;54:(suppl 7) S107

neuropathology of dementia associated with relapsing polychondritis an autoimmune disorder (Starr et al) 2003;54:(suppl 7) S68

onset of dementia is associated with age at menopause in women with Down's syndrome (Schupf et al) 2003;54:433

Dementia, ALS

longitudinal analysis of the anatomic, neuropsychological, and behavioral features of ALS dementia (Murphy et al) 2003;54:(suppl 7) S52

Dementia, atypical

atypical dementia with a novel presenilin-2 mutation (Binetti et al) 2003;54:833

Dementia, frontotemporal

cognitive impairment, frontotemporal dementia, and the motor neuron diseases (Strong et al) 2003;54:(suppl 5) S20

corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia (Boeve et al) 2003;54:(suppl 5) S15

epidemiology and genetics of frontotemporal dementia/Pick's disease (Bird et al) 2003;54:(suppl 5) S29

international approaches to frontotemporal dementia diagnosis: from social cognition to neuropsychology (Miller et al) 2003;54:(suppl 5) S7

laboratory investigations and treatment in frontotemporal dementia (Pasquier et al) 2003;54:(suppl 5) S32

the neuropathology and biochemistry of frontotemporal dementia (Munoz et al) 2003;54:(suppl 5) S24

preferred terminology (Kertesz et al) 2003;54:(suppl 5) S3

progressive supranuclear palsy presenting as frontotemporal dementia (Smoot et al) 2003;54:(suppl 7) S22

serotonin 5-HT_{1A} receptor binding potential in frontotemporal dementia (FTD) compared with controls using [¹¹C]WAY-100635 and PET (Lancôt) 2003;54:(suppl 7) S67

Dementia, incipient

cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (Han et al) 2003;54:693 (Correction)

Dementia, semantic

the core and halo of primary progressive aphasia and semantic dementia (Mesulam et al) 2003;54:(suppl 5) S11

Dementia, vascular

association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697

Dementia with Lewy bodies

comparisons of hallucinations in dementia with Lewy bodies (DLB) and Parkinson's disease (PD) with hallucinations: a case-control study (Goldman et al) 2003;54:(suppl 7) S72

retinal involvement in dementia with Lewy bodies: a clue to hallucinations? (Maurage et al) 2003;54:542

survival but not dementia progression differs in DLB versus AD (Williams et al) 2003;54:(suppl 7) S30

Demyelinating polyradiculoneuropathy, chronic inflammatory

rituximab-responsive chronic inflammatory demyelinating polyradiculoneuropathy (Briani et al) 2003;54:(suppl 7) S75

Demyelination, autoimmune

epitope recognition differentially controls effector functions of myelin/oligodendrocyte glycoprotein-specific autoantibodies and phenotypic expression of autoimmune demyelination (von Büdingen et al) 2003;54:(suppl 7) S37

Dependence, methamphetamine

methamphetamine dependence exacerbates neurometabolic abnormalities in HIV patients (Chang et al) 2003;54:(suppl 7) S48

Depression

determining the presence of depression in multiple sclerosis (Birnbaum et al) 2003;54:(suppl 7) S35

the economic impact of migraine and comorbid anxiety and depression in children: results from a case-control study (Pesa and Lage) 2003;54:(suppl 7) S33

the influence of comorbid depression on seizure severity (Cramer and Epilepsy Impact Project) 2003;54:(suppl 7) S55

a subgroup analysis of the association between depression and death in Alzheimer's disease (Lopez et al) 2003;54:(suppl 7) S67

Depression, perinatal

venous prominence on susceptibility-weighted MRI is associated with perinatal depression in neonates (Michelson et al) 2003;54:(suppl 7) S125

Depression, persistent

predictors of persistent depression and pain symptoms in neurology outpatients (Robinson et al) 2003;54:(suppl 7) S77

Development

entorhinal cortex hypermetabolism in Down's syndrome: implications for dementia and development (Haier et al) 2003;54:(suppl 7) S107

Development, brain

expression profiling of developing PS1-deficient brain (Korade Mirnics et al) 2003;54:(suppl 7) S119

MeCP2 expression is dynamically regulated during brain development (Mullaney et al) 2003;54:(suppl 7) S104

Reelin and Lis1 signaling are coordinated in brain development (Assadi et al) 2003;54:(suppl 7) S104

Developmental delay, global

developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146

Developmental disorder, pervasive

abnormalities of cerebral metabolite levels in children with pervasive developmental disorder: a preliminary ¹H magnetic resonance spectroscopy study (Gabis et al) 2003;54:(suppl 7) S146

Diabetes

incidence of seizures among ketotic and nonketotic diabetic patients (Gao-Hickman et al) 2003;54:(suppl 7) S56

Diabetic polyneuropathy, painful

a maximum tolerated dose study of tiagabine in painful diabetic polyneuropathy (Kirby and Belleau) 2003;54:(suppl 7) S46

Dialectic auras

heart rate analysis can differentiate dialectic temporal lobe epilepsy from dialectic auras and dialectic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55

Dialectic nonepileptic seizures

heart rate analysis can differentiate dialectic temporal lobe epilepsy from dialectic auras and dialectic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55

Diet

diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73

Diet, ketogenic

anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet (Likhodii et al) 2002;54:219

the effect of ketogenic diet on gene expression (Choi et al) 2003;54:(suppl 7) S56

should the ketogenic diet be considered first-line therapy? (Rubenstein et al) 2003;54:(suppl 7) S134

Diffuse axonal injury

association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

Digital skin innervation

quantification of myelinated endings and mechanoreceptors in human digital skin (Nolano et al) 2002;54:186

Disability

disability does not change substantially for most multiple sclerosis patients over a decade in a population-based cohort (Pittock et al) 2003;54:(suppl 7) S37

spinal cord atrophy and disability in multiple sclerosis over 4 years: application of a new technique in monitoring disease progression (Lin et al) 2003;54:(suppl 7) S78

Disinhibition-dysexecutive syndrome

disinhibition-dysexecutive syndrome associated with differential age of onset in a family with SCA-17 (Farbman and Kaufer) 2003;54:(suppl 7) S52

Dissection

clinical predictors of dissection in a stroke cohort (Hildebrand et al) 2003;54:(suppl 7) S137

Disseminated encephalomyelitis, acute

acute disseminated encephalomyelitis: a retrospective pediatric series (McGovern and DiMario Jr.) 2003;54:(suppl 7) S129

the role of plasmapheresis in the treatment of acute disseminated encephalomyelitis 2003;54:(suppl 7) S151

DJ-1 gene

early-onset Parkinson's disease caused by a compound heterozygous *DJ-1* mutation (Hague et al) 2002;54:271

genetics of Parkinson's disease: what do mutations in *DJ-1* tell us? (Moore et al) 2003;54:281

the role of pathogenic *DJ-1* mutations in Parkinson's disease (Abou-Sleiman et al) 2003;54:283

Do-not-resuscitate (DNR) orders

variability in utilization do-not-resuscitate orders for patients with ischemic stroke (Johnston et al) 2003;54:697

Dogs

seizure alerting and response behaviors in dogs living with epileptic children (Kirton et al) 2003;54:(suppl 7) S133

Dopamine agonists

longitudinal effects of dopamine agonist versus levodopa therapy on Parkinson's disease progression: proton magnetic resonance spectroscopic study (Terakawa et al) 2003;54:(suppl 7) S41

Dopamine deficiency

transgenic mouse models of dopamine deficiency (Chen and Zhuang) 2003;54:(suppl 6) S91

Dopamine receptors

psychostimulants depress cortical excitation of the striatum, an effect mediated by presynaptic corticostriatal D2 dopamine receptors (Bamford and Sulzer) 2003;54:(suppl 7) S106

Dopamine system

compensatory mechanisms in the dopamine system of patients with dominantly inherited parkinsonism (van Netten et al) 2003;54:(suppl 7) S19

rapid induction of proapoptotic proteins in nigral dopamine neurons by antipsychotic medication (Mazurek et al) 2003;54:(suppl 7) S42

Doppler imaging, spectral

spectral Doppler imaging of central retinal vessels in children: a potential non-invasive alternative method of

- measuring intracranial pressures (Chang et al) 2003;54:(suppl 7) S152
- Doppler imaging, transcranial**
sickle cell disease and stroke: primary prevention and transcranial Doppler (Adams et al) 2003;54:559 (Editorial)
- Dorsal root ganglia**
erythropoietin protects dorsal root ganglion neurons against gp120 and ddC-induced neurotoxicity (Keswani et al) 2003;54:(suppl 7) S77
- doublecortin gene**
nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30
- Down's syndrome**
entorhinal cortex hypermetabolism in Down's syndrome: implications for dementia and development (Haier et al) 2003;54:(suppl 7) S107
onset of dementia is associated with age at menopause in women with Down's syndrome (Schupf et al) 2003;54:433
parallel compensatory and pathological events in the hippocampus of middle aged individuals with Down's syndrome (Head et al) 2003;54:(suppl 7) S50
- Doxycycline**
minocycline and doxycycline are not beneficial in a model of Huntington's disease (Smith et al) 2002;54:186
- Drug delivery**
a phase I, open-label, three-way crossover study in healthy volunteers to compare the pharmacokinetics of apomorphine HCl delivered from a cartridge using a pen device to that delivered using a syringe manually filed from either a cartridge or an ampoule (Morton et al) 2003;54:(suppl 7) S72
- Drugs, antiepileptic**
antiepileptic drug use in nursing home admissions (Garrard et al) 2003;54:75
the Cincinnati antiepileptic drug side effect neurologic subscale detects and quantifies significant interpatient variability in antiepileptic drug neurologic toxicity (Morita et al) 2003;54:(suppl 7) S137
development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cincinnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136
- Drugs, antimuscarinic**
increased Alzheimer's pathology in Parkinson's disease related to antimuscarinic drugs (Perry et al) 2002;54:235
- Duchenne muscular dystrophy**
creatine and glutamine therapeutic trial in Duchenne muscular dystrophy (DMD) by the Cooperative International Neuromuscular Research Group (CINRG) (Escobar et al) 2003;54:850
- Dyscalculia**
functional magnetic resonance imaging in dyscalculia: preliminary observations (Morocz et al) 2003;54:(suppl 7) S145
- Dysferlin**
analysis of dysferlin in monocytes: a useful tool for the diagnosis of the Miyoshi myopathy phenotypes and the detection of carriers (De Luna et al) 2003;54:(suppl 7) S74
novel expression of dysferlin in recently denervated and apoptotic human muscle fibers (Fratta et al) 2003;54:(suppl 7) S43

Dyskinesia

- acute reduction of dyskinesias in Parkinson's disease by subthalamic nucleus stimulation: evidence for a direct effect (Gracies et al) 2003;54:(suppl 7) S71

Dysmorphic features

- a novel chromosome abnormality associated with severe mental retardation and dysmorphic features (Smathers et al) 2003;54:(suppl 7) S159

Dysplasia, cerebral

- magnetic resonance imaging for the diagnosis of cerebral dysplasia in new-onset seizures in children (Vanderver et al) 2003;54:(suppl 7) S114

Dysplastic neocortex

- anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132

Dysport

- does dysport retain its efficacy if diluted with lidocaine? (Evidente et al) 2003;54:(suppl 7) S46

Dystonia, cervical

- clinical experiences with botulinum toxin type B (Myobloc) in the treatment of cervical dystonia: secondary resistance and electrophysiologic observations (Gollop) 2003;54:(suppl 7) S41

Dystonia, childhood-onset

- approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia (Assmann et al) 2003;54:(suppl 6) S18

Dystonia, dopa-nonresponsive

- tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Dystonia, dopa-responsive

- the *HPH-1* mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

Dystonia, DYT1

- impaired sequence learning in carriers of the DYT1 dystonia mutation (Ghilardi et al) 2003;54:102
nuclear envelope mislocalization of torsinA: a potential molecular mechanism underlying DYT1 dystonia (Dauer et al) 2003;54:849

Dystonia, episodic

- creatine deficiency syndrome: a case of defective creatine transport presenting with episodic dystonia (Mazumdar and Rivkin) 2003;54:(suppl 7) S157

Dystonia, jaw opening

- jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pittock et al) 2003;54:(suppl 7) S70

Dystrophin gene

- therapeutic effect of combined CTLA4Ig and dystrophin gene transfer to *Mdx* muscle using high-capacity adenoviral vectors (Clemens and Jiang) 2003;54:(suppl 7) S42

Dystrophy, myotonic

- brain imaging, clinical correlates, and social consequences of intellectual impairment in myotonic dystrophy type 1 (Meola et al) 2003;54:(suppl 7) S75
CNS involvement in DM1: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74

- leukocyte CTG repeat length correlates with severity of myotonia in distal hand muscles in myotonic dystrophy type 1 (DM1) (Moxley IV et al) 2003;54:(suppl 7) S76
- ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2 (Mankodi et al) 2003;54:760
- DYT1 dystonia**
- impaired sequence learning in carriers of the DYT1 dystonia mutation (Ghilardi et al) 2003;54:102
- nuclear envelope mislocalization of torsinA: a potential molecular mechanism underlying DYT1 dystonia (Dauer et al) 2003;54:849
- Echocardiography**
- what is the role of echocardiography in pediatric stroke? (Pagotto et al) 2003;54:(suppl 7) S137
- Editorials**
- Alzheimer's disease: genetic evidence points to a single pathogenesis (Hardy) 2002;54:143
- chronically mad as a hatter: anticholinergics and Alzheimer's disease pathology (Levey) 2002;54:144
- cyclooxygenase-2 and stroke: the long and short of it (Iadecola) 2002;54:141
- genetics of Parkinson's disease: what do mutations in DJ-1 tell us? (Moore et al) 2003;54:281
- long-term neuroplasticity and functional consequences of single versus recurrent early-life seizures (Baram) 2003;54:701
- seeking clarity through the genetic lens: a work in progress (Nance) 2002;54:5
- sickle cell disease and stroke: primary prevention and transcranial Doppler (Adams et al) 2003;54:559
- a turn of the sulfatide in Alzheimer's disease (Irizarry) 2002;54:7
- Elderly**
- a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28
- Electrical stimulation**
- reappraisal of the human vestibular cortex by cortical electrical stimulation study (Kahane et al) 2003;54:615
- Electrocardiography**
- electrocardiographic activity after terminal cardiac arrest in catastrophic neurological injury: consequences for non-heart beating protocols? (Wijidick and Diringer) 2003;54:(suppl 7) S28
- Electrodiagnosis**
- congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy (Gurnett et al) 2003;54:(suppl 7) S155
- predictive value of electrodiagnostic studies in brachial plexus injuries (Vednarayanan et al) 2003;54:(suppl 7) S155
- Electroencephalography**
- correlation of copper levels and electroencephalogram abnormalities in patients with Menkes' disease (Valencia et al) 2003;54:(suppl 7) S150
- the effect of lamotrigine therapy on electroencephalogram in children with refractory epilepsies (Akman and Holmes) 2003;54:(suppl 7) S134
- interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy (Herzog et al) 2003;54:625
- periodic lateralized epileptiform discharges in neonatal EEG recordings (Wambara et al) 2003;54:(suppl 7) S114
- Electromyography**
- diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita (Kang et al) 2003;54:790
- the diagnostic value of electromyography and muscle pathology in the evaluation of arthrogryposis multiplex congenita (Kang et al) 2003;54:(suppl 7) S155
- Eletriptan**
- eletriptan: switching triptans for better efficacy (Krusz) 2003;54:(suppl 7) S34
- Emergency department**
- effectiveness and tolerability of ketorolac for severe headaches in children seen in the emergency department (Vasconcellos et al) 2003;54:(suppl 7) S150
- twenty-four hour risk of seizure recurrence in pediatric emergency department patients (Sogawa and Maytal) 2003;54:(suppl 7) S114
- Emotional reactions**
- is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Annoni and Khateb) 2003;54:556 (Reply)
- is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Gondim and de Oliveira) 2003;54:555 (Letter)
- Encephalitis, limbic**
- autoimmune limbic encephalitis associated with potassium channel antibodies (Theiben et al) 2003;54:(suppl 7) S22
- voltage-gated potassium channel antibodies in limbic encephalitis (Pozo-Rosich et al) 2003;54:530
- voltage-gated potassium channel antibody-associated limbic encephalitis is relatively common, potentially treatable, and usually nonaraneoplastic (Vincent et al) 2003;54:(suppl 7) S20
- Encephalitis, West Nile virus**
- neuropathological findings in West Nile virus encephalitis: a case report (Agamanolis et al) 2003;54:547
- Encephalomyelitis, acute disseminated**
- acute disseminated encephalomyelitis: a retrospective pediatric series (McGovern and DiMario Jr.) 2003;54:(suppl 7) S129
- the role of plasmapheresis in the treatment of acute disseminated encephalomyelitis 2003;54:(suppl 7) S151
- Encephalomyelitis, experimental allergic**
- reversal of clinical signs by IL-16-targeted therapy in MOG35-55-induced relapsing-remitting EAE in H-2b/s mice (Skundric et al) 2003;54:(suppl 7) S62
- time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
- Encephalopathy**
- encephalopathy associated with respiratory syncytial virus: a cohort study (Kho et al) 2003;54:(suppl 7) S130
- Encephalopathy, acute**
- acute infantile encephalopathy predominantly affecting the bilateral frontal lobes: a novel subtype of acute encephalopathy (Yamanouchi et al) 2003;54:(suppl 7) S127
- Encephalopathy, acute infantile**
- acute infantile encephalopathy predominantly affecting the bilateral frontal lobes: a novel subtype of acute encephalopathy (Yamanouchi et al) 2003;54:(suppl 7) S127
- Encephalopathy, Hashimoto's**
- central nystagmus associated with Hashimoto's encephalopathy (Fife et al) 2003;54:(suppl 7) S45

Encephalopathy, HIV

HIV encephalopathy in the post–highly active antiretroviral therapy (HAART) era: incidence, cumulative prevalence and clinical outcome among survivors (Chiriboga et al) 2003;54:(suppl 7) S112

Encephalopathy, neonatal

clinical signs predict 30-month neurodevelopmental outcome after neonatal encephalopathy (Miller et al) 2003;54:(suppl 7) S111

Encephalopathy, progressive

tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Endocannabinoids

the dark side of endocannabinoids: a neurotoxic role for anandamide (Faden et al) 2003;54:(suppl 7) S77

Endocrinopathy

neuroimaging and endocrinopathies in neonatal group B streptococcal meningitis (McLellan et al) 2003;54:(suppl 7) S125

Endothelin-1

ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space (Petzold et al) 2003;54:591

Energy metabolism

defective mitochondrial energy metabolism in creatine transporter 1 deficiency (Anselm et al) 2003;54:(suppl 7) S156

English kindred

an English kindred with a novel recessive tauopathy and respiratory failure (Nicholl et al) 2003;54:682

Entacapone

addition of levodopa in combination with entacapone increases "On" time without potentiating peak dyskinesias: a study in the MPTP-treated primate (Jenner et al) 2003;54:(suppl 7) S40

Entorhinal cortex

entorhinal cortex hypermetabolism in Down's syndrome: implications for dementia and development (Haier et al) 2003;54:(suppl 7) S107

Enzyme-linked immunosorbent assay

a capture ELISA and its use in an outpatient MS population to screen for antibody-mediated decreased bioactivity (Dail et al) 2003;54:(suppl 7) S63

Enzyme replacement therapy

effect of enzyme replacement therapy on sleep-disordered breathing in type II mucopolysaccharidosis (D'Cruz et al) 2003;54:(suppl 7) S151

enzyme replacement therapy in the tolerant mouse model of Pompe's disease (Raben et al) 2003;54:(suppl 7) S20

Ependymoma, childhood

childhood ependymomas: possible improved survival with the use of preirradiation chemotherapy followed by radiotherapy (Garvin et al) 2003;54:(suppl 7) S109

Epidermal growth factor receptor

small interfering RNAs directed against Δ EGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850

Epilepsy

chronic amnesic states and temporal lobe complex partial status epilepticus (Perez-Gosiengfiao et al) 2003;54:(suppl 7) S54

the cognitive consequences of epilepsy (Duncan and Thompson) 2003;54:421 (Editorial)

dynamical entrainment among epileptic brain areas (Shiau et al) 2003;54:(suppl 7) S55

epilepsy in low-grade gliomas: the impact on cognitive function and quality of life (Klein et al) 2003;54:514

epilepsy with auditory features: a *LGII* gene mutation suggests a loss-of-function mechanism (Pizzuti et al) 2003;54:137 (Correction)

impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model (Wong et al) 2002;54:251

interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy (Herzog et al) 2003;54:625

intravenous human neural stem cell transplantation ameliorated the epileptogenesis in rat epilepsy model (Chu et al) 2003;54:(suppl 7) S54

the prevalence of autistic spectrum disorder in children seen in a tertiary care epilepsy clinic (Clarke et al) 2003;54:(suppl 7) S149

tolerability and safety of topiramate as first-line monotherapy in children and adolescents (Dlugos et al) 2003;54:(suppl 7) S135

topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135

topiramate as first-line therapy in children/adolescents with newly diagnosed epilepsy (Pellock et al) 2003;54:(suppl 7) S112

topiramate as first-line therapy in epilepsy characterized by partial-onset or generalized tonic-clonic seizures (Levi-sohn et al) 2003;54:(suppl 7) S135

Epilepsy, absence

association between genetic variation of *CACNA1H* and childhood absence epilepsy (Chen et al) 2002;54:239

Epilepsy, childhood

association between genetic variation of *CACNA1H* and childhood absence epilepsy (Chen et al) 2002;54:239

baseline cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy (Mandelbaum et al) 2003;54:(suppl 7) S114

brain-derived neurotrophic factor and antibodies to brain-derived neurotrophic factor are elevated in children with autism, autism with regression, and epilepsy (Connolly et al) 2003;54:(suppl 7) S146

development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cincinnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136

the effect of lamotrigine therapy on electroencephalogram in children with refractory epilepsies (Akman and Holmes) 2003;54:(suppl 7) S134

the effect of music periodicity on rolandic spikes: a randomized, single-blinded, crossover, clinical trial of the effect of music with distinctive long-term periodicity and repeated melodic line on interictal spike discharges of children with benign childhood epilepsy with centrotemporal spikes (Turner) 2003;54:(suppl 7) S134

extensive clinical experience with oxcarbazepine (Trileptal) in children with epilepsy demonstrates good safety and tolerability profiles (Bourgeois) 2003;54:(suppl 7) S136

oxcarbazepine (Trileptal) is safe and tolerable in children with epilepsy (Brown and Black) 2003;54:(suppl 7) S112

a prospective study of topiramate in 500+ children/adolescents with refractory epilepsy (Ritter et al) 2003;54:(suppl 7) S112

seizure alerting and response behaviors in dogs living with epileptic children (Kirton et al) 2003;54:(suppl 7) S133

- tolerability and safety of topiramate as first-line monotherapy in children and adolescents (Dlugos et al) 2003;54:(suppl 7) S135
- topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135
- topiramate as add-on or monotherapy in pediatric epilepsy (Wang et al) 2003;54:(suppl 7) S135
- topiramate as first-line therapy in children/adolescents with newly diagnosed epilepsy (Pellock et al) 2003;54:(suppl 7) S112
- topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136
- Epilepsy, childhood-onset**
- comorbidity of childhood-onset epilepsy and psychiatric and behavioral disorders: a population-based study (Hedderick and buchhalter) 2003;54:(suppl 7) S115
- Epilepsy, chronic**
- chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy (Helmstaedter et al) 2003;54:425
- Epilepsy, cryptogenic**
- nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30
- Epilepsy, generalized**
- vagus nerve stimulation for refractory symptomatic generalized epilepsy (Hosain et al) 2003;54:(suppl 7) S113
- Epilepsy, hippocampal**
- the hyperpolarization-activated HCN channels in human and experimental hippocampal epilepsy: a novel, acquired channelopathy? (Bender et al) 2003;54:(suppl 7) S54
- Epilepsy, idiopathic**
- baseline cognition, behavior, and motor skills in children with new-onset, idiopathic epilepsy (Mandelbaum et al) 2003;54:(suppl 7) S114
- Epilepsy, myoclonus**
- the expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNA^{Lys} gene (Rossmanith et al) 2003;54:821
- Epilepsy, refractory**
- the effect of lamotrigine therapy on electroencephalogram in children with refractory epilepsies (Akman and Holmes) 2003;54:(suppl 7) S134
- a prospective study of topiramate in 500+ children/adolescents with refractory epilepsy (Ritter et al) 2003;54:(suppl 7) S112
- topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136
- Epilepsy, temporal lobe**
- chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy (Helmstaedter et al) 2003;54:425
- the correlation of histopathology to electrocorticographic pattern and postoperative outcome in temporal lobe epilepsy (Burakgazi et al) 2003;54:(suppl 7) S55
- heart rate analysis can differentiate dialeptic temporal lobe epilepsy from dialeptic auras and dialeptic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55
- is FDG-PET still useful for detecting temporal lobe foci? (Theodore et al) 2003;54:(suppl 7) S56
- microdysgenesis in mesial temporal lobe epilepsy: a clinicopathological study (Kasper et al) 2003;54:501
- Episodic ataxia, febrile**
- novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725
- Episodic neurological disease**
- the differential responsiveness of quality of life and health status instruments in chronic progressive and episodic neurological diseases: a measure of disease adaptation (Kern and Brown) 2003;54:696, (suppl 7) S18
- Epithelial cells**
- folate receptor function in cultured choroid plexus epithelial cells (Wollack et al) 2003;54:(suppl 7) S117
- Erythropoietin**
- erythropoietin protects dorsal root ganglion neurons against gp120 and ddC-induced neurotoxicity (Keswani et al) 2003;54:(suppl 7) S77
- Ethanol exposure, prenatal**
- preliminary studies on prenatal ethanol exposure and reduced grip strength in rats (Johnson and Smith) 2003;54:(suppl 7) S128
- Europe**
- NR4A2 mutations are rare among European patients with familial Parkinson's disease (Wellenbrock et al) 2003;54:415 (Letter)
- Evidence-based medicine**
- an evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis (Armon) 2003;54:(suppl 7) S78
- Excitotoxic neuronal injury**
- status epilepticus and excitotoxic neuronal injury: a case report (Tschida et al) 2003;54:(suppl 7) S159
- Exercise**
- diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73
- Exercise tests**
- a diagnostic cycle test for McArdle's disease (Vissing et al) 2003;54:539
- Experimental allergic encephalomyelitis**
- reversal of clinical signs by IL-16-targeted therapy in MOG35-55-induced relapsing-remitting EAE in H-2b/s mice (Skundric et al) 2003;54:(suppl 7) S62
- time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
- Experimental stroke**
- the 70kD heat shock protein protects against experimental stroke by suppressing microglial activation (Zheng et al) 2003;54:(suppl 7) S24
- F2 isoprostanes**
- patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately parallel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848
- Fabry's disease**
- hearing loss in Fabry's disease: the effect of α -galactosidase A replacement therapy (Hajioff et al) 2003;54:(suppl 7) S26
- Facial nerve avulsion**
- facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53

Facial nerve palsy

facial nerve palsy caused by Lyme disease: LP or no LP? that was our question (Freilich et al) 2003;54:(suppl 7) S131

Facial port-wine stains

autism with facial port-wine stain: a new syndrome? (Chugani et al) 2003;54:(suppl 7) S129

Factor V

the factor V G1691A mutation is significantly associated with childhood porencephaly in white children: a case-control study (Debus et al) 2003;54:(suppl 7) S110

Familial Alzheimer's disease

Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE ε4 (Leverenz et al) 2003;54:(suppl 7) S68

Familial Creutzfeldt-Jakob disease

characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67

homozygous prion protein genotype at codon 129 is not a predisposing factor for developing familial Creutzfeldt-Jakob disease with a point mutation of Val to Ile at codon 180 (Shiga et al) 2003;54:(suppl 7) S69

Familial hemiplegic migraine

novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360

Familial infantile convulsions, benign

novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360

Familial Parkinson's disease

NR4A2 mutations are rare among European patients with familial Parkinson's disease (Wellenbrock et al) 2003; 54:415 (Letter)

Fastigial nucleus stimulation

clinical research of fastigial nucleus stimulation in treatment of disorders of consciousness by brain damage (Yang et al) 2003;54:(suppl 7) S25

Fatigue

fatigue in subarachnoid hemorrhage survivors: predictors and impact on long-term outcome (Kowalski et al) 2003;54:698

Fatigue, motor

perception of motor fatigue during 30 seconds of sustained maximal voluntary contraction was significantly blunted in multiple sclerosis (Sanjak et al) 2003;54:(suppl 7) S36

Fatigue, rapid

a technique to monitor rapid fatigue in fatty acid oxidation disorders (Cook et al) 2003;54:(suppl 7) S151

Fatty acid oxidation disorders

a technique to monitor rapid fatigue in fatty acid oxidation disorders (Cook et al) 2003;54:(suppl 7) S151

Fc receptor ligands

regulation of immune function in multiple sclerosis and in controls using novel Fc receptor ligands (Jensen et al) 2003;54:(suppl 7) S38

FDG-PET

is FDG-PET still useful for detecting temporal lobe foci? (Theodore et al) 2003;54:(suppl 7) S56

Febrile episodic ataxia

novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725

Febrile seizures, repetitive

febrile seizures impair memory and cAMP response-element binding protein activation (Chang et al) 2003; 54:706

Feeding difficulties

agenesis of the corpus callosum is associated with significant feeding difficulties: oral/pharyngeal motor and sensory disorder (Ng et al) 2003;54:(suppl 7) S149

Fe65L2 gene

c954C→T polymorphism in the *Fe65L2* gene is associated with early-onset Alzheimer's disease (Tanahashi et al) 2002;54:137 (Correction)

Fetal nigral transplantation, bilateral

a double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (Olanow et al) 2003;54:403

Fetal Pelizaeus-Merzbacher disease

myelination of a fetus with Pelizaeus-Merzbacher disease: immunopathological study (Shiraishi et al) 2002;54:259

Fibronectin

decreased fibronectin expression in meningeal blood vessels of Sturge-Weber's syndrome (Comi et al) 2003;54:(suppl 7) S116

Fine motor function

fine motor and gross motor function in school-age children with a preschool diagnosis of specific language impairment (Webster et al) 2003;54:(suppl 7) S145

Flavonoids

some flavonoids prevent cytotoxicity and *cis*-effect of expanded CTG repeats in stable transformant of PC12 neuronal cell (Furuya et al) 2003;54:(suppl 7) S74

Fluoxetine withdrawal, neonatal

neonatal fluoxetine withdrawal secondary to maternal use during pregnancy: is fluoxetine safe? (Lavenstein et al) 2003;54:(suppl 7) S127

Folate receptor

folate receptor function in cultured choroid plexus epithelial cells (Wollack et al) 2003;54:(suppl 7) S117

Fontan procedure

prothrombotic risk factors in children with stroke after Fontan procedure (Smith and Garg) 2003;54:(suppl 7) S138

FP-CIT-SPECT

[¹²¹I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Katzenschlager R et al) 2002;54: 278 (Correction)

Fragile X syndrome

clinical response to psychopharmacology for behavior in fragile X syndrome (Berry-Kravis and Potanos) 2003; 54:(suppl 7) S144

increased protein acetylation in lymphocytes predicts autistic behavior in fragile X syndrome (Kaufmann et al) 2003;54:(suppl 7) S105

stimulant therapy in fragile X syndrome (Berry-Kravis and Potanos) 2003;54:(suppl 7) S150

Friedreich's ataxia

cardiac bioenergetics in Friedreich's ataxia (Bit-Avragim et al) 2003;54:552 (Reply)

cardiac bioenergetics in Friedreich's ataxia (Lodi et al) 2003;54:552 (Letter)

simultaneous tuberous sclerosis and Friedreich's ataxia: no evidence for interaction (Walker et al) 2003;54:(suppl 7) S57

Frontal behavior syndromes

frontal behavior syndromes in Huntington's disease and Parkinson's disease (Hulvershorn et al) 2003;54:(suppl 7) S70

Frontal-lobe damage

impaired social attention after frontal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

Frontal white matter

frontal white matter reductions in healthy boys with complex stereotypies (Kates et al) 2003;54:(suppl 7) S144

Frontotemporal degeneration

frontotemporal degeneration, Pick's disease, Pick complex, and Ravel (Kertesz et al) 2003;54:(suppl 5) S1

Frontotemporal dementia

cognitive impairment, frontotemporal dementia, and the motor neuron diseases (Strong et al) 2003;54:(suppl 5) S20

corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia (Boeve et al) 2003;54:(suppl 5) S15

epidemiology and genetics of frontotemporal dementia/Pick's disease (Bird et al) 2003;54:(suppl 5) S29

international approaches to frontotemporal dementia diagnosis: from social cognition to neuropsychology (Miller et al) 2003;54:(suppl 5) S7

laboratory investigations and treatment in frontotemporal dementia (Pasquier et al) 2003;54:(suppl 5) S32

the neuropathology and biochemistry of frontotemporal dementia (Munoz et al) 2003;54:(suppl 5) S24

preferred terminology (Kertesz et al) 2003;54:(suppl 5) S3

progressive supranuclear palsy presenting as frontotemporal dementia (Smoot et al) 2003;54:(suppl 7) S22

serotonin 5-HT_{1A} receptor binding potential in frontotemporal dementia (FTD) compared with controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S67

Frontotemporal network

subthalamic nucleus stimulation affects a frontotemporal network: a PET study (Schroeder et al) 2003;54:445

FTDP-17

mutation carriers versus noncarriers in a cohort of at-risk individuals in PPND family (FTDP-17, N279K tau mutation) (Wszolek et al) 2003;54:(suppl 7) S58

Functional imaging: see also specific modalities

functional neuroimaging provides evidence of anomalous cerebral laterality in adults with Klinefelter's syndrome (Itti et al) 2003;54:669

Funisitis

funisitis and neurologic abnormalities in term infants (Wu et al) 2003;54:(suppl 7) S126

Gait deficit

correlation of gait deficit with muscle activation latency impairment after stroke (Fredrickson et al) 2003;54:(suppl 7) S64

Gait disturbances

the effects of unilateral versus bilateral subthalamic nuclei stimulation on tremor and gait in persons with Parkinson's disease (Shumway-Cook et al) 2003;54:(suppl 7) S69

Galactocerebroside

time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38

α -Galactosidase A

hearing loss in Fabry's disease: the effect of α -galactosidase A replacement therapy (Hajioff et al) 2003;54:(suppl 7) S26

Galantamine

the sustained clinical efficacy of galantamine: effects of treatment withdrawal (Aronson and Kershaw) 2003;54:(suppl 7) S69

γ -aminobutyric acid

brain GABA in SSADH deficiency (Novotny Jr. et al) 2003;54:(suppl 7) S106

GABA, γ -aminobutyric acid, and neurological disease (Wong et al) 2003;54:(suppl 6) S3

Gangliosidosis, GM1

a new compound *N*-octyl-4-epi-b-valienamine for chemical chaperone therapy of GM1 gangliosidosis (Matsuda et al) 2003;54:(suppl 7) S107

Gender differences

association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697

the impact of gender and subtypes on attention deficit hyperactivity disorder (Gross-Tsur et al) 2003;54:(suppl 7) S144

patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately parallel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848

Gene expression

the effect of ketogenic diet on gene expression (Choi et al) 2003;54:(suppl 7) S56

Gene expression profiling

expression profiling of developing PS1-deficient brain (Korade Mirnics et al) 2003;54:(suppl 7) S119

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58

human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syndrome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118

Gene polymorphisms

absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Dermaut et al) 2003;54:555 (Reply)

absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Ohkubo et al) 2003;54:553 (Letter)

association between a polymorphism of *brain-derived neurotrophic factor* gene and sporadic Parkinson's disease (Masaki et al) 2002;54:276 (Letter)

c954C→T polymorphism in the *Fe65L2* gene is associated with early-onset Alzheimer's disease (Tanahashi et al) 2002;54:137 (Correction)

early cognitive decline is associated with prion protein codon 129 polymorphism (Croes et al) 2002;54:275 (Letter)

Gene therapy

imaging-guided convection-enhanced delivery and gene therapy of glioblastoma (Voges et al) 2003;54:479

a novel nonviral approach to gene therapy for muscle disease mediated by phage ϕ C31 integrase (Wheeler et al) 2003;54:(suppl 7) S43

- potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease (Kang and Nakamura) 2003;54:(suppl 6) S103
- Gene transfer**
- imaging-guided convection-enhanced delivery and gene therapy of glioblastoma (Voges et al) 2003;54:479
- therapeutic effect of combined CTLA4Ig and dystrophin gene transfer to *Mdx* muscle using high-capacity adenoviral vectors (Clemens and Jiang) 2003;54:(suppl 7) S42
- transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease (Yamada et al) 2003;54:352
- Genetics**
- epidemiology and genetics of frontotemporal dementia/Pick's disease (Bird et al) 2003;54:(suppl 5) S29
- investigation of 40 positional and functional candidate genes for autism (Huq et al) 2003;54:(suppl 7) S119
- seeking clarity through the genetic lens: a work in progress (Nance) 2002;54:5 (Editorial)
- Genomic fingerprinting**
- genomic fingerprint of acute ischemic stroke (Moore et al) 2003;54:(suppl 7) S24
- Genotype**
- genotypes from patients indicate no paternal mitochondrial DNA contribution (Taylor et al) 2003;54:521
- homozygous prion protein genotype at codon 129 is not a predisposing factor for developing familial Creutzfeldt-Jakob disease with a point mutation of Val to Ile at codon 180 (Shiga et al) 2003;54:(suppl 7) S69
- Genotype-phenotype correlations**
- ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis (Al-Chalabi et al) 2003;54:130
- CNS involvement in DM1: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74
- distal myopathy with rimmed vacuoles: phenotype/genotype relationship in Japanese families (Uyama et al) 2003;54:(suppl 7) S73
- how much phenotypic variation can be attributed to *parkin* genotype? (Lohmann et al) 2002;54:176
- novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151
- Gilles de la Tourette syndrome**
- neuroleptics and Gilles de la Tourette syndrome: patient knowledge and concern (Kompolti et al) 2003;54:(suppl 7) S41
- Girls**
- masturbation presenting as a movement disorder in young girls (Fullwood et al) 2003;54:(suppl 7) S130
- Glasgow Coma Scale**
- association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111
- Glaucoma**
- POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154
- Glial cell line-derived neurotrophic factor**
- unilateral intraputamenal administration of recombinant-methionyl human glial cell line-derived neurotrophic factor to treat idiopathic Parkinson's disease (Slevin et al) 2003;54:849
- Glial cells**
- cytokine-induced early gene regulation in glial cell cultures: differential effects of Th1, Th2, and monocyte cytokines (Lisak et al) 2003;54:(suppl 7) S38
- Glial fibrillary acidic protein**
- fulminant Alexander disease with a novel mutation in glial fibrillary acidic protein gene (Bassuk et al) 2003;54:(suppl 7) S157
- increased citrullinated GFAP in secondary progressive multiple sclerosis (Nicholas et al) 2003;54:(suppl 7) S60
- Glioblastoma multiforme**
- cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54:(suppl 7) S31
- glioblastoma multiforme presenting as bilateral internal auditory canal tumors mimicking neurofibromatosis type 2 (Lee et al) 2003;54:(suppl 7) S31
- imaging-guided convection-enhanced delivery and gene therapy of glioblastoma (Voges et al) 2003;54:479
- Glioma**
- alterations of γ -tubulin cellular distribution in human gliomas: implication of centrosome amplification in malignant tumor progression (Katsetos et al) 2003;54:(suppl 7) S117
- epilepsy in low-grade gliomas: the impact on cognitive function and quality of life (Klein et al) 2003;54:514
- glutamate transporter expression in human gliomas (Yohay et al) 2003;54:(suppl 7) S30
- monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas (Platten et al) 2003;54:388
- multitracer positron emission tomography in the management of patients with gliomas (Heiss et al) 2003;54:(suppl 7) S30
- small interfering RNAs directed against Δ EGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850
- temozolomide as long-term maintenance treatment for gliomas (Stern et al) 2003;54:(suppl 7) S31
- Global developmental delay**
- developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146
- Global ischemia**
- graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103
- Glutamate**
- disruption of glial glutamate transport by reactive oxygen species produced in motor neurons in response to excitotoxic activation: an in vitro model of ALS pathogenesis (Weiss et al) 2003;54:(suppl 7) S43
- glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128
- impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model (Wong et al) 2002;54:251
- olmesartan protects spinal motor neurons from glutamate-mediated neurotoxicity (Iwasaki et al) 2003;54:(suppl 7) S52

Glutamate transporters

acute and chronic neural injury alters splicing of functional glutamate transporters (Maragakis et al) 2003;54:(suppl 7) S20

glutamate transporter expression in human gliomas (Yohay et al) 2003;54:(suppl 7) S30

Glutamine

creatine and glutamine therapeutic trial in Duchenne muscular dystrophy (DMD) by the Cooperative International Neuromuscular Research Group (CINRG) (Escobar et al) 2003;54:850

glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128

Glycoprotein

epitope recognition differentially controls effector functions of myelin/oligodendrocyte glycoprotein-specific autoantibodies and phenotypic expression of autoimmune demyelination (von Büdingen et al) 2003;54:(suppl 7) S37

restriction of humoral responses to conformational epitopes after exposure to the native myelin oligodendrocyte glycoprotein polypeptide (Genain et al) 2003;54:(suppl 7) S60

Glycoprotein gp120

erythropoietin protects dorsal root ganglion neurons against gp120 and ddC-induced neurotoxicity (Keswani et al) 2003;54:(suppl 7) S77

Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons (Keswani et al) 2003;54:287

Glycosylation, congenital disorder of

mechanism of stroke-like events in congenital disorder of glycosylation (Dinopoulos et al) 2003;54:(suppl 7) S139

Gray matter

cerebellar gray matter MRI T2 hypointensity is independently associated with ambulatory dysfunction and clinical course in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59

subcortical gray matter MRI T2 hypointensity is independently associated with cognitive impairment in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59

Gray matter atrophy, progressive

progressive gray matter atrophy occurs in the earliest clinical stages of relapse onset multiple sclerosis (Dalton et al) 2003;54:(suppl 7) S38

Grip strength

preliminary studies on prenatal ethanol exposure and reduced grip strength in rats (Johnson and Smith) 2003;54:(suppl 7) S128

Gross motor function

fine motor and gross motor function in school-age children with a preschool diagnosis of specific language impairment (Webster et al) 2003;54:(suppl 7) S145

Group B streptococcal meningitis, neonatal

neuroimaging and endocrinopathies in neonatal group B streptococcal meningitis (McLellan et al) 2003;54:(suppl 7) S125

Growth hormone

growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression (Silva et al) 2003;54:605

Growth impairment, cerebellar

impaired cerebellar growth in preterm infants without brain injury (Limperopoulos et al) 2003;54:(suppl 7) S122

Guanosine triphosphate cyclohydrolase I deficiency, autosomal dominant

autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease) (Segawa et al) 2003;54:(suppl 6) S32

the *HPH-1* mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Hallucinations

comparisons of hallucinations in dementia with Lewy bodies (DLB) and Parkinson's disease (PD) with hallucinations: a case-control study (Goldman et al) 2003;54:(suppl 7) S72

retinal involvement in dementia with Lewy bodies: a clue to hallucinations? (Maurage et al) 2003;54:542

Hand myotonia

leukocyte CTG repeat length correlates with severity of myotonia in distal hand muscles in myotonic dystrophy type 1 (DM1) (Moxley IV et al) 2003;54:(suppl 7) S76

Hashimoto's encephalopathy

central nystagmus associated with Hashimoto's encephalopathy (Fife et al) 2003;54:(suppl 7) S45

Head injury, minor

prevalence and risk of sleep disturbances in adolescents after minor head injury (Ravid et al) 2003;54:(suppl 7) S128

Head tilt

head tilt and lateropulsion in Wallenberg's syndrome (Kim et al) 2003;54:(suppl 7) S79

Headache

effectiveness and tolerability of ketorolac for severe headaches in children seen in the emergency department (Vasconcellos et al) 2003;54:(suppl 7) S150

epidemiology and headache management in spontaneous intracranial hypotension (Diaz) 2003;54:(suppl 7) S32

topiramate monotherapy for the prevention of headaches in children (Vasconcellos et al) 2003;54:(suppl 7) S150

Headache, persistent

what causes new daily persistent headache in children? (Mack) 2003;54:(suppl 7) S130

Headache, tension-type

psychiatric characteristics of the patients with tension-type headache (Lee et al) 2003;54:(suppl 7) S34

Headache Screen

diagnosing migraine with a simple and efficient three-question Headache Screen (Cady et al) 2003;54:(suppl 7) S33

Health status instruments

the differential responsiveness of quality of life and health status instruments in chronic progressive and episodic neurological diseases: a measure of disease adaptation (Kern and Brown) 2003;54:696, (suppl 7) S18

Hearing loss

cellular mechanism of Cx26 mutations causing dominant hearing loss (Yum and Scherer) 2003;54:(suppl 7) S120

hearing loss in Fabry's disease: the effect of α -galactosidase A replacement therapy (Hajioff et al) 2003;54:(suppl 7) S26

- vertebrobasilar insufficiency and hearing loss in children: is there any link? (Melikishvili et al) 2003;54:(suppl 7) S141
- Hearing loss, meningitis-associated**
meningitis-associated hearing loss: protection by adjunctive antioxidant therapy (Klein et al) 2003;54:451
- Heart rate analysis**
heart rate analysis can differentiate dialeptic temporal lobe epilepsy from dialeptic auras and dialeptic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55
- Heat shock protein 70**
the 70kD heat shock protein protects against experimental stroke by suppressing microglial activation (Zheng et al) 2003;54:(suppl 7) S24
mechanisms of neuroprotection by the 70kD heat shock protein in transgenic mice: influence of astrocytes (Zheng et al) 2003;54:(suppl 7) S24
- Heat shock protein 105**
the role of immune responses to heat shock protein 105 in multiple sclerosis (Minohara et al) 2003;54:(suppl 7) S61
- Helper T cells**
cytokine-induced early gene regulation in glial cell cultures: differential effects of Th1, Th2, and monocyte cytokines (Lisak et al) 2003;54:(suppl 7) S38
- Hematology**
cerebral perfusion, cerebrovascular disease, and hematology in sickle cell disease: a longitudinal study (Prengler et al) 2003;54:(suppl 7) S138
- Hemimegalencephaly**
bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly (Alfonso et al) 2003;54:(suppl 7) S158
- Hemiparesis, pediatric**
a profile of pediatric hemiparesis (Oskoui and Shevell) 2003;54:(suppl 7) S141
- Hemiplegic cerebral palsy**
constraint-induced movement therapy in children with hemiplegic cerebral palsy (Weber and Delgado) 2003;54:(suppl 7) S149
- Hemiplegic migraine, familial**
novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360
- Hemoglobin**
ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space (Petzold et al) 2003;54:591
- Hemophagocytic lymphohistiocytosis**
neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158
- Hemorrhage**
association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111
- Hemorrhage, cerebellar**
ultrasonographic accompaniments and predictors of cerebellar hemorrhage in the preterm infant (Limperopoulos et al) 2003;54:(suppl 7) S122
- Hemorrhage, cerebral**
altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121
cerebral hemorrhage produced by ruptured dissecting aneurysm in milary aneurysm (Rosenblum) 2003;54:376
matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379
neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158
- Hemorrhage, intracerebral**
predictive model of 30-day mortality after supra- and infra-tentorial spontaneous intracerebral hemorrhages (Giraldo et al) 2003;54:(suppl 7) S25
protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage (Wang et al) 2003;54:655
a study of single photon emission computed tomography in patients with intracerebral hemorrhage receiving mannitol (Misra et al) 2003;54:(suppl 7) S64
- Hemorrhage, intracranial**
in acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? 2003;54:698
a prospective, longitudinal study of echo-planar T2*-weighted MRI for early detection of intracranial hemorrhage in premature infants (Neil et al) 2003;54:(suppl 7) S122
- Hemorrhage, intraventricular**
intraventricular hemorrhage and sinovenous thrombosis in term infants (Wul et al) 2003;54:(suppl 7) S138
intraventricular hemorrhage in term neonates caused by sinovenous thrombosis (Wu et al) 2003;54:123
- Hemorrhage, subarachnoid**
fatigue in subarachnoid hemorrhage survivors: predictors and impact on long-term outcome (Kowalski et al) 2003;54:698
ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space (Petzold et al) 2003;54:591
predictors of discharge functional outcome in good grade Hunt and Hess subarachnoid hemorrhage patients (Parra et al) 2003;54:(suppl 7) S26
predictors of occurrence and location of radiological stroke in subarachnoid hemorrhage (Rabinstein et al) 2003;54:(suppl 7) S66
- Hemorrhagic infarction, periventricular**
periventricular hemorrhagic infarction, clinical antecedents and ultrasonographic accompaniments (Bassan et al) 2003;54:(suppl 7) S124
- Hereditary chorea, benign**
benign hereditary chorea: clinical, genetic, and pathological findings (Kleiner-Fisman et al) 2002;54:244
- Hereditary motor and sensory neuropathy**
hereditary motor and sensory neuropathy with agenesis of the corpus callosum (Dupré et al) 2002;54:9
- Hereditary spastic paraparesis**
hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation (McDermott et al) 2003;54:748
- Hereditary spastic paraplegia**
a locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:796
- Herpes simplex virus type 1 (HSV-1)**
dually infected (HSV-1/VZV) single neurons in human trigeminal ganglia (Theil et al) 2003;54:678

- the multiple functions of herpes simplex virus type 1 latency-associated gene (LAG) in a LAG-expressing transgenic mouse (Steiner et al) 2003;54:(suppl 7) S48
- Herpesvirus**
herpesviruses in brains in Alzheimer's and Parkinson's diseases (Hemling et al) 2002;54:267
- Heterozygotes**
low ceruloplasmin in heterozygotes for Wilson's disease: a copper herring (Reich and O'Hearn) 2003;54:(suppl 7) S42
- Highly active antiretroviral therapy (HAART)**
HIV-associated painful neuropathy in the era of highly active antiretroviral therapy (Schifitto et al) 2003;54:(suppl 7) S50
HIV encephalopathy in the post-highly active antiretroviral therapy (HAART) era: incidence, cumulative prevalence and clinical outcome among survivors (Chiriboga et al) 2003;54:(suppl 7) S112
reduced dependence of BBB compromise on microglial activation in HIV patients on HAART (Avison et al) 2003;54:(suppl 7) S48
reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49
- Hippocampal epilepsy**
the hyperpolarization-activated HCN channels in human and experimental hippocampal epilepsy: a novel, acquired channelopathy? (Bender et al) 2003;54:(suppl 7) S54
- Hippocampus**
lesions of hippocampus in multiple system atrophy (Wang et al) 2003;54:(suppl 7) S52
parallel compensatory and pathological events in the hippocampus of middle aged individuals with Down's syndrome (Head et al) 2003;54:(suppl 7) S50
febrile seizures impair memory and cAMP response-element binding protein activation (Chang et al) 2003;54:706
- Histone acetylation**
histone acetylation in Rett's syndrome lymphocytes: characteristics and relationship with neurological impairment (Kaufmann et al) 2003;54:(suppl 7) S108
- HIVID; see ddC**
- Hormone therapy**
changes in perception of risks and benefits of hormone therapy in women with stroke (Bushnell et al) 2003;54:699
lack of impact of the Women's Health Initiative on hormone therapy use after stroke (Bushnell and Goldstein) 2003;54:697
- Human herpesvirus-6**
a novel model to study the viral pathogenesis of multiple sclerosis after infection with HHV-6 (Tanuma et al) 2003;54:(suppl 7) S47
- Human immunodeficiency virus**
effect of aging on brain metabolism in antiretroviral-naive HIV patients (Ernst and Chang) 2003;54:(suppl 7) S48
growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression (Silva et al) 2003;54:605
HIV-associated painful neuropathy in the era of highly active antiretroviral therapy (Schifitto et al) 2003;54:(suppl 7) S50
HIV encephalopathy in the post-highly active antiretroviral therapy (HAART) era: incidence, cumulative prevalence and clinical outcome among survivors (Chiriboga et al) 2003;54:(suppl 7) S112
- methamphetamine dependence exacerbates neurometabolic abnormalities in HIV patients (Chang et al) 2003;54:(suppl 7) S48
- physiological and morphological abnormalities in HIV-infected children (Luciano et al) 2003;54:(suppl 7) S74
- reduced dependence of BBB compromise on microglial activation in HIV patients on HAART (Avison et al) 2003;54:(suppl 7) S48
- reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49
- Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons (Keswani et al) 2003;54:287
- viremia in the presence of blood-brain barrier compromise increases severity of HIV-associated neurocognitive impairment (Avison et al) 2003;54:(suppl 7) S49
- Human immunodeficiency virus type 1**
selective stimulation of neuronal antigen expression when differentiating human neuroepithelial precursor cells are cocultured with HIV-1-infected human microglia (McCarthy et al) 2003;54:(suppl 7) S47
- Human lymphocyte antigen-DR15**
genetic interaction of *CTLA-4* with HLA-DR15 in multiple sclerosis patients (Alizadeh et al) 2003;54:119
- Humanin**
humanin improves bioenergetic state of cells harboring A3243G mitochondrial DNA mutations (Kariya et al) 2003;54:(suppl 7) S46
- Humoral responses**
restriction of humoral responses to conformational epitopes after exposure to the native myelin oligodendrocyte glycoprotein polypeptide (Genain et al) 2003;54:(suppl 7) S60
- Huntington's disease**
the effects of huperzine A on cognitive functioning and behavior in patients with Huntington's disease (Peavy et al) 2003;54:(suppl 7) S42
frontal behavior syndromes in Huntington's disease and Parkinson's disease (Hulvershorn et al) 2003;54:(suppl 7) S70
minocycline and doxycycline are not beneficial in a model of Huntington's disease (Smith et al) 2002;54:186
minocycline is not beneficial in a phenotypic mouse model of Huntington's disease (Diguett et al) 2003;54:843 (Letter)
minocycline is protective in a mouse model of Huntington's disease (Hersch et al) 2003;54:843 (Letter)
minocycline is protective in a mouse model of Huntington's disease (Hockly et al) 2003;54:844 (Reply)
prediction of neuropathological severity in 100 patients with Huntington's disease (Rosenblatt et al) 2003;54:488
- Huperzine A**
the effects of huperzine A on cognitive functioning and behavior in patients with Huntington's disease (Peavy et al) 2003;54:(suppl 7) S42
- Hydrocephalus**
is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Annoni and Khateb) 2003;54:556 (Reply)
is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Gondim and de Oliveira) 2003;54:555 (Letter)

Hydrogen peroxide

hydrogen peroxide accumulates in immature brain but not mature brain after similar hypoxic-ischemic insult (LaFemina et al) 2003;54:(suppl 7) S23

4-Hydroxybutyric acid

monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency (Ergezinger et al) 2003;54:686

5-Hydroxytryptamine_{1A} receptors

comparisons of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease (AD) versus controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S29

serotonin 5-HT_{1A} receptor binding potential in frontotemporal dementia (FTD) compared with controls using [¹¹C]WAY-100635 and PET (Lancôt) 2003;54:(suppl 7) S67

Hygroma, subdural

neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158

Hyperactivity; see Attention deficit hyperactivity disorder

Hyperpolarization

the hyperpolarization-activated HCN channels in human and experimental hippocampal epilepsy: a novel, acquired channelopathy? (Bender et al) 2003;54:(suppl 7) S54

Hypoalbuminemia

alternatively spliced transcripts of aprataxin in early-onset ataxia with oculomotor apraxia and hypoalbuminemia (Hirano et al) 2003;54:(suppl 7) S58

Hypoglycemia

neuronal death and cognitive impairment caused by severe hypoglycemia can be prevented by delayed administration of poly(ADP-ribose) polymerase inhibitors (Swanson et al) 2003;54:850

Hypokalemic periodic paralysis

reduced Na⁺ current is a common feature of both types of hypokalemic periodic paralysis (Ruff et al) 2003;54:(suppl 7) S44

Hypometabolism, limbic

limbic hypometabolism in Alzheimer's disease and mild cognitive impairment (Nestor et al) 2003;54:343

Hypomyelinating neuropathy, congenital

disturbance of muscle fiber differentiation in congenital hypomyelinating neuropathy caused by a novel *myelin protein zero* mutation (Szegedi et al) 2003;54:398

Hypotension, intracranial

epidemiology and headache management in spontaneous intracranial hypotension (Diaz) 2003;54:(suppl 7) S32

Hypothermia

induced hypothermia for the treatment of cardiac arrest survivors: a systematic review (Haas et al) 2003;54:(suppl 7) S66

Hypotonia

dual pathology in two hypotonic children with Prader-Willi syndrome and muscle mitochondrial complex I deficiency (Wassmer et al) 2003;54:(suppl 7) S157

Hypoxia

central nervous system microvascular pericyte response to hypoxia (Dore-Duffy et al) 2003;54:(suppl 7) S78

Hypoxia, acute

modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment

with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103

Hypoxic-ischemic injury

L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

hydrogen peroxide accumulates in immature brain but not mature brain after similar hypoxic-ischemic insult (LaFemina et al) 2003;54:(suppl 7) S23

neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103

Imaging; see also specific modalities

imaging-guided convection-enhanced delivery and gene therapy of glioblastoma (Voges et al) 2003;54:479

vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838

Imaging, diffusion-weighted

clinical and imaging follow-up of newborns with seizures and bright DWI lesions (Krishnamoorthy and Grant) 2003;54:(suppl 7) S127

Imaging, functional

functional neuroimaging provides evidence of anomalous cerebral laterality in adults with Klinefelter's syndrome (Itti et al) 2003;54:669

Immune-mediated cerebellar diseases

mouse model of immune-mediated cerebellar diseases (Golumbek et al) 2003;54:(suppl 7) S117

Immune responses

the role of immune responses to heat shock protein 105 in multiple sclerosis (Minohara et al) 2003;54:(suppl 7) S61

Immunoglobulins, oligoclonal

oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV (Burgoon et al) 2003;54:459

Inclusion body myositis, sporadic

inducible costimulatory molecule and ICOS-ligand are upregulated in patients with sporadic inclusion body myositis and correlate with perforin expression by the autoimmune cytotoxic T cells (Schmidt et al) 2003;54:(suppl 7) S75

novel identification of aggresomes in sporadic inclusion-body myositis (s-IBM) muscle fibers suggests that inhibition of 26S/20S proteasome and misfolded proteins play a pathogenic role (Fratta et al) 2003;54:848

Inducible costimulatory molecule

inducible costimulatory molecule and ICOS-ligand are upregulated in patients with sporadic inclusion body myositis and correlate with perforin expression by the autoimmune cytotoxic T cells (Schmidt et al) 2003;54:(suppl 7) S75

Infantile convulsions, benign familial

novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360

Infantile encephalopathy, acute

acute infantile encephalopathy predominantly affecting the bilateral frontal lobes: a novel subtype of acute encephalopathy (Yamanouchi et al) 2003;54:(suppl 7) S127

Infantile spinal muscular atrophy with respiratory distress type 1

infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann et al) 2003;54:719

Infants; see also Neonates; Pediatrics

- benign paroxysmal torticollis in infancy: not so benign? (Rosman et al) 2003;54:(suppl 7) S129
- frequency and lateralizing value of ictal nystagmus in infants (Loddenkemper et al) 2003;54:(suppl 7) S134
- long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111
- safety and efficacy of lamotrigine in infants aged 1 to 24 months with partial seizures: updated preliminary open-label results (Piña-Garza et al) 2003;54:(suppl 7) S113
- torsinA protein and mRNA expression in the human brain of newborns, infants, and children (Siegert et al) 2003; 54:(suppl 7) S116

Infants, extremely premature

- cerebral palsy in the extremely premature: additional clinical and anatomical description (Johnsen et al) 2003;54:(suppl 7) S123
- cerebral palsy in the extremely premature: frequency of cerebellar injury (Johnsen and Bodensteiner) 2003;54:(suppl 7) S123
- the Johnsen-Tarby-Lewis syndrome: a newly recognized but relatively common outcome of extremely premature infants (Bodensteiner and Johnsen) 2003;54:(suppl 7) S123

Infants, low-birth-weight

- neuropsychological outcome in low-birth-weight children at 3 to 4 years of age (Caravale et al) 2003;54:(suppl 7) S124

Infants, premature

- altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121
- impaired cerebellar growth in preterm infants without brain injury (Limperopoulos et al) 2003;54:(suppl 7) S122
- ontogeny of nonnutritive sucking by premature infants (Bingham and Stevens-Tuttle) 2003;54:(suppl 7) S120
- a primate model of cerebral injury in the premature infant (Inder et al) 2003;54:(suppl 7) S121
- a prospective, longitudinal study of echo-planar T2*-weighted MRI for early detection of intracranial hemorrhage in premature infants (Neil et al) 2003;54:(suppl 7) S122
- reduced cerebellar volume in premature infants with cerebral parenchymal injury (Limperopoulos et al) 2003;54:(suppl 7) S123
- reduction in N-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125
- ultrasonographic accompaniments and predictors of cerebellar hemorrhage in the preterm infant (Limperopoulos et al) 2003;54:(suppl 7) S122

Infants, term

- funisitis and neurologic abnormalities in term infants (Wu et al) 2003;54:(suppl 7) S126
- intraventricular hemorrhage and sinovenous thrombosis in term infants (Wul et al) 2003;54:(suppl 7) S138
- risk factors and neuroimaging findings in term infants with cerebral palsy (Wu et al) 2003;54:(suppl 7) S126
- selective cerebral white matter injury in asphyxiated term newborns (Landesman et al) 2003;54:(suppl 7) S126

Infants, very low-birth-weight

- altered MR cerebral volumes correlate with neurodevelopmental outcome at 2 years in VLBW infants (Inder et al) 2003;54:(suppl 7) S124

Infarction, pediatric

- the pathogenesis of pediatric infarcts: a retrospective immunohistochemical study (Askalan et al) 2003;54:(suppl 7) S141

Infection, dual

- dually infected (HSV-1/VZV) single neurons in human trigeminal ganglia (Theil et al) 2003;54:678

Inflammatory demyelinating polyradiculoneuropathy, chronic

- rituximab-responsive chronic inflammatory demyelinating polyradiculoneuropathy (Briani et al) 2003;54:(suppl 7) S75

Inflammatory myopathy

- analysis of calcium-dependent proteinase and cytoskeletal proteins in muscle from patients with inflammatory myopathy (Murata et al) 2003;54:(suppl 7) S44

Inflammatory response

- the release of tumor necrosis factor- α and the reduction of the inflammatory response are associated with human cerebrovascular ischemic tolerance (Castillo et al) 2003; 54:812

Infrared functional imaging

- intraoperative infrared functional imaging of human brain (Gorbach et al) 2003;54:297

Injury, birth

- new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156
- outcome following nonoperative treatment of brachial plexus birth injuries (DiTaranto et al) 2003;54:(suppl 7) S156

Injury, brachial plexus

- new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156
- outcome following nonoperative treatment of brachial plexus birth injuries (DiTaranto et al) 2003;54:(suppl 7) S156
- predictive value of electrodiagnostic studies in brachial plexus injuries (Vednarayanan et al) 2003;54:(suppl 7) S155

Injury, brain

- brain injury in children with sickle cell disease: prevalence and etiology (Steen et al) 2003;54:564
- L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

Injury, cerebral

- a primate model of cerebral injury in the premature infant (Inder et al) 2003;54:(suppl 7) S121
- stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003; 54:(suppl 7) S110

Injury, cerebral parenchymal

- reduced cerebellar volume in premature infants with cerebral parenchymal injury (Limperopoulos et al) 2003;54:(suppl 7) S123

Injury, cerebral white matter

- selective cerebral white matter injury in asphyxiated term newborns (Landesman et al) 2003;54:(suppl 7) S126

Injury, diffuse axonal

- association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

Injury, excitotoxic neuronal

status epilepticus and excitotoxic neuronal injury: a case report (Tschida et al) 2003;54:(suppl 7) S159

Injury, head

prevalence and risk of sleep disturbances in adolescents after minor head injury (Ravid et al) 2003;54:(suppl 7) S128

Injury, hypoxic-ischemic

L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128

hydrogen peroxide accumulates in immature brain but not mature brain after similar hypoxic-ischemic insult (LaFemina et al) 2003;54:(suppl 7) S23

neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103

Injury, neural

acute and chronic neural injury alters splicing of functional glutamate transporters (Maragakis et al) 2003;54:(suppl 7) S20

Injury, neuronal

microglia potentiate neuronal injury following ischemia-like insults: possible role of tissue plasminogen activator (tPA) (Huang et al) 2003;54:851

Injury, seizure-induced

the influence of cognitive reserve on seizure-induced injury (Akman et al) 2003;54:(suppl 7) S132

Injury, spinal cord

retrograde reactions of Clarke's nucleus neurons after human spinal cord injury (Schmitt et al) 2003;54:534

Injury, traumatic brain

association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128

proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153

Innervation

quantification of myelinated endings and mechanoreceptors in human digital skin (Nolano et al) 2002;54:186

Intellectual impairment

brain imaging, clinical correlates, and social consequences of intellectual impairment in myotonic dystrophy type 1 (Meola et al) 2003;54:(suppl 7) S75

oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133

Interferon

methodological considerations in a meta analysis of interferon treatments in relapsing remitting multiple sclerosis (Mikol) 2003;54:(suppl 7) S61

Interferon- β

abnormal levels of interferon- γ receptors in active multiple sclerosis are normalized by IFN- β therapy (Ahn and Reder) 2003;54:(suppl 7) S61

genomic effects of interferon- β in multiple sclerosis patients (Weinstock-Guttman et al) 2003;54:(suppl 7) S36

interferon- β inhibits IL-10 production in activated human monocytes and stimulates IL-10 in T cells: implications for multiple sclerosis therapy (Hamamcioglu and Reder) 2003;54:(suppl 7) S63

Interferon- β 1a

comparison of response to treatment with interferon β -1a in African Americans and Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S34

interferon- β 1a reduces plasma CD31+ endothelial microparticles in MS (Jy et al) 2003;54:(suppl 7) S60

the use of interferon β -1a in children and adolescents with multiple sclerosis (Pohl et al) 2003;54:(suppl 7) S152

Interferon- γ receptors

abnormal levels of interferon- γ receptors in active multiple sclerosis are normalized by IFN- β therapy (Ahn and Reder) 2003;54:(suppl 7) S61

Interleukin-10

interferon- β inhibits IL-10 production in activated human monocytes and stimulates IL-10 in T cells: implications for multiple sclerosis therapy (Hamamcioglu and Reder) 2003;54:(suppl 7) S63

Interleukin-16

reversal of clinical signs by IL-16-targeted therapy in MOG35-55-induced relapsing-remitting EAE in H-2b/s mice (Skundric et al) 2003;54:(suppl 7) S62

Internal auditory canal tumors, bilateral

glioblastoma multiforme presenting as bilateral internal auditory canal tumors mimicking neurofibromatosis type 2 (Lee et al) 2003;54:(suppl 7) S31

Intracerebral hemorrhage

predictive model of 30-day mortality after supra- and infra-tentorial spontaneous intracerebral hemorrhages (Giraldo et al) 2003;54:(suppl 7) S25

protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage (Wang et al) 2003;54:655

a study of single photon emission computed tomography in patients with intracerebral hemorrhage receiving mannitol (Misra et al) 2003;54:(suppl 7) S64

Intracranial hemorrhage

in acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? 2003;54:698

a prospective, longitudinal study of echo-planar T2*-weighted MRI for early detection of intracranial hemorrhage in premature infants (Neil et al) 2003;54:(suppl 7) S122

Intracranial hypotension, spontaneous

epidemiology and headache management in spontaneous intracranial hypotension (Diaz) 2003;54:(suppl 7) S32

Intracranial pressure

spectral Doppler imaging of central retinal vessels in children: a potential non-invasive alternative method of measuring intracranial pressures (Chang et al) 2003;54:(suppl 7) S152

Intraventricular hemorrhage

intraventricular hemorrhage and sinovenous thrombosis in term infants (Wul et al) 2003;54:(suppl 7) S138

intraventricular hemorrhage in term neonates caused by sinovenous thrombosis (Wu et al) 2003;54:123

Iron

high field strength (3T) magnetic resonance imaging of brain iron in Alzheimer's disease (Zimmerman et al) 2003;54:(suppl 7) S68

Ischemia, cerebral

early recovery after cerebral ischemia risk of subsequent neurological deterioration (Johnston et al) 2003;54:439

- early recovery of cerebral ischemia is associated with risk of subsequent neurological deterioration (Johnston et al) 2003;54:(suppl 7) S66
- ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the sub-arachnoid space (Petzold et al) 2003;54:591
- magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
- Ischemia, cerebrovascular**
- the release of tumor necrosis factor- α is associated with ischemic tolerance in human stroke (Castillo et al) 2003;54:812
- Ischemia, focal**
- cytokine and chemokine induction after neonatal focal ischemia reperfusion (Derugin et al) 2003;54:(suppl 7) S65
- increases in plasma arginine vasopressin after transient focal ischemia in rats (Chang et al) 2003;54:(suppl 7) S64
- magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
- pre-synaptic zinc dynamics in permanent and transient focal ischemia (Subramaniam et al) 2003;54:(suppl 7) S65
- stilbazulenyl nitron, a novel antioxidant, is highly neuro-protective in focal ischemia (Ginsberg et al) 2003;54:330
- Ischemia, global**
- graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103
- Ischemia-like insults**
- microglia potentiate neuronal injury following ischemia-like insults: possible role of tissue plasminogen activator (tPA) (Huang et al) 2003;54:851
- Ischemic injury**
- L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats (Wainwright et al) 2003;54:(suppl 7) S128
- hydrogen peroxide accumulates in immature brain but not mature brain after similar hypoxic-ischemic insult (LaFemina et al) 2003;54:(suppl 7) S23
- neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103
- Ischemic lesions, early**
- early ischemic lesion recurrence within a week after acute ischemic stroke (Kang et al) 2003;54:66
- Ischemic-reperfusion injury, focal**
- minocycline attenuates focal ischemic-reperfusion injury in the immature brain (Fox et al) 2003;54:(suppl 7) S26
- Ischemic striatal neurodegeneration, delayed**
- magnetic resonance imaging delayed ischemic striatal neurodegeneration (Fujioka et al) 2003;54:732
- Ischemic stroke**
- variability in utilization do-not-resuscitate orders for patients with ischemic stroke (Johnston et al) 2003;54:697
- Ischemic stroke, acute**
- in acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? 2003;54:698
- beyond the three hour time-window: multivariable patient-selection for thrombolytic therapy in acute ischemic stroke (Kent et al) 2003;54:696, (suppl 7) S18
- circulating β amyloid protein is elevated in patients with acute ischemic stroke (Lee et al) 2003;54:(suppl 7) S65
- early ischemic lesion recurrence within a week after acute ischemic stroke (Kang et al) 2003;54:66
- genomic *fingerprint* of acute ischemic stroke (Moore et al) 2003;54:(suppl 7) S24
- Ischemic stroke, neonatal arterial**
- neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138
- Isoprostanes**
- patterns of aging-, APOE allele-, and gender-dependent accumulation of brain F2 isoprostanes accurately parallel those of endogenous brain Alzheimer amyloid beta peptides (Gandy et al) 2003;54:848
- jams1 gene**
- identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice (Sherr et al) 2003;54:(suppl 7) S53
- Japan**
- absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Dermaut et al) 2003;54:555 (Reply)
- absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Ohkubo et al) 2003;54:553 (Letter)
- current incidence and clinicoradiological features of asymptomatic adult moyamoya disease on brain check-up in Japan (Ikeda et al) 2003;54:(suppl 7) S64
- distal myopathy with rimmed vacuoles: phenotype/genotype relationship in Japanese families (Uyama et al) 2003;54:(suppl 7) S73
- Jaw opening dystonia**
- jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pittock et al) 2003;54:(suppl 7) S70
- Johnsen-Tarby-Lewis syndrome**
- the Johnsen-Tarby-Lewis syndrome: a newly recognized but relatively common outcome of extremely premature infants (Bodensteiner and Johnsen) 2003;54:(suppl 7) S123
- Juvenile audiogenic seizures**
- identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice (Sherr et al) 2003;54:(suppl 7) S53
- Ketogenic diet**
- anticonvulsant properties of acetone, a brain ketone elevated by the ketogenic diet (Likhodii et al) 2002;54:219
- the effect of ketogenic diet on gene expression (Choi et al) 2003;54:(suppl 7) S56
- should the ketogenic diet be considered first-line therapy? (Rubenstein et al) 2003;54:(suppl 7) S134
- Ketorolac**
- effectiveness and tolerability of ketorolac for severe headaches in children seen in the emergency department (Vasconcellos et al) 2003;54:(suppl 7) S150
- Ketosis**
- incidence of seizures among ketotic and nonketotic diabetic patients (Gao-Hickman et al) 2003;54:(suppl 7) S56
- Klinefelter's syndrome**
- functional neuroimaging provides evidence of anomalous cerebral laterality in adults with Klinefelter's syndrome (Itti et al) 2003;54:669

Lafora's disease

cell death in transgenic mice model of Lafora's disease (Machado-Salas et al) 2003;54:(suppl 7) S54

Lambert, Edward H.

(Daube) 2003;54:690 (Obituary)

Lambert-Eaton myasthenic syndrome

oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravis (Burns and Jones) 2003;54:136 (Reply)

oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravis (Toyka and Schneider-Gold) 2003;54:135 (Letter)

Lamotrigine

the effect of lamotrigine therapy on electroencephalogram in children with refractory epilepsies (Akman and Holmes) 2003;54:(suppl 7) S134

safety and efficacy of lamotrigine in infants aged 1 to 24 months with partial seizures: updated preliminary open-label results (Piña-Garza et al) 2003;54:(suppl 7) S113

Language deficits

aphasia in hyperacute stroke: language follows brain penumbra dynamics (Croquelois et al) 2003;54:321

Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003;54:851

functional magnetic resonance imaging and neuropsychological testing reveals distinct language deficits and cortical activation in siblings with mitochondrial disease (Seyffert et al) 2003;54:(suppl 7) S148

Language impairment, specific

developmental and functional outcomes at school age of preschool children with specific language impairment (Shevell et al) 2003;54:(suppl 7) S105

fine motor and gross motor function in school-age children with a preschool diagnosis of specific language impairment (Webster et al) 2003;54:(suppl 7) S145

the predictive value of preschool diagnosis of specific language impairment at the time of school entry: a longitudinal study (Webster et al) 2003;54:(suppl 7) S146

Language networks

language networks underlying auditory based category decision in children identified with fMRI (Balsamo et al) 2003;54:(suppl 7) S105

Language organization

functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109

Laryngospasm

jaw opening dystonia and laryngospasm associated with paraneoplastic antineuronal nuclear autoantibody-type 2 (Pittock et al) 2003;54:(suppl 7) S70

Latency-associated genes

the multiple functions of herpes simplex virus type 1 latency-associated gene (LAG) in a LAG-expressing transgenic mouse (Steiner et al) 2003;54:(suppl 7) S48

Lateropulsion

head tilt and lateropulsion in Wallenberg's syndrome (Kim et al) 2003;54:(suppl 7) S79

Laughter, pathological

a case series of "pathological laughter and crying" and a proposal for a new classification (Gondim et al) 2003;54:(suppl 7) S22

Left middle cerebral artery stroke, perinatal

functional magnetic resonance imaging shows atypical language organization in children after perinatal left mid-

dle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109

Leigh syndrome

impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene (Ugalde et al) 2003;54:665

Leigh's disease

low mutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease (Kirby et al) 2003;54:473

Lenticulostriate vasculopathy

sonographic lenticulostriate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28

Lesions

lesions of hippocampus in multiple system atrophy (Wang et al) 2003;54:(suppl 7) S52

Lesions, cerebral hemorrhagic

altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121

Leukocytes

leukocyte CTG repeat length correlates with severity of myotonia in distal hand muscles in myotonic dystrophy type 1 (DM1) (Moxley IV et al) 2003;54:(suppl 7) S76

Leukomalacia, periventricular

AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia (Follett et al) 2003;54:(suppl 7) S103

graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103

is cystic periventricular leukomalacia disappearing? (Hamrick et al) 2003;54:(suppl 7) S121

Levetiracetam

the use of levetiracetam in myoclonus (Lim and Ahmed) 2003;54:(suppl 7) S41

Levodopa

addition of levodopa in combination with entacapone increases "On" time without potentiating peak dyskinesia: a study in the MPTP-treated primate (Jenner et al) 2003;54:(suppl 7) S40

longitudinal effects of dopamine agonist versus levodopa therapy on Parkinson's disease progression: proton magnetic resonance spectroscopic study (Terakawa et al) 2003;54:(suppl 7) S41

REAL-PET and CONSORT (Brooks and Whone) 2003;54:692 (Reply)

REAL-PET and CONSORT (Morrish) 2003;54:692 (Letter)

slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study (Whone et al) 2003;54:93

Levodopa-related motor fluctuations

a controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study) (Parkinson Study Group and Stern) 2003;54:(suppl 7) S27

Levodopa-responsive dystonia

the *HPH-1* mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

Lewy bodies

Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE ϵ 4 (Leverenz et al) 2003;54:(suppl 7) S68

- specification of 14-3-3 proteins in Lewy bodies (Berg et al) 2003;54:135 (Letter)
- Lewy body dementia**
 comparisons of hallucinations in dementia with Lewy bodies (DLB) and Parkinson's disease (PD) with hallucinations: a case-control study (Goldman et al) 2003;54:(suppl 7) S72
 retinal involvement in dementia with Lewy bodies: a clue to hallucinations? (Maurage et al) 2003;54:542
 survival but not dementia progression differs in DLB versus AD (Williams et al) 2003;54:(suppl 7) S30
- Lewy body disease, diffuse**
 triplication of alpha-synuclein is causal of neuropathologically confirmed Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy in a single kindred (Gwinn-Hardy et al) 2003;54:848
- LGII gene**
 epilepsy with auditory features: a *LGII* gene mutation suggests a loss-of-function mechanism (Pizzuti et al) 2003;54:137 (Correction)
- Lidocaine**
 does dysport retain its efficacy if diluted with lidocaine? (Evidente et al) 2003;54:(suppl 7) S46
- Limb-girdle muscular dystrophy type 2E**
 homozygous β -sarcoglycan gene deletion in a family with limb-girdle muscular dystrophy type 2E (Kaindl et al) 2003;54:(suppl 7) S154
- Limbic cortex**
 caspase activation in the limbic cortex of subjects with early Alzheimer's disease (Gastard et al) 2003;54:393
- Limbic encephalitis**
 voltage-gated potassium channel antibodies in limbic encephalitis (Pozo-Rosich et al) 2003;54:530
 voltage-gated potassium channel antibody-associated limbic encephalitis is relatively common, potentially treatable, and usually nonaneoplastic (Vincent et al) 2003;54:(suppl 7) S20
- Limbic encephalitis, autoimmune**
 autoimmune limbic encephalitis associated with potassium channel antibodies (Theiben et al) 2003;54:(suppl 7) S22
- Limbic hypometabolism**
 limbic hypometabolism in Alzheimer's disease and mild cognitive impairment (Nestor et al) 2003;54:343
- Linkage analysis**
 linkage and association to the NOS2A locus on ch.17q11 in multiple sclerosis (MS) (Barcellos et al) 2003;54:849
- Liposomes**
 intravenous prednisolone encapsulated in novel long-circulating liposomes is superior to free glucocorticosteroid pulse therapy in a model of multiple sclerosis (Schmidt et al) 2003;54:(suppl 7) S36
- Lis1**
 Reelin and Lis1 signaling are coordinated in brain development (Assadi et al) 2003;54:(suppl 7) S104
- Lobectomy, temporal**
 does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003;54:(suppl 7) S53
- Loss of heterozygosity**
 no preferential loss of paternal 19q alleles in oligodendroglial tumors (Hartmann et al) 2002;54:256
- Low-birth-weight infants**
 neuropsychological outcome in low-birth-weight children at 3 to 4 years of age (Caravale et al) 2003;54:(suppl 7) S124
- Lumbar puncture**
 the lumbar puncture for diagnosis of pediatric neurotransmitter diseases (Hyland) 2003;54:(suppl 6) S13
- Lyme disease**
 facial nerve palsy caused by Lyme disease: LP or no LP? that was our question (Freilich et al) 2003;54:(suppl 7) S131
- Lyme neuroborreliosis**
 a mouse model of Lyme neuroborreliosis: comparison of American and European strains of *B. burgdorferi* (Li et al) 2003;54:(suppl 7) S49
- Lymphocytes**
 increased protein acetylation in lymphocytes predicts autistic behavior in fragile X syndrome (Kaufmann et al) 2003;54:(suppl 7) S105
- Lymphohistiocytosis, hemophagocytic**
 neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158
- Machado-Joseph disease**
 disrupted nuclear organization and function in Machado-Joseph disease (Lewis et al) 2003;54:(suppl 7) S51
 visual function in Machado-Joseph disease (Subramony et al) 2003;54:(suppl 7) S40
- Macrophage/microglial inhibitory factor**
 protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage (Wang et al) 2003;54:655
- Magnetic resonance imaging**
 altered MR cerebral volumes correlate with neurodevelopmental outcome at 2 years in VLBW infants (Inder et al) 2003;54:(suppl 7) S124
 cerebellar gray matter MRI T2 hypointensity is independently associated with ambulatory dysfunction and clinical course in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
 cerebral blood volume measurements by T2*-weighted magnetic resonance imaging and contrast injection (Newman et al) 2003;54:(suppl 7) S24
 magnetic resonance imaging correlates of multiple sclerosis pathologic subtypes (Lucchinetti et al) 2003;54:(suppl 7) S37
 magnetic resonance imaging delayed ischemic striatal neurodegeneration (Fujioka et al) 2003;54:732
 magnetic resonance imaging for the diagnosis of cerebral dysplasia in new-onset seizures in children (Vanderver et al) 2003;54:(suppl 7) S114
 magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
 multiple sclerosis of late onset: clinical and MRI findings (Berlit et al) 2003;54:(suppl 7) S62
 neuroprotection and natural history in parkinson plus syndromes: cross-sectional description of magnetic resonance imaging findings in a large prospective cohort of patients with progressive supranuclear palsy and multiple system atrophy (Kraft et al) 2003;54:(suppl 7) S39
 subcortical gray matter MRI T2 hypointensity is independently associated with cognitive impairment in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- Magnetic resonance imaging, diffusion-weighted**
 characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67

Magnetic resonance imaging, echo-planar T2*-weighted
a prospective, longitudinal study of echo-planar T2*-weighted MRI for early detection of intracranial hemorrhage in premature infants (Neil et al) 2003;54:(suppl 7) S122

Magnetic resonance imaging, functional
functional magnetic resonance imaging and neuropsychological testing reveals distinct language deficits and cortical activation in siblings with mitochondrial disease (Seyffert et al) 2003;54:(suppl 7) S148

functional magnetic resonance imaging evidence of purely extrastriate basis for poststroke quadrantanopia (Moo and Slotnick) 2003;54:(suppl 7) S25

functional magnetic resonance imaging in dyscalculia: preliminary observations (Morocz et al) 2003;54:(suppl 7) S145

functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109

language networks underlying auditory based category decision in children identified with fMRI (Balsamo et al) 2003;54:(suppl 7) S105

Magnetic resonance imaging, pulsed arterial-spin-labeling perfusion

pulsed arterial-spin-labeling perfusion magnetic resonance imaging in pediatrics: strengths and advantages (Licht et al) 2003;54:(suppl 7) S153

Magnetic resonance imaging, susceptibility-weighted

association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

susceptibility-weighted magnetic resonance imaging: a new neuroimaging technology with application to children (Tong et al) 2003;54:(suppl 7) S153

venous prominence on susceptibility-weighted MRI is associated with perinatal depression in neonates (Michelson et al) 2003;54:(suppl 7) S125

Magnetic resonance imaging, 3T

high field strength (3T) magnetic resonance imaging of brain iron in Alzheimer's disease (Zimmerman et al) 2003;54:(suppl 7) S68

Magnetic resonance spectroscopy

abnormalities of cerebral metabolite levels in children with pervasive developmental disorder: a preliminary ¹H magnetic resonance spectroscopy study (Gabis et al) 2003;54:(suppl 7) S146

brain magnetic resonance spectroscopy in mild cognitive impairment predicts conversion to Alzheimer's disease (Modrego et al) 2003;54:(suppl 7) S30

identification of neural stem cells by magnetic resonance spectroscopy (Maletic-Savatic et al) 2003;54:(suppl 7) S118

longitudinal effects of dopamine agonist versus levodopa therapy on Parkinson's disease progression: proton magnetic resonance spectroscopic study (Terakawa et al) 2003;54:(suppl 7) S41

magnetic resonance spectroscopy of neurotransmitters in human brain (Novotny Jr. et al) 2003;54:(suppl 6) S25

reduction in *N*-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125

Magnetic resonance spectroscopy, proton

glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128

proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153

Malignant brain tumors

alterations of γ -tubulin cellular distribution in human gliomas: implication of centrosome amplification in malignant tumor progression (Katsetos et al) 2003;54:(suppl 7) S117

cerebrospinal fluid levels of butyrylcholinesterase and acetylcholinesterase in patients with glioblastoma multiforme and other malignant brain tumors: a possible disease marker for glioblastoma (Glantz et al) 2003;54:(suppl 7) S31

Manganese-induced parkinsonism

manganese-induced parkinsonism from total parenteral nutrition: report of a case and review of the literature (Reich et al) 2003;54:(suppl 7) S73

Mannitol

a study of single photon emission computed tomography in patients with intracerebral hemorrhage receiving mannitol (Misra et al) 2003;54:(suppl 7) S64

Mapping

Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003; 54:851

immature cortex lesions alter retinotopic maps and inter-hemispheric connections (Restrepo et al) 2003;54:51

Masturbation

masturbation presenting as a movement disorder in young girls (Fullwood et al) 2003;54:(suppl 7) S130

Matrix metalloproteinase-9

matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (Lee et al) 2003;54:379

McArdle's disease

a diagnostic cycle test for McArdle's disease (Vissing et al) 2003;54:539

Mechanical ventilation

mechanical ventilation and tracheostomy in multiple sclerosis (Pittock et al) 2003;54:(suppl 7) S63

Memory, long-term

repetitive febrile seizures in rat pups impair long-term memory and hippocampal cAMP response-element binding protein phosphorylation (Chang et al) 2003;54: 706

Memory, verbal

does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003; 54:(suppl 7) S53

Memory asymmetry, Wada

does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003; 54:(suppl 7) S53

Memory deficits

identification of a specific deficit in memory for narrative in children treated for craniopharyngioma (Waber et al) 2003;54:(suppl 7) S142

Meninges

decreased fibronectin expression in meningeal blood vessels of Sturge-Weber's syndrome (Comi et al) 2003;54:(suppl 7) S116

Meningitis, group B streptococcal

neuroimaging and endocrinopathies in neonatal group B streptococcal meningitis (McLellan et al) 2003;54:(suppl 7) S125

Meningitis-associated hearing loss

meningitis-associated hearing loss: protection by adjunctive antioxidant therapy (Klein et al) 2003;54:451

Menkes' disease

correlation of copper levels and electroencephalogram abnormalities in patients with Menkes' disease (Valencia et al) 2003;54:(suppl 7) S150

Menopause

onset of dementia is associated with age at menopause in women with Down's syndrome (Schupf et al) 2003;54:433

Menstrual disorders

interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy (Herzog et al) 2003;54:625

Menstrual migraine

oral zolmitriptan demonstrates high efficacy in the acute treatment of true menstrual migraine (Singer et al) 2003;54:(suppl 7) S32

Mental retardation

nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30

a novel chromosome abnormality associated with severe mental retardation and dysmorphic features (Smathers et al) 2003;54:(suppl 7) S159

POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154

Messages from the editor

(Johnson) 2002;54:1

Metabolites, cerebral

abnormalities of cerebral metabolite levels in children with pervasive developmental disorder: a preliminary ¹H magnetic resonance spectroscopy study (Gabis et al) 2003;54:(suppl 7) S146

Metaiodobenzylguanidine

cardiac ¹²³I-MIBG scintigraphy could assess disease severity and phenotype in patients with Parkinson's disease (Saiki et al) 2003;54:(suppl 7) S72

Metastasis, spinal epidural

spinal epidural metastases: rehabilitation increases survival and reduces pain (Adamson et al) 2003;54:(suppl 7) S63

Methamphetamine dependence

methamphetamine dependence exacerbates neurometabolic abnormalities in HIV patients (Chang et al) 2003;54:(suppl 7) S48

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine

presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration (McGeer et al) 2003;54:599

Methyl CpG binding protein 2

MeCP2 expression is dynamically regulated during brain development (Mullaney et al) 2003;54:(suppl 7) S104

Methylphenidate

once-daily dosing with the OROS formulation of methylphenidate has minimal impact on tics in children with ADHD (Palumbo et al) 2003;54:(suppl 7) S27

once-daily OROS methylphenidate: impact on tics in children with attention deficit hyperactivity disorder (Palumbo et al) 2003;54:(suppl 7) S143

OROS methylphenidate (MPH) treatment for attention deficit/hyperactivity disorder: long-term effect on growth (Giedd and Concerta Study Group) 2003;54:(suppl 7) S27

Microarray expression analysis

oligonucleotide microarray expression analysis of X-linked adrenoleukodystrophy fibroblasts (O'Neill et al) 2003;54:(suppl 7) S57

Microcephaly, autosomal recessive

multiple genetic loci lead to distinctive autosomal recessive microcephaly syndromes (Mochida et al) 2003;54:(suppl 7) S119

Microdysgenesis

microdysgenesis in mesial temporal lobe epilepsy: a clinicopathological study (Kasper et al) 2003;54:501

Microglial cells

the 70kD heat shock protein protects against experimental stroke by suppressing microglial activation (Zheng et al) 2003;54:(suppl 7) S24

microglia potentiate neuronal injury following ischemia-like insults: possible role of tissue plasminogen activator (tPA) (Huang et al) 2003;54:851

monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas (Platten et al) 2003;54:388

presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration (McGeer et al) 2003;54:599

reduced dependence of BBB compromise on microglial activation in HIV patients on HAART (Avison et al) 2003;54:(suppl 7) S48

selective stimulation of neuronal antigen expression when differentiating human neuroepithelial precursor cells are cocultured with HIV-1-infected human microglia (McCarthy et al) 2003;54:(suppl 7) S47

Microvascular biopsy

vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838

Middle cerebral artery stroke

functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109

Migraine

diagnosing migraine with a simple and efficient three-question Headache Screen (Cady et al) 2003;54:(suppl 7) S33

the economic impact of migraine and comorbid anxiety and depression in children: results from a case-control study (Pesa and Lage) 2003;54:(suppl 7) S33

eletriptan: switching triptans for better efficacy (Krusz) 2003;54:(suppl 7) S34

Migraine, acute

almotriptan efficacy in achieving pain relief and pain-free status 1 and 2 hours after treatment of acute migraine (Mathew) 2003;54:(suppl 7) S33

almotriptan in acute migraine: maximizing efficacy and minimizing adverse events (Smith) 2003;54:(suppl 7) S34

an evaluation of the effectiveness and tolerability of almotriptan for acute migraine in patients managed by neurologists in Spain (Pascual et al) 2003;54:(suppl 7) S33

a single dose of zolmitriptan nasal spray is efficacious over multiple attacks (Charlesworth et al) 2003;54:(suppl 7) S32

- zolmitriptan nasal spray is highly efficacious, very fast acting and produces sustained relief in the treatment of acute migraine in a real life setting; results from phase I of the REALIZE study (Gawel et al) 2003;54:(suppl 7) S32
- Migraine, familial hemiplegic**
 novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360
- Migraine, menstrual**
 oral zolmitriptan demonstrates high efficacy in the acute treatment of true menstrual migraine (Singer et al) 2003;54:(suppl 7) S32
- Migration inhibitory factor**
 high expression of macrophage migration inhibitory factor (MIF) in spinal cord and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients (Ogata et al) 2003;54:(suppl 7) S51
- Miliary aneurysm**
 cerebral hemorrhage produced by ruptured dissecting aneurysm in miliary aneurysm (Rosenblum) 2003;54:376
- Military veterans**
 amyotrophic lateral sclerosis (ALS) outcomes in US military veterans compared with non-veterans: neuroepidemiological insights from the ALS CARE Database (Brooks et al) 2003;54:700
- Mini-Mental State Examination (MMSE)**
 prediction of neuropathological severity in 100 patients with Huntington's disease (Rosenblatt et al) 2003;54:488
- Minocycline**
 minocycline and doxycycline are not beneficial in a model of Huntington's disease (Smith et al) 2002;54:186
 minocycline attenuates focal ischemic-reperfusion injury in the immature brain (Fox et al) 2003;54:(suppl 7) S26
 minocycline is not beneficial in a phenotypic mouse model of Huntington's disease (Diguert et al) 2003;54:843 (Letter)
 minocycline is protective in a mouse model of Huntington's disease (Hersch et al) 2003;54:843 (Letter)
 minocycline is protective in a mouse model of Huntington's disease (Hockley et al) 2003;54:844 (Reply)
- Misfolded proteins**
 novel identification of aggresomes in sporadic inclusion-body myositis (s-IBM) muscle fibers suggests that inhibition of 26S/20S proteasome and misfolded proteins play a pathogenic role (Fratta et al) 2003;54:848
- Mitochondrial disease**
 functional magnetic resonance imaging and neuropsychological testing reveals distinct language deficits and cortical activation in siblings with mitochondrial disease (Seyffert et al) 2003;54:(suppl 7) S148
- Mitochondrial DNA**
 bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene (Solano et al) 2003;54:527
 genotypes from patients indicate no paternal mitochondrial DNA contribution (Taylor et al) 2003;54:521
 humanin improves bioenergetic state of cells harboring A3243G mitochondrial DNA mutations (Kariya et al) 2003;54:(suppl 7) S46
 lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies (Filosto et al) 2003;54:524
 low mutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease (Kirby et al) 2003;54:473
- paternal transmission of mitochondrial DNA is (fortunately) rare (Johns) 2003;54:422 (Editorial)
- Mitochondrial energy metabolism**
 defective mitochondrial energy metabolism in creatine transporter 1 deficiency (Anselm et al) 2003;54:(suppl 7) S156
- Mitochondrial myopathy**
 lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies (Filosto et al) 2003;54:524
 oxidative capacity correlates with muscle mutation load in mitochondrial myopathy (Jeppesen et al) 2003;54:86
- Mitochondrial tRNA^{Lys} gene**
 the expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNA^{Lys} gene (Rossmanith et al) 2003;54:821
- Miyoshi myopathy**
 analysis of dysferlin in monocytes: a useful tool for the diagnosis of the Miyoshi myopathy phenotypes and the detection of carriers (De Luna et al) 2003;54:(suppl 7) S74
- Molecular imaging**
 magnetic resonance molecular imaging of early endothelial activation in focal cerebral ischemia in mice (Barber et al) 2003;54:(suppl 7) S25
- Molecular neuropsychiatry**
 toward a molecular neuropsychiatry of neurodegenerative diseases (Cummings) 2002;54:147
- Monocyte chemoattractant protein-1**
 monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas (Platten et al) 2003;54:388
- Monocytes**
 analysis of dysferlin in monocytes: a useful tool for the diagnosis of the Miyoshi myopathy phenotypes and the detection of carriers (De Luna et al) 2003;54:(suppl 7) S74
- Mood disorders**
 oxcarbazepine for the treatment of behavior/mood disorders in children (Alberts et al) 2003;54:(suppl 7) S148
- Mosaicism**
 mosaicism and ring 20 chromosome (Nishiwaki et al) 2003;54:(suppl 7) S56
- Motoneuron degeneration**
 facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53
- Motoneuron disease**
 the effects of bone marrow transplants on the progression of motoneuron disease in PU.1^{-/-} mice (Beers et al) 2003;54:(suppl 7) S43
- Motor axonal neuropathy, acute**
 acute motor axonal neuropathy rabbit model: immune attack on nerve root axons (Susuki et al) 2003;54:383
- Motor cortex, ipsilateral**
 contribution of the ipsilateral motor cortex to recovery after chronic stroke (Werhahn et al) 2003;54:464
- Motor-evoked potentials**
 maturation of motor-evoked potentials in healthy children (Timoshkin et al) 2003;54:(suppl 7) S129
 new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156
- Motor fatigue**
 perception of motor fatigue during 30 seconds of sustained maximal voluntary contraction was significantly

- blunted in multiple sclerosis (Sanjak et al) 2003;54:(suppl 7) S36
- Motor fluctuations, levodopa-related**
- a controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study) (Parkinson Study Group and Stern) 2003;54:(suppl 7) S27
- Motor neuron diseases**
- cognitive impairment, frontotemporal dementia, and the motor neuron diseases (Strong et al) 2003;54:(suppl 5) S20
- Motor neurons**
- disruption of glial glutamate transport by reactive oxygen species produced in motor neurons in response to excitotoxic activation: an in vitro model of ALS pathogenesis (Weiss et al) 2003;54:(suppl 7) S43
- Motor neuropathy, hereditary**
- hereditary motor and sensory neuropathy with agenesis of the corpus callosum (Dupré et al) 2002;54:9
- Movement Disorder Society**
- achieving interrater reliability in Parkinson's disease: utility of the Movement Disorder Society-owned teaching tape of the Unified Parkinson's Disease Rating Scale (Goetz and Stebbins) 2003;54:(suppl 7) S40
- Movement disorders**
- masturbation presenting as a movement disorder in young girls (Fullwood et al) 2003;54:(suppl 7) S130
- Movement therapy, constraint-induced**
- constraint-induced movement therapy in children with hemiplegic cerebral palsy (Weber and Delgado) 2003;54:(suppl 7) S149
- Moyamoya disease**
- vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838
- Moyamoya disease, asymptomatic**
- current incidence and clinicoradiological features of asymptomatic adult moyamoya disease on brain check-up in Japan (Ikeda et al) 2003;54:(suppl 7) S64
- Moyamoya syndrome**
- clinical and radiological features of moyamoya syndrome in British children (Ganesan et al) 2003;54:(suppl 7) S140
- moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140
- Mucopolysaccharidosis**
- effect of enzyme replacement therapy on sleep-disordered breathing in type II mucopolysaccharidosis (D'Cruz et al) 2003;54:(suppl 7) S151
- Multietnic studies**
- designing multi-ethnic stroke studies: the Brain Attack Surveillance in Corpus Christi (BASIC) project (Morgenstern et al) 2003;54:(suppl 7) S65
- Multiple sclerosis, active**
- abnormal levels of interferon- γ receptors in active multiple sclerosis are normalized by IFN- β therapy (Ahn and Reder) 2003;54:(suppl 7) S61
- Multiple sclerosis, analysis**
- antibodies to specific proteins of *Acinetobacter* sp. and *Pseudomonas aeruginosa* in multiple sclerosis patients (Hughes et al) 2003;54:(suppl 7) S63
- cross-reactive antibodies against myelin basic protein, *Acinetobacter* sp. and *Pseudomonas aeruginosa* in multiple sclerosis patients (Wilson et al) 2003;54:(suppl 7) S62
- determining the presence of depression in multiple sclerosis (Birnbaum et al) 2003;54:(suppl 7) S35
- increased osteopontin in cerebrospinal fluid and brains from patients with multiple sclerosis (Fukaura et al) 2003;54:(suppl 7) S61
- interferon- β 1a reduces plasma CD31+ endothelial microparticles in MS (Jy et al) 2003;54:(suppl 7) S60
- perception of motor fatigue during 30 seconds of sustained maximal voluntary contraction was significantly blunted in multiple sclerosis (Sanjak et al) 2003;54:(suppl 7) S36
- the role of immune responses to heat shock protein 105 in multiple sclerosis (Minohara et al) 2003;54:(suppl 7) S61
- serial diffusion tensor imaging studies of the effects of MS lesions on white matter fiber tracts (Henry et al) 2003;54:(suppl 7) S35
- subcortical gray matter MRI T2 hypointensity is independently associated with cognitive impairment in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- Multiple sclerosis, course**
- African American multiple sclerosis patients suffer from a more aggressive disease course than Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S35
- cerebellar gray matter MRI T2 hypointensity is independently associated with ambulatory dysfunction and clinical course in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- disability does not change substantially for most multiple sclerosis patients over a decade in a population-based cohort (Pittock et al) 2003;54:(suppl 7) S37
- time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38
- Multiple sclerosis, exacerbation**
- Chlamydia pneumoniae* and the risk for exacerbation in multiple sclerosis patients (Buljevica et al) 2003;54:829
- Multiple sclerosis, genetics**
- genetic interaction of *CTLA-4* with HLA-DR15 in multiple sclerosis patients (Alizadeh et al) 2003;54:119
- genomic effects of interferon- β in multiple sclerosis patients (Weinstock-Guttman et al) 2003;54:(suppl 7) S36
- linkage and association to the NOS2A locus on ch.17q11 in multiple sclerosis (MS) (Barcellos et al) 2003;54:849
- a new genetic variant associated with multiple sclerosis on 12p12 in a large North American pedigree (Subramanian et al) 2003;54:(suppl 7) S58
- Multiple sclerosis, histopathology**
- the histopathological correlates of ring enhancement in multiple sclerosis lesions (Lucchinetti et al) 2003;54:(suppl 7) S37
- Multiple sclerosis, late-onset**
- multiple sclerosis of late onset: clinical and MRI findings (Berlit et al) 2003;54:(suppl 7) S62
- Multiple sclerosis, management**
- mechanical ventilation and tracheostomy in multiple sclerosis (Pittock et al) 2003;54:(suppl 7) S63
- regulation of immune function in multiple sclerosis and in controls using novel Fc receptor ligands (Jensen et al) 2003;54:(suppl 7) S38
- Multiple sclerosis, opticoptical**
- missense mutation in platelet-activating factor acetylhydrolase: a genetic severity factor in opticoptical multiple sclerosis (Osoegawa et al) 2003;54:(suppl 7) S62

Multiple sclerosis, pathogenesis

a novel model to study the viral pathogenesis of multiple sclerosis after infection with HHV-6 (Tanuma et al) 2003;54:(suppl 7) S47

Multiple sclerosis, progression

spinal cord atrophy and disability in multiple sclerosis over 4 years: application of a new technique in monitoring disease progression (Lin et al) 2003;54:(suppl 7) S78

Multiple sclerosis, relapse-onset

progressive gray matter atrophy occurs in the earliest clinical stages of relapse onset multiple sclerosis (Dalton et al) 2003;54:(suppl 7) S38

Multiple sclerosis, relapsing remitting

methodological considerations in a meta analysis of interferon treatments in relapsing remitting multiple sclerosis (Mikol) 2003;54:(suppl 7) S61

Multiple sclerosis, screening

a capture ELISA and its use in an outpatient MS population to screen for antibody-mediated decreased bioactivity (Dail et al) 2003;54:(suppl 7) S63

Multiple sclerosis, secondary progressive

increased citrullinated GFAP in secondary progressive multiple sclerosis (Nicholas et al) 2003;54:(suppl 7) S60

Multiple sclerosis, subtypes

magnetic resonance imaging correlates of multiple sclerosis pathologic subtypes (Lucchinetti et al) 2003;54:(suppl 7) S37

Multiple sclerosis, treatment

comparison of response to treatment with interferon β -1a in African Americans and Caucasian American multiple sclerosis patients (Cree et al) 2003;54:(suppl 7) S34

interferon- β inhibits IL-10 production in activated human monocytes and stimulates IL-10 in T cells: implications for multiple sclerosis therapy (Hamamcioglu and reder) 2003;54:(suppl 7) S63

intravenous prednisolone encapsulated in novel long-circulating liposomes is superior to free glucocorticosteroid pulse therapy in a model of multiple sclerosis (Schmidt et al) 2003;54:(suppl 7) S36

the use of interferon β -1a in children and adolescents with multiple sclerosis (Pohl et al) 2003;54:(suppl 7) S152

Multiple Sclerosis Impact Scale (MSIS-29)

assessing the psychometric properties of the Multiple Sclerosis Impact Scale (MSIS-29) in community and outpatient populations (McGuigan and Hutchinson) 2003;54:(suppl 7) S36

Multiple system atrophy

cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: the NNIPPS project (Leigh et al) 2003;54:(suppl 7) S70

lesions of hippocampus in multiple system atrophy (Wang et al) 2003;54:(suppl 7) S52

neuroprotection and natural history in parkinson plus syndromes: construction and validation of a clinical scale to assess disease progression in progressive supranuclear palsy and multiple system atrophy (Payan et al) 2003;54:(suppl 7) S39

neuroprotection and natural history in parkinson plus syndromes: cross-sectional description of magnetic resonance imaging findings in a large prospective cohort of patients with progressive supranuclear palsy and multiple system atrophy (Kraft et al) 2003;54:(suppl 7) S39

triplication of alpha-synuclein is causal of neuropathologically confirmed Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy in a single kindred (Gwinn-Hardy et al) 2003;54:848

Muscle

lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies (Filosto et al) 2003;54:524

novel expression of dysferlin in recently denervated and apoptoid human muscle fibers (Fratta et al) 2003;54:(suppl 7) S43

Muscle, skeletal

expression of aquaporin 7 and its localization in normal human skeletal myofibers (Wakayama et al) 2003;54:(suppl 7) S45

muscle trophic factors: subtraction analysis of differentially expressed genes of regenerating skeletal muscle under innervation (Jimi et al) 2003;54:(suppl 7) S73

ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2 (Mankodi et al) 2003;54:760

Muscle activation latency impairment

correlation of gait deficit with muscle activation latency impairment after stroke (Fredrickson et al) 2003;54:(suppl 7) S64

Muscle biopsy

congenital myasthenic syndrome: presentation, electrodiagnosis, and muscle biopsy (Gurnett et al) 2003;54:(suppl 7) S155

diagnostic value of electromyography and muscle biopsy in arthrogryposis multiplex congenita (Kang et al) 2003;54:790

Muscle disease

a novel nonviral approach to gene therapy for muscle disease mediated by phage ϕ C31 integrase (Wheeler et al) 2003;54:(suppl 7) S43

Muscle trophic factors

muscle trophic factors: subtraction analysis of differentially expressed genes of regenerating skeletal muscle under innervation (Jimi et al) 2003;54:(suppl 7) S73

Muscular atrophy, spinal

infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann et al) 2003;54:719

valproic acid increases SMN levels in spinal muscular atrophy patient cells (Sumner et al) 2003;54:647

Muscular dystrophy, congenital

natural history and response to weekly oral prednisolone in the *dyw* mouse model of congenital muscular dystrophy (Connolly et al) 2003;54:(suppl 7) S155

POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154

Muscular dystrophy, Duchenne

creatine and glutamine therapeutic trial in Duchenne muscular dystrophy (DMD) by the Cooperative International Neuromuscular Research Group (CINRG) (Escobar et al) 2003;54:850

Muscular dystrophy, tibial

tibial muscular dystrophy in a Belgian family (Van den Bergh et al) 2002;54:248

Music

the effect of music periodicity on rolandic spikes: a randomized, single-blinded, crossover, clinical trial of the effect of music with distinctive long-term periodicity and repeated melodic line on interictal spike discharges of children with benign childhood epilepsy with centrotemporal spikes (Turner) 2003;54:(suppl 7) S134

Mutations

apolipoprotein E ϵ 4 modifies Alzheimer's disease onset in an E280A PS1 kindred (Pastor et al) 2002;54:163

atypical dementia with a novel presenilin-2 mutation (Bionetti et al) 2003;54:833

- bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene (Solano et al) 2003;54:527
- cellular mechanism of Cx26 mutations causing dominant hearing loss (Yum and Scherer) 2003;54:(suppl 7) S120
- characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67
- disturbance of muscle fiber differentiation in congenital hypomyelinating neuropathy caused by a novel *myelin protein zero* mutation (Szigeti et al) 2003;54:398
- do loss-of-function UBE3A mutations account for the complete Angelman's syndrome phenotype? (Gerry and Graf) 2003;54:(suppl 7) S119
- dual mutation of alpha-glucosidase gene presenting as adult-onset respiratory failure (Kern et al) 2003;54:(suppl 7) S76
- early-onset Parkinson's disease caused by a compound heterozygous *DJ-1* mutation (Hague et al) 2002;54:271
- an English kindred with a novel recessive tauopathy and respiratory failure (Nicholl et al) 2003;54:682
- epilepsy with auditory features: a *LGII* gene mutation suggests a loss-of-function mechanism (Pizzuti et al) 2003;54:137 (Correction)
- the expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNA^{Lys} gene (Rossmanith et al) 2003;54:821
- facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53
- the factor V G1691A mutation is significantly associated with childhood porencephaly in white children: a case-control study (Debus et al) 2003;54:(suppl 7) S110
- frequency of *parkin* mutations in late-onset Parkinson's disease (Klein et al) 2003;54:415 (Letter)
- frequency of *parkin* mutations in late-onset Parkinson's disease (Oliveira et al) 2003;54:416 (Reply)
- fulminant Alexander disease with a novel mutation in glial fibrillary acidic protein gene (Bassuk et al) 2003;54:(suppl 7) S157
- genetics of Parkinson's disease: what do mutations in DJ-1 tell us? (Moore et al) 2003;54:281
- hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation (McDermott et al) 2003;54:748
- humanin improves bioenergetic state of cells harboring A3243G mitochondrial DNA mutations (Kariya et al) 2003;54:(suppl 7) S46
- impaired sequence learning in carriers of the DYT1 dystonia mutation (Ghilardi et al) 2003;54:102
- insertion of mutant proteolipid protein results in missorting of myelin proteins (Vauris-Barriere et al) 2003;54:769
- Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE ε4 (Leverenz et al) 2003;54:(suppl 7) S68
- low mutant load of mitochondrial DNA G13513A mutation can cause Leigh's disease (Kirby et al) 2003;54:473
- mutation carriers versus noncarriers in a cohort of at-risk individuals in PPND family (FTDP-17, N279K tau mutation) (Wszolek et al) 2003;54:(suppl 7) S58
- myofibrillar myopathy caused by novel dominant negative αB-crystallin mutations (Selcen and Engel) 2003;54:805
- nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30
- novel CACNA1A mutation causes febrile episodic ataxia with interictal cerebellar deficits (Subramony et al) 2003;54:725
- novel mutations in the Na⁺,K⁺-ATPase pump gene *ATP1A2* associated with familial hemiplegic migraine and benign familial infantile convulsions (Vanmolkot et al) 2003;54:360
- novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151
- a novel PLP mutation is associated with neurobehavioral phenotype (Cambi et al) 2003;54:(suppl 7) S57
- NR4A2* mutations are rare among European patients with familial Parkinson's disease (Wellenbrock et al) 2003;54:415
- oxidative capacity correlates with muscle mutation load in mitochondrial myopathy (Jeppesen et al) 2003;54:86
- POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154
- pyruvate protects motor neuronal cells expressing mutated superoxide dismutase (SOD1) against Cu/Zn-induced toxicity (Kim et al) 2003;54:(suppl 7) S53
- the role of pathogenic *DJ-1* mutations in Parkinson's disease (Abou-Sleiman et al) 2003;54:283
- small interfering RNAs directed against ΔEGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850
- spinocerebellar ataxia type 14 is caused by a mutation in protein kinase C γ (Yabe et al) 2003;54:(suppl 7) S21
- on symptomatic heterozygous alpha-sarcoglycan gene mutation carriers (Fischer et al) 2003;54:674
- variable phenotypic expression and extensive tau pathology in two families with the novel *tau* mutation L315R (van Herpen et al) 2003;54:573
- Mutations, missense**
- impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene (Ugalde et al) 2003;54:665
- missense mutation in platelet-activating factor acetylhydrolase: a genetic severity factor in opticospinal multiple sclerosis (Osoegawa et al) 2003;54:(suppl 7) S62
- myosin storage myopathy associated with a heterozygous missense mutation in *MYH7* (Tajsharghi et al) 2003;54:494
- Mutations, point**
- homozygous prion protein genotype at codon 129 is not a predisposing factor for developing familial Creutzfeldt-Jakob disease with a point mutation of Val to Ile at codon 180 (Shiga et al) 2003;54:(suppl 7) S69
- Myasthenia gravis**
- oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravis (Burns and Jones) 2003;54:136 (Reply)
- oculomotor signs in Lambert-Eaton myasthenic syndrome-coincidence with myasthenia gravis (Toyka and Schneider-Gold) 2003;54:135 (Letter)
- terbutaline in the treatment of myasthenia gravis: a pilot study (Soliven et al) 2003;54:(suppl 7) S45
- Myelin basic protein**
- cross-reactive antibodies against myelin basic protein, *Acinetobacter* sp. and *Pseudomonas aeruginosa* in multiple sclerosis patients (Wilson et al) 2003;54:(suppl 7) S62

Myelin oligodendrocyte glycoprotein

restriction of humoral responses to conformational epitopes after exposure to the native myelin oligodendrocyte glycoprotein polypeptide (Genain et al) 2003;54:(suppl 7) S60

Myelin protein zero gene

disturbance of muscle fiber differentiation in congenital hypomyelinating neuropathy caused by a novel *myelin protein zero* mutation (Szigeti et al) 2003;54:398

Myelin proteins

insertion of mutant proteolipid protein results in missorting of myelin proteins (Vaur-Barriere et al) 2003;54:769

time course of antibody responses to myelin proteins and galactocerebroside in marmoset experimental allergic encephalomyelitis and multiple sclerosis (Menge et al) 2003;54:(suppl 7) S38

Myelination

myelination of a fetus with Pelizaeus-Merzbacher disease: immunopathological study (Shiraishi et al) 2002;54:259

MYH7 gene

myosin storage myopathy associated with a heterozygous missense mutation in *MYH7* (Tajsharghi et al) 2003;54:494

Myobloc

clinical experiences with botulinum toxin type B (Myobloc) in the treatment of cervical dystonia: secondary resistance and electrophysiologic observations (Gollop) 2003;54:(suppl 7) S41

Myoclonus

the use of levetiracetam in myoclonus (Lim and Ahmed) 2003;54:(suppl 7) S41

Myoclonus epilepsy with ragged-red fibers

the expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNA^{Lys} gene (Rossmanith et al) 2003;54:821

Myofibrillar myopathy

myofibrillar myopathy caused by novel dominant negative α B-crystallin mutations (Selcen and Engel) 2003;54:805

Myoinositol

proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153

Myopathy, distal

distal myopathy with rimmed vacuoles: phenotype/genotype relationship in Japanese families (Uyama et al) 2003;54:(suppl 7) S73

Myopathy, inflammatory

analysis of calcium-dependent proteinase and cytoskeletal proteins in muscle from patients with inflammatory myopathy (Murata et al) 2003;54:(suppl 7) S44

Myopathy, mitochondrial

lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies (Filosto et al) 2003;54:524

oxidative capacity correlates with muscle mutation load in mitochondrial myopathy (Jeppesen et al) 2003;54:86

Myopathy, Miyoshi

analysis of dysferlin in monocytes: a useful tool for the diagnosis of the Miyoshi myopathy phenotypes and the detection of carriers (De Luna et al) 2003;54:(suppl 7) S74

Myopathy, myofibrillar

myofibrillar myopathy caused by novel dominant negative α B-crystallin mutations (Selcen and Engel) 2003;54:805

Myopathy, myosin storage

myosin storage myopathy associated with a heterozygous missense mutation in *MYH7* (Tajsharghi et al) 2003;54:494

Myosin storage myopathy

myosin storage myopathy associated with a heterozygous missense mutation in *MYH7* (Tajsharghi et al) 2003;54:494

Myositis, inclusion body

inducible costimulatory molecule and ICOS-ligand are upregulated in patients with sporadic inclusion body myositis and correlate with perforin expression by the autoinvasive cytotoxic T cells (Schmidt et al) 2003;54:(suppl 7) S75

Myotonia, hand

leukocyte CTG repeat length correlates with severity of myotonia in distal hand muscles in myotonic dystrophy type 1 (DM1) (Moxley IV et al) 2003;54:(suppl 7) S76

Myotonic dystrophy type 1

brain imaging, clinical correlates, and social consequences of intellectual impairment in myotonic dystrophy type 1 (Meola et al) 2003;54:(suppl 7) S75

CNS involvement in DM1: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74

leukocyte CTG repeat length correlates with severity of myotonia in distal hand muscles in myotonic dystrophy type 1 (DM1) (Moxley IV et al) 2003;54:(suppl 7) S76

ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2 (Mankodi et al) 2003;54:760

Myotonic dystrophy type 2

ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2 (Mankodi et al) 2003;54:760

N-acetyl aspartate

reduction in *N*-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125

N-methyl-D-aspartate receptors

role of *N*-methyl-D-aspartate receptors in cerebral transendothelial migration of neutrophils (Sharp et al) 2003;54:(suppl 7) S59

N-octyl-4-epi-b-valienamine

a new compound *N*-octyl-4-epi-b-valienamine for chemical chaperone therapy of GM1 gangliosidosis (Matsuda et al) 2003;54:(suppl 7) S107

Narrative recall impairment

identification of a specific deficit in memory for narrative in children treated for craniopharyngioma (Waber et al) 2003;54:(suppl 7) S142

ND6 gene

bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene (Solano et al) 2003;54:527

impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene (Ugalde et al) 2003;54:665

Necrosis, radiation

clinical outcome, including response to therapy, in cerebral radiation necrosis: 31 patients (Rogers et al) 2003;54:(suppl 7) S31

Neocortex, dysplastic

anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and

- calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132
- Neonatal arterial ischemic stroke**
neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138
- Neonatal encephalopathy**
clinical signs predict 30-month neurodevelopmental outcome after neonatal encephalopathy (Miller et al) 2003;54:(suppl 7) S111
- Neonatal fluoxetine withdrawal**
neonatal fluoxetine withdrawal secondary to maternal use during pregnancy: is fluoxetine safe? (Lavenstein et al) 2003;54:(suppl 7) S127
- Neonatal group B streptococcal meningitis**
neuroimaging and endocrinopathies in neonatal group B streptococcal meningitis (McLellan et al) 2003;54:(suppl 7) S125
- Neonatal seizures**
clinical and imaging follow-up of newborns with seizures and bright DWI lesions (Krishnamoorthy and Grant) 2003;54:(suppl 7) S127
timing of neonatal seizures and intrapartum obstetrical factors (Scher et al) 2003;54:(suppl 7) S125
- Neonatal sleep behaviors**
cyclicality of neonatal sleep behaviors at 25 to 30 weeks corrected gestational age (Scher and Johnson) 2003;54:(suppl 7) S121
- Neonates**
bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly (Alfonso et al) 2003;54:(suppl 7) S158
cytokine and chemokine induction after neonatal focal ischemia reperfusion (Derugin et al) 2003;54:(suppl 7) S65
intraventricular hemorrhage in term neonates caused by sinovenous thrombosis (Wu et al) 2003;54:123
neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103
periodic lateralized epileptiform discharges in neonatal EEG recordings (Wambera et al) 2003;54:(suppl 7) S114
stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003;54:(suppl 7) S110
torsinA protein and mRNA expression in the human brain of newborns, infants, and children (Siebert et al) 2003;54:(suppl 7) S116
venous prominence on susceptibility-weighted MRI is associated with perinatal depression in neonates (Michelson et al) 2003;54:(suppl 7) S125
- Nerve growth factor**
Bcl-2-mediated induction of neural differentiation: a role for NGF/TrkA (Liang et al) 2003;54:(suppl 7) S105
cell and receptor dose dependence of NGF function in primitive neural crest cells (Yan et al) 2003;54:(suppl 7) S120
- Neural crest cells**
cell and receptor dose dependence of NGF function in primitive neural crest cells (Yan et al) 2003;54:(suppl 7) S120
- Neural injury**
acute and chronic neural injury alters splicing of functional glutamate transporters (Maragakis et al) 2003;54:(suppl 7) S20
- Neural stem cell transplantation**
intravenous human neural stem cell transplantation ameliorated the epileptogenesis in rat epilepsy model (Chu et al) 2003;54:(suppl 7) S54
- Neural stem cells**
identification of neural stem cells by magnetic resonance spectroscopy (Maletic-Savatic et al) 2003;54:(suppl 7) S118
- Neuro-intensivists**
the impact of a neuro-intensivist on stroke outcomes in the Neurosciences Intensive Care Unit (Varelas et al) 2003;54:697
- Neurobehavioral status**
validation of the Baylor College of Medicine Cognitive and Neurobehavioral Status Examination (West and Ringholz) 2003;54:(suppl 7) S22
- Neuroblastoma**
genetic analyses of murine neuroblastoma: implications for human disease (Hackett et al) 2003;54:(suppl 7) S109
- Neuroborreliosis**
C1q expression increases in the central and peripheral nervous system during neuroborreliosis (Bai et al) 2003;54:(suppl 7) S49
- Neurodegeneration**
growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression (Silva et al) 2003;54:605
- Neurodegeneration, corticobasal**
corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia (Boeve et al) 2003;54:(suppl 5) S15
- Neurodegeneration, frontotemporal**
frontotemporal degeneration, Pick's disease, Pick complex, and Ravel (Kertesz et al) 2003;54:(suppl 5) S1
- Neurodegeneration, striatal**
magnetic resonance imaging delayed ischemic striatal neurodegeneration (Fujioka et al) 2003;54:732
- Neurodegenerative disease**
chick embryo spinal cord electroelution as a tool in investigations of neurovirological and neurodegenerative disease (Roos et al) 2003;54:(suppl 7) S76
modeling human neurodegenerative diseases in *Drosophila* (Daga et al) 2003;54:(suppl 7) S57
toward a molecular neuropsychiatry of neurodegenerative diseases (Cummings) 2002;54:147
- Neurodevelopment**
altered MR cerebral volumes correlate with neurodevelopmental outcome at 2 years in VLBW infants (Inder et al) 2003;54:(suppl 7) S124
- Neuroepithelial precursor cells**
selective stimulation of neuronal antigen expression when differentiating human neuroepithelial precursor cells are cocultured with HIV-1-infected human microglia (McCarthy et al) 2003;54:(suppl 7) S47
- Neurofibromatosis**
neurofibromatosis in African Americans: is there a delay in diagnosis? (Jones et al) 2003;54:(suppl 7) S131
- Neurofibromatosis type 1**
human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108
human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58
human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syn-

- drome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118
- spectrum of cerebrovascular disease in a population of children with neurofibromatosis type 1 (Rosser et al) 2003;54:(suppl 7) S139
- Neurofibromatosis type 2**
glioblastoma multiforme presenting as bilateral internal auditory canal tumors mimicking neurofibromatosis type 2 (Lee et al) 2003;54:(suppl 7) S31
- Neurofilament inclusion body disease**
neurofilament inclusion body disease (Josephs et al) 2003;54:(suppl 7) S51
- Neuroglial reaction**
neuroglial activation in autism: a potential neuroinflammatory pathogenic mechanism (Vargas et al) 2003;54:(suppl 7) S147
- Neuroimaging; see also specific modalities**
neuroimaging and endocrinopathies in neonatal group B streptococcal meningitis (McLellan et al) 2003;54:(suppl 7) S125
risk factors and neuroimaging findings in term infants with cerebral palsy (Wu et al) 2003;54:(suppl 7) S126
- Neuroleptics**
neuroleptics and Gilles de la Tourette syndrome: patient knowledge and concern (Kompolti et al) 2003;54:(suppl 7) S41
- Neurologic abnormalities**
funisitis and neurologic abnormalities in term infants (Wu et al) 2003;54:(suppl 7) S126
- Neuronal development**
olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome (Ronnelt et al) 2002;54:206
- Neuronal injury**
microglia potentiate neuronal injury following ischemia-like insults: possible role of tissue plasminogen activator (tPA) (Huang et al) 2003;54:851
- Neuronal injury, excitotoxic**
status epilepticus and excitotoxic neuronal injury: a case report (Tschida et al) 2003;54:(suppl 7) S159
- Neuropathic pain**
diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73
- Neuropathy, acute**
acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44
- Neuropathy, alcoholic**
alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy (Koike et al) 2003;54:19
- Neuropathy, autoimmune autonomic**
passive transfer of autoimmune autonomic neuropathy (Vernino and Lennon) 2003;54:(suppl 7) S19
- Neuropathy, HIV-associated painful**
HIV-associated painful neuropathy in the era of highly active antiretroviral therapy (Schifitto et al) 2003;54:(suppl 7) S50
- Neuropathy, hypomyelinating**
disturbance of muscle fiber differentiation in congenital hypomyelinating neuropathy caused by a novel *myelin protein zero* mutation (Szigeti et al) 2003;54:398
- Neuropathy, motor**
acute motor axonal neuropathy rabbit model: immune attack on nerve root axons (Susuki et al) 2003;54:383
- Neuropathy, motor and sensory**
hereditary motor and sensory neuropathy with agenesis of the corpus callosum (Dupré et al) 2002;54:9
- Neuropathy, small fiber**
the Utah Early Neuropathy Scale, a clinical scale sensitive to early small fiber neuropathy (Smith et al) 2003;54:(suppl 7) S44
- Neuropathy, thiamine-deficiency**
alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy (Koike et al) 2003;54:19
- Neuroplasticity**
long-term neuroplasticity and functional consequences of single versus recurrent early-life seizures (Baram) 2003;54:701 (Editorial)
- Neuropsychiatric disorders**
sonographic lentiform striate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28
- Neuropsychiatry, molecular**
toward a molecular neuropsychiatry of neurodegenerative diseases (Cummings) 2002;54:147
- Neuropsychological development**
neuropsychological outcome in low-birth-weight children at 3 to 4 years of age (Caravale et al) 2003;54:(suppl 7) S124
- Neuropsychological profiles**
neuropsychological profiles after brain surgery in childhood (Kuroda et al) 2003;54:(suppl 7) S142
- Neurosciences Intensive Care Unit**
the impact of a neuro-intensivist on stroke outcomes in the Neurosciences Intensive Care Unit (Varelas et al) 2003;54:697
- Neurotoxicity, anandamide**
the dark side of endocannabinoids: a neurotoxic role for anandamide (Faden et al) 2003;54:(suppl 7) S77
- Neurotoxicity, Cu/Zn-induced**
pyruvate protects motor neuronal cells expressing mutated superoxide dismutase (SOD1) against Cu/Zn-induced toxicity (Kim et al) 2003;54:(suppl 7) S53
- Neurotoxicity, ddC-induced**
erythropoietin protects dorsal root ganglion neurons against gp120 and ddC-induced neurotoxicity (Keswani et al) 2003;54:(suppl 7) S77
- Neurotoxicity, glutamate**
olmesartan protects spinal motor neurons from glutamate-mediated neurotoxicity (Iwasaki et al) 2003;54:(suppl 7) S52
- Neurotoxicity, gp120**
Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons (Keswani et al) 2003;54:287
- Neurotransmitter diseases, diagnosis**
approach to the diagnosis of neurotransmitter diseases exemplified by the differential diagnosis of childhood-onset dystonia (Assmann et al) 2003;54:(suppl 6) S18
the lumbar puncture for diagnosis of pediatric neurotransmitter diseases (Hyland) 2003;54:(suppl 6) S13
- Neurotransmitter diseases, pediatric**
foreword (DeVivo and Johnston) 2003;54:(suppl 6) S1
the lumbar puncture for diagnosis of pediatric neurotransmitter diseases (Hyland) 2003;54:(suppl 6) S13
magnetic resonance spectroscopy of neurotransmitters in human brain (Novotny Jr. et al) 2003;54:(suppl 6) S25
potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease (Kang and Nakamura) 2003;54:(suppl 6) S103
- Neurotrophin-3**
neurotrophin-3 treatment promotes nerve regeneration and improvements in sensory function in patients with CMT1A (Sahenk et al) 2003;54:(suppl 7) S19

Neurovirological disease

chick embryo spinal cord electroelution as a tool in investigations of neurovirological and neurodegenerative disease (Roos et al) 2003;54:(suppl 7) S76

Neutrophil migration

role of *N*-methyl-D-aspartate receptors in cerebral transendothelial migration of neutrophils (Sharp et al) 2003;54:(suppl 7) S59

Nigral transplantation, fetal

a double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (Olanow et al) 2003;54:403

Nitric oxide synthase inhibitors

modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103

NMNAT gene

protein-protein interactions of *Ube4b*/*NMNAT*, a gene responsible for slow Wallerian degeneration (Torre et al) 2003;54:(suppl 7) S51

NNIPPS project

cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or multiple system atrophy: the NNIPPS project (Leigh et al) 2003;54:(suppl 7) S70

Northern Manhattan Study

serum calcium is associated with carotid artery plaque thickness: the Northern Manhattan Study (Rundek et al) 2003;54:(suppl 7) S23

NOS2A

linkage and association to the NOS2A locus on ch.17q11 in multiple sclerosis (MS) (Barcellos et al) 2003;54:849

NR4A2 gene

NR4A2 mutations are rare among European patients with familial Parkinson's disease (Wellenbrock et al) 2003;54:415 (Letter)

Nursing home admissions

antiepileptic drug use in nursing home admissions (Garard et al) 2003;54:75

expected cognitive decline and risk of nursing home admission for patients with mild or moderate Alzheimer's disease (Ward et al) 2003;54:698

Nystagmus, central

central nystagmus associated with Hashimoto's encephalopathy (Fife et al) 2003;54:(suppl 7) S45

Nystagmus, ictal

frequency and lateralizing value of ictal nystagmus in infants (Loddenkemper et al) 2003;54:(suppl 7) S134

Obituaries

Edward H. Lambert (Daube) 2003;54:690

Occipital cephalocele, variable

variable occipital cephalocele with autosomal-dominant inheritance: a three-generation pedigree (Bassuk et al) 2003;54:(suppl 7) S157

OCTN2 gene

novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151

Oculomotor apraxia

alternatively spliced transcripts of aprataxin in early-onset ataxia with oculomotor apraxia and hypoalbuminemia (Hirano et al) 2003;54:(suppl 7) S58

Olfactory biopsy

olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome (Ronnelt et al) 2002;54:206

Olfactory bulb

retinoic acid stimulates neurogenesis in the postnatal rodent subventricular zone-olfactory bulb pathway (Wang et al) 2003;54:(suppl 7) S77

Oligodendroglial tumors

no preferential loss of paternal 19q alleles in oligodendroglial tumors (Hartmann et al) 2002;54:256

Oligophrenin

characterization of oligophrenin, a RhoBAP, and its binding partners, using an in vitro cell culture model (Gropman et al) 2003;54:(suppl 7) S116

Olmesartan

olmesartan protects spinal motor neurons from glutamate-mediated neurotoxicity (Iwasaki et al) 2003;54:(suppl 7) S52

On/Off

addition of levodopa in combination with entacapone increases "On" time without potentiating peak dyskinesia: a study in the MPTP-treated primate (Jenner et al) 2003;54:(suppl 7) S40

Open heart surgery

long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111

Opioid receptors

κ opioid receptor selectivity for ischemic neuroprotection with *BRL-52537* in rats (Zhang et al) 2003;54:(suppl 7) S26

prolonged therapeutic window for ischemic neuroprotection with selective κ opioid receptor agonist, *BRL-52537* in rat (Chen et al) 2003;54:(suppl 7) S66

Optic neuritis, autoimmune

paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38

Optic neuritis, paraneoplastic

paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38

Optic neuritis, recurrent

the natural history of recurrent optic neuritis (Pirko and Weinshenker) 2003;54:(suppl 7) S60

Opticospinal multiple sclerosis

missense mutation in platelet-activating factor acetylhydrolase: a genetic severity factor in opticospinal multiple sclerosis (Osogawa et al) 2003;54:(suppl 7) S62

Oral/pharyngeal motor and sensory disorder

agenesis of the corpus callosum is associated with significant feeding difficulties: oral/pharyngeal motor and sensory disorder (Ng et al) 2003;54:(suppl 7) S149

OROS methylphenidate

once-daily dosing with the OROS formulation of methylphenidate has minimal impact on tics in children with ADHD (Palumbo et al) 2003;54:(suppl 7) S27

once-daily OROS methylphenidate: impact on tics in children with attention deficit hyperactivity disorder (Palumbo et al) 2003;54:(suppl 7) S143

OROS methylphenidate (MPH) treatment for attention deficit/hyperactivity disorder: long-term effect on growth (Giedd and Concerta Study Group) 2003;54:(suppl 7) S27

Orthostatic tremor

[¹²³I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Katzenschlager R et al) 2002;54:278 (Correction)

Osteopontin

increased osteopontin in cerebrospinal fluid and brains from patients with multiple sclerosis (Fukaura et al) 2003;54:(suppl 7) S61

Oxcarbazepine (Trileptal)

an analysis of seizure-free rates: oxcarbazepine add-on treatment in children with inadequately controlled partial seizures (Glauser and Sfikas) 2003;54:(suppl 7) S113

extensive clinical experience with oxcarbazepine (Trileptal) in children with epilepsy demonstrates good safety and tolerability profiles (Bourgeois) 2003;54:(suppl 7) S136
oxcarbazepine for the treatment of behavior/mood disorders in children (Alberts et al) 2003;54:(suppl 7) S148
oxcarbazepine (Trileptal) is safe and tolerable in children with epilepsy (Brown and Black) 2003;54:(suppl 7) S112

Oxcarbazepine-induced status epilepticus

oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133

Oxidative capacity

oxidative capacity correlates with muscle mutation load in mitochondrial myopathy (Jeppesen et al) 2003;54:86

Oxygenation, bilateral

bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly (Alfonso et al) 2003;54:(suppl 7) S158

Oxygenation, cerebral tissue

altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121

p53

growth hormone prevents human immunodeficiency virus-induced neuronal p53 expression (Silva et al) 2003;54:605

P84

SIRPa-associated molecules (SGT and ArsA) in the brain (Narayanan et al) 2003;54:(suppl 7) S116

Pain, persistent

predictors of persistent depression and pain symptoms in neurology outpatients (Robinson et al) 2003;54:(suppl 7) S77

Pain relief

almotriptan efficacy in achieving pain relief and pain-free status 1 and 2 hours after treatment of acute migraine (Mathew) 2003;54:(suppl 7) S33

diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73

spinal epidural metastases: rehabilitation increases survival and reduces pain (Adamson et al) 2003;54:(suppl 7) S63

Painful diabetic polyneuropathy

a maximum tolerated dose study of tiagabine in painful diabetic polyneuropathy (Kirby and Belleau) 2003;54:(suppl 7) S46

Painful neuropathy, HIV-associated

HIV-associated painful neuropathy in the era of highly active antiretroviral therapy (Schifitto et al) 2003;54:(suppl 7) S50

Pallidopontonigral degeneration

mutation carriers versus noncarriers in a cohort of at-risk individuals in PPND family (FTDP-17, N279K tau mutation) (Wszolek et al) 2003;54:(suppl 7) S58

Pallidotomy

bilateral STN DBS for Parkinson's disease after successful pallidotomy (Kleiner-Fisman et al) 2003;54:(suppl 7) S70

Papillomavirus-like particle Aβ vaccine

papillomavirus-like particle Aβ vaccine induces strong antibody response in APP/PS1 transgenic mice (Zamora et al) 2003;54:(suppl 7) S29

Paralysis, periodic

reduced Na⁺ current is a common feature of both types of hypokalemic periodic paralysis (Ruff et al) 2003;54:(suppl 7) S44

Paraneoplastic autoimmune optic neuritis

paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38

Paraneoplastic degeneration, cerebellar

paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Motomura et al) 2002;54:277 (Reply)

paraneoplastic cerebellar degeneration and antibodies to P/Q-type calcium channels (Pinto and Lang) 2002;54:277 (Letter)

Paraparesis, hereditary spastic

hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation (McDermott et al) 2003;54:748

Paraplegia, complicated spastic

a locus for complicated spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:(suppl 7) S57

Paraplegia, hereditary spastic

a locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:796

Parenteral nutrition, total

manganese-induced parkinsonism from total parenteral nutrition: report of a case and review of the literature (Reich et al) 2003;54:(suppl 7) S73

Parietal-lobe damage

the resolution of spatial attention after parietal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

***parkin* gene**

frequency of *parkin* mutations in late-onset Parkinson's disease (Klein et al) 2003;54:415 (Letter)

frequency of *parkin* mutations in late-onset Parkinson's disease (Oliveira et al) 2003;54:416 (Reply)

how much phenotypic variation can be attributed to *parkin* genotype? (Lohmann et al) 2002;54:176

Parkinson plus syndromes

neuroprotection and natural history in parkinson plus syndromes: construction and validation of a clinical scale to assess disease progression in progressive supranuclear palsy and multiple system atrophy (Payan et al) 2003;54:(suppl 7) S39

neuroprotection and natural history in parkinson plus syndromes: cross-sectional description of magnetic resonance imaging findings in a large prospective cohort of patients with progressive supranuclear palsy and multiple system atrophy (Kraft et al) 2003;54:(suppl 7) S39

Parkinsonism, dominantly inherited

compensatory mechanisms in the dopamine system of patients with dominantly inherited parkinsonism (van Netten et al) 2003;54:(suppl 7) S19

Parkinsonism, manganese-induced

manganese-induced parkinsonism from total parenteral nutrition: report of a case and review of the literature (Reich et al) 2003;54:(suppl 7) S73

Parkinsonism, SCA2-related

SCA2-related parkinsonism in Taiwan: clinical and PET studies (Shan et al) 2003;54:(suppl 7) S40

Parkinsonism, vascular

vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838

Parkinson's disease, analysis

comparisons of hallucinations in dementia with Lewy bodies (DLB) and Parkinson's disease (PD) with hallucinations: a case-control study (Goldman et al) 2003;54:(suppl 7) S72

frontal behavior syndromes in Huntington's disease and Parkinson's disease (Hulvershorn et al) 2003;54:(suppl 7) S70

herpesviruses in brains in Alzheimer's and Parkinson's diseases (Hemling et al) 2002;54:267

longitudinal stability of cognitive and affective functioning in PD patients: a dissociation between behavioral and motoric decline (Bernard et al) 2003;54:(suppl 7) S69

progressive sleep destructuring in Parkinson's disease: polysomnographic study in 48 subjects (Diederich et al) 2003;54:(suppl 7) S47

reduction of the useful field of view in Parkinson's disease (Uc et al) 2003;54:(suppl 7) S39

Parkinson's disease, early-onset

early-onset Parkinson's disease caused by a compound heterozygous *DJ-1* mutation (Hague et al) 2002;54:271

familial aggregation of early- and late-onset Parkinson's disease (Marder et al) 2003;54:507, 693 (Correction)

Parkinson's disease, evaluation

cardiac ¹²³I-MIBG scintigraphy could assess disease severity and phenotype in patients with Parkinson's disease (Saiki et al) 2003;54:(suppl 7) S72

Parkinson's disease, familial

NR4A2 mutations are rare among European patients with familial Parkinson's disease (Wellenbrock et al) 2003;54:415 (Letter)

Parkinson's disease, genetics

characterization of tau association with Parkinson disease (Oliveira et al) 2003;54:(suppl 7) S50

genetics of Parkinson's disease: what do mutations in *DJ-1* tell us? (Moore et al) 2003;54:281

the role of pathogenic *DJ-1* mutations in Parkinson's disease (Abou-Sleiman et al) 2003;54:283

Parkinson's disease, idiopathic

unilateral intraputamenal administration of recombinant-methionyl human glial cell line-derived neurotrophic factor to treat idiopathic Parkinson's disease (Slevin et al) 2003;54:849

Parkinson's disease, incidence

alcohol consumption and the incidence of Parkinson's disease (Hernán et al) 2002;54:170

Parkinson's disease, late-onset

familial aggregation of early- and late-onset Parkinson's disease (Marder et al) 2003;54:507, 693 (Correction)

frequency of *parkin* mutations in late-onset Parkinson's disease (Klein et al) 2003;54:415 (Letter)

frequency of *parkin* mutations in late-onset Parkinson's disease (Oliveira et al) 2003;54:416 (Reply)

Parkinson's disease, management

factors of caregiver burden in Parkinson's disease (Janko et al) 2003;54:(suppl 7) S72

is there stigma associated with Parkinson's disease? evidence from patients and the general public (Siderowf et al) 2003;54:699

Parkinson's disease, pathology

increased Alzheimer's pathology in Parkinson's disease related to antimuscarinic drugs (Perry et al) 2002;54:235

triplication of alpha-synuclein is causal of neuropathologically confirmed Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy in a single kindred (Gwinn-Hardy et al) 2003;54:848

Parkinson's disease, progression

longitudinal effects of dopamine agonist versus levodopa therapy on Parkinson's disease progression: proton magnetic resonance spectroscopic study (Terakawa et al) 2003;54:(suppl 7) S41

REAL-PET and CONSORT (Brooks and Whone) 2003;54:692 (Reply)

REAL-PET and CONSORT (Morrish) 2003;54:692 (Letter)

slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study (Whone et al) 2003;54:93

Parkinson's disease, quality of care indicators

development of quality of care indicators for Parkinson's disease (Cheng et al) 2003;54:695, (suppl 7) S17

Parkinson's disease, rating scales

achieving interrater reliability in Parkinson's disease: utility of the Movement Disorder Society-owned teaching tape of the Unified Parkinson's Disease Rating Scale (Goetz and Stebbins) 2003;54:(suppl 7) S40

Parkinson's disease, sporadic

association between a polymorphism of *brain-derived neurotrophic factor* gene and sporadic Parkinson's disease (Masaki et al) 2002;54:276 (Letter)

Parkinson's disease, treatment

acute reduction of dyskinesias in Parkinson's disease by subthalamic nucleus stimulation: evidence for a direct effect (Gracies et al) 2003;54:(suppl 7) S71

bilateral STN DBS for Parkinson's disease after successful pallidotomy (Kleiner-Fisman et al) 2003;54:(suppl 7) S70

a controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study) (Parkinson Study Group and Stern) 2003;54:(suppl 7) S27

a double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (Olanow et al) 2003;54:403

the effects of carbidopa on sinemet CR in Parkinson's disease (Fang et al) 2003;54:(suppl 7) S71

the effects of unilateral versus bilateral subthalamic nuclei stimulation on tremor and gait in persons with Parkinson's disease (Shumway-Cook et al) 2003;54:(suppl 7) S69

potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease (Kang and Nakamura) 2003;54:(suppl 6) S103

subthalamic nucleus stimulation reduces the cost of the pharmacologic treatment of Parkinson's disease (Newman et al) 2003;54:700

transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease (Yamada et al) 2003;54:352

unilateral stimulation of the subthalamic nucleus in Parkinson's disease: a prospective double-blind 12-month study (Germano et al) 2003;54:(suppl 7) S71

Paroxysmal torticollis, benign

benign paroxysmal torticollis in infancy: not so benign? (Rosman et al) 2003;54:(suppl 7) S129

Pars opercularis, right

speech production after stroke: the role of the right pars opercularis (Blank et al) 2003;54:310

Parvalbumin

anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132

Paternal transmission

genotypes from patients indicate no paternal mitochondrial DNA contribution (Taylor et al) 2003;54:521
lack of paternal inheritance of muscle mitochondrial DNA in sporadic mitochondrial myopathies (Filosto et al) 2003;54:524

paternal transmission of mitochondrial DNA is (fortunately) rare (Johns) 2003;54:422 (Editorial)

Pathological laughter and crying

a case series of "pathological laughter and crying" and a proposal for a new classification (Gondim et al) 2003;54:(suppl 7) S22

Pediatric hemiparesis

a profile of pediatric hemiparesis (Oskoui and Shevell) 2003;54:(suppl 7) S141

Pediatric infarcts

the pathogenesis of pediatric infarcts: a retrospective immunohistochemical study (Askalan et al) 2003;54:(suppl 7) S141

Pediatric neurotransmitter diseases

foreword (DeVivo and Johnston) 2003;54:(suppl 6) S1
the lumbar puncture for diagnosis of pediatric neurotransmitter diseases (Hyland) 2003;54:(suppl 6) S13
magnetic resonance spectroscopy of neurotransmitters in human brain (Novotny Jr. et al) 2003;54:(suppl 6) S25
potential of gene therapy for pediatric neurotransmitter diseases: lessons from Parkinson's disease (Kang and Nakamura) 2003;54:(suppl 6) S103

Pediatric stroke

functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109
prothrombotic risk factors in children with stroke after Fontan procedure (Smith and Garg) 2003;54:(suppl 7) S138
suspected central nervous system vasculitis in young stroke patients (Berlit et al) 2003;54:(suppl 7) S25
what is the role of echocardiography in pediatric stroke? (Pagotto et al) 2003;54:(suppl 7) S137

Pediatrics; see also Children; Infants

acute disseminated encephalomyelitis: a retrospective pediatric series (McGovern and DiMario Jr.) 2003;54:(suppl 7) S129
a comparative audit of clinical research in pediatric neurology (Al-Futaisi and Shevell) 2003;54:(suppl 7) S148
pulsed arterial-spin-labeling perfusion magnetic resonance imaging in pediatrics: strengths and advantages (Licht et al) 2003;54:(suppl 7) S153
twenty-four hour risk of seizure recurrence in pediatric emergency department patients (Sogawa and Maytal) 2003;54:(suppl 7) S114

Pelizaeus-Merzbacher disease, fetal

myelination of a fetus with Pelizaeus-Merzbacher disease: immunopathological study (Shiraishi et al) 2002;54:259

Penumbra

aphasia in hyperacute stroke: language follows brain penumbra dynamics (Croquelois et al) 2003;54:321

Perforin

inducible costimulatory molecule and ICOS-ligand are upregulated in patients with sporadic inclusion body myositis and correlate with perforin expression by the autoimmune cytotoxic T cells (Schmidt et al) 2003;54:(suppl 7) S75

Pericytes

central nervous system microvascular pericyte response to hypoxia (Dore-Duffy et al) 2003;54:(suppl 7) S78

Perinatal left middle cerebral artery stroke

functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109

Periodic lateralized epileptiform discharges

periodic lateralized epileptiform discharges in neonatal EEG recordings (Wambera et al) 2003;54:(suppl 7) S114

Periodic paralysis, hypokalemic

reduced Na⁺ current is a common feature of both types of hypokalemic periodic paralysis (Ruff et al) 2003;54:(suppl 7) S44

Peripheral blood stem cell transplantation

acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44

Peripheral myelin protein 22

clinical and histological variability of PMP22 deletions (Diamond et al) 2003;54:(suppl 7) S75

Peripheral nervous system

Agent Orange exposure is adversely associated with peripheral nerve function (Li et al) 2003;54:698
C1q expression increases in the central and peripheral nervous system during neuroborreliosis (Bai et al) 2003;54:(suppl 7) S49
why doesn't a specific antibody kill spirochetes? expression of dbpA by *B. burgdorferi* in peripheral nerve in the presence of high titers of anti-dbpA antibody (Narayan et al) 2003;54:(suppl 7) S50

Periventricular hemorrhagic infarction

periventricular hemorrhagic infarction, clinical antecedents and ultrasonographic accompaniments (Bassan et al) 2003;54:(suppl 7) S124

Periventricular leukomalacia

AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia (Follett et al) 2003;54:(suppl 7) S103
graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103

Periventricular leukomalacia, cystic

is cystic periventricular leukomalacia disappearing? (Hamrick et al) 2003;54:(suppl 7) S121

Personal digital assistants (PDAs)

a novel child neurology resident case-log program: improved utilization, compliance, and resident satisfaction (Lorze and Clark) 2003;54:(suppl 7) S154

Phenobarbital

phenobarbital and benzodiazepines alter expression of genes involved in inhibitory transmission long after treatment has stopped (Raol et al) 2003;54:(suppl 7) S104

Phenotype

agenesis of the corpus callosum: analysis of the phenotypic spectrum (Sherr et al) 2003;54:(suppl 7) S108
analysis of dysferlin in monocytes: a useful tool for the diagnosis of the Miyoshi myopathy phenotypes and the

- detection of carriers (De Luna et al) 2003;54:(suppl 7) S74
- cardiac ^{123}I -MIBG scintigraphy could assess disease severity and phenotype in patients with Parkinson's disease (Saiki et al) 2003;54:(suppl 7) S72
- do loss-of-function UBE3A mutations account for the complete Angelman's syndrome phenotype? (Gerry and Graf) 2003;54:(suppl 7) S119
- minocycline is not beneficial in a phenotypic mouse model of Huntington's disease (Diguët et al) 2003;54: 843 (Letter)
- a novel PLP mutation is associated with neurobehavioral phenotype (Cambi et al) 2003;54:(suppl 7) S57
- variable phenotypic expression and extensive tau pathology in two families with the novel *tau* mutation L315R (van Herpen et al) 2003;54:573
- Phenotype-genotype correlations**
- ciliary neurotrophic factor genotype does not influence clinical phenotype in amyotrophic lateral sclerosis (Al-Chalabi et al) 2003;54:130
- CNS involvement in DMI: definition of the pattern of cognitive impairment and analysis of genotype-phenotype correlations (Modoni et al) 2003;54:(suppl 7) S74
- distal myopathy with rimmed vacuoles: phenotype/genotype relationship in Japanese families (Uyama et al) 2003;54:(suppl 7) S73
- how much phenotypic variation can be attributed to *parkin* genotype? (Lohmann et al) 2002;54:176
- novel *OCTN2* mutations: absence of genotype-phenotype correlations and prevention of cardiomyopathy by early carnitine therapy (Lamhonwah et al) 2003;54:(suppl 7) S151
- Physical activity**
- mechanisms of stroke prevention by physical activity (Endres et al) 2003;54:582
- Pick complex**
- frontotemporal degeneration, Pick's disease, Pick complex, and Ravel (Kertesz et al) 2003;54:(suppl 5) S1
- Pick's disease**
- epidemiology and genetics of frontotemporal dementia/ Pick's disease (Bird et al) 2003;54:(suppl 5) S29
- frontotemporal degeneration, Pick's disease, Pick complex, and Ravel (Kertesz et al) 2003;54:(suppl 5) S1
- preferred terminology (Kertesz et al) 2003;54:(suppl 5) S3
- Plasma**
- increases in plasma arginine vasopressin after transient focal ischemia in rats (Chang et al) 2003;54:(suppl 7) S64
- interferon- β 1a reduces plasma CD31+ endothelial microparticles in MS (Jy et al) 2003;54:(suppl 7) S60
- Plasmapheresis**
- the role of plasmapheresis in the treatment of acute disseminated encephalomyelitis 2003;54:(suppl 7) S151
- Platelet-activating factor acetylhydrolase**
- missense mutation in platelet-activating factor acetylhydrolase: a genetic severity factor in opticospinal multiple sclerosis (Osoegawa et al) 2003;54:(suppl 7) S62
- Polychondritis, relapsing**
- neuropathology of dementia associated with relapsing polychondritis an autoimmune disorder (Starr et al) 2003;54:(suppl 7) S68
- Polyneuropathy, diabetic**
- diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73
- a maximum tolerated dose study of tiagabine in painful diabetic polyneuropathy (Kirby and Belleau) 2003;54:(suppl 7) S46
- Poly(ADP-ribose) polymerase inhibitors**
- neuronal death and cognitive impairment caused by severe hypoglycemia can be prevented by delayed administration of poly(ADP-ribose) polymerase inhibitors (Swanson et al) 2003;54:850
- Polyradiculoneuropathy, chronic inflammatory demyelinating**
- rituximab-responsive chronic inflammatory demyelinating polyradiculoneuropathy (Briani et al) 2003;54:(suppl 7) S75
- Polysomnography**
- progressive sleep restructuring in Parkinson's disease: polysomnographic study in 48 subjects (Diederich et al) 2003;54:(suppl 7) S47
- POMGnT1 gene**
- POMGnT1 gene mutations in a family with mental retardation, glaucoma, and congenital muscular dystrophy (Vervoort et al) 2003;54:(suppl 7) S154
- Pompe's disease**
- enzyme replacement therapy in the tolerant mouse model of Pompe's disease (Raben et al) 2003;54:(suppl 7) S20
- Porencephaly, childhood**
- the factor V G1691A mutation is significantly associated with childhood porencephaly in white children: a case-control study (Debus et al) 2003;54:(suppl 7) S110
- Port-wine stains**
- autism with facial port-wine stain: a new syndrome? (Chugani et al) 2003;54:(suppl 7) S129
- Positron emission tomography**
- the clinical application of positron emission tomography in childhood brain tumors (Kaplan et al) 2003;54:(suppl 7) S149
- comparisons of serotonin 5-HT $_{1A}$ receptor binding potential in Alzheimer's disease (AD) versus controls using [^{11}C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S29
- is FDG-PET still useful for detecting temporal lobe foci? (Theodore et al) 2003;54:(suppl 7) S56
- multitracer positron emission tomography in the management of patients with gliomas (Heiss et al) 2003;54:(suppl 7) S30
- REAL-PET and CONSORT (Brooks and Whone) 2003; 54:692 (Reply)
- REAL-PET and CONSORT (Morrish) 2003;54:692 (Letter)
- SCA2-related parkinsonism in Taiwan: clinical and PET studies (Shan et al) 2003;54:(suppl 7) S40
- serotonin 5-HT $_{1A}$ receptor binding potential in frontotemporal dementia (FTD) compared with controls using [^{11}C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S67
- slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study (Whone et al) 2003;54:93
- subthalamic nucleus stimulation affects a frontotemporal network: a PET study (Schroeder et al) 2003;54:445
- Potassium**
- reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49
- Potassium channel antibodies**
- autoimmune limbic encephalitis associated with potassium channel antibodies (Theiben et al) 2003;54:(suppl 7) S22

Potassium channels, voltage-gated

voltage-gated potassium channel antibody-associated limbic encephalitis is relatively common, potentially treatable, and usually nonneoplastic (Vincent et al) 2003; 54:(suppl 7) S20

Prader-Willi syndrome

dual pathology in two hypotonic children with Prader-Willi syndrome and muscle mitochondrial complex I deficiency (Wassmer et al) 2003;54:(suppl 7) S157

Prediabetes

diet and exercise compliance decreases neuropathic pain in patients with polyneuropathy associated with prediabetes (Singleton et al) 2003;54:(suppl 7) S73

Prednisolone

intravenous prednisolone encapsulated in novel long-circulating liposomes is superior to free glucocorticosteroid pulse therapy in a model of multiple sclerosis (Schmidt et al) 2003;54:(suppl 7) S36

natural history and response to weekly oral prednisolone in the *dyw* mouse model of congenital muscular dystrophy (Connolly et al) 2003;54:(suppl 7) S155

Prednisone

outcome for biopsy-proven primary angitis of the central nervous system in children treated with pulse cyclophosphamide and prednisone (McGrath et al) 2003;54:(suppl 7) S140

Premature infants

altered cerebral tissue oxygenation associated with cerebral hemorrhagic lesions in premature infants (Bassan et al) 2003;54:(suppl 7) S121

cerebral palsy in the extremely premature: additional clinical and anatomical description (Johnsen et al) 2003;54:(suppl 7) S123

cerebral palsy in the extremely premature: frequency of cerebellar injury (Johnsen and Bodensteiner) 2003;54:(suppl 7) S123

impaired cerebellar growth in preterm infants without brain injury (Limperopoulos et al) 2003;54:(suppl 7) S122

the Johnsen-Tarby-Lewis syndrome: a newly recognized but relatively common outcome of extremely premature infants (Bodensteiner and Johnsen) 2003;54:(suppl 7) S123

ontogeny of nonnutritive sucking by premature infants (Bingham and Stevens-Tuttle) 2003;54:(suppl 7) S120

a primate model of cerebral injury in the premature infant (Inder et al) 2003;54:(suppl 7) S121

a prospective, longitudinal study of echo-planar T2*-weighted MRI for early detection of intracranial hemorrhage in premature infants (Neil et al) 2003;54:(suppl 7) S122

reduced cerebellar volume in premature infants with cerebral parenchymal injury (Limperopoulos et al) 2003;54:(suppl 7) S123

reduction in *N*-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125

ultrasonographic accompaniments and predictors of cerebellar hemorrhage in the preterm infant (Limperopoulos et al) 2003;54:(suppl 7) S122

Preschool children

developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146

developmental and functional outcomes at school age of preschool children with specific language impairment (Shevell et al) 2003;54:(suppl 7) S105

long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111

Presenilin 1 (PSN1)

apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred (Pastor et al) 2002;54:163

Presenilin 1 (PSN1)-deficiency

expression profiling of developing PS1-deficient brain (Korade Mirnics et al) 2003;54:(suppl 7) S119

Presenilin-2 gene (PSEN2)

atypical dementia with a novel presenilin-2 mutation (Bionetti et al) 2003;54:833

Primary stroke centers

are the Brain Attack Coalition's recommended criteria for primary stroke centers associated with better care and outcomes in patients with stroke? (Douglas et al) 2003; 54:696, (suppl 7) S17

Prion protein

absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Dermaut et al) 2003;54:555 (Reply)

absence of association between codon 129/219 polymorphisms of the prion protein gene and Alzheimer's disease in Japan (Ohkubo et al) 2003;54:553 (Letter)

characteristic diffusion-weighted MRI findings for sporadic CJD with VV2 and familial CJD with V180I (Shiga et al) 2003;54:(suppl 7) S67

early cognitive decline is associated with prion protein codon 129 polymorphism (Croes et al) 2002;54:275 (Letter)

homozygous prion protein genotype at codon 129 is not a predisposing factor for developing familial Creutzfeldt-Jakob disease with a point mutation of Val to Ile at codon 180 (Shiga et al) 2003;54:(suppl 7) S69

Proteasome

novel identification of aggresomes in sporadic inclusion-body myositis (s-IBM) muscle fibers suggests that inhibition of 26S/20S proteasome and misfolded proteins play a pathogenic role (Fratta et al) 2003;54:848

Protein kinase C γ

spinocerebellar ataxia type 14 is caused by a mutation in protein kinase C γ (Yabe et al) 2003;54:(suppl 7) S21

Proteinase, calcium-dependent

analysis of calcium-dependent proteinase and cytoskeletal proteins in muscle from patients with inflammatory myopathy (Murata et al) 2003;54:(suppl 7) S44

Proteolipid protein gene (PLP)

insertion of mutant proteolipid protein results in misrouting of myelin proteins (Vaur-Barriere et al) 2003;54: 769

a novel PLP mutation is associated with neurobehavioral phenotype (Cambi et al) 2003;54:(suppl 7) S57

Proteolipid protein gene (PLP1)

myelination of a fetus with Pelizaeus-Merzbacher disease: immunopathological study (Shiraishi et al) 2002;54:259

Prothrombotic disorders

recurrent stroke: the role of prothrombotic disorders (Kirkham et al) 2003;54:(suppl 7) S110

Pseudomonas aeruginosa

antibodies to specific proteins of *Acinetobacter* sp. and *Pseudomonas aeruginosa* in multiple sclerosis patients (Hughes et al) 2003;54:(suppl 7) S63

- cross-reactive antibodies against myelin basic protein, *Acinetobacter* sp. and *Pseudomonas aeruginosa* in multiple sclerosis patients (Wilner et al) 2003;54:(suppl 7) S62
- Pseudotumor cerebri**
pseudotumor cerebri: retrospective review of 58 cases between 1985 and 2002 (Acosta et al) 2003;54:(suppl 7) S152
- Psychiatric disorders**
comorbidity of childhood-onset epilepsy and psychiatric and behavioral disorders: a population-based study (Hedderick and Buchhalter) 2003;54:(suppl 7) S115
- Psychopharmacology**
clinical response to psychopharmacology for behavior in fragile X syndrome (Berry-Kravis and Potanos) 2003;54:(suppl 7) S144
- Psychostimulants**
psychostimulant use in children with autistic spectrum disorder (Chez et al) 2003;54:(suppl 7) S147
psychostimulants depress cortical excitation of the striatum, an effect mediated by presynaptic corticostriatal D2 dopamine receptors (Bamford and Sulzer) 2003;54:(suppl 7) S106
- Public opinion**
is there stigma associated with Parkinson's disease? evidence from patients and the general public (Siderowf et al) 2003;54:699
- Purkinje cells**
modifications of acute hypoxia-induced alterations of calbindin-D28 and caspase-3 immunoreactivity in cerebellar Purkinje cells of newborn piglet by pretreatment with selective neuronal nitric oxide synthase inhibitor (Khurana et al) 2003;54:(suppl 7) S103
- Pyridoxine**
sulthiame is effective in the initial therapy of West's syndrome: a randomized placebo-controlled add-on trial on baseline pyridoxine (Debus and Kurlmann) 2003;54:(suppl 7) S113
- Pyruvate**
pyruvate protects motor neuronal cells expressing mutated superoxide dismutase (SOD1) against Cu/Zn-induced toxicity (Kim et al) 2003;54:(suppl 7) S53
- Quadrantanopia**
functional magnetic resonance imaging evidence of purely extrastriate basis for poststroke quadrantanopia (Moo and Slotnick) 2003;54:(suppl 7) S25
- Quality of care indicators**
development of quality of care indicators for Parkinson's disease (Cheng et al) 2003;54:695, (suppl 7) S17
- Quality of life**
epilepsy in low-grade gliomas: the impact on cognitive function and quality of life (Klein et al) 2003;54:514
how mild is mild stroke? predictors of diminished quality of life after very mild stroke (Edwards et al) 2003;54:699
- Quality of life instruments**
the differential responsiveness of quality of life and health status instruments in chronic progressive and episodic neurological diseases: a measure of disease adaptation (Kern and Brown) 2003;54:696, (suppl 7) S18
- Quantified Neurological Examination (QNE)**
prediction of neuropathological severity in 100 patients with Huntington's disease (Rosenblatt et al) 2003;54:488
- Racial differences**
association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697
- Radiation necrosis, cerebral**
clinical outcome, including response to therapy, in cerebral radiation necrosis: 31 patients (Rogers et al) 2003;54:(suppl 7) S31
- Radiotherapy**
childhood ependymomas: possible improved survival with the use of preirradiation chemotherapy followed by radiotherapy (Garvin et al) 2003;54:(suppl 7) S109
intensive chemotherapy followed by response-based radiotherapy: preliminary results of the Beth Israel Germinoma Consortium (Allen et al) 2003;54:(suppl 7) S109
- Radiotherapy, cranial**
moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140
the occurrence of central nervous system vascular disease following cranial radiotherapy (Keene et al) 2003;54:(suppl 7) S141
- Ragged-red fibers**
the expanding mutational spectrum of MERRF substitution G8361A in the mitochondrial tRNA^{Lys} gene (Rossmanith et al) 2003;54:821
- Ramelteon (TAK-375)**
behavioral pharmacology of ramelteon (TAK-375) in small mammals (Miyamoto et al) 2003;54:(suppl 7) S46
- Rasagiline**
a controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study) (Parkinson Study Group and Stern) 2003;54:(suppl 7) S27
- Rating scales**
achieving interrater reliability in Parkinson's disease: utility of the Movement Disorder Society-owned teaching tape of the Unified Parkinson's Disease Rating Scale (Goetz and Stebbins) 2003;54:(suppl 7) S40
development and validation of a tool to objectively measure antiepileptic drug side effects in children with epilepsy: Cincinnati antiepileptic drug side effect Scale (Morita et al) 2003;54:(suppl 7) S136
the Utah Early Neuropathy Scale, a clinical scale sensitive to early small fiber neuropathy (Smith et al) 2003;54:(suppl 7) S44
- Ravel's disease**
frontotemporal degeneration, Pick's disease, Pick complex, and Ravel (Kertesz et al) 2003;54:(suppl 5) S1
- Reactive oxygen species**
disruption of glial glutamate transport by reactive oxygen species produced in motor neurons in response to excitotoxic activation: an in vitro model of ALS pathogenesis (Weiss et al) 2003;54:(suppl 7) S43
- Reelin**
Reelin and Lis1 signaling are coordinated in brain development (Assadi et al) 2003;54:(suppl 7) S104
- Rehabilitation**
spinal epidural metastases: rehabilitation increases survival and reduces pain (Adamson et al) 2003;54:(suppl 7) S63
- Reproductive hormones**
interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy (Herzog et al) 2003;54:625

Research, clinical

a comparative audit of clinical research in pediatric neurology (Al-Futaisi and Shevell) 2003;54:(suppl 7) S148

Resident case-log programs

a novel child neurology resident case-log program: improved utilization, compliance, and resident satisfaction (Lorze and Clark) 2003;54:(suppl 7) S154

Respiratory distress, infantile spinal muscular atrophy with

infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann et al) 2003;54:719

Respiratory failure

an English kindred with a novel recessive tauopathy and respiratory failure (Nicholl et al) 2003;54:682

Respiratory failure, adult-onset

dual mutation of alpha-glucosidase gene presenting as adult-onset respiratory failure (Kern et al) 2003;54:(suppl 7) S76

Respiratory syncytial virus

encephalopathy associated with respiratory syncytial virus: a cohort study (Kho et al) 2003;54:(suppl 7) S130

neurological complications associated with respiratory syncytial virus (Sweetman et al) 2003;54:(suppl 7) S130

Retinal changes

retinal involvement in dementia with Lewy bodies: a clue to hallucinations? (Maurage et al) 2003;54:542

Retinal vessels

spectral Doppler imaging of central retinal vessels in children: a potential non-invasive alternative method of measuring intracranial pressures (Chang et al) 2003;54:(suppl 7) S152

Retinitis

paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG (Cross et al) 2003;54:38

Retinoic acid

retinoic acid stimulates neurogenesis in the postnatal rodent subventricular zone-olfactory bulb pathway (Wang et al) 2003;54:(suppl 7) S77

Retinotopic maps

immature cortex lesions alter retinotopic maps and inter-hemispheric connections (Restrepo et al) 2003;54:51

Rett's syndrome

determination of presynaptic acetylcholine terminal densities and its clinical correlation in Rett's syndrome (Bibat et al) 2003;54:(suppl 7) S118

histone acetylation in Rett's syndrome lymphocytes: characteristics and relationship with neurological impairment (Kaufmann et al) 2003;54:(suppl 7) S108

olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome (Ronnelt et al) 2002;54:206

Riluzole

inhibition of brain tumor-mediated excitotoxic destruction and invasion implementing a glutamate release antagonist (Haque et al) 2003;54:851

Rimmed vacuoles

distal myopathy with rimmed vacuoles: phenotype/genotype relationship in Japanese families (Uyama et al) 2003;54:(suppl 7) S73

Ring 20 chromosome

mosaicism and ring 20 chromosome (Nishiwaki et al) 2003;54:(suppl 7) S56

Ritalin LA

comparative school-day efficacy of Ritalin LA, Concerta, and placebo in children with attention deficit hyperactivity disorder (Lopez et al) 2003;54:(suppl 7) S143

Rituximab

rituximab-responsive chronic inflammatory demyelinating polyradiculoneuropathy (Briani et al) 2003;54:(suppl 7) S75

RNA, small interfering

small interfering RNAs directed against Δ EGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850

Ropinirole

REAL-PET and CONSORT (Brooks and Whone) 2003;54:692 (Reply)

REAL-PET and CONSORT (Morrish) 2003;54:692 (Letter)

slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study (Whone et al) 2003;54:93

Saccadic intrusions

pathogenesis of clinical signs in recessive ataxia with saccadic intrusions (Swartz et al) 2003;54:825

β -Sarcoglycan gene (SGCB)

homozygous β -sarcoglycan gene deletion in a family with limb-girdle muscular dystrophy type 2E (Kaindl et al) 2003;54:(suppl 7) S154

School-age children

developmental and functional outcomes at school age of preschool children with global developmental delay (Shevell et al) 2003;54:(suppl 7) S146

developmental and functional outcomes at school age of preschool children with specific language impairment (Shevell et al) 2003;54:(suppl 7) S105

fine motor and gross motor function in school-age children with a preschool diagnosis of specific language impairment (Webster et al) 2003;54:(suppl 7) S145

Schwann cells

Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons (Keswani et al) 2003;54:287

Scintigraphy, cardiac

cardiac 123 I-MIBG scintigraphy could assess disease severity and phenotype in patients with Parkinson's disease (Saiki et al) 2003;54:(suppl 7) S72

Screening

diagnosing migraine with a simple and efficient three-question Headache Screen (Cady et al) 2003;54:(suppl 7) S33

validation of the Baylor College of Medicine Cognitive and Neurobehavioral Status Examination (West and Ringholz) 2003;54:(suppl 7) S22

Sedation, postoperative

postoperative sedation and the incidence of delirium and cognitive deficits in cardiac surgery patients (Maldonado and Wysong) 2003;54:(suppl 7) S27

Segawa disease

autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease) (Segawa et al) 2003;54:(suppl 6) S32

the *HPH-1* mouse: a model for dominantly inherited GTP-cyclohydrolase deficiency (Hyland et al) 2003;54:(suppl 6) S46

tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Seizure alerting and response behaviors

seizure alerting and response behaviors in dogs living with epileptic children (Kirton et al) 2003;54:(suppl 7) S133

Seizure-induced injury

the influence of cognitive reserve on seizure-induced injury (Akman et al) 2003;54:(suppl 7) S132

Seizures

incidence of seizures among ketotic and nonketotic diabetic patients (Gao-Hickman et al) 2003;54:(suppl 7) S56

the influence of comorbid depression on seizure severity (Cramer and Epilepsy Impact Project) 2003;54:(suppl 7) S55

Seizures, complex partial

oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133

Seizures, dialeptic nonepileptic

heart rate analysis can differentiate dialeptic temporal lobe epilepsy from dialeptic auras and dialeptic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55

Seizures, early-life

long-term neuroplasticity and functional consequences of single versus recurrent early-life seizures (Baram) 2003; 54:701 (Editorial)

Seizures, febrile

repetitive febrile seizures in rat pups impair long-term memory and hippocampal cAMP response-element binding protein phosphorylation (Chang et al) 2003;54: 706

Seizures, generalized tonic-clonic

topiramate as first-line therapy in epilepsy characterized by partial-onset or generalized tonic-clonic seizures (Levi-sohn et al) 2003;54:(suppl 7) S135

Seizures, intractable

anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132

Seizures, juvenile audiogenic

identification of a monogenic locus (jams1) causing juvenile audiogenic seizures in mice (Sherr et al) 2003;54: (suppl 7) S53

Seizures, neonatal

clinical and imaging follow-up of newborns with seizures and bright DWI lesions (Krishnamoorthy and Grant) 2003;54:(suppl 7) S127

timing of neonatal seizures and intrapartum obstetrical factors (Scher et al) 2003;54:(suppl 7) S125

Seizures, new-onset

magnetic resonance imaging for the diagnosis of cerebral dysplasia in new-onset seizures in children (Vanderver et al) 2003;54:(suppl 7) S114

sleep disruption and behavioral problems in children with new-onset seizures (Dunn et al) 2003;54:(suppl 7) S133

Seizures, partial

an analysis of seizure-free rates: oxcarbazepine add-on treatment in children with inadequately controlled partial seizures (Glauser and Sfikas) 2003;54:(suppl 7) S113

safety and efficacy of lamotrigine in infants aged 1 to 24 months with partial seizures: updated preliminary open-label results (Piña-Garza et al) 2003;54:(suppl 7) S113

topiramate as first-line therapy in epilepsy characterized by partial-onset or generalized tonic-clonic seizures (Levi-sohn et al) 2003;54:(suppl 7) S135

Seizures, recurrent

twenty-four hour risk of seizure recurrence in pediatric emergency department patients (Sogawa and Maytal) 2003;54:(suppl 7) S114

Seizures, subclinical

stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003; 54:(suppl 7) S110

Semantic dementia

the core and halo of primary progressive aphasia and semantic dementia (Mesulam et al) 2003;54:(suppl 5) S11

Sensory neuropathy, hereditary

hereditary motor and sensory neuropathy with agenesis of the corpus callosum (Dupré et al) 2002;54:9

Sequence learning

impaired sequence learning in carriers of the DYT1 dystonia mutation (Ghilardi et al) 2003;54:102

Serotonin 5-HT_{1A} receptors

comparisons of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease (AD) versus controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54: (suppl 7) S29

serotonin 5-HT_{1A} receptor binding potential in fronto-temporal dementia (FTD) compared with controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54: (suppl 7) S67

Serum calcium

serum calcium is associated with carotid artery plaque thickness: the Northern Manhattan Study (Rundek et al) 2003;54:(suppl 7) S23

Serum potassium

reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49

Sex

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58

Siblings

functional magnetic resonance imaging and neuropsychological testing reveals distinct language deficits and cortical activation in siblings with mitochondrial disease (Seyffert et al) 2003;54:(suppl 7) S148

Sickle cell disease

brain injury in children with sickle cell disease: prevalence and etiology (Steen et al) 2003;54:564

cerebral perfusion, cerebrovascular disease, and hematology in sickle cell disease: a longitudinal study (Prengler et al) 2003;54:(suppl 7) S138

sickle cell disease and stroke: primary prevention and transcranial Doppler (Adams et al) 2003;54:559 (Editorial)

Sinemet

the effects of carbidopa on sinemet CR in Parkinson's disease (Fang et al) 2003;54:(suppl 7) S71

Single photon emission computed tomography

[¹²¹I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Katzenschlager R et al) 2002;54: 278 (Correction)

a study of single photon emission computed tomography in patients with intracerebral hemorrhage receiving mannitol (Misra et al) 2003;54:(suppl 7) S64

Sinovenous thrombosis

- intraventricular hemorrhage and sinovenous thrombosis in term infants (Wul et al) 2003;54:(suppl 7) S138
- intraventricular hemorrhage in term neonates caused by sinovenous thrombosis (Wu et al) 2003;54:123

Sinovenous thrombosis, cerebral

- neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138

SIRPa

- SIRPa-associated molecules (SGT and ArsA) in the brain (Narayanan et al) 2003;54:(suppl 7) S116

Skeletal muscle

- expression of aquaporin 7 and its localization in normal human skeletal myofibers (Wakayama et al) 2003;54:(suppl 7) S45
- muscle trophic factors: subtraction analysis of differentially expressed genes of regenerating skeletal muscle under innervation (Jimi et al) 2003;54:(suppl 7) S73
- ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2 (Mankodi et al) 2003;54:760

Skin innervation

- quantification of myelinated endings and mechanoreceptors in human digital skin (Nolano et al) 2002;54:186

Sleep behavior, neonatal

- cyclicity of neonatal sleep behaviors at 25 to 30 weeks corrected gestational age (Scher and Johnson) 2003;54:(suppl 7) S121

Sleep-disordered breathing

- effect of enzyme replacement therapy on sleep-disordered breathing in type II mucopolysaccharidosis (D'Cruz et al) 2003;54:(suppl 7) S151

Sleep disturbances

- prevalence and risk of sleep disturbances in adolescents after minor head injury (Ravid et al) 2003;54:(suppl 7) S128
- progressive sleep restructuring in Parkinson's disease: polysomnographic study in 48 subjects (Diederich et al) 2003;54:(suppl 7) S47
- sleep disruption and behavioral problems in children with new-onset seizures (Dunn et al) 2003;54:(suppl 7) S133

Sleepiness, daytime

- daytime sleepiness in children with attention deficit hyperactivity disorder (Ravid et al) 2003;54:(suppl 7) S144

Small fiber neuropathy, early

- the Utah Early Neuropathy Scale, a clinical scale sensitive to early small fiber neuropathy (Smith et al) 2003;54:(suppl 7) S44

Small interfering RNAs

- small interfering RNAs directed against Δ EGFR inhibit the growth of glioma cells (Weiss and Fan) 2003;54:850

Social attention impairment

- impaired social attention after frontal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

Sodium channels

- reduced Na^+ current is a common feature of both types of hypokalemic periodic paralysis (Ruff et al) 2003;54:(suppl 7) S44

Sonography

- sonographic lenticulostriate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28

Sonography, brain parenchyma

- differential findings on brain parenchyma sonography in tauopathies and synucleinopathies (Walter et al) 2003;54:(suppl 7) S41

Spain

- an evaluation of the effectiveness and tolerability of almotriptan for acute migraine in patients managed by neurologists in Spain (Pascual et al) 2003;54:(suppl 7) S33

Spastic paraparesis, hereditary

- hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation (McDermott et al) 2003;54:748

Spastic paraplegia, complicated

- a locus for complicated spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:(suppl 7) S57

Spastic paraplegia, hereditary

- a locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32 (Blumen et al) 2003;54:796

Spastin

- hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation (McDermott et al) 2003;54:748

Spatial attention

- the resolution of spatial attention after parietal-lobe damage (Vecera et al) 2003;54:(suppl 7) S23

Spatial neglect, unilateral

- persistent unilateral spatial neglect in young children with early focal brain damage (Heeren and Trauner) 2003;54:(suppl 7) S142

Speech production

- speech production after stroke: the role of the right pars opercularis (Blank et al) 2003;54:310

Spinal cord

- high expression of macrophage migration inhibitory factor (MIF) in spinal cord and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients (Ogata et al) 2003;54:(suppl 7) S51

- olmesartan protects spinal motor neurons from glutamate-mediated neurotoxicity (Iwasaki et al) 2003;54:(suppl 7) S52

Spinal cord atrophy

- spinal cord atrophy and disability in multiple sclerosis over 4 years: application of a new technique in monitoring disease progression (Lin et al) 2003;54:(suppl 7) S78

Spinal cord injury

- retrograde reactions of Clarke's nucleus neurons after human spinal cord injury (Schmitt et al) 2003;54:534

Spinal cord tumors

- cat scratch disease mimicking a spinal cord tumor (Hmaïess et al) 2003;54:(suppl 7) S159

Spinal epidural metastasis

- spinal epidural metastases: rehabilitation increases survival and reduces pain (Adamson et al) 2003;54:(suppl 7) S63

Spinal muscular atrophy

- valproic acid increases SMN levels in spinal muscular atrophy patient cells (Sumner et al) 2003;54:647

Spinal muscular atrophy with respiratory distress type 1, infantile

- infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1) (Grohmann et al) 2003;54:719

Spinocerebellar ataxia, autosomal dominant

- clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) (Röls et al) 2003;54:367

Spinocerebellar ataxia type 2

SCA2-related parkinsonism in Taiwan: clinical and PET studies (Shan et al) 2003;54:(suppl 7) S40

Spinocerebellar ataxia type 3

disrupted nuclear organization and function in Machado-Joseph disease (Lewis et al) 2003;54:(suppl 7) S51
visual function in Machado-Joseph disease (Subramony et al) 2003;54:(suppl 7) S40

Spinocerebellar ataxia type 8

do CTG expansions at the SCA8 locus cause ataxia? (Schöls et al) 2003;54:110
seeking clarity through the genetic lens: a work in progress (Nance) 2002;54:5 (Editorial)

Spinocerebellar ataxia type 14

spinocerebellar ataxia type 14 is caused by a mutation in protein kinase C γ (Yabe et al) 2003;54:(suppl 7) S21

Spinocerebellar ataxia type 17

clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17) (Röls et al) 2003;54:367
disinhibition-dysexecutive syndrome associated with differential age of onset in a family with SCA-17 (Farbman and Kaufer) 2003;54:(suppl 7) S52

Spinocerebellar ataxia with saccadic intrusions

pathogenesis of clinical signs in recessive ataxia with saccadic intrusions (Swartz et al) 2003;54:825

Spirochetes

why doesn't a specific antibody kill spirochetes? expression of dbpA by *B. burgdorferi* in peripheral nerve in the presence of high titers of anti-dbpA antibody (Narayan et al) 2003;54:(suppl 7) S50

Status epilepticus

status epilepticus and excitotoxic neuronal injury: a case report (Tschida et al) 2003;54:(suppl 7) S159

Status epilepticus, focal

bilateral decreased oxygenation during focal status epilepticus in a neonate with hemimegalencephaly (Alfonso et al) 2003;54:(suppl 7) S158

Status epilepticus, oxcarbazepine-induced

oxcarbazepine-induced status epilepticus during treatment of intractable complex partial seizures in children with intellectual disability (Vaisleib et al) 2003;54:(suppl 7) S133

Stem cell transplantation

acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44
intravenous human neural stem cell transplantation ameliorated the epileptogenesis in rat epilepsy model (Chu et al) 2003;54:(suppl 7) S54
transplanted neural stem cells improve regeneration through chronically denervated peripheral nerves (Heine et al) 2003;54:(suppl 7) S19

Stem cells

pediatric brain tumor stem cells (Hemmati et al) 2003;54:(suppl 7) S117

Stem cells, neural

identification of neural stem cells by magnetic resonance spectroscopy (Maletic-Savatic et al) 2003;54:(suppl 7) S118

Stereotypies

clinical features of physiologic stereotypies in children (Mahone et al) 2003;54:(suppl 7) S145

Stereotypies, complex

frontal white matter reductions in healthy boys with complex stereotypies (Kates et al) 2003;54:(suppl 7) S144

Stiff-person syndrome

autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45

Stilbazulenyl nitrore

stilbazulenyl nitrore, a novel antioxidant, is highly neuroprotective in focal ischemia (Ginsberg et al) 2003;54:330

Stimulants

stimulant therapy in fragile X syndrome (Berry-Kravis and Potanos) 2003;54:(suppl 7) S150

Story recall impairment

identification of a specific deficit in memory for narrative in children treated for craniopharyngioma (Waber et al) 2003;54:(suppl 7) S142

Striatal necrosis, bilateral

bilateral striatal necrosis associated with a novel mutation in the mitochondrial ND6 gene (Solano et al) 2003;54:527

Striatal neurodegeneration, delayed ischemic

magnetic resonance imaging delayed ischemic striatal neurodegeneration (Fujioka et al) 2003;54:732

Striatum

psychostimulants depress cortical excitation of the striatum, an effect mediated by presynaptic corticostriatal D2 dopamine receptors (Bamford and Sulzer) 2003;54:(suppl 7) S106

Stroke

are the Brain Attack Coalition's recommended criteria for primary stroke centers associated with better care and outcomes in patients with stroke? (Douglas et al) 2003;54:696, (suppl 7) S17

Broca's area and beyond: a new twist on lesion/deficit correlation studies to localize brain functions (Hillis) 2003;54:851

changes in perception of risks and benefits of hormone therapy in women with stroke (Bushnell et al) 2003;54:699

clinical predictors of dissection in a stroke cohort (Hildebrand et al) 2003;54:(suppl 7) S137

correlation of gait deficit with muscle activation latency impairment after stroke (Fredrickson et al) 2003;54:(suppl 7) S64

cyclooxygenase-2 and stroke: the long and short if (Iadecola) 2002;54:141 (Editorial)

designing multi-ethnic stroke studies: the Brain Attack Surveillance in Corpus Christi (BASIC) project (Morgenstern et al) 2003;54:(suppl 7) S65

functional magnetic resonance imaging evidence of purely extrastriate basis for poststroke quadrantanopia (Moo and Slotnick) 2003;54:(suppl 7) S25

the impact of a neuro-intensivist on stroke outcomes in the Neurosciences Intensive Care Unit (Varelas et al) 2003;54:697

lack of impact of the Women's Health Initiative on hormone therapy use after stroke (Bushnell and Goldstein) 2003;54:697

mechanisms of stroke prevention by physical activity (Endres et al) 2003;54:582

sickle cell disease and stroke: primary prevention and transcranial Doppler (Adams et al) 2003;54:559 (Editorial)

speech production after stroke: the role of the right pars opercularis (Blank et al) 2003;54:310

stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003;54:(suppl 7) S110

- suspected central nervous system vasculitis in young stroke patients (Berlit et al) 2003;54:(suppl 7) S25
- Stroke, acute ischemic**
 in acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous? 2003;54:698
 beyond the three hour time-window: multivariable patient-selection for thrombolytic therapy in acute ischemic stroke (Kent et al) 2003;54:696, (suppl 7) S18
 circulating β amyloid protein is elevated in patients with acute ischemic stroke (Lee et al) 2003;54:(suppl 7) S65
 early ischemic lesion recurrence within a week after acute ischemic stroke (Kang et al) 2003;54:66
 genomic *fingerprint* of acute ischemic stroke (Moore et al) 2003;54:(suppl 7) S24
- Stroke, cerebellar**
 is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Annoni and Khateb) 2003;54:556 (Reply)
 is decoupling of autonomic and cognitive emotional reactions a manifestation of cerebellar stroke or hydrocephalus? (Gondim and de Oliveira) 2003;54:555 (Letter)
- Stroke, chronic**
 contribution of the ipsilateral motor cortex to recovery after chronic stroke (Werhahn et al) 2003;54:464
- Stroke, cryptogenic**
 frequency and mechanisms of stroke recurrence after cryptogenic stroke (Bang et al) 2002;54:227
- Stroke, experimental**
 the 70kD heat shock protein protects against experimental stroke by suppressing microglial activation (Zheng et al) 2003;54:(suppl 7) S24
- Stroke, hyperacute**
 aphasia in hyperacute stroke: language follows brain penumbra dynamics (Croquelois et al) 2003;54:321
- Stroke, ischemic**
 variability in utilization do-not-resuscitate orders for patients with ischemic stroke (Johnston et al) 2003;54:697
- Stroke, left middle cerebral artery**
 functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109
- Stroke, mild**
 how mild is mild stroke? predictors of diminished quality of life after very mild stroke (Edwards et al) 2003;54:699
- Stroke, neonatal arterial ischemic**
 neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138
- Stroke, pediatric**
 functional magnetic resonance imaging shows atypical language organization in children after perinatal left middle cerebral artery stroke (Schapiro et al) 2003;54:(suppl 7) S109
 prothrombotic risk factors in children with stroke after Fontan procedure (Smith and Garg) 2003;54:(suppl 7) S138
 what is the role of echocardiography in pediatric stroke? (Pagotto et al) 2003;54:(suppl 7) S137
- Stroke, progressing**
 VA Stroke Study (VAsT Study): progressing stroke (Goldstein et al) 2003;54:695, (suppl 7) S17
- Stroke, radiological**
 predictors of occurrence and location of radiological stroke in subarachnoid hemorrhage (Rabinstein et al) 2003;54:(suppl 7) S66
- Stroke, recurrent**
 frequency and mechanisms of stroke recurrence after cryptogenic stroke (Bang et al) 2002;54:227
 recurrent stroke: the role of prothrombotic disorders (Kirkham et al) 2003;54:(suppl 7) S110
- Stroke-like events**
 mechanism of stroke-like events in congenital disorder of glycosylation (Dinopoulos et al) 2003;54:(suppl 7) S139
- Stroke risk**
 a population study of the risk of stroke after transient ischemic attack (Hill et al) 2003;54:695, (suppl 7) S17
 reduced serum potassium levels with highly active antiretroviral therapy: implications for stroke risk in HIV-infected individuals (Felix et al) 2003;54:(suppl 7) S49
- Sturge-Weber's syndrome**
 autism with facial port-wine stain: a new syndrome? (Chugani et al) 2003;54:(suppl 7) S129
 decreased fibronectin expression in meningeal blood vessels of Sturge-Weber's syndrome (Comi et al) 2003;54:(suppl 7) S116
- Subarachnoid hemorrhage**
 fatigue in subarachnoid hemorrhage survivors: predictors and impact on long-term outcome (Kowalski et al) 2003;54:698
 ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space (Petzold et al) 2003;54:591
 predictors of discharge functional outcome in good grade Hunt and Hess subarachnoid hemorrhage patients (Parra et al) 2003;54:(suppl 7) S26
 predictors of occurrence and location of radiological stroke in subarachnoid hemorrhage (Rabinstein et al) 2003;54:(suppl 7) S66
- Subcortical gray matter**
 subcortical gray matter MRI T2 hypointensity is independently associated with cognitive impairment in multiple sclerosis (Bakshi et al) 2003;54:(suppl 7) S59
- Subdural hygroma**
 neurological presentation of hemophagocytic lymphohistiocytosis: unusual neuropathological findings including cerebral hemorrhage and subdural hygroma (Kothare et al) 2003;54:(suppl 7) S158
- Substantia nigra**
 presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration (McGeer et al) 2003;54:599
 rapid induction of proapoptotic proteins in nigral dopamine neurons by antipsychotic medication (Mazurek et al) 2003;54:(suppl 7) S42
- Subthalamic nucleus stimulation**
 acute reduction of dyskinesias in Parkinson's disease by subthalamic nucleus stimulation: evidence for a direct effect (Gracies et al) 2003;54:(suppl 7) S71
 the effects of unilateral versus bilateral subthalamic nuclei stimulation on tremor and gait in persons with Parkinson's disease (Shumway-Cook et al) 2003;54:(suppl 7) S69
 subthalamic nucleus stimulation affects a frontotemporal network: a PET study (Schroeder et al) 2003;54:445
 subthalamic nucleus stimulation reduces the cost of the pharmacologic treatment of Parkinson's disease (Newman et al) 2003;54:700

Subthalamic nucleus stimulation, bilateral

bilateral STN DBS for Parkinson's disease after successful pallidotomy (Kleiner-Fisman et al) 2003;54:(suppl 7) S70

Subthalamic nucleus stimulation, unilateral

unilateral stimulation of the subthalamic nucleus in Parkinson's disease: a prospective double-blind 12-month study (Germano et al) 2003;54:(suppl 7) S71

Subtraction analysis

muscle trophic factors: subtraction analysis of differentially expressed genes of regenerating skeletal muscle under innervation (Jimi et al) 2003;54:(suppl 7) S73

Subventricular zone

neonatal hypoxic-ischemic injury increases subventricular zone cell proliferation and neurogenesis in the mouse forebrain (Plane et al) 2003;54:(suppl 7) S103

retinoic acid stimulates neurogenesis in the postnatal rodent subventricular zone-olfactory bulb pathway (Wang et al) 2003;54:(suppl 7) S77

Succinate

succinate improves clinical symptoms and whole-cell oxidation in a patient with complex-I deficiency (Wassmer et al) 2003;54:(suppl 7) S158

Succinic semialdehyde dehydrogenase deficiency

brain GABA in SSADH deficiency (Novotny Jr. et al) 2003;54:(suppl 7) S106

clinical and metabolic investigations offer new insights into pathophysiology of succinic semialdehyde dehydrogenase deficiency (Pearl et al) 2003;54:(suppl 7) S107

monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency (Ergezinger et al) 2003;54:686

murine succinic semialdehyde dehydrogenase deficiency (Gupta et al) 2003;54:(suppl 6) S81

succinic semialdehyde dehydrogenase deficiency in children and adults (Pearl et al) 2003;54:(suppl 6) S73

vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency (Gropman) 2003;54:(suppl 6) S66

Sucking, nonnutritive

ontogeny of nonnutritive sucking by premature infants (Bingham and Stevens-Tuttle) 2003;54:(suppl 7) S120

Sulfatide

cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (Han et al) 2003;54:693 (Correction)

a turn of the sulfatide in Alzheimer's disease (Irizarry) 2002;54:7 (Editorial)

Sulthiame

sulthiame is effective in the initial therapy of West's syndrome: a randomized placebo-controlled add-on trial on baseline pyridoxine (Debus and Kurlmann) 2003;54:(suppl 7) S113

Superoxide dismutase

facial nerve avulsion accelerates motoneuron degeneration in pre-symptomatic transgenic rats expressing mutant human Cu/Zn superoxide dismutase (Ikeda et al) 2003;54:(suppl 7) S53

pyruvate protects motor neuronal cells expressing mutated superoxide dismutase (SOD1) against Cu/Zn-induced toxicity (Kim et al) 2003;54:(suppl 7) S53

Supranuclear palsy, progressive

corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia (Boeve et al) 2003;54:(suppl 5) S15

cross-sectional clinical description of a large prospective cohort of patients with progressive supranuclear palsy or

multiple system atrophy: the NNIPPS project (Leigh et al) 2003;54:(suppl 7) S70

neuroprotection and natural history in parkinson plus syndromes: construction and validation of a clinical scale to assess disease progression in progressive supranuclear palsy and multiple system atrophy (Payan et al) 2003;54:(suppl 7) S39

neuroprotection and natural history in parkinson plus syndromes: cross-sectional description of magnetic resonance imaging findings in a large prospective cohort of patients with progressive supranuclear palsy and multiple system atrophy (Kraft et al) 2003;54:(suppl 7) S39

progressive supranuclear palsy presenting as frontotemporal dementia (Smoot et al) 2003;54:(suppl 7) S22

Surgery; see also specific procedures

association between surgical specialty and appropriateness of carotid endarterectomy (Kennedy et al) 2003;54:696, (suppl 7) S18

cognitive outcomes after coronary artery bypass surgery: a prospective controlled study (Selnes et al) 2003;54:(suppl 7) S67

the correlation of histopathology to electrocorticographic pattern and postoperative outcome in temporal lobe epilepsy (Burakgazi et al) 2003;54:(suppl 7) S55

intraoperative infrared functional imaging of human brain (Gorbach et al) 2003;54:297

new method for intraoperative, motor-evoked potentials during surgical repair of brachial plexus birth injuries (Yaylali et al) 2003;54:(suppl 7) S156

prothrombotic risk factors in children with stroke after Fontan procedure (Smith and Garg) 2003;54:(suppl 7) S138

Surgery, brain

neuropsychological profiles after brain surgery in childhood (Kuroda et al) 2003;54:(suppl 7) S142

Surgery, cardiac

postoperative sedation and the incidence of delirium and cognitive deficits in cardiac surgery patients (Maldonado and Wyson) 2003;54:(suppl 7) S27

stroke and acute cerebral injuries presenting as subclinical seizures after newborn heart surgery (Ichord et al) 2003;54:(suppl 7) S110

Surgery, open heart

long-term neuromotor outcome at preschool age of infants with congenital heart defects with required open heart surgery (Majnemer et al) 2003;54:(suppl 7) S111

Survival motor neuron protein

the effects of survival motor neuron protein overexpression in survival motor neuron fibroblasts (Acsadi et al) 2003;54:(suppl 7) S108

valproic acid increases SMN levels in spinal muscular atrophy patient cells (Sumner et al) 2003;54:647

 α -Synuclein

α -synuclein toxicity in yeast (Dixon et al) 2003;54:(suppl 7) S39

triplication of alpha-synuclein is causal of neuropathologically confirmed Parkinson's disease, diffuse Lewy body disease, and multiple system atrophy in a single kindred (Gwinn-Hardy et al) 2003;54:848

Synucleinopathy

differential findings on brain parenchyma sonography in tauopathies and synucleinopathies (Walter et al) 2003;54:(suppl 7) S41

T cells

autoreactive T-cells in the blood and cerebrospinal fluid of patients with stiff-person syndrome: studies using T-cell

- cloning and combinatorial peptide libraries (Raju et al) 2003;54:(suppl 7) S45
- cytokine-induced early gene regulation in glial cell cultures: differential effects of Th1, Th2, and monocyte cytokines (Lisak et al) 2003;54:(suppl 7) S38
- Taiwan**
- SCA2-related parkinsonism in Taiwan: clinical and PET studies (Shan et al) 2003;54:(suppl 7) S40
- TAK-375 (ramelteon)**
- behavioral pharmacology of ramelteon (TAK-375) in small mammals (Miyamoto et al) 2003;54:(suppl 7) S46
- Tau**
- characterization of tau association with Parkinson disease (Oliveira et al) 2003;54:(suppl 7) S50
- tau gene**
- an English kindred with a novel recessive tauopathy and respiratory failure (Nicholl et al) 2003;54:682
- mutation carriers versus noncarriers in a cohort of at-risk individuals in PPND family (FTDP-17, N279K tau mutation) (Wszolek et al) 2003;54:(suppl 7) S58
- variable phenotypic expression and extensive tau pathology in two families with the novel *tau* mutation L315R (van Herpen et al) 2003;54:573
- Tauopathy**
- differential findings on brain parenchyma sonography in tauopathies and synucleinopathies (Walter et al) 2003;54:(suppl 7) S41
- Temozolomide**
- temozolomide as long-term maintenance treatment for gliomas (Stern et al) 2003;54:(suppl 7) S31
- Temporal lobe complex partial status epilepticus**
- chronic amnesic states and temporal lobe complex partial status epilepticus (Perez-Gosienigfiao et al) 2003;54:(suppl 7) S54
- Temporal lobe epilepsy**
- chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy (Helmstaedter et al) 2003;54:425
- the correlation of histopathology to electrocorticographic pattern and postoperative outcome in temporal lobe epilepsy (Burakgazi et al) 2003;54:(suppl 7) S55
- heart rate analysis can differentiate dialeptic temporal lobe epilepsy from dialeptic auras and dialeptic nonepileptic seizures (Oliveira et al) 2003;54:(suppl 7) S55
- is FDG-PET still useful for detecting temporal lobe foci? (Theodore et al) 2003;54:(suppl 7) S56
- microdysgenesis in mesial temporal lobe epilepsy: a clinicopathological study (Kasper et al) 2003;54:501
- Temporal lobectomy**
- does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003;54:(suppl 7) S53
- Temporo-peri-Sylvian vestibular cortex (TPSVC)**
- reappraisal of the human vestibular cortex by cortical electrical stimulation study (Kahane et al) 2003;54:615
- Tension-type headache**
- psychiatric characteristics of the patients with tension-type headache (Lee et al) 2003;54:(suppl 7) S34
- Terbutaline**
- terbutaline in the treatment of myasthenia gravis: a pilot study (Soliven et al) 2003;54:(suppl 7) S45
- Terminology**
- preferred terminology (Kertesz et al) 2003;54:(suppl 5) S3
- Tertiary care epilepsy clinics**
- the prevalence of autistic spectrum disorder in children seen in a tertiary care epilepsy clinic (Clarke et al) 2003;54:(suppl 7) S149
- Thiamine-deficiency neuropathy**
- alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy (Koike et al) 2003;54:19
- Thrombolytic therapy**
- accuracy of coding for cerebral thrombolysis administration (Chaturvedi et al) 2003;54:699
- beyond the three hour time-window: multivariable patient-selection for thrombolytic therapy in acute ischemic stroke (Kent et al) 2003;54:696, (suppl 7) S18
- Thrombosis, cerebral sinovenous**
- neurological outcome in survivors of neonatal arterial ischemic stroke and cerebral sinovenous thrombosis: a prospective longitudinal study (Domi et al) 2003;54:(suppl 7) S138
- Thrombosis, sinovenous**
- intraventricular hemorrhage and sinovenous thrombosis in term infants (Wul et al) 2003;54:(suppl 7) S138
- intraventricular hemorrhage in term neonates caused by sinovenous thrombosis (Wu et al) 2003;54:123
- Tiagabine**
- a maximum tolerated dose study of tiagabine in painful diabetic polyneuropathy (Kirby and Belleau) 2003;54:(suppl 7) S46
- Tibial muscular dystrophy**
- tibial muscular dystrophy in a Belgian family (Van den Bergh et al) 2002;54:248
- Tics**
- atomoxetine for the treatment of attention deficit hyperactivity disorder and comorbid tics in children (Lewis et al) 2003;54:(suppl 7) S106
- once-daily dosing with the OROS formulation of methylphenidate has minimal impact on tics in children with ADHD (Palumbo et al) 2003;54:(suppl 7) S27
- once-daily OROS methylphenidate: impact on tics in children with attention deficit hyperactivity disorder (Palumbo et al) 2003;54:(suppl 7) S143
- sonographic lenticulostriate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28
- Tissue plasminogen activator**
- microglia potentiate neuronal injury following ischemia-like insults: possible role of tissue plasminogen activator (tPA) (Huang et al) 2003;54:851
- Topiramate**
- a prospective study of topiramate in 500+ children/adolescents with refractory epilepsy (Ritter et al) 2003;54:(suppl 7) S112
- tolerability and safety of topiramate as first-line monotherapy in children and adolescents (Dlugos et al) 2003;54:(suppl 7) S135
- topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135
- topiramate as add-on or monotherapy in pediatric epilepsy (Wang et al) 2003;54:(suppl 7) S135
- topiramate as first-line therapy in children/adolescents with newly diagnosed epilepsy (Pellock et al) 2003;54:(suppl 7) S112
- topiramate as first-line therapy in epilepsy characterized by partial-onset or generalized tonic-clonic seizures (Levisohn et al) 2003;54:(suppl 7) S135
- topiramate in children/adolescents with refractory epilepsy: effects on growth measure as age- and gender-specific body mass index (Wheless et al) 2003;54:(suppl 7) S136
- topiramate monotherapy for the prevention of headaches in children (Vasconcellos et al) 2003;54:(suppl 7) S150

TorsinA

nuclear envelope mislocalization of torsinA: a potential molecular mechanism underlying DYT1 dystonia (Dauer et al) 2003;54:849

torsinA protein and mRNA expression in the human brain of newborns, infants, and children (Siebert et al) 2003;54:(suppl 7) S116

Torticollis, benign paroxysmal

benign paroxysmal torticollis in infancy: not so benign? (Rosman et al) 2003;54:(suppl 7) S129

Total parenteral nutrition

manganese-induced parkinsonism from total parenteral nutrition: report of a case and review of the literature (Reich et al) 2003;54:(suppl 7) S73

Tourette's syndrome

association of autistic spectrum disorders and Tourette's syndrome (Hussein and Kuban) 2003;54:(suppl 7) S147

association of cortical versus behavioral disinhibition in Tourette's syndrome and attention deficit hyperactivity disorder (Gilbert et al) 2003;54:(suppl 7) S143

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58

human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syndrome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118

neuroleptics and Gilles de la Tourette syndrome: patient knowledge and concern (Kompolti et al) 2003;54:(suppl 7) S41

Toxicity

amyloid β protein toxicity mediated by the formation of amyloid- β protein precursor complexes (Lu et al) 2003;54:781

the Cincinnati antiepileptic drug side effect neurologic subscale detects and quantifies significant interpatient variability in antiepileptic drug neurologic toxicity (Morita et al) 2003;54:(suppl 7) S137

Tracheostomy

mechanical ventilation and tracheostomy in multiple sclerosis (Pittcock et al) 2003;54:(suppl 7) S63

Transcranial Doppler

sickle cell disease and stroke: primary prevention and transcranial Doppler (Adams et al) 2003;54:559 (Editorial)

Transcranial magnetic stimulation, repetitive

identification of areas with relevant functional activation by rTMS (Heiss et al) 2003;54:(suppl 7) S78

Transient ischemic attacks

a population study of the risk of stroke after transient ischemic attack (Hill et al) 2003;54:695, (suppl 7) S17

Transplantation, bone marrow

acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44

the effects of bone marrow transplants on the progression of motoneuron disease in PU.1^{-/-} mice (Beers et al) 2003;54:(suppl 7) S43

Transplantation, nigral

a double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (Olanow et al) 2003;54:403

Transplantation, stem cell

acute neuropathies after peripheral blood stem cell and bone marrow transplantation (Rabinstein et al) 2003;54:(suppl 7) S44

intravenous human neural stem cell transplantation ameliorated the epileptogenesis in rat epilepsy model (Chu et al) 2003;54:(suppl 7) S54

transplanted neural stem cells improve regeneration through chronically denervated peripheral nerves (Heine et al) 2003;54:(suppl 7) S19

Traumatic brain injury

association between GCS, duration of coma and outcomes with the extent of hemorrhagic DAI lesions determined by susceptibility weighted MRI in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S111

glutamate/glutamine detected by proton magnetic resonance spectroscopy is increased in children with traumatic brain injury (Ashwal et al) 2003;54:(suppl 7) S128

proton magnetic resonance spectroscopy-detected myoinositol is increased in children with traumatic brain injury and correlates with neurologic outcome (Ashwal et al) 2003;54:(suppl 7) S153

Tremors

the effects of unilateral versus bilateral subthalamic nuclei stimulation on tremor and gait in persons with Parkinson's disease (Shumway-Cook et al) 2003;54:(suppl 7) S69

Tremors, orthostatic

[¹²¹I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor (Katzenschlager R et al) 2002;54:278 (Correction)

Trigeminal ganglia

dually infected (HSV-1/VZV) single neurons in human trigeminal ganglia (Theil et al) 2003;54:678

Trileptal; see Oxcarbazepine

TrkA/NGF

Bcl-2-mediated induction of neural differentiation: a role for NGF/TrkA (Liang et al) 2003;54:(suppl 7) S105

Tuberous sclerosis

anomalous inhibitory circuits in tubers of human tuberous sclerosis and in cortical microdysgenesis associated with intractable seizures: expression of parvalbumin and calbindin-D28k in dysplastic neocortex (Valencia et al) 2003;54:(suppl 7) S132

impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model (Wong et al) 2002;54:251

simultaneous tuberous sclerosis and Friedreich's ataxia: no evidence for interaction (Walker et al) 2003;54:(suppl 7) S57

Tuberous sclerosis type 2

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S108

human blood genomic profiles unique for age, sex, neurofibromatosis type 1, Tourette's, and tuberous sclerosis type 2 (Tang et al) 2003;54:(suppl 7) S58

human blood genomic profiles unique for autosomal dominant CNS disorders: a pilot study of Tourette's syndrome, neurofibromatosis type 1, and tuberous sclerosis type 2 (Gilbert et al) 2003;54:(suppl 7) S118

γ -Tubulin

alterations of γ -tubulin cellular distribution in human gliomas: implication of centrosome amplification in malignant tumor progression (Katsaros et al) 2003;54:(suppl 7) S117

Tufts fragment 1-3

protective role of tufts fragment 1-3 in an animal model of intracerebral hemorrhage (Wang et al) 2003;54:655

Tumor necrosis factor- α

the release of tumor necrosis factor- α is associated with ischemic tolerance in human stroke (Castillo et al) 2003;54:812

Tumors

molecular mechanisms for cyclophosphamide induction of oncolytic viral proliferation in tumor (Fontana et al) 2003;54:851

Tumors, brain

the clinical application of positron emission tomography in childhood brain tumors (Kaplan et al) 2003;54:(suppl 7) S149

inhibition of brain tumor-mediated excitotoxic destruction and invasion implementing a glutamate release antagonist (Haque et al) 2003;54:851

moyamoya after cranial irradiation for primary brain tumors in children (Ullrich et al) 2003;54:(suppl 7) S140

pediatric brain tumor stem cells (Hemmati et al) 2003;54:(suppl 7) S117

Tumors, internal auditory canal

glioblastoma multiforme presenting as bilateral internal auditory canal tumors mimicking neurofibromatosis type 2 (Lee et al) 2003;54:(suppl 7) S31

Tumors, malignant

alterations of γ -tubulin cellular distribution in human gliomas: implication of centrosome amplification in malignant tumor progression (Katsetos et al) 2003;54:(suppl 7) S117

Tumors, oligodendroglial

no preferential loss of paternal 19q alleles in oligodendroglial tumors (Hartmann et al) 2002;54:256

Tumors, spinal cord

cat scratch disease mimicking a spinal cord tumor (Hmaïmess et al) 2003;54:(suppl 7) S159

Twins

brainstem auditory evoked potential abnormalities in twins in the first year of life (Zafeiriou et al) 2003;54:(suppl 7) S132

Tyrosine hydrolase deficiency

tyrosine hydrolase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia (Hoffmann et al) 2003;54:(suppl 6) S56

Ube4b/NMNAT gene

protein-protein interactions of *Ube4b/NMNAT*, a gene responsible for slow Wallerian degeneration (Torre et al) 2003;54:(suppl 7) S51

Ubiquitin protein ligase E3A (UBE3A) gene

do loss-of-function UBE3A mutations account for the complete Angelman's syndrome phenotype? (Gerry and Graf) 2003;54:(suppl 7) S119

Ultrasonography

differential findings on brain parenchyma sonography in tauopathies and synucleinopathies (Walter et al) 2003;54:(suppl 7) S41

periventricular hemorrhagic infarction, clinical antecedents and ultrasonographic accompaniments (Bassan et al) 2003;54:(suppl 7) S124

sonographic lenticulostriate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28

ultrasonographic accompaniments and predictors of cerebellar hemorrhage in the preterm infant (Limperopoulos et al) 2003;54:(suppl 7) S122

Unified Parkinson's Disease Rating Scale (UPDRS)

achieving interrater reliability in Parkinson's disease: utility of the Movement Disorder Society-owned teaching tape of the Unified Parkinson's Disease Rating Scale (Goetz and Stebbins) 2003;54:(suppl 7) S40

United Kingdom

clinical and radiological features of moyamoya syndrome in British children (Ganesan et al) 2003;54:(suppl 7) S140

United States military veterans

amyotrophic lateral sclerosis (ALS) outcomes in US military veterans compared with non-veterans: neuroepidemiological insights from the ALS CARE Database (Brooks et al) 2003;54:700

Useful field of view

reduction of the useful field of view in Parkinson's disease (Uc et al) 2003;54:(suppl 7) S39

Utah Early Neuropathy Scale (UENS)

the Utah Early Neuropathy Scale, a clinical scale sensitive to early small fiber neuropathy (Smith et al) 2003;54:(suppl 7) S44

VA Stroke Study (VAST Study)

VA Stroke Study (VAST Study): progressing stroke (Goldstein et al) 2003;54:695, (suppl 7) S17

Vaccines

papillomavirus-like particle A β vaccine induces strong antibody response in APP/PS1 transgenic mice (Zamora et al) 2003;54:(suppl 7) S29

Vagus nerve stimulation

vagus nerve stimulation for refractory symptomatic generalized epilepsy (Hosain et al) 2003;54:(suppl 7) S113

Valproate

topiramate, carbamazepine, and valproate as first-line monotherapy in children/adolescents with newly diagnosed epilepsy (Wheless et al) 2003;54:(suppl 7) S135

Valproic acid

valproic acid increases SMN levels in spinal muscular atrophy patient cells (Sumner et al) 2003;54:647

Variable occipital cephalocele, autosomal-dominant

variable occipital cephalocele with autosomal-dominant inheritance: a three-generation pedigree (Bassuk et al) 2003;54:(suppl 7) S157

Varicella zoster virus

dually infected (HSV-1/VZV) single neurons in human trigeminal ganglia (Theil et al) 2003;54:678

oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV (Burgoon et al) 2003;54:459

Varicella zoster virus vasculopathy

oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV (Burgoon et al) 2003;54:459

Vascular dementia

association of cerebrovascular disease with Alzheimer's disease and vascular dementia: outcome by race and gender (Moonis et al) 2003;54:697

Vascular disease, central nervous system

the occurrence of central nervous system vascular disease following cranial radiotherapy (Keene et al) 2003;54:(suppl 7) S141

Vascular parkinsonism

vascular parkinsonism in moyamoya: microvascular biopsy and imaging correlates (Tan et al) 2003;54:838

Vasculitis, central nervous system

suspected central nervous system vasculitis in young stroke patients (Berlit et al) 2003;54:(suppl 7) S25

Vasculopathy, lenticulostriate

sonographic lenticulostriate vasculopathy in infancy: tic and other neuropsychiatric disorders developed at 7 to 9-year follow-up (Wang et al) 2003;54:(suppl 7) S28

Vasculopathy, varicella zoster virus

oligoclonal immunoglobulins in cerebrospinal fluid during varicella zoster virus (VZV) vasculopathy are directed against VZV (Burgoon et al) 2003;54:459

Vein of Galen malformations

neurodevelopmental outcome after endovascular treatment of vein of Galen malformations (Fullerton et al) 2003;54:(suppl 7) S139

Venous prominence

venous prominence on susceptibility-weighted MRI is associated with perinatal depression in neonates (Michelson et al) 2003;54:(suppl 7) S125

Ventilation, mechanical

mechanical ventilation and tracheostomy in multiple sclerosis (Pittock et al) 2003;54:(suppl 7) S63

Verbal memory

does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003;54:(suppl 7) S53

Vertebrobasilar insufficiency

vertebrobasilar insufficiency and hearing loss in children: is there any link? (Melikishvili et al) 2003;54:(suppl 7) S141

Very low-birth-weight infants

altered MR cerebral volumes correlate with neurodevelopmental outcome at 2 years in VLBW infants (Inder et al) 2003;54:(suppl 7) S124

Vestibular cortex

reappraisal of the human vestibular cortex by cortical electrical stimulation study (Kahane et al) 2003;54:615

Veterans

amyotrophic lateral sclerosis (ALS) outcomes in US military veterans compared with non-veterans: neuroepidemiological insights from the ALS CARE Database (Brooks et al) 2003;54:700

View, useful field of

reduction of the useful field of view in Parkinson's disease (Uc et al) 2003;54:(suppl 7) S39

Vigabatrin

monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency (Ergezinger et al) 2003;54:686
vigabatrin and newer interventions in succinic semialdehyde dehydrogenase deficiency (Gropman) 2003;54:(suppl 6) S66

Viral proliferation

molecular mechanisms for cyclophosphamide induction of oncolytic viral proliferation in tumor (Fontana et al) 2003;54:851

Viremia

viremia in the presence of blood-brain barrier compromise increases severity of HIV-associated neurocognitive impairment (Avison et al) 2003;54:(suppl 7) S49

Visual function

visual function in Machado-Joseph disease (Subramony et al) 2003;54:(suppl 7) S40

Visual impairment

retinal involvement in dementia with Lewy bodies: a clue to hallucinations? (Maurage et al) 2003;54:542

Vitamin B12 (cobalamin)-deficiency

cobalamin (vitamin B12)-deficiency-induced changes in the proteome of rat cerebrospinal fluid (Gianazza et al) 2003;54:(suppl 7) S52

Volga Germans

Lewy body pathology in familial Alzheimer's disease: a clinical-neuropathological study in ethnic Volga Germans with a PS-2 mutation or APOE $\epsilon 4$ (Leverenz et al) 2003;54:(suppl 7) S68

Voltage-gated potassium channel antibody

voltage-gated potassium channel antibody-associated limbic encephalitis is relatively common, potentially treatable, and usually nonaraneoplastic (Vincent et al) 2003;54:(suppl 7) S20

Voltage-gated potassium channels

voltage-gated potassium channel antibodies in limbic encephalitis (Pozo-Rosich et al) 2003;54:530

von Hippel-Lindau gene

transfer of the von Hippel-Lindau gene to neuronal progenitor cells in treatment for Parkinson's disease (Yamada et al) 2003;54:352

Wada memory asymmetry

does Wada memory asymmetry predict verbal memory change after temporal lobectomy? (Majors et al) 2003;54:(suppl 7) S53

Wallenberg's syndrome

head tilt and lateropulsion in Wallenberg's syndrome (Kim et al) 2003;54:(suppl 7) S79

Wallerian degeneration, slow

protein-protein interactions of *Ube4b/NMNAT*, a gene responsible for slow Wallerian degeneration (Torre et al) 2003;54:(suppl 7) S51

WAY-100635

comparisons of serotonin 5-HT_{1A} receptor binding potential in Alzheimer's disease (AD) versus controls using [¹¹C]WAY-100635 and PET (Lancôt et al) 2003;54:(suppl 7) S29

serotonin 5-HT_{1A} receptor binding potential in fronto-temporal dementia (FTD) compared with controls using [¹¹C]WAY-100635 and PET (Lancôt) 2003;54:(suppl 7) S67

West Nile virus encephalitis

neuropathological findings in West Nile virus encephalitis: a case report (Agamanolis et al) 2003;54:547

West's syndrome

sulthiame is effective in the initial therapy of West's syndrome: a randomized placebo-controlled add-on trial on baseline pyridoxine (Debus and Kurlemann) 2003;54:(suppl 7) S113

White matter

AMPA receptor subunit expression in human white matter during window of susceptibility to periventricular leukomalacia (Follett et al) 2003;54:(suppl 7) S103

frontal white matter reductions in healthy boys with complex stereotypes (Kates et al) 2003;54:(suppl 7) S144
graded cerebral white matter injury in a fetal sheep global ischemia model of periventricular leukomalacia (Back et al) 2003;54:(suppl 7) S103

heterogeneous age-related breakdown of white matter structural integrity: implications for "disconnection" in aging and Alzheimer's disease (Bartzokis et al) 2003;54:(suppl 7) S29

reduction in *N*-acetyl aspartate by magnetic resonance spectroscopy in cerebral white matter of preterm infants compared with term infants at 1 year of age (Soul et al) 2003;54:(suppl 7) S125

selective cerebral white matter injury in asphyxiated term newborns (Landesman et al) 2003;54:(suppl 7) S126

serial diffusion tensor imaging studies of the effects of MS lesions on white matter fiber tracts (Henry et al) 2003;54:(suppl 7) S35

Wilson's disease

low ceruloplasmin in heterozygotes for Wilson's disease: a *copper herring* (Reich and O'Hearn) 2003;54:(suppl 7) S42

Withdrawal, fluoxetine

neonatal fluoxetine withdrawal secondary to maternal use during pregnancy: is fluoxetine safe? (Lavenstein et al) 2003;54:(suppl 7) S127

Women

changes in perception of risks and benefits of hormone therapy in women with stroke (Bushnell et al) 2003;54:699

nonsyndromic mental retardation and cryptogenic epilepsy in women with *doublecortin* gene mutations (Guerrini et al) 2003;54:30

onset of dementia is associated with age at menopause in women with Down's syndrome (Schupf et al) 2003;54:433

Women's Health Initiative (WHI)

lack of impact of the Women's Health Initiative on hormone therapy use after stroke (Bushnell and Goldstein) 2003;54:697

X-linked adrenoleukodystrophy

oligonucleotide microarray expression analysis of X-linked adrenoleukodystrophy fibroblasts (O'Neill et al) 2003;54:(suppl 7) S57

Yeast

α -synuclein toxicity in yeast (Dixon et al) 2003;54:(suppl 7) S39

Yorkshire kindred

an English kindred with a novel recessive tauopathy and respiratory failure (Nicholl et al) 2003;54:682

Zalcitabine; see ddC

Zinc

pre-synaptic zinc dynamics in permanent and transient focal ischemia (Subramaniam et al) 2003;54:(suppl 7) S65

a randomized, controlled trial of antioxidants and zinc and the impact on cognition in the elderly: the AREDS Ancillary Trial (Yaffe et al) 2003;54:(suppl 7) S28

Zolmitriptan

oral zolmitriptan demonstrates high efficacy in the acute treatment of true menstrual migraine (Singer et al) 2003;54:(suppl 7) S32

a single dose of zolmitriptan nasal spray is efficacious over multiple attacks (Charlesworth et al) 2003;54:(suppl 7) S32

zolmitriptan nasal spray is highly efficacious, very fast acting and produces sustained relief in the treatment of acute migraine in a real life setting: results from phase I of the REALIZE study (Gawel et al) 2003;54:(suppl 7) S32